<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.2" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">64977</article-id><article-id pub-id-type="doi">10.7554/eLife.64977</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cell Biology</subject></subj-group></article-categories><title-group><article-title>Unique integrated stress response sensors regulate cancer cell susceptibility when Hsp70 activity is compromised</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="author-216956"><name><surname>Sannino</surname><given-names>Sara</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-9125-9098</contrib-id><email>sannino.sara1986@gmail.com</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-239904"><name><surname>Yates</surname><given-names>Megan E</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-216958"><name><surname>Schurdak</surname><given-names>Mark E</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-54539"><name><surname>Oesterreich</surname><given-names>Steffi</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-239905"><name><surname>Lee</surname><given-names>Adrian V</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-216957"><name><surname>Wipf</surname><given-names>Peter</given-names></name><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-94528"><name><surname>Brodsky</surname><given-names>Jeffrey L</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-6984-8486</contrib-id><email>jbrodsky@pitt.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund4"/><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund6"/><xref ref-type="other" rid="fund7"/><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution>Department of Biological Sciences, University of Pittsburgh</institution><addr-line><named-content content-type="city">Pittsburgh</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution>Women's Cancer Research Center, UPMC Hillman Cancer Center, Magee-Women Research Institute</institution><addr-line><named-content content-type="city">Pittsburgh</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution>Integrative Systems Biology Program, University of Pittsburgh</institution><addr-line><named-content content-type="city">Pittsburgh</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution>Medical Scientist Training Program, University of Pittsburgh School of Medicine</institution><addr-line><named-content content-type="city">Pittsburgh</named-content></addr-line><country>United States</country></aff><aff id="aff5"><label>5</label><institution>Department of Computational and Systems Biology, University of Pittsburgh</institution><addr-line><named-content content-type="city">Pittsburgh</named-content></addr-line><country>United States</country></aff><aff id="aff6"><label>6</label><institution>University of Pittsburgh Drug Discovery Institute</institution><addr-line><named-content content-type="city">Pittsburgh</named-content></addr-line><country>United States</country></aff><aff id="aff7"><label>7</label><institution>Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine</institution><addr-line><named-content content-type="city">Pittsburgh</named-content></addr-line><country>United States</country></aff><aff id="aff8"><label>8</label><institution>Department of Chemistry, University of Pittsburgh</institution><addr-line><named-content content-type="city">Pittsburgh</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Hartl</surname><given-names>Franz-Ulrich</given-names></name><role>Reviewing Editor</role><aff><institution>Max Planck Institute for Biochemistry</institution><country>Germany</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Murphy</surname><given-names>Maureen E</given-names></name><role>Senior Editor</role><aff><institution>The Wistar Institute</institution><country>United States</country></aff></contrib></contrib-group><pub-date date-type="publication" publication-format="electronic"><day>28</day><month>06</month><year>2021</year></pub-date><pub-date pub-type="collection"><year>2021</year></pub-date><volume>10</volume><elocation-id>e64977</elocation-id><history><date date-type="received" iso-8601-date="2020-11-18"><day>18</day><month>11</month><year>2020</year></date><date date-type="accepted" iso-8601-date="2021-06-27"><day>27</day><month>06</month><year>2021</year></date></history><permissions><copyright-statement>© 2021, Sannino et al</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Sannino et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-64977-v3.pdf"/><abstract><p>Molecular chaperones, such as Hsp70, prevent proteotoxicity and maintain homeostasis. This is perhaps most evident in cancer cells, which overexpress Hsp70 and thrive even when harboring high levels of misfolded proteins. To define the response to proteotoxic challenges, we examined adaptive responses in breast cancer cells in the presence of an Hsp70 inhibitor. We discovered that the cells bin into distinct classes based on inhibitor sensitivity. Strikingly, the most resistant cells have higher autophagy levels, and autophagy was maximally activated only in resistant cells upon Hsp70 inhibition. In turn, resistance to compromised Hsp70 function required the integrated stress response transducer, GCN2, which is commonly associated with amino acid starvation. In contrast, sensitive cells succumbed to Hsp70 inhibition by activating PERK. These data reveal an unexpected route through which breast cancer cells adapt to proteotoxic insults and position GCN2 and autophagy as complementary mechanisms to ensure survival when proteostasis is compromised.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>proteostasis</kwd><kwd>molecular chaperone</kwd><kwd>autophagy</kwd><kwd>unfolded protein response</kwd><kwd>apoptosis</kwd><kwd>MAL3-101</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100004410</institution-id><institution>European Molecular Biology Organization</institution></institution-wrap></funding-source><award-id>ALTF 823-2016 post-doctoral fellowship</award-id><principal-award-recipient><name><surname>Sannino</surname><given-names>Sara</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>F30CA250167</award-id><principal-award-recipient><name><surname>Yates</surname><given-names>Megan E</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>GM131732</award-id><principal-award-recipient><name><surname>Brodsky</surname><given-names>Jeffrey L</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>DK079307</award-id><principal-award-recipient><name><surname>Brodsky</surname><given-names>Jeffrey L</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>P30CA047904</award-id><principal-award-recipient><name><surname>Brodsky</surname><given-names>Jeffrey L</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000011</institution-id><institution>Howard Hughes Medical Institute</institution></institution-wrap></funding-source><award-id>Howard Hughes Medical Institute Collaborative Innovation award</award-id><principal-award-recipient><name><surname>Brodsky</surname><given-names>Jeffrey L</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100007921</institution-id><institution>University of Pittsburgh</institution></institution-wrap></funding-source><award-id>Translational and Precision Pharmacology programs (pilot grant)</award-id><principal-award-recipient><name><surname>Brodsky</surname><given-names>Jeffrey L</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Unique integrate stress response sensors differentially trigger pro-survival versus pro-apoptotic responses in cells confronted with Hsp70 inhibitor-associated proteotoxic challenges.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>The many pathways that ensure the maintenance of protein homeostasis (proteostasis) must be tightly regulated to maintain cell function. Several proteostasis pathways are required to fold nascent or damaged proteins or mediate their degradation, which prevents the formation of toxic protein intermediates and aggregates that impair cellular homeostasis (<xref ref-type="bibr" rid="bib9">Balch et al., 2008</xref>; <xref ref-type="bibr" rid="bib110">Mu et al., 2008</xref>). The regulation and maintenance of cellular proteostasis is especially vital for cancer cells that thrive under hostile conditions, including anoxia, hypoglycemia, and oxidative stress (<xref ref-type="bibr" rid="bib103">Mei et al., 2013</xref>; <xref ref-type="bibr" rid="bib186">Yan et al., 2015</xref>). In addition, cancer cells grow uncontrollably, which requires high levels of protein biosynthesis, and are also aneuploid, producing orphaned proteins that should otherwise reside in multiprotein complexes (<xref ref-type="bibr" rid="bib182">Williams and Amon, 2009</xref>). Each of these events disturb cellular proteostasis, thereby provoking cellular stress responses. As a result, tumor progression requires proteostasis adaptation and modulation of cellular stress responses (<xref ref-type="bibr" rid="bib15">Benbrook and Long, 2012</xref>; <xref ref-type="bibr" rid="bib35">Cubillos-Ruiz et al., 2017</xref>; <xref ref-type="bibr" rid="bib101">McConkey, 2017</xref>; <xref ref-type="bibr" rid="bib177">Wang and Kaufman, 2014</xref>).</p><p>One proteostatic mechanism to reduce proteotoxic stress is to slow translation. Indeed, reduced translation in cancer cells, which decreases the protein burden, allows for the selective production of proteins required for proliferation, tumor initiation, progression, and metastasis. This phenomenon commonly arises from phosphorylation of the alpha subunit of translation initiation factor 2 (eIF2α) (<xref ref-type="bibr" rid="bib18">Blagden and Willis, 2011</xref>; <xref ref-type="bibr" rid="bib53">Guo et al., 2017</xref>; <xref ref-type="bibr" rid="bib81">Koromilas, 2015</xref>; <xref ref-type="bibr" rid="bib179">Wek and Cavener, 2007</xref>). In mammals, four kinases, the dsRNA-activated kinase (PKR), the heme-regulated inhibitor (HRI), the general control non-derepressible two factor (GCN2), and the PKR-like ER resident kinase (PERK), promote eIF2α phosphorylation (<xref ref-type="bibr" rid="bib56">Harding et al., 2000</xref>; <xref ref-type="bibr" rid="bib121">Pakos-Zebrucka et al., 2016</xref>; <xref ref-type="bibr" rid="bib156">Sidrauski et al., 2015</xref>). The resulting integrated stress response (ISR) also facilitates cancer cell survival (<xref ref-type="bibr" rid="bib37">Darini et al., 2019</xref>; <xref ref-type="bibr" rid="bib156">Sidrauski et al., 2015</xref>; <xref ref-type="bibr" rid="bib178">Wek, 2018</xref>), yet the role of each of the four ISR transducers in tumor initiation—or in maintenance of cellular homeostasis in most cells—is unclear. Moreover, how a single phosphorylation event integrates multiple stress stimuli and orchestrates different biological outcomes is incompletely understood.</p><p>Proteotoxic stress is especially problematic for secretory pathway function. Since cancer cells grow uncontrollably and require copious levels of growth factors, extracellular matrix components, and plasma membrane receptors and transporters, the unfolded protein response (UPR) mitigates the accumulation of toxic misfolded proteins in the endoplasmic reticulum (ER) in the cells (<xref ref-type="bibr" rid="bib62">Hetz et al., 2020</xref>; <xref ref-type="bibr" rid="bib119">Ojha and Amaravadi, 2017</xref>; <xref ref-type="bibr" rid="bib139">Ron and Walter, 2007</xref>; <xref ref-type="bibr" rid="bib186">Yan et al., 2015</xref>). The UPR is induced by three ER-localized transmembrane sensors, namely inositol-required enzyme 1 (IRE1), activating transcription factor 6 (ATF6), and PERK, which as noted above is also a component of the ISR (<xref ref-type="bibr" rid="bib17">Bi et al., 2005</xref>; <xref ref-type="bibr" rid="bib176">Walter and Ron, 2011</xref>). Among other events, the UPR favors the production of pro-folding molecular chaperones, augments protein secretion, and increases ER-associated degradation as well as lipid synthesis, which expands the ER. Together, the ISR and the UPR reestablish proteostasis or can alternatively initiate a cell death pathway if stress cannot be rectified (<xref ref-type="bibr" rid="bib17">Bi et al., 2005</xref>; <xref ref-type="bibr" rid="bib114">Nam and Jeon, 2019</xref>; <xref ref-type="bibr" rid="bib120">Oyadomari and Mori, 2004</xref>; <xref ref-type="bibr" rid="bib176">Walter and Ron, 2011</xref>). How cancer cells and most other cells avoid ISR/UPR-activated apoptosis is also poorly understood (<xref ref-type="bibr" rid="bib25">Cerezo et al., 2016</xref>; <xref ref-type="bibr" rid="bib35">Cubillos-Ruiz et al., 2017</xref>; <xref ref-type="bibr" rid="bib91">Lin et al., 2019</xref>).</p><p>To mitigate misfolded protein toxicity, the activity of the ubiquitin-proteasome and autophagy pathways also rise upon UPR/ISR induction in cancer cells (<xref ref-type="bibr" rid="bib34">Clarke et al., 2011</xref>; <xref ref-type="bibr" rid="bib74">Kim et al., 2015</xref>; <xref ref-type="bibr" rid="bib149">Schönthal, 2012</xref>). These protective pathways additionally favor amino acid recycling and cancer cell survival (<xref ref-type="bibr" rid="bib5">Amaravadi et al., 2016</xref>; <xref ref-type="bibr" rid="bib7">B'chir et al., 2013</xref>; <xref ref-type="bibr" rid="bib88">Levine and Kroemer, 2008</xref>; <xref ref-type="bibr" rid="bib95">Ma et al., 2014</xref>; <xref ref-type="bibr" rid="bib107">Mizushima et al., 2008</xref>). Based on the vital roles played by the UPR, ISR, and protein degradation pathways—and their known links to cell proliferation, apoptosis, chemotherapeutic resistance, and metastasis—inhibitors of these pathways represent new therapeutic targets (<xref ref-type="bibr" rid="bib38">Deshaies, 2014</xref>; <xref ref-type="bibr" rid="bib50">Grandjean and Wiseman, 2020</xref>; <xref ref-type="bibr" rid="bib59">Hazari et al., 2016</xref>; <xref ref-type="bibr" rid="bib87">Lazova et al., 2012</xref>; <xref ref-type="bibr" rid="bib152">Sharifi et al., 2016</xref>) Molecular chaperones, via their ability to augment protein folding and protect cells from proteotoxic damage, are also induced in cancer cells. In fact, molecular chaperones, such as Hsp70 and Hsp90, are predictors of poor prognoses in cancer patients and have emerged as new therapeutic targets (<xref ref-type="bibr" rid="bib22">Calderwood and Gong, 2016</xref>; <xref ref-type="bibr" rid="bib69">Joshi et al., 2018</xref>; <xref ref-type="bibr" rid="bib131">Powers et al., 2009</xref>; <xref ref-type="bibr" rid="bib147">Sannino and Brodsky, 2017</xref>; <xref ref-type="bibr" rid="bib181">Whitesell and Lindquist, 2005</xref>).</p><p>Through the application of the Hsp70 inhibitor, MAL3-101, we previously reported that Hsp70 plays a crucial role in the survival of rhabdomyosarcoma, a childhood cancer that is largely refractory to conventional therapies (<xref ref-type="bibr" rid="bib144">Sabnis et al., 2016</xref>; <xref ref-type="bibr" rid="bib146">Sannino et al., 2018</xref>). MAL3-101 binds a unique site in Hsp70 where it blocks allosteric activation by the Hsp40 co-chaperone. The compound, a pyrimidinone peptoid, primarily targets cytosolic Hsp70 with minor effects on the activity of the ER resident Hsp70 chaperone, BiP, and lacks toxicity in non-transformed cells and rodents (<xref ref-type="bibr" rid="bib2">Adam et al., 2014</xref>; <xref ref-type="bibr" rid="bib42">Fewell et al., 2004</xref>; <xref ref-type="bibr" rid="bib125">Patham et al., 2009</xref>; <xref ref-type="bibr" rid="bib144">Sabnis et al., 2016</xref>; <xref ref-type="bibr" rid="bib158">Singh et al., 2020</xref>; <xref ref-type="bibr" rid="bib183">Wisén et al., 2010</xref>). MAL3-101-mediated Hsp70 inhibition led to the accumulation of p-eIF2α and CHOP in rhabdomyosarcoma cell lines and in a mouse model, thereby initiating an apoptotic response (<xref ref-type="bibr" rid="bib144">Sabnis et al., 2016</xref>). Interestingly, components of the autophagy pathway and autophagic flux appeared to be higher in Hsp70 inhibitor resistant cells that were isolated after drug escalation (<xref ref-type="bibr" rid="bib146">Sannino et al., 2018</xref>). However, the molecular mechanisms that led to Hsp70 inhibitor resistance and thereby rewired the rhabdomyosarcoma proteostasis pathways were unclear. A deeper understanding of how drug resistance arises when cancer cells are challenged with proteostasis inhibitors is critical for enabling future clinical applications.</p><p>In contrast to rhabdomyosarcoma, which is relatively rare, breast cancer represents one of the most common causes of death worldwide (<xref ref-type="bibr" rid="bib20">Bray et al., 2018</xref>; <xref ref-type="bibr" rid="bib79">Kohler et al., 2015</xref>). Breast cancer is a heterogeneous group of tumors subdivided into luminal, HER2, and Triple Negative Breast Cancer (TNBC) types depending on the expression of the estrogen receptor, progesterone receptor, and epidermal growth factor receptor 2 (HER2) (<xref ref-type="bibr" rid="bib11">Bareche et al., 2018</xref>; <xref ref-type="bibr" rid="bib23">Cancer Genome Atlas Network, 2012</xref>; <xref ref-type="bibr" rid="bib127">Perou et al., 2000</xref>). We now report that breast cancer cells bin into distinct groups when challenged with the specific Hsp70 inhibitor, MAL3-101. Although both resistant and sensitive breast cancer cell lines accumulated p-eIF2α when Hsp70 activity was thwarted, the resistant cells exclusively required the autophagy pathway to survive when challenged with MAL3-101. We then discovered that the ISR sensor, GCN2, was also essential for drug resistance. In contrast, the dual UPR/ISR sensor, PERK, initiated cell death in inhibitor-sensitive cells. These findings delineate distinct roles of ISR inducers in cell survival and highlight the interplay between the ISR/UPR, Hsp70, and protective protein degradation pathways.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Breast cancer cells exhibit a range of sensitivities to Hsp70 inhibition</title><p>Elevated Hsp70 is associated with resistance to chemotherapy in several cancers (<xref ref-type="bibr" rid="bib21">Brondani Da Rocha et al., 2004</xref>; <xref ref-type="bibr" rid="bib115">Nanbu et al., 1998</xref>; <xref ref-type="bibr" rid="bib173">Vargas-Roig et al., 1998</xref>), and Hsp70 overexpression correlates with metastasis in breast cancer murine models and in patients (<xref ref-type="bibr" rid="bib132">Powers et al., 2010</xref>; <xref ref-type="bibr" rid="bib164">Sun et al., 2008</xref>). To determine if Hsp70 activity is required for breast cancer cell survival, we performed a pilot study in which sensitivity to the Hsp70 inhibitor, MAL3-101 (<xref ref-type="bibr" rid="bib42">Fewell et al., 2004</xref>), was measured in a panel of 14 breast cancer lines (<xref ref-type="fig" rid="fig1">Figure 1A</xref> and <xref ref-type="table" rid="table1">Table 1</xref>). MAL3-101 targets an allosteric site in the ATP-binding domain of Hsp70, specifically inhibits the ability of Hsp40 co-chaperones to activate Hsp70 ATPase activity, and has demonstrated <italic>in vitro</italic> and <italic>in vivo</italic> efficacy in Merkel Cell carcinoma and multiple myeloma as well as rhabdomyosarcoma cell lines (<xref ref-type="bibr" rid="bib2">Adam et al., 2014</xref>; <xref ref-type="bibr" rid="bib19">Braunstein et al., 2011</xref>; <xref ref-type="bibr" rid="bib144">Sabnis et al., 2016</xref>; <xref ref-type="bibr" rid="bib146">Sannino et al., 2018</xref>; <xref ref-type="bibr" rid="bib183">Wisén et al., 2010</xref>). Among the luminal, HER2, and TNBC breast cancer subtypes, we were able to bin each line into sensitive, intermediate, and resistant groups (<xref ref-type="fig" rid="fig1">Figure 1A</xref> and <xref ref-type="table" rid="table1">Table 1</xref>). Breast cancer cells with an IC<sub>50</sub>≤ 3.5 µM were considered MAL3-101 sensitive, whereas cells with an IC<sub>50</sub> ≥ 30 µM were considered resistant. IC<sub>50</sub>s of breast cancer cells with an intermediate sensitivity were between 4 µM and 14 µM (<xref ref-type="table" rid="table1">Table 1</xref>). Interestingly, among identical breast cancer subtypes, breast cancer cells could be sensitive or insensitive to the Hsp70 inhibitor, indicating that other features dictate sensitivity to increased proteotoxic stress.</p><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Breast cancer cells exhibit a range of sensitivities to MAL3-101, a specific Hsp70 inhibitor.</title><p>The indicated breast cancer lines were seeded into 96-well plates and treated with increasing doses of the indicated compounds for 72 hr. Viability was measured using the CellTiter-Glo assay. IC<sub>50</sub> values were generate using a sigmoidal nonlinear regression with SigmaPlot 11.0. ND stands for an undetermined value. MAL3-101 sensitivities of Hsp70 inhibitor resistant cells are in bold.</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Breast cancer subtype</th><th>Cell line</th><th>MAL3-101</th><th>CQ</th><th>Bafilomycin</th><th>Bortezomib</th><th>CB-5083</th><th>17-AAG</th><th>VER155008</th></tr></thead><tbody><tr><td rowspan="6">TNBC</td><td>MDA MB 231</td><td>3.3 µM</td><td>40 µM</td><td>2.0 nM</td><td>5.9 nM</td><td>0.6 µM</td><td>1.3 µM</td><td>18.3 µM</td></tr><tr><td>MDA MB 468</td><td>3.1 µM</td><td>30 µM</td><td>2.0 nM</td><td>5.2 nM</td><td>0.8 µM</td><td>1.5 µM</td><td>&gt;100 µM</td></tr><tr><td>HCC1937</td><td>7.5 µM</td><td>42 µM</td><td>5.9 nM</td><td>5.0 nM</td><td>1.0 µM</td><td>5.6 nM</td><td>ND</td></tr><tr><td>HCC1395</td><td>11.6 µM</td><td>16 µM</td><td>3.0 nM</td><td>9.2 nM</td><td>0.3 µM</td><td>ND</td><td>ND</td></tr><tr><th>HCC38</th><td><bold>&gt;30 µM</bold></td><td>60 µM</td><td>2.7 nM</td><td>6.0 nM</td><td>0.5 µM</td><td>17.6 nM</td><td>&gt;100 µM</td></tr><tr><th>MDA MB 453</th><td><bold>&gt;30 µM</bold></td><td>23 µM</td><td>2.0 nM</td><td>4.3 nM</td><td>1.1 µM</td><td>13.5 nM</td><td>&gt;100 µM</td></tr><tr><td rowspan="6">Luminal</td><td>MDA MB 134</td><td>1.9 µM</td><td>18 µM</td><td>8.2 nM</td><td>3.7 nM</td><td>ND</td><td>ND</td><td>ND</td></tr><tr><td>MCF7</td><td>3.0 µM</td><td>10 µM</td><td>1.0 nM</td><td>40.0 nM</td><td>0.5 µM</td><td>63 nM</td><td>&gt;100 µM</td></tr><tr><td>T47D</td><td>6.6 µM</td><td>18 µM</td><td>2.7 nM</td><td>9.8 nM</td><td>ND</td><td>1.3 µM</td><td>&gt;100 µM</td></tr><tr><td>BT-474</td><td>4.0 µM</td><td>12 µM</td><td>2.5 nM</td><td>16.3 nM</td><td>ND</td><td>15.8 nM</td><td>&gt;100 µM</td></tr><tr><td>SUM44-PE</td><td>13.5 µM</td><td>42 µM</td><td>1.5 nM</td><td>16.0 nM</td><td>ND</td><td>ND</td><td>ND</td></tr><tr><th>MDA MB 361</th><td><bold>&gt;30 µM</bold></td><td>13 µM</td><td>1.7 nM</td><td>13.0 nM</td><td>1.0 µM</td><td>25.8 nM</td><td>&gt;100 µM</td></tr><tr><td rowspan="2">HER2</td><td>SKBR3</td><td>4.5 µM</td><td>28 µM</td><td>2.0 nM</td><td>4.4 nM</td><td>0.6 µM</td><td>18.5 nM</td><td>&gt;100 µM</td></tr><tr><td>HCC1419</td><td>8.2 µM</td><td>34 µM</td><td>1.5 nM</td><td>7.8 nM</td><td>0.8 µM</td><td>54.5 nM</td><td>100 µM</td></tr></tbody></table></table-wrap><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Breast cancer cell lines exhibit unique sensitivities to an Hsp70 inhibitor, MAL3-101.</title><p>(<bold>A</bold>) HER2 (diamonds), TNBC (circles), and luminal (squares and triangles) breast cancer lines were seeded into 96-well plates and treated with increasing doses of MAL3-101 for 72 hr. Viability is expressed as the average of three or more independent experiments, ± SEM. (<bold>B</bold>) MAL3-101-sensitive (MCF7 and MDA MB 231, denoted in blue) and resistant (MDA MB 453 and MDA MB 361, denoted in black) cells were treated with 12 µM MAL3-101 for the indicated times, and lysates were prepared and immunoblotted for cleaved caspase-3, caspase-7, and caspase-8. β-actin serves as a loading control. (<bold>C</bold>) The corresponding fold-increase of the indicated apoptotic markers relative to the DMSO control are plotted, ± SEM (n≥3 for cleaved caspase-3, n=3 for cleaved caspase-7, and n≥4 for cleaved caspase-8). Black asterisks correspond to statistical significance between MDA MB 231 cells (closed circle) and MDA MB 453 and MDA MB 361 (open circle and triangle, respectively), and the red asterisk represents statistical significance between MCF7 (closed triangle) and MDA MB 453 and MDA MB 361 (open circle and triangle) cells; * denotes p&lt;0.05, ** denotes p&lt;0.005.</p><p> <supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>Source data for cell viability assay and apoptotic marker accumulation in <xref ref-type="fig" rid="fig1">Figure 1</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-64977-fig1-data1-v3.xlsx"/></supplementary-material> </p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64977-fig1-v3.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>MAL3-101 sensitivity is independent of Hsp70 levels or induction.</title><p>(<bold>A</bold>) The fold change increase of the major Hsp70 gene (HSPA1A) in MAL3-101-treated cells relative to DMSO is plotted, ± SEM (n=3). MAL3-101-sensitive cells are indicated with closed symbols, while MAL3-101-resistant lines are represented with open symbols. (<bold>B</bold>) The relative fold change of Hsp70 protein levels in MAL3-101 relative to DMSO-treated conditions is plotted, ± SEM (n≥3). Symbols correspond to those indicated in part A. (<bold>C</bold>) The indicated proteins were analyzed by immunoblot in 12 breast cancer lines. Blue, purple, and back text indicates MAL3-101-sensitive, intermediate, and resistant lines, respectively. β-actin serves as a loading control.</p><p> <supplementary-material id="fig1s1sdata1"><label>Figure 1—figure supplement 1—source data 1.</label><caption><title>Raw data for Hsp70 mRNA and protein abundance.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-64977-fig1-figsupp1-data1-v3.xlsx"/></supplementary-material> </p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64977-fig1-figsupp1-v3.tif"/></fig></fig-group><p>To confirm these results, we measured the levels of apoptosis markers in two representative MAL3-101-sensitive lines (<xref ref-type="fig" rid="fig1">Figure 1B,C</xref>; MDA MB 231 and MCF7, indicated in blue text) and resistant lines (MDA MB 453 and MDA MB 361, indicated in black text). In each group, one cell line represents a luminal cancer cell type (MCF7 and MDA MB 361) and one is categorized as a TNBC cell line (MDA MB 231 and MDA MB 453). Induction of apoptosis in the MAL3-101-sensitive line, MDA MB 231, was evident by the accumulation of cleaved caspase-3, caspase-7, and caspase-8. Because MCF7 cells are caspase-3 deficient (<xref ref-type="bibr" rid="bib71">Kagawa et al., 2001</xref>; <xref ref-type="bibr" rid="bib172">Turner et al., 2003</xref>), the cleavage of only caspase-7 was detected after Hsp70 inhibition (<xref ref-type="fig" rid="fig1">Figure 1B,C</xref>). In contrast, apoptotic markers were absent in the MDA MB 453 and MDA MB 361-resistant lines. MAL3-101 treatment also increased Hsp70 mRNA abundance (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>), and a variable but general increase in Hsp70 protein levels was apparent (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B</xref>) that failed to correlate with Hsp70 inhibitor sensitivity and resistance. The muted levels of Hsp70 protein induction compared to the massive increase (~20–40-fold) in gene expression are consistent with previous data in which a heat shock trigger was administered to cells in culture and the effects on Hsp70 protein and mRNA levels were examined (<xref ref-type="bibr" rid="bib128">Petersen and Lindquist, 1989</xref>; <xref ref-type="bibr" rid="bib167">Theodorakis and Morimoto, 1987</xref>). A general increase in Hsp70 mRNA is also consistent with MAL3-101-dependent inhibition of Hsp70, which compromises proteostasis (<xref ref-type="bibr" rid="bib144">Sabnis et al., 2016</xref>; <xref ref-type="bibr" rid="bib146">Sannino et al., 2018</xref>). In addition, when the steady-state abundance of cytoplasmic Hsp70 and the constitutively expressed isoform, Hsc70, were measured (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1C</xref>), no correlation between protein levels and MAL3-101 sensitivity was apparent. These data strongly suggest that sensitivity/resistance arise from an independent phenomenon.</p><p>Hsp70 is a critical component of the Hsp90 ‘chaperome’ and facilitates the folding of oncogenic proteins such as BRAF, HER2, and AKT (<xref ref-type="bibr" rid="bib14">Basso et al., 2002</xref>; <xref ref-type="bibr" rid="bib69">Joshi et al., 2018</xref>; <xref ref-type="bibr" rid="bib147">Sannino and Brodsky, 2017</xref>; <xref ref-type="bibr" rid="bib150">Schopf et al., 2017</xref>; <xref ref-type="bibr" rid="bib181">Whitesell and Lindquist, 2005</xref>; <xref ref-type="bibr" rid="bib185">Xu et al., 2005</xref>). To examine whether Hsp90 and Hsp70 inhibitor sensitivities correlate, we applied the Hsp90 inhibitor 17-AAG (17-allylamino-17-demethoxy-geldanamycin, also known as tanespimycin) (<xref ref-type="bibr" rid="bib39">Doddareddy et al., 2011</xref>; <xref ref-type="bibr" rid="bib151">Schulte and Neckers, 1998</xref>; <xref ref-type="bibr" rid="bib165">Taldone et al., 2009</xref>) to each cell line. In accordance with previous reports (<xref ref-type="bibr" rid="bib33">Citri et al., 2004</xref>; <xref ref-type="bibr" rid="bib124">Patel et al., 2013</xref>; <xref ref-type="bibr" rid="bib185">Xu et al., 2005</xref>), HER2-expressing breast cancer cells were more sensitive to 17-AAG (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1C</xref> and <xref ref-type="table" rid="table1">Table 1</xref>), but again there was no correlation with MAL3-101 sensitivity/resistance. Thus, the compounds appear to selectively affect different downstream effectors and compensatory mechanisms.</p></sec><sec id="s2-2"><title>Enhanced protein degradation pathways compensate for impaired proteostasis</title><p>Hsp70 plays an essential role in cellular protein folding, degradation, transport, modification, and assembly (<xref ref-type="bibr" rid="bib10">Balchin et al., 2016</xref>; <xref ref-type="bibr" rid="bib40">Evans et al., 2010</xref>; <xref ref-type="bibr" rid="bib49">Goloudina et al., 2012</xref>; <xref ref-type="bibr" rid="bib140">Rosenzweig et al., 2019</xref>). Thus, reducing Hsp70 activity favors the accumulation of unfolded proteins. However, induction of compensatory proteostatic pathways, such as proteasome-dependent degradation and autophagy, might temper sensitivity to Hsp70 inhibitors. We previously demonstrated that rhabdomyosarcoma cells are hypersensitive to Hsp70 inhibition and acquired MAL3-101 resistance as a result of increased protein degradation pathway activity (<xref ref-type="bibr" rid="bib146">Sannino et al., 2018</xref>). To define which compensatory pathway(s) might be altered and thus restrict breast cancer cell death in the presence of MAL3-101, we first asked if proteasome-dependant protein turnover was higher in MAL3-101 resistant lines. To this end, we measured the levels of ubiquitinated proteins in sensitive (MDA MB 231 and MCF7, in blue), intermediate (BT-474, in purple), and resistant (MDA MB 453 and MDA MB 361, in black) cells in the presence or absence of the proteasome inhibitor bortezomib (also known as Velcade) (<xref ref-type="bibr" rid="bib26">Chen et al., 2011</xref>). As expected, bortezomib-mediated proteasome inhibition increased polyubiquitinated protein accumulation in all cell lines, but the level of total ubiquitinated proteins was greater in MAL3-101-resistant cells compared to cell lines with increased MAL3-101 sensitivity (<xref ref-type="fig" rid="fig2">Figure 2A</xref>, compare lanes 2 and 4 with lanes 8 and 10). These data suggest that resistant lines rely to a greater extent on the removal of misfolded proteins to survive.</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Ubiquitinated proteins are lower in MAL3-101-resistant breast cancer cells.</title><p>(<bold>A</bold>) MAL3-101 sensitive (in blue), intermediate (in purple), and resistant (in black) lines were treated with DMSO or bortezomib for 4 hr followed by immunoblot analysis to detect total levels of ubiquitinated proteins in the cell. β-actin serves as a loading control. Data for MAL3-101 sensitive and resistant lines (raw counts from imaging) are plotted in the graph to the right, ± SEM (n=8 for MDA MB 231, n=3 for MCF7, n=10 for MDA MB 453, and n=6 for MDA B 361). Normalized ubiquitin levels relative to β-actin signals are plotted in the graph. There was a ~2-fold increase in ubiquitinated protein levels in MAL3-101 resistant cells (open symbols) versus the MAL3-101-sensitive lines (closed symbols) in the presence of bortezomib. * denotes p&lt;0.05, ** denotes p&lt;0.005, and *** denotes p&lt;0.0005. (<bold>B–C</bold>) MAL3-101-sensitive lines (closed symbols) and resistant cells (open symbols) were seeded into 96-well plates and treated with increasing doses of (<bold>B</bold>) bortezomib, a proteasome inhibitor, or (<bold>C</bold>) chloroquine (CQ), an autophagy inhibitor, for 72 hr. Cell viability data represent the average of three or more independent experiments, ± SEM. (<bold>D</bold>) The levels of autophagy related proteins in MAL3-101 sensitive (in blue) and resistant (in black) lines were analyzed by immunoblotting in presence or absence of CQ or bafilomycin for 6 hr. Purple and red dots respectively indicate the soluble (LC3BI) and the autophagosome-associated isoform (LC3BII) of LC3B. An overexposed image is also shown to better visualize the LC3BI and LC3BII isoforms in the cell lines.</p><p> <supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Source data for <xref ref-type="fig" rid="fig2">Figure 2</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-64977-fig2-data1-v3.xlsx"/></supplementary-material> </p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64977-fig2-v3.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Autophagy pathway activity is higher in MAL3-101-resistant cells.</title><p>(<bold>A</bold>) Chymotrypsin-like proteasome activity was measured by monitoring AMC fluorescence after Suc-LLVY-AMC was added to cell lysates prepared from MAL3-101 sensitive (closed symbols) and resistant (open symbols) cells. Proteasome-independent activity was established by conducting experiments in the presence of MG 132, which was negligible. Data represent averaged net proteasome activity (in pmol substrate hydrolyzed), ± SEM (n=3). (<bold>B–C</bold>) MAL3-101-sensitive (closed symbols) and resistant (open symbols) cell lines were treated with increasing doses of (<bold>B</bold>) CB-5083 (an ERAD inhibitor) or (<bold>C</bold>) bafilomycin (an autophagy inhibitor) for 72 hr, and cell viability was measured. Data represent the means of three independent experiments, ± SEM. (<bold>D–E</bold>) The levels of (<bold>D</bold>) LC3BII and (<bold>E</bold>) the LC3BII:I ratio were determined from data in <xref ref-type="fig" rid="fig2">Figure 2</xref> and are expressed as the fold change relative to DMSO under the indicated conditions, ± SEM (n≥3 for bafilomycin and n≥4 for CQ). (<bold>F</bold>) LC3BII accumulation under starvation conditions (EBSS) was analyzed in MAL3-101-sensitive (closed symbols) and resistant (open symbols) cells. Black asterisks correspond to the statistical significance between MDA MB 231 cells (closed circle) and MDA MB 453 and MDA MB 361 (open circle and triangle, respectively), and red asterisks represent the statistical significance between MCF7 cells (closed triangle) and MDA MB 453 and MDA MB 361 (open circle and triangle, respectively). Data represent the fold increase relative to DMSO, ± SEM (n=3). * denotes p&lt;0.05, ** denotes p&lt;0.005.</p><p> <supplementary-material id="fig2s1sdata1"><label>Figure 2—figure supplement 1—source data 1.</label><caption><title>Raw data for <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-64977-fig2-figsupp1-data1-v3.xlsx"/></supplementary-material> </p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64977-fig2-figsupp1-v3.tif"/></fig></fig-group><p>Next, to determine whether proteasome activity might be higher in resistant cells, we prepared lysates and examined proteasome activity by measuring the MG 132-dependent signal produced from the fluorogenic substrate, Suc-LLVY-7-amino-4-methylcoumarin (<xref ref-type="bibr" rid="bib161">Stein et al., 1996</xref>). As shown in <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref>, no statistically significant differences in proteasome activity were detected between the sensitive and resistant lines. These data indicate that even though MAL3-101-resistant cells rely more heavily on protein degradation pathways to mitigate the accumulation of misfolded proteins (<xref ref-type="fig" rid="fig2">Figure 2A</xref>), overall proteasome activity is unchanged in Hsp70 inhibitor sensitive and resistant cells under non-stress conditions. The increased accumulation of polyubiquitinated protein in MAL3-101-resistant cells might be due to a differential, compensatory involvement of the ubiquitination machinery between MAL3-101 sensitive and resistant lines upon proteasome inhibition, perhaps even reflecting altered E3 activity. Interestingly, however, the growth of the MAL3-101 sensitive and resistant lines displayed a range of sensitivities to the proteasome inhibitor bortezomib (<xref ref-type="fig" rid="fig2">Figure 2B</xref> and <xref ref-type="table" rid="table1">Table 1</xref>), but sensitivity still failed to correlate with Hsp70-inhibitor sensitivity. These results suggest that inhibition of the proteasome and Hsp70 kill breast cancer cells through independent mechanisms.</p><p>Another cellular quality control pathway that modulates proteostasis is the endoplasmic reticulum associated degradation pathway (ERAD). ERAD substrates are recognized by chaperones, including Hsp70, ubiquitinated at the ER membrane, retrotranslocated to the cytoplasm in a p97-dependent manner, and delivered to the proteasome (<xref ref-type="bibr" rid="bib8">Bagola et al., 2011</xref>; <xref ref-type="bibr" rid="bib116">Needham and Brodsky, 2013</xref>; <xref ref-type="bibr" rid="bib159">Smith et al., 2011</xref>; <xref ref-type="bibr" rid="bib171">Tsai and Weissman, 2011</xref>). It was previously reported that p97 expression is higher in HER2 positive breast cancer cells than other cells, suggesting that ERAD contributes to HER2 breast cancer cell survival (<xref ref-type="bibr" rid="bib157">Singh et al., 2015</xref>). Therefore, we tested ERAD pathway dependence in resistant and sensitive breast cancer cells by applying a clinical drug candidate, CB-5083, which targets the p97 ATPase domain (<xref ref-type="bibr" rid="bib195">Zhou et al., 2015</xref>). As shown in <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B</xref>, minimal differences were detected in CB-5083 sensitivity between the lines (<xref ref-type="table" rid="table1">Table 1</xref>). Moreover, in contrast to previous work (<xref ref-type="bibr" rid="bib157">Singh et al., 2015</xref>), the sensitivities of the examined HER2 positive and HER2 negative breast cancer cell lines were comparable (<xref ref-type="table" rid="table1">Table 1</xref>).</p><p>In contrast to ERAD, the autophagy pathway destroys not only misfolded and long-lived proteins, but also protein aggregates and damaged organelles (<xref ref-type="bibr" rid="bib5">Amaravadi et al., 2016</xref>; <xref ref-type="bibr" rid="bib7">B'chir et al., 2013</xref>; <xref ref-type="bibr" rid="bib24">Cavalli and Cenci, 2020</xref>; <xref ref-type="bibr" rid="bib109">Mizushima, 2017</xref>; <xref ref-type="bibr" rid="bib168">Towers and Thorburn, 2016</xref>). During this process, cytoplasmic proteins are captured in double-membrane autophagosomes, and upon fusion with lysosomes the vesicle contents are degraded in autophagolysosomes (also termed autolysosomes). This pathway can be stimulated by cellular stressors, including nutrient or growth factor deprivation, the UPR, hypoxia, reactive oxygen species, DNA damage, drug treatments, or after pathogen invasion (<xref ref-type="bibr" rid="bib61">He and Klionsky, 2009</xref>; <xref ref-type="bibr" rid="bib83">Kroemer et al., 2010</xref>; <xref ref-type="bibr" rid="bib106">Miracco et al., 2010</xref>; <xref ref-type="bibr" rid="bib142">Rubinsztein et al., 2007</xref>; <xref ref-type="bibr" rid="bib184">Wojcik, 2013</xref>). Moreover, autophagy can serve as a back-up for the ubiquitin-proteasome pathway (<xref ref-type="bibr" rid="bib41">Fan et al., 2018</xref>; <xref ref-type="bibr" rid="bib78">Kocaturk and Gozuacik, 2018</xref>; <xref ref-type="bibr" rid="bib184">Wojcik, 2013</xref>) as well as the ERAD pathway (<xref ref-type="bibr" rid="bib67">Ishida et al., 2009</xref>; <xref ref-type="bibr" rid="bib84">Kruse et al., 2006</xref>). Therefore, we first asked if MAL3-101 sensitive and resistant breast cancer cells exhibited unique sensitivities to chloroquine (CQ) and bafilomycin, which block the final step in the autophagy pathway and impair the degradation of autophagosomal contents (<xref ref-type="bibr" rid="bib3">Ahlberg et al., 1985</xref>; <xref ref-type="bibr" rid="bib77">Klionsky et al., 2016</xref>; <xref ref-type="bibr" rid="bib96">Manic et al., 2014</xref>; <xref ref-type="bibr" rid="bib108">Mizushima et al., 2011</xref>). However, Hsp70 inhibitor resistance failed to correlate with increased CQ and bafilomycin sensitivity (<xref ref-type="fig" rid="fig2">Figure 2C</xref> and <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1C</xref>; also see <xref ref-type="table" rid="table1">Table 1</xref>). We next measured the abundance of key autophagy markers, LC3B and ATG5–ATG12 (<xref ref-type="bibr" rid="bib70">Kabeya et al., 2000</xref>; <xref ref-type="bibr" rid="bib134">Pyo et al., 2005</xref>). Immunoblot analysis showed greater amounts of ATG5–ATG12 in the resistant MDA MB 453 and MDA MB 361 lines compared to the MDA MB 231 and MCF7-sensitive cell lines (<xref ref-type="fig" rid="fig2">Figure 2D</xref>), suggesting that the elongation phase of autophagy was induced in resistant cells (<xref ref-type="bibr" rid="bib108">Mizushima et al., 2011</xref>; <xref ref-type="bibr" rid="bib162">Strømhaug et al., 2004</xref>). Consistent with this hypothesis, lipidated LC3B (LC3BII), which is appended to autophagosomal membranes, accumulated to a greater extent in the resistant (MDA MB 453 and MDA MB 361) cells when autophagy was inhibited by CQ or bafilomycin (<xref ref-type="fig" rid="fig2">Figure 2D</xref>, indicated by a red dot, and quantified in <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1D</xref>). Moreover, the conversion of LC3BI (the soluble LC3B isoform) into LC3BII was enhanced in resistant cells (<xref ref-type="fig" rid="fig2">Figure 2D</xref> and <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1E</xref>), as evidenced by the increased LC3BII:LC3BI ratio (<xref ref-type="bibr" rid="bib13">Barth et al., 2010</xref>; <xref ref-type="bibr" rid="bib102">McLeland et al., 2011</xref>; <xref ref-type="bibr" rid="bib193">Zhang et al., 2016</xref>). The magnitude of this effect is consistent with other studies demonstrating autophagy induction (<xref ref-type="bibr" rid="bib77">Klionsky et al., 2016</xref>; <xref ref-type="bibr" rid="bib90">Li et al., 2018</xref>; <xref ref-type="bibr" rid="bib141">Rouschop et al., 2010</xref>; <xref ref-type="bibr" rid="bib146">Sannino et al., 2018</xref>).</p><p>Cancer cells induce autophagy to survive nutrient deprivation (<xref ref-type="bibr" rid="bib5">Amaravadi et al., 2016</xref>; <xref ref-type="bibr" rid="bib76">Klionsky, 2005</xref>; <xref ref-type="bibr" rid="bib107">Mizushima et al., 2008</xref>). Thus, we asked whether autophagy pathway activation was also higher in resistant cells upon starvation. As shown in <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1F</xref>, LC3BII accumulated to a greater extent when CQ was added to resistant cells under short-term starvation in nutrient-depleted (EBSS) medium compared to sensitive lines. Together, these data indicate that autophagic flux is magnified in the inhibitor resistant (MDA MB 453 and MDA MB 361) breast cancer cells.</p></sec><sec id="s2-3"><title>Autophagy inhibition re-sensitizes resistant cells to Hsp70 inhibitor</title><p>The data in the previous section suggest that misfolded proteins are directed to both the ubiquitin-proteasome and autophagy pathways, but only autophagy favors the survival of Hsp70 inhibitor resistant cells in the presence of MAL3-101. Therefore, we asked if modest inhibition of the autophagy and ubiquitin-proteasome pathways increased Hsp70 inhibitor sensitivity. First, MAL3-101 sensitivity in the presence of sub-maximal concentrations of either CQ or bortezomib in MAL3-101 sensitive and resistant lines was examined (see <xref ref-type="table" rid="table2">Table 2</xref> for CQ and bortezomib doses). As shown in <xref ref-type="fig" rid="fig3">Figure 3A</xref>, little effect was seen in the sensitive (MDA MB 231 and MCF7) cells, but CQ more prominently increased MAL3-101 sensitivity in the resistant (MDA MB 453 and MDA MB 361) line. A similar phenomenon was observed when MAL3-101 was administered in presence of a sub-maximal dose of bafilomycin (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref> and <xref ref-type="table" rid="table2">Tables 2</xref> and <xref ref-type="table" rid="table3">3</xref>). Second, we found that bortezomib modestly increased the sensitivity of both a sensitive (MDA MB 231) and a resistant (MDA MB 453) cell line, but to a significantly lesser extent compared to CQ (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). No increase in sensitivity to MAL3-101 was apparent in the presence of bortezomib in the other lines (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). Consequently, a combination of enhanced proteotoxic stress, via the addition of MAL3-101, and sub-optimal levels of autophagy can re-sensitize otherwise resistant cells to an Hsp70 inhibitor.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>The autophagy pathway contributes to MAL3-101 resistance.</title><p>MAL3-101 sensitive and resistant lines (closed and open symbols, respectively) were treated with increasing doses of MAL3-101 in the presence or absence of a sub-lethal dose of (<bold>A</bold>) CQ or (<bold>B</bold>) bortezomib (see <xref ref-type="table" rid="table2">Table 2</xref> and <xref ref-type="table" rid="table3">Table 3</xref>). Cell viability was detected at 72 hr, and data represent the means of three independent experiments, ± SEM. * denotes p&lt;0.05, ** denotes p&lt;0.005.</p><p> <supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>Source data for cell viability assays in <xref ref-type="fig" rid="fig3">Figure 3</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-64977-fig3-data1-v3.xlsx"/></supplementary-material> </p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64977-fig3-v3.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Autophagy inhibition re-sensitizes resistant cells to MAL3-101.</title><p>(<bold>A</bold>) MAL3-101 sensitive (top graphs) and resistant (bottom graphs) cells were treated with increasing doses of MAL3-101 in the presence or absence of a sub-lethal dose of bafilomycin for 72 hr (see Table 2 ), and cell viability was calculated ± SEM (n=3); * denotes p&lt;0.05, ** denotes p&lt;0.005. (<bold>B</bold>) MAL3-101 sensitive (top graphs) and resistant (bottom graphs) cells were transfected with a control siRNA or two different ATG5 siRNAs to block autophagy, treated with increasing doses of MAL3-101 for 48 hr, and cell viability was calculated, ± SEM (n=3). Black asterisks correspond to the statistical significance between the control (circles) and oligonucleotide 1 (squares), and red asterisks represent the statistical significance between the control (circles) and oligonucleotide 2 (triangles). * denotes p&lt;0.05, ** denotes p&lt;0.005, *** denotes p&lt;0.0005 and **** denotes p&lt;0.0001. (<bold>C</bold>) ATG5 knockdown efficiency was measured by immunoblotting ATG5-12 in MAL3-101 sensitive (in blue) and resistant (in black) cell lysates. β-actin serves as a loading control. A representative experiment (reproduced three times) is shown.</p><p> <supplementary-material id="fig3s1sdata1"><label>Figure 3—figure supplement 1—source data 1.</label><caption><title>Source data for <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-64977-fig3-figsupp1-data1-v3.xlsx"/></supplementary-material> </p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64977-fig3-figsupp1-v3.tif"/></fig></fig-group><table-wrap id="table2" position="float"><label>Table 2.</label><caption><title>The cell numbers and autophagy or proteasome inhibitor concentrations used for the cell viability assay in combination with increasing doses of MAL3-101 are shown.</title><p>The concentrations of bortezomib, CQ, and bafilomycin to induce no greater than 30% of cell death in each line after 72 hr treatment are shown. ND stands for undetermined value.</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Breast cancer subtype</th><th>Cell line</th><th>Number of cells/well</th><th>Everolimus</th><th>CQ</th><th>Bafilomycin</th><th>Bortezomib</th></tr></thead><tbody><tr><td rowspan="6">TNBC</td><td>MDA MB 231</td><td>3000</td><td>2.0 µM</td><td>14 µM</td><td>0.8 nM</td><td>4.0 nM</td></tr><tr><td>MDA MB 468</td><td>2500</td><td>ND</td><td>14 µM</td><td>0.6 nM</td><td>2.7 nM</td></tr><tr><td>HCC1937</td><td>2000</td><td>ND</td><td>21 µM</td><td>2.2 nM</td><td>2.0 nM</td></tr><tr><td>HCC1395</td><td>3000</td><td>ND</td><td>5.0 µM</td><td>1.6 nM</td><td>3.5 nM</td></tr><tr><td>HCC38</td><td>3000</td><td>ND</td><td>33 µM</td><td>1.0 nM</td><td>3.0 nM</td></tr><tr><td>MDA MB 453</td><td>3000</td><td>2.0 µM</td><td>12 µM</td><td>1.0 nM</td><td>2.5 nM</td></tr><tr><td rowspan="6">Luminal</td><td>MDA MB 134</td><td>5000</td><td>ND</td><td>15 µM</td><td>6.6 nM</td><td>2.5 nM</td></tr><tr><td>MCF7</td><td>1000</td><td>ND</td><td>7 µM</td><td>0.5 nM</td><td>13.0 nM</td></tr><tr><td>T47D</td><td>2000</td><td>ND</td><td>9.5 µM</td><td>1.3 nM</td><td>ND</td></tr><tr><td>BT-474</td><td>3000</td><td>ND</td><td>6.0 µM</td><td>1.4 nM</td><td>10.2 nM</td></tr><tr><td>SUM44-PE</td><td>8000</td><td>ND</td><td>25 µM</td><td>ND</td><td>7.0 nM</td></tr><tr><td>MDA MB 361</td><td>4500</td><td>ND</td><td>8.0 µM</td><td>1.0 nM</td><td>6.5 nM</td></tr><tr><td rowspan="2">HER2</td><td>SKBR3</td><td>2500</td><td>ND</td><td>13 µM</td><td>1.0 nM</td><td>2.5 nM</td></tr><tr><td>HCC1419</td><td>4000</td><td>ND</td><td>12 µM</td><td>0.8 nM</td><td>2.5 nM</td></tr></tbody></table></table-wrap><table-wrap id="table3" position="float"><label>Table 3.</label><caption><title>Breast cancer cells exhibit a range of sensitivities to MAL3-101 in the presence of either autophagy or proteasome inhibitors.</title><p>Cells were seeded into 96-well plates and treated with increasing doses of MAL3-101 in the presence or absence of subcritical doses of bortezomib (proteasome inhibitor), or CQ or bafilomycin (autophagy inhibitors) for 72 hr. Viability was measured using the CellTiter-Glo assay. IC<sub>50</sub> values were generate using a sigmoidal nonlinear regression with SigmaPlot 11.0. ND stands for undetermined value. MAL3-101 resistant cells are highlighted in yellow.</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Breast cancer subtype</th><th>Cell line</th><th>MAL3-101</th><th>MAL3-101 + CQ</th><th>MAL3-101 + Bafilomycin</th><th>MAL3-101 + Bortezomib</th><th valign="top">MAL3-101+ Everolimus</th></tr></thead><tbody><tr><td rowspan="6">TNBC</td><td>MDA MB 231</td><td>3.3 µM</td><td>3.3 µM</td><td>3.4 µM</td><td>1.5 µM</td><td>5.1 µM</td></tr><tr><td>MDA MB 468</td><td>3.1 µM</td><td>3.0 µM</td><td>3.2 µM</td><td>1.8 µM</td><td>ND</td></tr><tr><td>HCC1937</td><td>7.5 µM</td><td>5.1 µM</td><td>6.4 µM</td><td>7.1 µM</td><td>ND</td></tr><tr><td>HCC1395</td><td>11.6 µM</td><td>5.8 µM</td><td>3.9 µM</td><td>10.6 µM</td><td>ND</td></tr><tr><td style="author-callout-style-b4">HCC38</td><td style="author-callout-style-b4">&gt;30 µM</td><td style="author-callout-style-b4">17.0 µM</td><td style="author-callout-style-b4">20.0 µM</td><td style="author-callout-style-b4">&gt;30 µM</td><td style="author-callout-style-b4">ND</td></tr><tr><td style="author-callout-style-b4">MDA MB 453</td><td style="author-callout-style-b4">&gt;30 µM</td><td style="author-callout-style-b4">10.0 µM</td><td style="author-callout-style-b4">6.1 µM</td><td style="author-callout-style-b4">&gt;30 µM</td><td style="author-callout-style-b4">&gt;30 µM</td></tr><tr><td rowspan="6">Luminal</td><td>MDA MB 134</td><td>1.9 µM</td><td>2.1 µM</td><td>1.9 µM</td><td>1.9 µM</td><td>ND</td></tr><tr><td>MCF7</td><td>3.0 µM</td><td>1.9 µM</td><td>2.7 µM</td><td>3.0 µM</td><td>ND</td></tr><tr><td>T47D</td><td>6.6 µM</td><td>3.1 µM</td><td>4.2 µM</td><td>ND</td><td>ND</td></tr><tr><td>BT-474</td><td>4.0 µM</td><td>2.0 µM</td><td>2.0 µM</td><td>6.2 µM</td><td>ND</td></tr><tr><td>SUM44-PE</td><td>13.5 µM</td><td>4.5 µM</td><td>ND</td><td>8.0 µM</td><td>ND</td></tr><tr><td style="author-callout-style-b4">MDA MB 361</td><td style="author-callout-style-b4">&gt;30 µM</td><td style="author-callout-style-b4">26 µM</td><td style="author-callout-style-b4">30.0 µM</td><td style="author-callout-style-b4">&gt;30 µM</td><td style="author-callout-style-b4">ND</td></tr><tr><td rowspan="2">HER2</td><td>SKBR3</td><td>4.5 µM</td><td>1.3 µM</td><td>2.3 µM</td><td>2.6 µM</td><td>ND</td></tr><tr><td>HCC1419</td><td>8.2 µM</td><td>2.9 µM</td><td>3.4 µM</td><td>5.5 µM</td><td>ND</td></tr></tbody></table></table-wrap><p>To support this conclusion, we silenced ATG5 in MAL3-101-resistant cells with two different siRNA oligonucleotides. ATG5 facilitates the autophagy elongation step and, together with ATG12 and ATG16L, links LC3BII to the growing autophagosomal membrane (<xref ref-type="bibr" rid="bib1">Acevo-Rodríguez et al., 2020</xref>; <xref ref-type="bibr" rid="bib36">Cuervo, 2004</xref>; <xref ref-type="bibr" rid="bib108">Mizushima et al., 2011</xref>). While MAL3-101 sensitivities were unaffected by the transfection of a control siRNA, ATG5 knockdown decreased ATG5-12 abundance by ~70% and again re-sensitized the resistant cells to MAL3-101 (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1B and C</xref>). As noted above, no significant changes in MAL3-101 sensitivity were detected in the MDA MB 231 sensitive cell line and only a slight increase in MCF7 cell sensitivity was apparent upon ATG5 knockdown.</p></sec><sec id="s2-4"><title>Hsp70 inhibition triggers autophagy pathway induction in resistant breast cancer cells</title><p>Based on a potential compensatory role played by the autophagy pathway in cells with magnified proteotoxic stress, we investigated if autophagy is also acutely activated when Hsp70 function is muted. When the abundance of select autophagy-related genes and the gene encoding LC3B (MAP1LC3B) were measured 6 hr after MAL3-101 was added, the expression levels of ATG3, ATG5, ATG12, and MAP1LC3B were increased to a significantly higher extent in the resistant (MDA MB 453 and MDA MB 361) cell lines compared to the sensitive (MDA MB 231 and MCF7) cells (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). Of note, the magnitude of the effect is in accordance with the increased levels of autophagy related genes detected in other studies (<xref ref-type="bibr" rid="bib7">B'chir et al., 2013</xref>; <xref ref-type="bibr" rid="bib43">Füllgrabe et al., 2016</xref>; <xref ref-type="bibr" rid="bib146">Sannino et al., 2018</xref>). RNA collected from cells was also used to analyze the time-dependent, relative amplitude of the transcriptional response in the MAL3-101 sensitive and resistant cells 3 and 6 hr after Hsp70 was inhibited. Quantitative PCR analysis showed that each message rose over time to a greater degree in MAL3-101 resistant cells (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). That autophagy was induced primarily in the resistant cells was confirmed by quantifying the abundance of LC3BII and the conversion rate of LC3BI in LC3BII when autophagy was inhibited with CQ (<xref ref-type="fig" rid="fig4">Figure 4C</xref>). In line with gene expression data, autophagy was also elevated more prominently in the resistant cells (MDA MB 453 and MDA MB 361) after Hsp70 activity was compromised with MAL3-101 for 6 hr (<xref ref-type="fig" rid="fig4">Figure 4C and D</xref>, see relative ‘CQ’ levels).</p><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Hsp70 inhibition induces higher levels of autophagy in MAL3-101-resistant cells.</title><p>(<bold>A–B</bold>) The expression of autophagy-associated genes relative to β-actin was detected by qPCR in the presence of DMSO or 12 µM MAL3-101 for 3 and/or 6 hr in sensitive (MCF7 and MDA MB 231, closed symbols) and resistant (MDA MB 453 and MDA MB 361, open symbols) cells. The mean fold change of the indicated mRNAs is shown, ± SEM (n≥3). * denotes p&lt;0.05, ** denotes p&lt;0.005. (<bold>C</bold>) MAL3-101 sensitive (in blue) and resistant (in back) cells were treated for 6 hr with 12 µM MAL3-101 and CQ was added during the last 2 hr of the treatment to assess autophagic flux; that is, ‘CQ’ indicates a 4 hr treatment with DMSO plus a 2 hr acute treatment with CQ. Aliquots of cell lysates were resolved by SDS-PAGE and immunoblotted for LC3B. LC3BI is indicated by a purple dot, and the autophagosome associated form LC3BII is highlighted with a red dot. β-actin serves as a loading control. (<bold>D</bold>) The fold change in LC3BII levels and the LC3BII/LC3BI ratio between chloroquine (CQ)-treated cells relative to untreated cells was calculated, ± SEM (n≥4). Symbols are defined in panel A. * denotes p&lt;0.05. MAL3-101-sensitive cells are represented with closed symbols, while open symbols indicate MAL3-101-resistant lines.</p><p> <supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Raw data for <xref ref-type="fig" rid="fig4">Figure 4</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-64977-fig4-data1-v3.xlsx"/></supplementary-material> </p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64977-fig4-v3.tif"/></fig><p>To better characterize the effect of Hsp70 inhibition on autophagic flux, we engineered a sensitive (MDA MB 231) and resistant (MDA MB 453) cell line to stably express an mRFP-GFP-tagged LC3B autophagy reporter (also known as tfLC3) (<xref ref-type="bibr" rid="bib75">Kimura et al., 2007</xref>). Dual color analysis with this reporter provides a direct measure of autophagic flux (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). In brief, when mRFP-GFP-LC3 decorated autophagosomes fuse with lysosomes, the lower intravesicular pH quenches GFP, permitting visualization of red fluorescence (via the mRFP fluorophore) and a rise in RFP<sup>+</sup>GFP<sup>-</sup> puncta. An increase in the number of RFP<sup>+</sup>GFP<sup>-</sup> puncta therefore indicates more robust delivery of autophagosomes to lysosomes, and consequently an increase in autophagolysosome formation (<xref ref-type="bibr" rid="bib77">Klionsky et al., 2016</xref>; <xref ref-type="bibr" rid="bib193">Zhang et al., 2016</xref>).</p><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Hsp70 inhibition alters autophagic flux in MAL3-101-resistant cells.</title><p>(<bold>A</bold>) The mRFP-GFP-LC3 reporter monitors autophagic flux. RFP<sup>+</sup>GFP<sup>+</sup> and RFP<sup>+</sup>GFP<sup>-</sup> puncta distinguish autophagosomes and autophagolysosomes, thereby allowing for measurements of different stages in the autophagy pathway. (<bold>B</bold>) Confocal images of MAL3-101 sensitive (MDA MB 231, in blue) and resistant (MDA MB 453, in black) clones stably expressing mRFP-GFP-LC3B were treated with 5 µM MAL3-101 or EBSS (starvation media), as a positive control, for 22 hr. White arrows indicate LC3B-positive (acidic) compartments (i.e. RFP<sup>+</sup>GFP<sup>-</sup> puncta). (<bold>C</bold>) The percentage of RFP<sup>+</sup>GFP<sup>-</sup> on RFP<sup>+</sup>GFP<sup>+</sup> puncta per cell is reported for MAL3-101 sensitive (squares) and resistant (circles) lines treated as indicated in B, ± SEM (n≥80). Statistically significant differences between DMSO and cells incubated in starvation media (EBSS) or with MAL3-101 are indicated by black asterisks. Red asterisks represent the statistical significance between the MAL3-101 and EBSS samples. * denotes p&lt;0.05, ** denotes p&lt;0.005, and **** denotes p&lt;0.0001.</p><p> <supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>Fluorescent puncta quantification.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-64977-fig5-data1-v3.xlsx"/></supplementary-material> </p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64977-fig5-v3.tif"/></fig><p>As shown in <xref ref-type="fig" rid="fig5">Figure 5B</xref> (and quantified in <xref ref-type="fig" rid="fig5">Figure 5C</xref>), Hsp70 inhibition favored the accumulation of RFP<sup>+</sup>GFP<sup>-</sup> puncta, which are representative of increased autophagolysosome formation in resistant cells (MDA MB 453), but not in the MAL3-101 sensitive line (MDA MB 231). These data confirm that Hsp70 inhibition induces autophagy only in MAL3-101-resistant cells. In contrast, the percentage of RFP<sup>+</sup>GFP<sup>-</sup> puncta in both MAL3-101 sensitive and resistant lines increased upon starvation in EBSS media (<xref ref-type="fig" rid="fig5">Figure 5B and C</xref>), indicating that autophagy flux remains competent in sensitive cells (<xref ref-type="fig" rid="fig5">Figure 5B and C</xref>). Because the percentage of RFP<sup>+</sup>GFP<sup>-</sup> puncta per cell was comparable after MAL3-101 and EBSS treatment in the resistant (MDA MB 453) cells, the magnitude of the effect of MAL3-101 is akin to that triggered by nutrient depletion. We conclude that Hsp70 inhibition acutely induces autophagy in the MAL3-101-resistant line to compensate for proteotoxic stress.</p></sec><sec id="s2-5"><title>Combined inhibition of autophagy and Hsp70 leads to apoptotic cell death</title><p>We next investigated whether CQ and MAL3-101 not only prevented cell growth but also triggered apoptosis in resistant cells. MAL3-101 treatment alone was unable to induce apoptosis in the MAL3-101-resistant line (MDA MB 453). In contrast, cleaved caspase-3, caspase-7, and caspase-8 along with the pro-apoptotic protein, CHOP, accumulated when CQ was administrated for 2 hr to MAL3-101-treated cells (<xref ref-type="fig" rid="fig6">Figure 6A</xref> and <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1A</xref>). As anticipated by monitoring cell growth (<xref ref-type="fig" rid="fig3">Figure 3</xref>), induction of the apoptotic pathway in the MDA MB 231 (sensitive) cell line was unchanged regardless of whether MAL3-101 was added alone or in the presence of CQ (<xref ref-type="fig" rid="fig6">Figure 6A</xref> and <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1A</xref>).</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Combined inhibition of autophagy and Hsp70 induces apoptosis in MAL3-101 resistant cells.</title><p>(<bold>A</bold>) MAL3-101 sensitive (in blue) and resistant (in black) cells were treated with 12 µM MAL3-101 for 6 hr and CQ was added during the last 2 hr of the treatment to block autophagy. Lysates prepared from the treated cells were immunoblotted for cleaved caspase-3, caspase-8, and caspase-7, as well as CHOP to monitor apoptosis. β-actin serves as a loading control. * indicates a non-specific band present in the cleaved caspase-7 immunoblot. (<bold>B</bold>) Cells were treated as in panel A before aliquots were removed and stained for annexin-V and PI. The sum of the annexin-V positive and the PI and annexin-V double positive cells is represented in the graph and indicated as a percentage of apoptotic cells. MAL3-101-sensitive cells are indicated with closed symbols and MAL3-101-resistant cells are represented by open symbols. The means of independent experiments, ± SEM, are indicated (n=5 for MDA MB 453 and MDA MB 361 cells, and n=2 for MCF7 and MDA MB 231 cells, 50,000 cells were analyzed for each sample). * denotes p&lt;0.05, ** denotes p&lt;0.005, *** denotes p&lt;0.0005, and **** denotes p&lt;0.0001. (<bold>C</bold>) MAL3-101 sensitive (closed symbols) and resistant (open symbols) cells were treated with increasing doses of everolimus (an mTOR inhibitor) for 72 hr, and cell viability was measured. Data represent the means of three or more independent experiments, ± SEM; * denotes p&lt;0.05. (<bold>D</bold>) MAL3-101 sensitive and resistant lines (closed and open symbols, respectively) were treated with increasing doses of MAL3-101 in the presence or absence of 2 µM everolimus, as indicated. Cell viability was detected after 72 hr, and data represent the means of two or more independent experiments, ± SEM. * denotes p&lt;0.05, ** denotes p&lt;0.005. Log<sub>10</sub> concentration of everolimus (<bold>C</bold>) or MAL3-101 (<bold>D</bold>) are represented on the x-axis.</p><p> <supplementary-material id="fig6sdata1"><label>Figure 6—source data 1.</label><caption><title>Cell viability and apoptotic cell quantification data.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-64977-fig6-data1-v3.xlsx"/></supplementary-material> </p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64977-fig6-v3.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>MAL3-101 induces apoptosis when autophagy is impaired in resistant cells.</title><p>The fold increase of the indicated apoptotic markers in MAL3-101 sensitive (closed circle) and resistant (open circle) cell lines relative to DMSO are plotted, ± SEM (cleaved caspase-3, n≥4; cleaved caspase-7 and CHOP, n≥3; cleaved caspase-8, n≥7). * denotes p&lt;0.05, ** denotes p&lt;0.005, and **** denotes p&lt;0.0001.</p><p> <supplementary-material id="fig6s1sdata1"><label>Figure 6—figure supplement 1—source data 1.</label><caption><title>Raw data for <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-64977-fig6-figsupp1-data1-v3.xlsx"/></supplementary-material> </p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64977-fig6-figsupp1-v3.tif"/></fig></fig-group><p>To confirm these observations, annexin-V–propidium iodide (PI) staining (<xref ref-type="bibr" rid="bib80">Koopman et al., 1994</xref>; <xref ref-type="bibr" rid="bib175">Vermes et al., 1995</xref>) was used to analyze the percentage of apoptotic cells in the presence or absence of CQ and/or MAL3-101 treatment (<xref ref-type="fig" rid="fig6">Figure 6B</xref>). Although CQ-mediated inhibition of autophagy had no significant effect on the population of apoptotic cells in both MAL3-101 sensitive and resistant lines, addition of CQ for 2 hr increased the percentage of apoptotic cells when Hsp70 activity was impaired in the resistant cells (MDA MB 453 and MDA MB 361). In contrast, Hsp70 inhibition alone had no effect on the percentage of apoptotic-resistant cells. In addition—and also consistent with the data shown above—MAL3-101 initiated apoptosis in the sensitive (MCF7 and MDA MB 231) cells and the percentage of apoptotic cells were unaltered by CQ (<xref ref-type="fig" rid="fig6">Figure 6B</xref>). These data establish that combined application of Hsp70 and autophagy inhibitors kills resistant cells.</p><p>To better characterize the role of autophagy as a compensatory mechanism upon Hsp70 inhibition, we asked if autophagy induction was sufficient to reduce MAL3-101 sensitivity in the Hsp70 inhibitor-sensitive (MDA MB 231) cell line. The mTOR complex, together with AMPK and HIF1α, are the major autophagy regulators and serve as nutrient, energy, and growth factor sensors (<xref ref-type="bibr" rid="bib63">Hindupur et al., 2015</xref>; <xref ref-type="bibr" rid="bib86">Laplante and Sabatini, 2012</xref>). Thus, we first asked if MAL3-101 sensitive and resistant breast cancer cells exhibited unique sensitivities to the mTOR inhibitor, everolimus (also known as Afinitor), an FDA-approved rapamycin derivative that directly inhibits mTORC1 and indirectly inhibits mTORC2 (<xref ref-type="bibr" rid="bib29">Chen and Zhou, 2020</xref>; <xref ref-type="bibr" rid="bib30">Chiang and Abraham, 2007</xref>; <xref ref-type="bibr" rid="bib104">Meng and Zheng, 2015</xref>). As shown in <xref ref-type="fig" rid="fig6">Figure 6C</xref>, negligible differences were seen in the sensitivities to everolimus between MAL3-101 sensitive and resistant cell lines (IC<sub>50</sub>23.0 µM and 18.7 µM, respectively). Second, we monitored cell viability in Hsp70 inhibitor sensitive and resistant lines when MAL3-101 was administrated in the presence of sub-maximal doses (2 µM) of everolimus. We found that mTOR inhibition decreased MAL3-101 sensitivity in the MDA MD 231-sensitive line (<xref ref-type="fig" rid="fig6">Figure 6D</xref>). As expected, no change in MAL3-101 sensitivity was apparent in the presence of everolimus in resistant cells (MDA MB 453, <xref ref-type="fig" rid="fig6">Figure 6D</xref>). These data are consistent with the model that enhanced proteotoxic stress—via Hsp70 inhibition—and induction of the autophagy pathway protect MAL3-101 sensitive cells when challenged with an Hsp70 inhibitor.</p></sec><sec id="s2-6"><title>The UPR and ISR are activated upon Hsp70 inhibition</title><p>Defects in chaperone activity cause profound changes in cancer cell proteostasis, leading to induction of the UPR and/or the ISR to modulate folding capacity and attenuate stress (<xref ref-type="bibr" rid="bib35">Cubillos-Ruiz et al., 2017</xref>; <xref ref-type="bibr" rid="bib74">Kim et al., 2015</xref>; <xref ref-type="bibr" rid="bib81">Koromilas, 2015</xref>; <xref ref-type="bibr" rid="bib121">Pakos-Zebrucka et al., 2016</xref>). A consequence of the accumulation of unfolded proteins in the ER is the increased expression of the UPR-related chaperone, BiP (<xref ref-type="bibr" rid="bib16">Bertolotti et al., 2000</xref>; <xref ref-type="bibr" rid="bib176">Walter and Ron, 2011</xref>). In fact, a modest but significant increase in the abundance of the message encoding BiP, HSPA5, was evident in each line examined 6 hr after MAL3-101 treatment, indicating that MAL3-101 mounts an ER stress response in both the MAL3-101 resistant and sensitive lines (<xref ref-type="fig" rid="fig7">Figure 7A</xref>, right panel), yet leads to cell death only in sensitive cells.</p><fig-group><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>Hsp70 inhibition induces the UPR and ISR in breast cancer cells.</title><p>The relative fold change of (<bold>A</bold>) spliced Xbp1 (sXbpI) and HSPA5A (BiP) mRNA levels relative to β-actin, (<bold>B</bold>) full length ATF6 protein, and (<bold>C</bold>) the ATF4 and DDIT3 (CHOP) transcripts are shown. In part <bold>B</bold>, asterisks represent p&lt;0.05, and in part <bold>C</bold>, black asterisks correspond to p&lt;0.05 between the sensitive (MDA MB 231) (closed circles) and resistant (MDA MB 453 and MDA MB 361) cell lines (open symbols). Red asterisks represent p&lt;0.05 between MCF7 (open triangles) and MDA MB 453 and MDA MB 361 cells (open symbols). In all cases, cells were treated with MAL3-101 for 6 hr. In parts <bold>A</bold> and <bold>C</bold>, the bars represent the amounts of the indicated transcripts in treated cells relative to the DMSO control. In part <bold>B</bold>, a 2 hr DTT treatment was used as a positive control. Note that the levels of induction by DTT and MAL3-101 are similar. Data depict ± SEM (n≥3). (<bold>D</bold>) Immunoblots for eIF2α and its phosphorylated isoform in MAL3-101 sensitive (in blue) and resistant (in black) cell lines treated with 12 μM MAL3-101 or DMSO for 6 hr are shown. (<bold>E</bold>) MAL3-101 sensitive (in blue) and resistant (in black) cells were treated with 12 μM MAL3-101 or DMSO for the indicated time and lysates were immunoblotted for CHOP and PERK expression. In part D and E, a 2 hr DTT treatment was used as a positive control and β-actin serves as a loading control.</p><p> <supplementary-material id="fig7sdata1"><label>Figure 7—source data 1.</label><caption><title>Source data for <xref ref-type="fig" rid="fig7">Figure 7</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-64977-fig7-data1-v3.xlsx"/></supplementary-material> </p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64977-fig7-v3.tif"/></fig><fig id="fig7s1" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 1.</label><caption><title>eIF2α is phosphorylated in response to MAL3-101.</title><p>(<bold>A</bold>) The relative steady state levels of the Ire1α protein in MAL3-101 sensitive (closed symbols) and resistant (open symbols) cells are depicted, ± SEM (n≥3). (<bold>B</bold>) MAL3-101 sensitive (closed symbols) and resistant (open symbols) lines were treated for the indicated times with MAL3-101, and DDIT3 (CHOP) transcript levels were measured and are reported as the mean fold increase relative to DMSO, ± SEM (n≥3); * denotes p&lt;0.05. (<bold>C</bold>) MAL3-101 sensitive (closed symbols) and resistant (open symbols) lines were treated for the indicated times with MAL3-101, and BBC3 (PUMA) transcript levels were measured and are reported as the mean fold increase relative to DMSO. Data depict ± SEM (n=3). * denotes p&lt;0.05 and ** denotes p&lt;0.005. (<bold>D</bold>) MAL3-101 sensitive (closed symbols) and resistant (open symbols) lines were treated for the indicated times with MAL3-101, and p-eIF2α proteins levels were measured and are reported as the mean fold increase relative to DMSO, ± SEM (n≥7). A 2 hr DTT treatment was used as positive control. *** denotes p&lt;0.0005, and **** denotes p&lt;0.0001. (<bold>E</bold>) MAL3-101 sensitive (closed symbols) and resistant (open symbols) lines were treated for the indicated times with MAL3-101, and CHOP proteins levels were measured and are reported as the mean fold increase relative to DMSO, ± SEM (n≥3). DTT treatment was again used as positive control, as above. * denotes p&lt;0.05, ** denotes p&lt;0.005.</p><p> <supplementary-material id="fig7s1sdata1"><label>Figure 7—figure supplement 1—source data 1.</label><caption><title>UPR marker quanficiation raw data.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-64977-fig7-figsupp1-data1-v3.xlsx"/></supplementary-material> </p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64977-fig7-figsupp1-v3.tif"/></fig></fig-group><p>To dissect the contribution of each UPR branch on the effect of MAL3-101, we monitored the transcriptional response in MAL3-101 sensitive and resistant lines by quantifying the abundance of UPR related genes. To investigate the role of Ire1α, the degree to which spliced XbpI (sXbpI) accumulated after MAL3-101 administration was measured. A variable but significant accumulation of sXbpI, which is a product of the activated Ire1α endonuclease (<xref ref-type="bibr" rid="bib189">Yoshida et al., 2001a</xref>), was detected after MAL3-101 treatment in both sensitive and resistant cells (<xref ref-type="fig" rid="fig7">Figure 7A</xref>). MCF7 cells exhibited the greatest accumulation of sXbpI upon MAL3-101 treatment, and, interestingly, ERN1 (the gene that encodes Ire1α) copy number is higher in this line (<ext-link ext-link-type="uri" xlink:href="https://depmap.org/portal/">https://depmap.org/portal/</ext-link>). This is further reflected by the high level of increased Ire1α protein expression in these cell lines among the four lines examined (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1A</xref>).</p><p>Next, we monitored the ATF6 branch of the UPR by quantifying the abundance of full-length ATF6 after addition of MAL3-101. Upon activation, full-length ATF6 translocates to the Golgi apparatus where it is cleaved to produce an active, soluble ATF6 transcription factor (<xref ref-type="bibr" rid="bib60">Haze et al., 1999</xref>; <xref ref-type="bibr" rid="bib153">Shen et al., 2002</xref>). Thus, a decrease in full-length ATF6 isoform is consistent with enhanced ATF6 cleavage and induction. As shown in <xref ref-type="fig" rid="fig7">Figure 7B</xref>, the abundance of the ATF6 full-length isoform declined in the presence of DTT, which activates each branch of the UPR, but was unchanged between the MAL3-101 sensitive (MCF7 and MDA MB 231) and resistant (MDA MB 453 and MDA MB 361) breast cancer cells after MAL3-101 treatment.</p><p>We then monitored the presence of the DNA damage inducible transcript 3 (DDIT3), which encodes CHOP, as well as the mRNA corresponding to ATF4, which are induced downstream of the p-eIF2α/PERK pathway (<xref ref-type="bibr" rid="bib81">Koromilas, 2015</xref>; <xref ref-type="bibr" rid="bib176">Walter and Ron, 2011</xref>). While ATF4 mRNA was induced to variable levels after MAL3-101 treatment in both the MAL3-101 sensitive and resistant lines, DDIT3 accumulated only in the sensitive (MDA MB 231 and MCF7) cell line (<xref ref-type="fig" rid="fig7">Figure 7C</xref> and <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1B</xref>). This result is consistent with the fact that a pro-apoptotic response is elicited selectively in lines with increased sensitivity to MAL3-101. Because CHOP acts downstream of the p-eIF2α response (<xref ref-type="bibr" rid="bib97">Marciniak et al., 2004</xref>; <xref ref-type="bibr" rid="bib122">Palam et al., 2011</xref>), we then quantified the message encoding another pro-apoptotic factor, PUMA (also known as BBC3), which is transcriptionally activated by ATF4–CHOP (<xref ref-type="bibr" rid="bib44">Galehdar et al., 2010</xref>; <xref ref-type="bibr" rid="bib100">Matus et al., 2013</xref>). Consistent with the data shown in <xref ref-type="fig" rid="fig7">Figure 7C</xref>, BBC3 (PUMA) mRNA also rose after MAL3-101 treatment in the sensitive but not resistant lines, thereby confirming an apoptotic response in the MAL3-101 sensitive MCF7 and MDA MB 231 lines (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1C</xref>).</p><p>To further establish the contribution of the p-eIF2α/PERK pathway in mediating the apoptotic response in select breast cancer cell lines, we measured MAL3-101-dependent changes in select proteins in sensitive and resistant cells. As shown in <xref ref-type="fig" rid="fig7">Figure 7D</xref> and quantified in <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1D</xref>, p-eIF2α accumulated to a similar extent in MAL3-101 sensitive and resistant cells when Hsp70 was inhibited and was indistinguishable when compared to the level observed when cells were treated with DTT. In contrast, and consistent with quantitative PCR data (<xref ref-type="fig" rid="fig7">Figure 7C</xref> and <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1B</xref>), significant CHOP induction was detected only in Hsp70 inhibitor sensitive cells (MCF7 and MDA MB 231) after MAL3-101 addition (<xref ref-type="fig" rid="fig7">Figure 7E</xref> and <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1E</xref>).</p><p>Together, the activation of each branch of the UPR—Ire1α, ATF6, and PERK—is consistent with the fact that the sensitive and resistant cells can induce the UPR, but a protective autophagy-dependent response resides selectively in resistant cells. Based on these data, we suggest that resistant cells have been rewired to better counteract proteotoxic insults.</p></sec><sec id="s2-7"><title>Ire1α is dispensable for induction of the MAL3-101 stress response</title><p>To define the role of Ire1, if any, on MAL3-101-dependent apoptosis, Ire1α was silenced and sensitive (MDA MB 231) and resistant (MDA MB 453) cell survival was examined after MAL3-101 was added. We first noted that less than ~25–35% of Ire1α protein remained 48 hr after siRNA transfection (<xref ref-type="fig" rid="fig8">Figure 8A and B</xref>), a level similar to that observed in other systems when this message was silenced (<xref ref-type="bibr" rid="bib89">Li et al., 2017</xref>; <xref ref-type="bibr" rid="bib94">Luhr et al., 2019</xref>; <xref ref-type="bibr" rid="bib110">Mu et al., 2008</xref>; <xref ref-type="bibr" rid="bib118">Notte et al., 2015</xref>). In addition—and as anticipated—sXbpI RNA abundance fell when Ire1α was silenced (<xref ref-type="fig" rid="fig8">Figure 8C</xref>). In contrast, Hsp70 protein abundance was unaffected when Ire1α was silenced (<xref ref-type="fig" rid="fig8">Figure 8A</xref>), indicating the lack of compensatory Hsp70-dependent effects on cellular homeostasis (also see <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). In addition, the relative levels of p-eIF2α were unaffected by the loss of Ire1α after MAL3-101 was added to either sensitive or resistant cells, as expected since phosphorylation is induced downstream of PERK. Finally, MAL3-101 only increased the levels of CHOP in sensitive cells (MDA MB 231), consistent with data shown in <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1E</xref>; nevertheless, the response was again unaffected by the absence of Ire1α (<xref ref-type="fig" rid="fig8">Figure 8A and D</xref>, compare CTRL and Ire1αi samples).</p><fig id="fig8" position="float"><label>Figure 8.</label><caption><title>The MAL3-101 response is Ire1-independent.</title><p>(<bold>A</bold>) MAL3-101-sensitive cells (in blue) and MAL3-101-resistant cells (in black) were transfected with a control or an Ire1α-targeted siRNA. Forty-eight hr after transfection, the cells were treated with 12 μM MAL3-101 or DMSO for 6 hr, and lysates were immunoblotted for the indicated proteins. * indicates a nonspecific band in the CHOP immunoblot. β-actin served as a loading control. (<bold>B</bold>) Ire1α knockdown efficiency was measured by immunoblot in MAL3-101 sensitive (closed symbols) and resistant (open symbols) cells and the fold decrease is shown compared to the siRNA control, ± SEM (n=7). *** denotes p&lt;0.0005 and **** denotes p&lt;0.00001. (<bold>C</bold>) The means, ± SEM, of the relative level of sXbpI message were calculated after qPCR in control MAL3-101 sensitive (closed symbols) and resistant (open symbols) cells transfected with a control siRNA or an siRNA directed against Ire1α, which were then treated with 12 µM MAL3-101 or DMSO for 6 hr. * denotes p&lt;0.05 and ** denotes p&lt;0.005. (<bold>D</bold>) The means of the corresponding fold increase in MAL3-101 sensitive (closed symbols) and resistant (open symbols) cells of the indicated apoptotic markers and p-eIF2α were obtained in control and Ire1α siRNA transfected cells which were then treated with MAL3-101 or DMSO for 6 hr, ± SEM (n=4).</p><p> <supplementary-material id="fig8sdata1"><label>Figure 8—source data 1.</label><caption><title>Source data for <xref ref-type="fig" rid="fig8">Figure 8</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-64977-fig8-data1-v3.xlsx"/></supplementary-material> </p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64977-fig8-v3.tif"/></fig></sec><sec id="s2-8"><title>Differential effects of eIF2α kinases in breast cancer cell survival</title><p>The data outlined above implicate the UPR/ISR in the MAL3-101-dependent response that can lead to cell death. In mammals, four kinases (PERK, GCN2, PKR, and HRI) are linked to the ISR and eIF2α phosphorylation and—as a result to their diverse roles as sensors— myriad stress stimuli can be produced via the ISR (<xref ref-type="bibr" rid="bib143">Ryoo and Vasudevan, 2017</xref>; <xref ref-type="bibr" rid="bib178">Wek, 2018</xref>). PKR is induced upon viral infection and participates in the lysosomal clearance of misfolded proteins (<xref ref-type="bibr" rid="bib37">Darini et al., 2019</xref>; <xref ref-type="bibr" rid="bib123">Pataer et al., 2020</xref>; <xref ref-type="bibr" rid="bib178">Wek, 2018</xref>), GCN2 activation depends on the ribosome P-stalk after amino acid depletion (<xref ref-type="bibr" rid="bib58">Harding et al., 2019</xref>; <xref ref-type="bibr" rid="bib66">Inglis et al., 2019</xref>; <xref ref-type="bibr" rid="bib187">Ye et al., 2010</xref>), and the HRI kinase triggers the ISR when mitochondrial function is altered or heme is depleted. It was also reported that HRI contributes to the general cytosolic unfolded protein response (<xref ref-type="bibr" rid="bib28">Chen and London, 1995</xref>; <xref ref-type="bibr" rid="bib54">Guo et al., 2020</xref>; <xref ref-type="bibr" rid="bib111">Mukherjee et al., 2021</xref>; <xref ref-type="bibr" rid="bib194">Zhang et al., 2019</xref>). Thus, we focused on whether HRI, PERK, PKR, and/or GCN2 were required for MAL3-101 resistance. To this end, we transfected two different siRNAs directed against each kinase. Knockdown efficiency was assessed by immunoblot analysis 72 hr after transfection.</p><p>We first investigated the role of HRI during the induction of MAL3-101-mediated apoptosis. siRNA oligo transfection decreased HRI expression levels by 80% in both the MDA MB 231 and MDA MB 453 cells (<xref ref-type="fig" rid="fig9">Figure 9A and B</xref>), a level comparable to that observed in other systems when HRI was silenced (<xref ref-type="bibr" rid="bib180">White et al., 2018</xref>; <xref ref-type="bibr" rid="bib194">Zhang et al., 2019</xref>). However, HRI knockdown failed to increase Hsp70 abundance, indicating the absence of a compensatory response to MAL3-101 in sensitive and resistant cells. We next measured the apoptotic response upon MAL3-101 treatment in control and HRI knockdown cells. As shown in <xref ref-type="fig" rid="fig9">Figure 9A</xref> and quantified in <xref ref-type="fig" rid="fig9">Figure 9C</xref>, HRI silencing modestly increased the accumulation of cleaved caspase-8 and CHOP, but not cleaved caspase-3 (compare CTRL and HRIi samples in <xref ref-type="fig" rid="fig9">Figure 9A</xref>) in the MAL3-101 sensitive line, MDA MB 231. However, this effect was not statistically significant. Moreover, when HRI expression was blunted in the resistant (MDA MB 453) cells, MAL3-101 failed to induce an apoptotic response. Thus, we conclude that HRI is dispensable for the survival of MAL3-101 resistant cells, but might contribute minimally to MAL3-101-dependent apoptosis in sensitive cells.</p><fig id="fig9" position="float"><label>Figure 9.</label><caption><title>HRI is largely dispensable for the survival of breast cancer cells challenged with MAL3-101.</title><p>(<bold>A</bold>) MAL3-101 sensitive (in blue) and resistant (in black) lines were transfected with a control siRNA or an siRNA oligo directed against HRI, and 72 hr post transfection cells were treated with DMSO or 12 μM MAL3-101 for 6 hr. Lysates were prepared for immunoblot analysis. β-actin serves as a loading control. (<bold>B</bold>) HRI knockdown efficiency was measured by immunoblot 72 hr post siRNA transfection in MAL3-101 sensitive (MDA MB 231, closed circles) and resistant (MDA MB 453, open circles) cell lines. The relative fold change of HRI protein levels in knockdown to control samples is plotted ± SEM. ** denotes p&lt;0.005. (<bold>C</bold>) The corresponding fold increase of cleaved caspase-8, cleaved caspase-3, and CHOP in MAL3-101 sensitive (closed symbols) and resistant (open symbols) cells was measured after treatment with control, or HRI siRNAs. The fold change is shown relative to the DMSO control, ± SEM (n=3).</p><p> <supplementary-material id="fig9sdata1"><label>Figure 9—source data 1.</label><caption><title>Source data for <xref ref-type="fig" rid="fig9">Figure 9</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-64977-fig9-data1-v3.xlsx"/></supplementary-material> </p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64977-fig9-v3.tif"/></fig><p>Next, we investigated the role of other two ISR sensors, PERK and PKR. Knockdown using targeted siRNAs against PERK and PKR decreased levels by 85% in MDA MB 231 cells and by 85% (PKR) and 70% (PERK) in MDA MB 453 cells (<xref ref-type="fig" rid="fig10">Figure 10A and B</xref>). Comparable knockdown efficiencies were observed in other systems (<xref ref-type="bibr" rid="bib94">Luhr et al., 2019</xref>; <xref ref-type="bibr" rid="bib110">Mu et al., 2008</xref>; <xref ref-type="bibr" rid="bib123">Pataer et al., 2020</xref>; <xref ref-type="bibr" rid="bib166">Tang et al., 2019</xref>). Nevertheless, to show that these knockdown conditions were sufficient, we found that p-eIF2α and CHOP levels fell when PERK was silenced compared to control transfected samples in sensitive and resistant cells treated with the UPR stressor tunicamycin (<xref ref-type="fig" rid="fig10s1">Figure 10—figure supplement 1B</xref>).</p><fig-group><fig id="fig10" position="float"><label>Figure 10.</label><caption><title>PERK is required for apoptosis induction in Hsp70 inhibitor sensitive cells.</title><p>(<bold>A</bold>) MAL3-101 sensitive (in blue) and resistant (in black) cells lines were transfected with a control siRNA or two different siRNAs that were directed against PERK or PKR. 72 hr post transfection cells were treated with DMSO or 12 μM MAL3-101 for 6 hr and lysates were prepared for immunoblot analysis. β-actin serves as a loading control, and the asterisk denotes a non-specific band in the Hsp70 blot. (<bold>B</bold>) PERK and PKR knockdown efficiency were measured by immunoblot 72 hr post siRNA transfection in MAL3-101 sensitive (MDA MB 231, closed circles) and resistant (MDA MB 453, open circles) cell lines. The relative fold change of PERK and PKR protein levels in knockdown to control samples is plotted ± SEM. *** denotes p&lt;0.0005 and **** denotes p&lt;0.00001. (<bold>C</bold>) MAL3-101 sensitive and resistant cells were treated with 12 μM MAL3-101, DMSO for 6 hr or with 10 μg/μl tunicamycin for 3 hr. PERK mobility was analyzed by immunoblot. (<bold>D</bold>) MAL3-101 sensitive (in blue) and resistant (in black) cells lines pre-treated with GSK-2606414 (GSK, 2 μM) for 2 hr prior to addition of DMSO or 12 μM MAL3-101 for 6 hr. Lysates were prepared for immunoblot analysis. β-actin serves as a loading control.</p><p> <supplementary-material id="fig10sdata1"><label>Figure 10—source data 1.</label><caption><title>PERK and PKR raw quantification.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-64977-fig10-data1-v3.xlsx"/></supplementary-material> </p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64977-fig10-v3.tif"/></fig><fig id="fig10s1" position="float" specific-use="child-fig"><label>Figure 10—figure supplement 1.</label><caption><title>PERK knockdown reduces apoptosis.</title><p>(<bold>A–C</bold>) The corresponding fold increase of (<bold>A</bold>) cleaved caspase-8, cleaved caspase-3, CHOP and (<bold>C</bold>) p-eIF2α in the same cells were measured after treatment with control, PKR, or PERK siRNAs. The fold change is shown relative to the DMSO control, ± SEM (n=3 for CHOP and cleaved caspase-8, and n=4 for p-eIF2α and cleaved caspase-3). * denotes p&lt;0.05, ** denotes p&lt;0.005. (<bold>B</bold>) The fold increase of CHOP and p-eIF2α in MAL3-101 sensitive (closed symbols) and resistant (open symbols) cells was measured after treatment with control (circles), or PERK (squares) siRNAs in the presence or absence of 10 µg/mL tunicamycin for 3 hr. The fold change is shown relative to the DMSO control, ± SEM (n=3 for p-eIF2α for both MDA MB 231 and MDA MB 453 cells and n=3 and n=2 for CHOP in MDA MB231 and MDA MB 453 cells, respectively). * denotes p&lt;0.05, ** denotes p&lt;0.005. (<bold>D</bold>) The corresponding fold increase of cleaved caspase-8, cleaved caspase-3, and CHOP in MAL3-101 sensitive (closed symbols) and resistant (open symbols) cells was measured after treatment with a vehicle control or GSK-2606414 (GSK) in the presence or absence of MAL3-101. The fold change is shown relative to the DMSO control, ± SEM (n=3). * denotes p&lt;0.05, ** denotes p&lt;0.005.</p><p> <supplementary-material id="fig10s1sdata1"><label>Figure 10—figure supplement 1—source data 1.</label><caption><title>Source data for <xref ref-type="fig" rid="fig10s1">Figure 10—figure supplement 1</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-64977-fig10-figsupp1-data1-v3.xlsx"/></supplementary-material> </p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64977-fig10-figsupp1-v3.tif"/></fig></fig-group><p>Having validated the knockdown conditions, we next measured the induction of apoptotic markers under control or knockdown conditions and in the presence or absence of MAL3-101. As shown in <xref ref-type="fig" rid="fig10">Figure 10A</xref> and quantified in <xref ref-type="fig" rid="fig10s1">Figure 10—figure supplement 1A</xref> (see relative ‘CTRL’ levels), PKR silencing had no effect on the accumulation of cleaved caspase-3, cleaved caspase-8, or CHOP, but in contrast reduced PERK activity decreased the levels of the apoptotic markers in sensitive (MDA MB 231) cells in the presence of MAL3-101. However, when PERK or PKR was silenced in the resistant (MDA MB 453) cells, an apoptotic response was absent when MAL3-101 was added. To confirm PERK activation upon MAL3-101 treatment, its phosphorylation status (p-PERK) was monitored by examining whether mobility was slowed after SDS-PAGE and immunoblotting (<xref ref-type="fig" rid="fig10">Figure 10C</xref>). We found that PERK mobility was reduced to a similar extent in MAL3-101 sensitive and resistant cells when Hsp70 was inhibited with MAL3-101 or when cells were treated with tunicamycin. These data confirm that PERK is activated in both MAL3-101 sensitive and resistant cells upon Hsp70 inhibition, yet PERK is only responsible for drug-dependent apoptosis in the sensitive cell lines.</p><p>To confirm the contribution of PERK in MAL3-101-mediated apoptosis in sensitive cells, we pre-treated sensitive and resistant cells with a PERK inhibitor, GSK-2606414 (‘GSK’), prior to MAL3-101 administration (<xref ref-type="bibr" rid="bib6">Axten et al., 2012</xref>). We then monitored the induction of apoptosis in the presence or absence of PERK inhibition when Hsp70 activity was impaired (MAL3-101 addition) or in control (DMSO) conditions (<xref ref-type="fig" rid="fig10">Figure 10D</xref> and <xref ref-type="fig" rid="fig10s1">Figure 10—figure supplement 1D</xref>). In line with our data, above, on the role played by PERK in initiating apoptosis in the sensitive cell line, GSK reduced MAL3-101-mediated apoptosis in MDA MB 231 cells upon Hsp70 inhibition (<xref ref-type="fig" rid="fig10">Figure 10D</xref> and <xref ref-type="fig" rid="fig10s1">Figure 10—figure supplement 1D</xref>). In contrast, and also in line with the data presented above, PERK activity was dispensable for triggering MAL3-101-driven cell death in the resistant MDA MB 453 cell line.</p><p>Finally, we examined the role of GCN2 in breast cancer cell survival upon Hsp70 inhibition. Only ~25% of GCN2 remained after knockdown in either cell line (<xref ref-type="fig" rid="fig11">Figure 11A and B</xref>), a level comparable to that observed in other systems in which the contribution of this kinase on cellular stress responses was analyzed (<xref ref-type="bibr" rid="bib136">Rajanala et al., 2019</xref>; <xref ref-type="bibr" rid="bib155">Shi et al., 2019</xref>). We subsequently measured the accumulation of CHOP, cleaved caspase-3, and cleaved caspase-8 in MAL3-101-sensitive cells (MDA MB 231) after GCN2 was silenced, but the levels of these reporters were unaltered (<xref ref-type="fig" rid="fig11">Figure 11A and C</xref>). Notably, GCN2 knockdown failed to increase Hsp70 levels, indicating that a compensatory response to MAL3-101 was absent in the sensitive cells.</p><fig-group><fig id="fig11" position="float"><label>Figure 11.</label><caption><title>GCN2 is required for resistant cell survival when challenged with MAL3-101.</title><p>(<bold>A</bold>) MAL3-101 sensitive (MDA MB 231, in blue) and resistant (MDA MB 453, in black) cells were transfected with a control siRNA or two different siRNAs directed against GCN2, and 72 hr post transfection cells were treated with DMSO or 12 μM MAL3-101 for 6 hr. Lysates were immunoblotted to detect the indicated proteins. A non-specific band in the Hsp70 immunoblot is indicated with an asterisk (*), and β-actin served as a loading control. (<bold>B</bold>) GCN2 knockdown efficiency was measured by immunoblot 72 hr post siRNA transfection in MAL3-101-sensitive (MDA MB 231, closed circles) and MAL3-101-resistant (MDA MB 453, open circles) lines. The relative GCN2 fold change in knockdown to control samples is plotted, ± SEM (n≥3); **** denotes p&lt;0.00001. (<bold>C</bold>) The corresponding fold increase of the indicated apoptotic markers and p-eIF2α in MAL3-101-sensitive (MDA MB 231, closed symbols) and MAL3-101-resistant (MDA MB 453, open symbols) cells treated with a control or siRNAs directed against GCN2 and treated with DMSO or MAL3-101 is shown, ± SEM (n≥3) * denotes p&lt;0.05, *** denotes p&lt;0.0005 and **** denotes p&lt;0.00001.</p><p> <supplementary-material id="fig11sdata1"><label>Figure 11—source data 1.</label><caption><title>Source data for <xref ref-type="fig" rid="fig11">Figure 11</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-64977-fig11-data1-v3.xlsx"/></supplementary-material> </p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64977-fig11-v3.tif"/></fig><fig id="fig11s1" position="float" specific-use="child-fig"><label>Figure 11—figure supplement 1.</label><caption><title>ISR orchestrates a cell survival response when Hsp70 is inhibited.</title><p>(<bold>A</bold>) MAL3-101 sensitive (MDA MB 231, in blue) and resistant (MDA MB 453, in black) cells were treated with 10 µM ISRIB for 10 hr and 15 µM MAL3-101 or DMSO was present during the last 6 hr of the treatment. Lysates prepared from the treated cells were immunoblotted to detect the indicated proteins. β-actin serves as a loading control. (<bold>B–C</bold>) The corresponding fold increase of (<bold>B</bold>) p-eIF2α and (<bold>C</bold>) cleaved caspase 3, cleaved caspase 8, and CHOP in MAL3-101-sensitive (MDA MB 231, closed symbols) and MAL3-101-resistant (MDA MB 453, open symbols) cells treated with or not with ISRIB in the presence or absence of MAL3-101 is shown, ± SEM (n=3 for cleaved caspase 3 and caspase8; n=4 for CHOP and p-eIF2α). Data represent the fold increase relative to DMSO. * denotes p&lt;0.05, and *** denotes p&lt;0.0005.</p><p> <supplementary-material id="fig11s1sdata1"><label>Figure 11—figure supplement 1—source data 1.</label><caption><title>Source data for <xref ref-type="fig" rid="fig11s1">Figure 11—figure supplement 1</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-64977-fig11-figsupp1-data1-v3.xlsx"/></supplementary-material> </p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64977-fig11-figsupp1-v3.tif"/></fig></fig-group><p>We next asked if GCN2 plays a role in the pro-survival response in MDA MB 453 resistant cells. In contrast to the modest effect of PERK and PKR on eIF2α phosphorylation, p-eIF2α levels significantly decreased when GCN2 was silenced in these cells in the presence of MAL3-101 (<xref ref-type="fig" rid="fig11">Figure 11A and C</xref>, see relative ‘CTRL’ levels). GCN2 knockdown also induced apoptosis when Hsp70 activity was impaired with MAL3-101 (<xref ref-type="fig" rid="fig11">Figure 11A and C</xref>). Interestingly, the phosphorylation of Thr-899 in the activation-loop of GCN2 was unaltered by MAL3-101 addition (pGCN2, <xref ref-type="fig" rid="fig11s1">Figure 11—figure supplement 1A</xref>). This result suggests that other sites might be phosphorylated when Hsp70 activity is impaired. By analogy, a previous report hinted that other residues might be phosphorylated in response to ribosome P-stalk-mediated activation of GCN2, and multiple GCN2 phosphorylation events were detected upon amino acid starvation which were independent of Thr-899 phosphorylation (<xref ref-type="bibr" rid="bib58">Harding et al., 2019</xref>). In addition, the increased accumulation of CHOP upon MAL3-101 treatment when GCN2 expression was silenced suggests that apoptosis might depend on the activation of another ISR sensor (<xref ref-type="fig" rid="fig11">Figure 11A and C</xref>) in resistant (MDA MB 453) cells. Regardless, these results position the GCN2-dependent phosphorylation of eIF2α as a trigger for protection against compromised proteostasis and the induction of a pro-survival degradation pathway, that is, autophagy, in MAL3-101-sensitive cells.</p><p>To confirm the role of the ISR in MAL3-101-associated apoptosis, we monitored apoptotic induction in the presence or absence of the ISR inhibitor, ISRIB (<xref ref-type="bibr" rid="bib55">Halliday et al., 2015</xref>; <xref ref-type="bibr" rid="bib135">Rabouw et al., 2019</xref>; <xref ref-type="bibr" rid="bib156">Sidrauski et al., 2015</xref>; <xref ref-type="bibr" rid="bib197">Zyryanova et al., 2018</xref>). ISRIB is an allosteric inhibitor of the downstream eIF2α target, eIF2B, and ultimately blocks the ISR (<xref ref-type="bibr" rid="bib197">Zyryanova et al., 2018</xref>). We found that ISRIB had no effect on p-eIF2α accumulation (<xref ref-type="fig" rid="fig11s1">Figure 11—figure supplements 1A and B</xref>, compare ‘MAL3-101’ and ‘MAL3-101+ISRIB’), yet ISRIB treatment decreased CHOP, cleaved caspase-3, and cleaved caspase-8 accumulation in sensitive (MDA MB 231) cells after MAL3-101 was added (<xref ref-type="fig" rid="fig11s1">Figure 11—figure supplements 1A and C</xref>, see relative ‘MAL3-101’ levels). When the ISR was inhibited with ISRIB in the resistant MDA MB 453 cells, only a modest accumulation of cleaved caspase-8 was induced when MAL3-101 was present (<xref ref-type="fig" rid="fig11s1">Figure 11—figure supplements 1A and C</xref>). Thus, taken together with the data presented above, these results identify the ISR as an apoptotic trigger in sensitive breast cancer cell lines when proteostasis is compromised.</p></sec><sec id="s2-9"><title>GCN2 regulates the autophagy pathway in MAL3-101-resistant breast cancer cells</title><p>Hsp70 inhibition induces the accumulation of p-eIF2α to a similar extent in MAL3-101 sensitive and resistant breast cancer lines, but the eIF2α kinases (PERK versus GCN2) and the final cellular outcomes (apoptosis versus autophagy, respectively) are distinct: PERK knockdown blunted the death response in sensitive cells after MAL3-101 treatment, whereas the silencing of GCN2 favored the death of resistant cells after the same treatment. To better define the roles of the PERK and GCN2 kinases in the induction of the compensatory (i.e., autophagy) response in resistant cells, we monitored autophagy activation in control and PERK and GCN2 silenced cells in the presence or absence of MAL3-101. In this experiment, CQ was added during the last 2 hr of MAL3-101 treatment to block autophagolysosome-dependent degradation, which allowed us to focus on autophagic flux under each condition.</p><p>First, we confirmed that autophagy—as measured by both the level of LC3BII and the LC3BII:LC3BI ratio—was present at a higher level in resistant (MDA MB 453) compared to sensitive cells (MDA MB 231) transfected with a control siRNA and were either treated or left untreated with MAL3-101 (<xref ref-type="fig" rid="fig12">Figure 12A</xref>, and data quantified in <xref ref-type="fig" rid="fig12s1">Figure 12—figure supplement 1A,B</xref>; see relative ‘CTRL’ levels). Next, we found that the accumulation of the autophagy marker LC3BII and the LC3BII:LC3BI ratio decreased in CQ-treated resistant cells (MDA MB 453) in which PERK expression was blunted compared to control cells. This result suggests that PERK enhances basal autophagic flux in MAL3-101-resistant cells. However, MAL3-101 treatment still increased the amount of LC3BII as well as the LC3BII:LC3BI ratio, suggesting that PERK is dispensable for MAL3-101-mediated autophagy induction in the resistant cells. In contrast, and as anticipated, there was no significant change in LC3BII accumulation and the LC3BII:LC3BI ratio between control and PERK siRNA transfected sensitive (MDA MB 231) cells in the presence of MAL3-101 (<xref ref-type="fig" rid="fig12">Figure 12A</xref>, <xref ref-type="fig" rid="fig12s1">Figure 12—figure supplement 1A,B</xref>; compare ‘MAL3-101’ CTRL with ‘MAL3-101’ PERKi).</p><fig-group><fig id="fig12" position="float"><label>Figure 12.</label><caption><title>GCN2 is required to activate autophagy in MAL3-101-treated resistant cells.</title><p>(<bold>A</bold>) MAL3-101 sensitive (MDA MB 231, in blue) and resistant (MDA MB 453, in black) cells were transfected with a control siRNA or a mixture of two siRNAs against PERK, and 72 hr after transfection the cells were treated with 12 µM MAL3-101 for 6 hr and CQ was added during the last 2 hr of the treatment to block autophagy. Lysates were prepared for each condition immunoblotted for LC3B to monitor autophagy induction. (<bold>B</bold>) The same cells were used and treated as above except that a control or mixture of oligo 1 and 2 against GCN2 was used. (<bold>C</bold>) The same cells were again used and treated as above except that a control or mixture of siRNAs against both PERK and GCN2 was used. In each panel, β-actin serves as a loading control and the purple and red dot indicate the LC3BI and LC3BII isoforms, respectively.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64977-fig12-v3.tif"/></fig><fig id="fig12s1" position="float" specific-use="child-fig"><label>Figure 12—figure supplement 1.</label><caption><title>PERK and GCN2 contribute to autophagy induction in MAL3-101 resistant cells.</title><p>(<bold>A–B</bold>) LC3BII levels and the LC3BII:I ratio are reported as the fold change of CQ treated versus untreated samples, ± SEM. The accumulation of autophagy markers in control siRNA transfected cells was compared to PERK and GCN2 single knockdowns and the PERK-GCN2 double knockdown samples (n≥8 for CTRL; n=3 for PERKi, n≥3 for GCN2i, and n≥4 for GCN2i-PERKi samples). Black asterisks correspond to the statistical significance between the CQ versus the MAL3-101 ratios, and red asterisks represent the statistical significance between the MAL3-101 value in the control (CTRL) versus the GCN2i and GCN2i-PERKi cells treated with MAL3-101; * denotes p&lt;0.05, ** denotes p&lt;0.005, *** denotes p&lt;0.0005 and **** denotes p&lt;0.00001.</p><p> <supplementary-material id="fig12s1sdata1"><label>Figure 12—figure supplement 1—source data 1.</label><caption><title>LC3BII and LC3BII/I raw data for <xref ref-type="fig" rid="fig12s1">Figure 12—figure supplement 1</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-64977-fig12-figsupp1-data1-v3.xlsx"/></supplementary-material> </p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64977-fig12-figsupp1-v3.tif"/></fig></fig-group><p>Second, we asked if GCN2 activates autophagy in the presence or absence of MAL3-101. In resistant cells (MDA MB 453), the accumulation of the autophagy marker LC3BII and the LC3BII:LC3BI ratio decreased when GCN2 was silenced and when Hsp70 was inhibited, suggesting that GCN2 is critical for MAL3-101-mediated autophagy induction (<xref ref-type="fig" rid="fig12">Figure 12B</xref>, <xref ref-type="fig" rid="fig12s1">Figure 12—figure supplement 1B</xref>; note decreased signal for ‘MAL3-101’, ‘GCN2i’). On the contrary, no change in autophagy marker abundance was detected in resistant cells (MDA MB 453) treated only with CQ, suggesting that the basal autophagy flux is unaltered by GNC2 silencing (<xref ref-type="fig" rid="fig11">Figure 11B</xref>, <xref ref-type="fig" rid="fig12s1">Figure 12—figure supplement 1B</xref>). Autophagy was also unaltered in sensitive cells (MDA MB 231) upon GCN2 protein ablation (<xref ref-type="fig" rid="fig12">Figure 12B</xref>, <xref ref-type="fig" rid="fig12s1">Figure 12—figure supplement 1A</xref>; ‘GCN2i’). These data confirm the role of GCN2 in autophagy induction when proteotoxic stress rises in resistant cells.</p><p>PERK partially compensates for autophagy induction in GCN2<sup>-/-</sup> MEF cells under stress conditions (<xref ref-type="bibr" rid="bib187">Ye et al., 2010</xref>). Therefore, to better define the role of PERK and GCN2 in MAL3-101-mediated autophagy in sensitive and resistant cells, we performed a PERK-GCN2 double knockdown and compared both LC3BII accumulation and the LC3BI:LC3BII ratio to the control (<xref ref-type="fig" rid="fig12">Figure 12C</xref>). Genetic ablation of the two eIF2α kinases impaired basal and MAL3-101-mediated autophagy in MAL3-101 resistant (MDA MB 453), but not in sensitive (MDA MB 231) cells (<xref ref-type="fig" rid="fig12">Figure 12C</xref>, <xref ref-type="fig" rid="fig12s1">Figure 12—figure supplement 1A and B</xref>; ‘PERKi GCN2i’). Moreover, the knockdown of both PERK and GCN2 showed an additive effect as LC3BII accumulation along with LC3BI to LC3BII conversion in resistant cells (MDA MB 453) decreased even more compared to the single knockdowns, at least in the absence of MAL3-101 (<xref ref-type="fig" rid="fig12">Figure 12C</xref> and <xref ref-type="fig" rid="fig12s1">Figure 12—figure supplement 1B</xref>). Taken together, our data demonstrate that PERK oversees autophagy in the absence of Hsp70 inhibition, but GNC2 is fundamental for MAL3-101-dependent autophagy in resistant cells.</p></sec><sec id="s2-10"><title>Induction of the ER stress response and protein folding pathway genes correlate with Hsp70 inhibition in sensitive cells</title><p>To better define the difference in the sensitivities of breast cancer cells to MAL3-101, we analyzed publicly available RNA sequencing (RNAseq) databases from the Broad Institute Cancer Cell Line Encyclopedia (CCLE) (<xref ref-type="bibr" rid="bib12">Barretina et al., 2012</xref>) and RNAseq data published in prior work (<xref ref-type="bibr" rid="bib98">Marcotte et al., 2016</xref>). We also evaluated the breast cancer cell proteome using the public available RPPA datasets (<xref ref-type="bibr" rid="bib98">Marcotte et al., 2016</xref>; <xref ref-type="fig" rid="fig13">Figure 13A and B</xref>). Interestingly, Hsp70 inhibitor sensitivity failed to correlate with the transcriptional profiles of the 14 breast cancer cells examined in our study (<xref ref-type="fig" rid="fig13">Figure 13A</xref>). On the contrary, the RPPA dataset analysis revealed that resistant breast cell lines (MDA MB 453, MDA MB 361 and HCC38) have higher levels of activated AMPK (AMPKα-pT172) and of the ribosomal S6 kinase (p70-S6K-pT389) (<xref ref-type="fig" rid="fig13">Figure 13B</xref>). These proteins, respectively, are direct autophagy inducers in response to energy availability and regulate translation elongation downstream of mTOR signaling (<xref ref-type="bibr" rid="bib63">Hindupur et al., 2015</xref>). Increased pT172 AMPK levels also suggest that MAL3-101-resistant cells exploit AMPK activation to modulate their metabolic state to maintain an adequate energy balance even under proteotoxic stress conditions (<xref ref-type="bibr" rid="bib45">Garcia and Shaw, 2017</xref>). In agreement with this hypothesis, both increased pT172 AMPK and p70-S6K-pT389 levels accumulate upon glucose starvation in HEK293 cells when autophagy is induced (<xref ref-type="bibr" rid="bib73">Kim et al., 2011</xref>). Thus, MAL3-101-resistant cells are primed to modulate metabolism (i.e. inducing autophagy) to counteract imbalanced proteostasis.</p><fig id="fig13" position="float"><label>Figure 13.</label><caption><title>Transcriptional upregulation of the unfolded protein response is a signature of MAL3-101 sensitive cells.</title><p>(<bold>A</bold>) Principal component analysis plot of publicly available RNAseq datasets is presented for tested breast cancer cell lines. MAL3-101-sensitive cells are indicated in aqua green while resistant cell lines are indicated in light red. (<bold>B</bold>) Heatmap representation of significantly differentially expressed proteins between publicly available RPPA datasets for sensitive and resistant cells (MDA MB 231 and MDA MB 453). Wilcoxon signed-rank test between resistant and sensitive cell lines was used to determine proteins that were differentially expressed. p&lt;0.1 was considered significant. (<bold>C</bold>) Principal component analysis plot of RNAseq performed on MAL3-101 treated (Samples A4, <bold>A5, A6, B4, B5, B7</bold>) or DMSO (Samples A1, <bold>A2, A7, B1, B2, B3</bold>) treated sensitive and resistant cells. MDA MB 453 cells (MAL3-101 resistant, sample A) are represented in light red and MDA MB 231 cells (MAL3-101 sensitive, sample B) in aqua green. (<bold>D</bold>) The top 35 differentially expressed genes detected in MAL3-101 treated and untreated cell lines (MDA MB 231 in green and MDA MB 453 in light red) are represented in a heatmap graph. (<bold>E</bold>) Gene Ontology enrichment plot of Biological Processes using significantly differential genes in MDA MB 231 cell lines with and without MAL3-101 treatment. p&lt;0.05 was considered significant.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64977-fig13-v3.tif"/></fig><p>To further define the pathways involved in the differential MAL3-101 response between sensitive and resistant cells, we also performed an RNAseq analysis after sensitive (MDA MB 231) and resistant (MDA MB 453) cells were treated with MAL3-101 or the DMSO control. MAL3-101 treatment had a minor impact on the global transcriptional profile of the resistant cells (MDA MB 453, samples A), whereas significantly more variability in the transcriptional profile of MDA MB 231 cells was detected when comparing the MAL3-101 and DMSO-treated samples (samples B, <xref ref-type="fig" rid="fig13">Figure 13C</xref>). In agreement with the global transcriptomic analysis, above, hierarchical clustering of the samples based on differential gene analysis revealed that MAL3-101-treated sensitive cells (MDA MB 231) cluster with resistant MDA MB 453 cells (<xref ref-type="fig" rid="fig13">Figure 13D</xref>), while no change was visible in between MAL3-101 and DMSO treated resistant cells (MDA MB 453). These transcriptomic analyses suggest that MAL3-101 sensitivity is more tightly linked to changes in the cancer cell proteome and metabolome compared to the transcriptional profiles. This hypothesis will be pursued in future work. In fact, the top 35 genes differentially regulated between sensitive and resistant cells failed to correlate with any specific molecular mechanism or biological process (<xref ref-type="fig" rid="fig13">Figure 13D</xref>).</p><p>Finally, to identify other factors that might dictate ISR-related circuits in MAL3-101 sensitive cells, we compared the two sample cohorts in MDA MB 231 cells to assess the presence of genes that may drive MAL3-101 sensitivity. We found that protein folding and the ER stress response pathways were upregulated in MAL3-101-sensitive cells, MDA MB 231, when Hsp70 activity was inhibited (<xref ref-type="fig" rid="fig13">Figure 13E</xref>). These data confirm the key role of the UPR and, in particular, of the PERK branch of this pathway in dictating the fate of MAL3-101 sensitive cells when Hsp70 activity is inhibited.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Protein homeostasis, that is, proteostasis, balances metabolic demands via protein synthesis with protein quality control, which clears the cell of potentially toxic misfolded proteins (<xref ref-type="bibr" rid="bib9">Balch et al., 2008</xref>; <xref ref-type="bibr" rid="bib68">Jayaraj et al., 2020</xref>; <xref ref-type="bibr" rid="bib93">Luh and Bertolotti, 2020</xref>). In some cancer cells, proteostasis modulation is essential for cell survival, rapid rates of cell division, and metastasis (<xref ref-type="bibr" rid="bib114">Nam and Jeon, 2019</xref>; <xref ref-type="bibr" rid="bib177">Wang and Kaufman, 2014</xref>). In this work, we utilized an established allosteric inhibitor of Hsp70-mediated proteostasis, MAL3-101 (<xref ref-type="bibr" rid="bib47">Gestwicki and Shao, 2019</xref>; <xref ref-type="bibr" rid="bib65">Huryn et al., 2011</xref>), to explore how cells resist a proteostasis collapse. This goal was justified based on Hsp70’s prominent role in almost every branch of the proteostasis pathway. As a model system for these studies, we used breast cancer cells since Hsp70 is overexpressed in metastatic breast cancer, prevents apoptosis, and contributes to the limited efficacy of Hsp90-based treatments in clinical trials (<xref ref-type="bibr" rid="bib46">Garrido et al., 2006</xref>; <xref ref-type="bibr" rid="bib49">Goloudina et al., 2012</xref>; <xref ref-type="bibr" rid="bib52">Guo et al., 2005</xref>; <xref ref-type="bibr" rid="bib132">Powers et al., 2010</xref>; <xref ref-type="bibr" rid="bib133">Powers et al., 2013</xref>). Ultimately, our analysis identified a range of sensitivities to MAL3-101 among the tested cell lines. The lines included the main breast cancer subtypes, confirming the heterogeneity of this type of cancer. The focus on Hsp70 in these cancer-derived cells lines also highlights the importance of precision medicine strategies based on tumor proteostasis (<xref ref-type="bibr" rid="bib112">Naito and Urasaki, 2018</xref>).</p><p>Prior work indicated that MAL3-101 primarily targets cytosolic Hsp70, but the activity of the ER resident Hsp70 chaperone, BiP, is also somewhat affected by the drug (<xref ref-type="bibr" rid="bib42">Fewell et al., 2004</xref>; <xref ref-type="bibr" rid="bib125">Patham et al., 2009</xref>; <xref ref-type="bibr" rid="bib144">Sabnis et al., 2016</xref>; <xref ref-type="bibr" rid="bib146">Sannino et al., 2018</xref>; <xref ref-type="bibr" rid="bib158">Singh et al., 2020</xref>). Therefore, effects on both cytosolic stress responses as well as the UPR/ISR were anticipated, as shown in the current study. Specifically, we find that Hsp70 inhibition initiates a p-eIF2α-mediated stress response in Hsp70 inhibitor sensitive and resistant lines, suggesting that cancer cells attempt to ameliorate stress by modulating their transcriptomes and proteomes to survive and proliferate. Yet, apoptosis can result if key changes in a new proteostasis set-point cannot be attained. By using archived, well established cancer cell lines, we capitalized on naturally occurring variations in these responses. Indeed, prior work indicated that the ISR/UPR and eIF2α phosphorylation can regulate cancer cell fate, depending on the nature of the stress and metabolic state (<xref ref-type="bibr" rid="bib18">Blagden and Willis, 2011</xref>; <xref ref-type="bibr" rid="bib31">Chiti and Dobson, 2006</xref>; <xref ref-type="bibr" rid="bib37">Darini et al., 2019</xref>; <xref ref-type="bibr" rid="bib53">Guo et al., 2017</xref>; <xref ref-type="bibr" rid="bib74">Kim et al., 2015</xref>; <xref ref-type="bibr" rid="bib81">Koromilas, 2015</xref>; <xref ref-type="bibr" rid="bib82">Kouroku et al., 2007</xref>; <xref ref-type="bibr" rid="bib114">Nam and Jeon, 2019</xref>; <xref ref-type="bibr" rid="bib121">Pakos-Zebrucka et al., 2016</xref>; <xref ref-type="bibr" rid="bib170">Travers et al., 2000</xref>; <xref ref-type="bibr" rid="bib189">Yoshida et al., 2001a</xref>; <xref ref-type="bibr" rid="bib190">Yoshida et al., 2001b</xref>). In this study, we discovered that p-eIF2α signaling elicits an apoptotic response at both the mRNA and protein levels in MAL3-101 sensitive cells. On the other hand, MAL3-101-resistant cells exploit p-eIF2α signaling to augment a specific protein degradation—autophagy—which overcomes the rise in toxic proteins and prevents cell death. In accordance with these findings, induction of autophagy via mTOR inhibition reduced the survival of MAL3-101-sensitive cells in the presence of MAL3-101. The role of autophagy as a pro-survival mechanism is supported further by other studies in which this pathway was shown to confer resistance to chemotherapy, immunotherapy, and HER2- and ER-targeted therapies in breast cancer (<xref ref-type="bibr" rid="bib99">Martin et al., 2009</xref>; <xref ref-type="bibr" rid="bib138">Robainas et al., 2017</xref>; <xref ref-type="bibr" rid="bib145">Samaddar et al., 2008</xref>; <xref ref-type="bibr" rid="bib148">Schoenlein et al., 2009</xref>; <xref ref-type="bibr" rid="bib163">Sui et al., 2013</xref>; <xref ref-type="bibr" rid="bib169">Tracey et al., 2020</xref>; <xref ref-type="bibr" rid="bib174">Vazquez-Martin et al., 2009</xref>; <xref ref-type="bibr" rid="bib192">Zambrano and Yeh, 2016</xref>). In addition, we previously reported that lab-generated MAL3-101-resistant rhabdomyosarcoma cells, which were obtained by long-term dose escalation, were partially resensitized to MAL3-101 if autophagy was simultaneously inhibited (<xref ref-type="bibr" rid="bib146">Sannino et al., 2018</xref>). Together, our study supports the importance of monitoring autophagy efficiency in various cancers in parallel to the development of specific autophagy inhibitors that can be administrated alone or in combination with approved secondary therapies (<xref ref-type="bibr" rid="bib4">Amaravadi et al., 2011</xref>; <xref ref-type="bibr" rid="bib32">Chude and Amaravadi, 2017</xref>; <xref ref-type="bibr" rid="bib130">Piffoux et al., 2021</xref>; <xref ref-type="bibr" rid="bib137">Rebecca et al., 2019</xref>; <xref ref-type="bibr" rid="bib154">Shi et al., 2017</xref>).</p><p>While the current work employed a cancer cell model, the survival of all cells during homeostatic changes requires proteostasis adaptation through modulation of the ISR and UPR (<xref ref-type="bibr" rid="bib50">Grandjean and Wiseman, 2020</xref>; <xref ref-type="bibr" rid="bib62">Hetz et al., 2020</xref>). What is a matter of investigation—and can be specifically investigated by genetic approaches—is the role of each stress sensor in cell survival. To our knowledge, our work highlights the first example in which different ISR sensors dictate unique fates in a specific cell type. While PERK primarily initiates a pro-apoptotic response in MAL3-101 sensitive cells, GCN2 oversees an autophagy-mediated pro-survival mechanism in resistant cells when Hsp70 is inhibited. Specifically, GCN2 knockdown blunted the MAL3-101-dependent induction of autophagy, leading to CHOP accumulation and cell death (<xref ref-type="fig" rid="fig10">Figures 10</xref> and <xref ref-type="fig" rid="fig11">11</xref>). Based on our results, we propose a model (<xref ref-type="fig" rid="fig14">Figure 14</xref>) in which Hsp70 inhibition increases the accumulation of unfolded proteins that trigger the ISR. Because GCN2 regulates the amino acid response in a manner that depends on the tRNA-sensing ribosomal P-stalk (<xref ref-type="bibr" rid="bib58">Harding et al., 2019</xref>; <xref ref-type="bibr" rid="bib57">Harding et al., 2003</xref>; <xref ref-type="bibr" rid="bib66">Inglis et al., 2019</xref>; <xref ref-type="bibr" rid="bib113">Nakamura et al., 2018</xref>; <xref ref-type="bibr" rid="bib187">Ye et al., 2010</xref>), we reason that Hsp70 inhibition favors the accumulation of unfolded ubiquitinated proteins (<xref ref-type="fig" rid="fig2">Figure 2A</xref>; <xref ref-type="bibr" rid="bib146">Sannino et al., 2018</xref>), thereby limiting amino acid availability and protein translation. Numerous other examples exist in which a rise in unfolded proteins, by inhibiting the ubiquitin-proteasome pathway, similarly activates a starvation response (<xref ref-type="bibr" rid="bib41">Fan et al., 2018</xref>; <xref ref-type="bibr" rid="bib78">Kocaturk and Gozuacik, 2018</xref>; <xref ref-type="bibr" rid="bib184">Wojcik, 2013</xref>).</p><fig id="fig14" position="float"><label>Figure 14.</label><caption><title>A model for cancer cell adaptation to Hsp70 inhibition.</title><p>(1) In MAL3-101 resistant and sensitive cells, Hsp70 inhibition lead to activation of the ISR due to the accumulation of misfolded proteins (only misfolded proteins in the cytoplasm are shown). (2) GCN2-mediated eIF2α phosphorylation, which can be induced by amino acid starvation (see Discussion), also induces (3) the transcription of autophagy-related genes, favoring autophagy induction and (4) protecting MAL3-101-resistant breast cancer cells. (5) If GCN2 activity is impaired or (6) autophagy is inhibited (for example by chloroquine), Hsp70 inhibition is cytotoxic so (7) CHOP accumulates and resistant cells undergo apoptosis. (7) In contrast, in MAL3-101-sensitive cells, PERK induces ATF4 and CHOP, which results in cell death.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64977-fig14-v3.tif"/></fig><p>In the resistant cells, we also found that induction of GCN2/p-eIF2α signaling increases the levels of autophagy-related genes when Hsp70 is inhibited, favoring breast cancer cell survival (<xref ref-type="fig" rid="fig12">Figure 12</xref>). Accordingly, the GCN2/ATF4 pathway was reported to play a role in the transcriptional activation of autophagy genes such as MAP1LC3B, ATG3, ATG12, and Becn1 upon amino acid starvation (<xref ref-type="bibr" rid="bib7">B'chir et al., 2013</xref>). In line with the contribution of GCN2 signaling in balancing amino acid availability in resistant cells, asparagine synthetase expression (ASNS) is induced in MAL3-101-resistant cells but not in MAL3-101 sensitive lines when Hsp70 activity is perturbed (data not shown). Also in accordance with our discovery, other reports suggested that GCN2/ATF4 signaling plays a role in the survival and proliferation of cell lines and cancer xenografts under suboptimal growth conditions as a result of amino acid/nutrient deprivation and unbalanced protein synthesis (<xref ref-type="bibr" rid="bib58">Harding et al., 2019</xref>; <xref ref-type="bibr" rid="bib113">Nakamura et al., 2018</xref>; <xref ref-type="bibr" rid="bib136">Rajanala et al., 2019</xref>; <xref ref-type="bibr" rid="bib187">Ye et al., 2010</xref>). Moreover, GCN2 sustains mTORC1 suppression when amino acids are limited (<xref ref-type="bibr" rid="bib188">Ye et al., 2015</xref>). Based on our results and these related studies, we conclude that chaperone-mediated proteotoxic stress cannot be attenuated and cancer cell apoptosis is induced when autophagy fails to compensate for Hsp70 inhibition, or when GCN2 activity is impaired.</p><p>In summary, we provide evidence that ISR sensors are differentially integrated in proteostasis networks in cancer cells and most likely other cell types. Our work highlights the importance of investigating the interplay between different proteostatic pathways and supports ongoing efforts to modulate GCN2 and eIF2a phosphorylation in cancer (<xref ref-type="bibr" rid="bib72">Kardos et al., 2020</xref>). The targeted regulation of different ISR pathways will also prove valuable in a range of other maladies, including neurodegenerative disease, retinal degeneration, and ischemia (<xref ref-type="bibr" rid="bib27">Chen et al., 2019</xref>; <xref ref-type="bibr" rid="bib51">Grzmil and Hemmings, 2012</xref>; <xref ref-type="bibr" rid="bib55">Halliday et al., 2015</xref>; <xref ref-type="bibr" rid="bib85">Krzyzosiak et al., 2018</xref>; <xref ref-type="bibr" rid="bib93">Luh and Bertolotti, 2020</xref>; <xref ref-type="bibr" rid="bib117">Nguyen et al., 2018</xref>; <xref ref-type="bibr" rid="bib135">Rabouw et al., 2019</xref>; <xref ref-type="bibr" rid="bib196">Zhu et al., 2019</xref>; <xref ref-type="bibr" rid="bib197">Zyryanova et al., 2018</xref>). In parallel, further investigation and chemical optimization of inhibitors of Hsp70 and other chaperones will augment progress on the development of effective combinatorial treatments for breast cancer (<xref ref-type="bibr" rid="bib40">Evans et al., 2010</xref>; <xref ref-type="bibr" rid="bib69">Joshi et al., 2018</xref>).</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Cancer cell lines and chemicals</title><p>MDA MB 453, MDA MB 468, HCC1419, MCF7, MDA MB 231, HCC1395, BT-474, MDA MB 361, SKBR-3, T47D, HCC38, MDA MB 134, and HCC1937 were purchased from ATCC, and SUM44PE was purchased from Asterand Bioscience Inc (Detroit, MI). Cells were tested to be mycoplasm-free by use of a standard diagnostic PCR using the ATCC universal mycoplasma detection kit. Cell authentication was performed using the University of Arizona Genetics Core according to their protocol. All cell lines were grown at 37°C and 5% CO<sub>2</sub>. The HCC38, HCC1419, MDA MB 231, MDA MB 453, HCC1395, HCC1937, and MDA MB 468 lines were grown in RPMI-1640 media (#SH30027.FS, GE Healthcare Hyclone, Logan, UT) supplemented with 10% FBS (#SH30071.03, GE Healthcare Hyclone) and 1x penicillin/streptomycin (#15-140-122, Gibco, Thermo Fisher Scientific, Waltham, MA), while BT-474, MDA MB 361, MCF7, T47D cells were grown in DMEM-Hi glucose media with sodium pyruvate (#D6429, Millipore Sigma, Saint Louis, MO) which was supplemented with 10% FBS (GE Healthcare Hyclone) and 1x penicillin/streptomycin (Gibco, Thermo Fisher Scientific, Waltham, MA). SKBR-3 cells were cultured in McCoy's 5A with L-Glutamine media (#SH30200FS, Thermo Fisher Scientific, Waltham, MA) supplemented with 10% FBS (GE Healthcare Hyclone) and 1x penicillin/streptomycin (Gibco, Thermo Fisher Scientific, Waltham, MA). MDA MB 134 cells were grown in L-15 (Leibovitz) media (#L5520, Millipore Sigma, Saint Louis, MO) with 10% FBS (GE Healthcare Hyclone) and 1x penicillin/streptomycin (Gibco, Thermo Fisher Scientific, Waltham, MA), and SUM44PE cells were cultured in DMEM/F-12 media (#11330057, Gibco, Thermo Fisher Scientific, Waltham, MA) supplemented with 2% Charcoal/Dextran stripped FBS (#100–119, Gemini Bio-Products, West Sacramento, CA), along with 5 μg/mL human recombinant insulin (#I2643), 1 μg/mL hydrocortisone solution (#H6909), 5 mM ethanolamine (#E0135), 5 μg/mL human apo-transferrin (#T2252), 6.6 ng/mL 3',3',5-triiodo-<sc>l</sc>-thyronine sodium salt (#T5518), and 8.7 ng/mL sodium selenite (#S9133), all purchased from Millipore Sigma, Saint Louis, MO.</p><p>MAL3-101 (<xref ref-type="bibr" rid="bib42">Fewell et al., 2004</xref>), MG 132 (EMD Millipore, Burlington, MA), everolimus (Sigma-Aldrich, Saint Louis, MO), 17-AAG, and CB-5082 (Selleck Chemicals, Houston, TX) were dissolved in DMSO to a final concentration of 20 mM, while bafilomycin (Selleck Chemicals, Houston, TX) and bortezomib (Cell Signaling Technology, Danvers, MA) were prepared at a final concentration of 1 mM in DMSO. ISRIB and tunicamycin (Sigma-Aldrich, Saint Louis, MO) were suspended to a final concentration of 10 mg/mL and GSK-2606414 (GSK; Tocris Bioscience, Bristol, UK) was dissolved to a final concentration of 50 mM in DMSO. Chloroquine (CQ; Sigma-Aldrich, Saint Louis, MO) was dissolved in sterile water to a final concentration of 100 mM. All compounds were stored at −20°C. Prior to use, the desired amount of each compound was added to pre-warmed media, mixed thoroughly, and added directly onto cells.</p></sec><sec id="s4-2"><title>siRNA transfection</title><p>To silence ATG5, cells were seeded at a density of 150,000 in a six-well plate, and after 24 hr, two different siRNA oligos against ATG5 (siGENOME9474, D-004374–03 and D-004374–05, Dharmacon, Lafayette, CO) or a control siRNA (BLOCK-iT Alexa Fluor Red Fluorescent Control, Invitrogen, Thermo Fisher Scientific) were transfected using Lipofectamine RNAiMAX (Invitrogen, Thermo Fisher Scientific) at 20 nM according to the manufacturer’s instructions. After 6 hr, cells were harvested and seeded at a density of 1,500 cells/100 µL in 96-well clear-bottomed plates (Greiner bio-one, North Carolina) for cell viability assays (see below). The remaining transfected cells were collected for protein extraction 72 hr post-transfection to detect knock-down efficiency, as described below. The optimal time frame and concentration of siRNA were selected after conducting time course experiments in which ATG5-12 and Hsp70 protein abundance were analyzed by immunoblot (data not shown).</p><p>To silence specific ISR sensors, MDA MB231 and MDA MB 453 cells were seeded at a density of 1,000,000 in a 10 cm dish, and after 24 hr two oligos for PERK (EIF2AK3), PKR (EIF2AK2) (#s18101 and #s18103, #s11186 and #s11185, Ambion Fisher Scientific Waltham, MA) or GCN2 (EIF2AK4) (#D-005314–16, #D-005314–13, Dharmacon, Lafayette, CO), or one oligo for HRI (EIF2AK1) (#D-005007–04) or a control siRNA (BLOCK-iT Alexa Fluor Red Fluorescent Control, Invitrogen, Thermo Fisher Scientific) were transfected using Lipofectamine RNAiMAX (Invitrogen, Thermo Fisher Scientific) at 20 nM according to the manufacturer’s instructions. After 48 hr, cells were harvested and seeded at a density of 150,000 cells/well in a six-well plate. After 24 hr, cells were treated with the indicated compounds and processed for protein extraction, as described below. In the experiment where both GCN2 and PERK were knocked down 5 nM of each siRNA oligo (#s18101 and #s18103, #D-005314–16 and D-005314–13) where transfected using Lipofectamine RNAiMAX and the samples where processed as indicated before in the single knock down experiments.</p><p>For experiments in which the UPR transducer Ire1α was knocked down, MDA MB 231 and MDA MB 453 cells were seeded at a density of 1,200,000 in a 10 cm dish, and after 24 hr, a set of oligos at 10 nM for Ire1α (ERN1) (#s200430, Ambion Fisher Scientific, Waltham, MA) or a control siRNA were transfected as above. After 24 hr, cells were harvested and seeded at a density of 150,000 cells/well in a six-well plate, and after 24 hr, cells were treated with the indicated compounds and processed for protein or RNA extraction (see below).</p></sec><sec id="s4-3"><title>Generation of stable cell lines and confocal microscopy</title><p>To transfect the plasmid encoding the RFP-GFP-LC3B tandem autophagy reporter (provided by Dr. Charlene Chu, Department of Pathology, University of Pittsburgh) (<xref ref-type="bibr" rid="bib75">Kimura et al., 2007</xref>), MDA MB 231 and MDA MB 453 cells were seeded at a density of 1,200,000 in 10 cm dish, and after 24 hr, a total of 12 µg of the plasmid was introduced using the FuGENE6 reagent (Promega, Madison, WI) according to the manufacturer’s instructions. Cells were selected for G418 resistance (350 µg/mL, GE Healthcare Hyclone) for 8 days, and fresh G418-containing media was added every 3 days. Once a G418 resistant polyclonal population was obtained, the cells were trypsinized and resuspended at a density of 1 cell/100 μL in a 96-well plate. After 2 weeks, single clones where isolated, expanded, and tested for RFP-GFP-LC3B reporter expression by microscopy. MAL3-101 sensitivity in the obtained clones was tested as described in assays for cell viability (see below; two clones for MDA MB 231 and MDA MB 453 lines, data not shown). One clone for each line was used to test the autophagy induction rate upon Hsp70 inhibition in MAL3-101. Each RFP-GFP-LC3B expressing clone was seeded at a density of 200,000 cells in poly-<sc>d</sc>-Lysine Coated 35 mm MatTek dishes (P35GC-1.5–10 C, MatTek Corporation, Ashland, MA). After 24 hr, cells were independently treated with EBSS, MAL3-101 (5 µM), or vehicle (DMSO) for 22 hr. The samples were observed with a Nikon A1 point scanning confocal microscope without fixation to measure autophagosome and autophagolysosome formation by monitoring the distribution and alteration of RFP and GFP fluorescent signal after the indicated treatments. Complete volumes of cells were acquired at 0.2 μm steps, and volumes were reconstructed and analyzed using Nikon’s NIS-Elements software (Nikon Instrument, Melville, NY). Bright spot detection tool was used to identify and quantify the number of RFP and GFP positive (‘dots’) per cell after equalizing signal intensity suing the LUTs - Non-destructive Image Enhancement tool. A non-parametric Kruskal-Wallis test analysis was performed using Prism software (GraphPad, La Jolla, CA). Asterisks in figures indicate statistically significant differences between the samples. To obtain representative images from this experiment, maximum intensity projections of 0.2 μm steps though the entire cell were generated using Nikon’s NIS-Elements software. The scale shown is 10 µm.</p></sec><sec id="s4-4"><title>Assays for cell viability</title><p>Cells were plated at the indicated densities in <xref ref-type="table" rid="table2">Table 2</xref> in 96-well clear-bottomed plates (Greiner bio-one, North Carolina), and after 72 hr, of the indicated treatment the cells were lysed and incubated with the CellTiter-Glo reagent (Promega) and luminescence was read on a Bio-Rad ChemiDoc XRS+ with the associated Image Lab software (Bio-Rad, Thermo Fisher Scientific). Under conditions in which cells were treated with more than one compound (e.g. <xref ref-type="fig" rid="fig3">Figure 3A and B</xref>; <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>; <xref ref-type="table" rid="table3">Table 3</xref>), the cells were incubated with a range of doses of MAL3-101 in the presence of subcritical doses of bortezomib, everolimus, CQ, or bafilomycin that induced no greater than 30% of cell death in each line 72 hr after treatment at these concentrations (see <xref ref-type="table" rid="table2">Table 2</xref>). Viability was quantified after normalizing values obtained after bortezomib, CQ, or bafilomycin treatment alone at the indicated concentrations (<xref ref-type="table" rid="table2">Tables 2</xref> and <xref ref-type="table" rid="table3">3</xref>). When viability was measured after ATG5 knock-down, MAL3-101 sensitivity was measured 48 hr after treatment and 72 hr after siRNA transfection.</p><p>Analysis of cell surface Annexin-V was performed by staining cells with the Annexin-V Apoptosis Detection Kit (eBioscience, Thermo Fisher Scientific) following the manufacturer’s instructions. In brief, cells were seeded at a density of 220,000 cells/well for the MDA MB 361 line and at 150,000 cells/well for the other indicated lines in 6-well plates and allowed to adhere overnight before performing the indicated treatments. After mild trypsinization, the cells were harvested and washed in ice-cold PBS and then equilibrated in Annexin-V binding buffer. A cell resuspension of 150,000 cells in 100 μL was incubated with 5 µL of Annexin-V APC for 15 min in the dark. After three washes with binding buffer, the cells were suspended in 500 μL of Annexin-V binding buffer containing 5 μL of Propidium iodide (PI) and analyzed on an Accuri C6 FACS apparatus (BD-Biosciences, San Diego). Single-cell staining was used to discriminate Annexin-V- and PI-positive cells, respectively. Annexin-V and Annexin-V/PI double positive cells were summed and are represented as the percentage of apoptotic cells.</p></sec><sec id="s4-5"><title>Immunoblot analysis</title><p>All antibodies used in this study were obtained from Cell Signaling Technology (Danvers, MA), unless indicated otherwise. To measure the levels of endogenous proteins, cells were plated at a density of 150,000 cells/well for all cell lines except for MDA MB 361 cells (220,000 cells/well) in six-well plates and allowed to adhere overnight before the indicated treatments. The supernatant/media was collected, and after the cells were washed in PBS cell lysates were obtained after resuspending adherent cells in 1% SDS RIPA buffer (100 mM Tris-HCl, pH 7.5, 1% NP40, 1% SDS, 300 mM NaCl and 0.5% sodium deoxycholate) supplemented with protease inhibitors (cOmplete Mini EDTA free tablets; Roche, Indianapolis, IN), phosphatase inhibitors (PhosSTOP, phosphatase inhibitor tablets; Millipore Sigma, Saint Louis, MO), 10 mM N-ethylmaleimide (NEM; Sigma-Aldrich), and 5 mM phenylmethanesulfonyl fluoride (PMSF; Sigma-Aldrich) on ice. The lysate was clarified by sonication and centrifugation at 13,000 g for 5 min at 4°C, and total protein was quantified with the BCA assay kit (Thermo Fisher Scientific). Aliquots containing 35 µg of total protein were incubated in sample buffer at 95°C for 5 min, subjected to SDS-PAGE using a 15% polyacrylamide gel, and after transfer to PVDF membranes (Immobilon-FL, #IPFL85E, Sigma-Aldrich) the blots were incubated with the following antibodies: anti-LC3B (2775S; at 1:1000), anti-ATG5 (D5F5U, #12994S; at 1:1000), anti-p62/SQSTM1 (P0067, Sigma-Aldrich; at 1:2000), anti-CHOP (L63FZ, #2895S; at 1:500), anti-cleaved Caspase-3 (#9661S; at 1:750), and anti-cleaved Caspase-7 (D6H1, #8438S; at 1:500). For the remaining proteins aliquots from the same lysates were instead heated to 37°C for 30 min prior to SDS-PAGE using 4–20% Tris-Glycine gradient gels (XP04202Box, Thermo Fisher Scientific), and after transfer on nitrocellulose membranes (#84–874, Prometheus Laboratories Inc, California), the blots were incubated with anti-cleaved Caspase-8 (18C8, #9496; at 1:1000), anti-BiP (C50B12, #3177S; at 1:1000), anti-Hsp70 (smc-113, StressMarq Biosciences, Victoria, British Columbia; at 1:1000), anti-Hsc/Hsp70 (#4872S; at 1:1000), anti-HER2 (29D8, #2165; at 1:2000), anti-eIF2α (#9722S; at 1:2000), anti-phospho-eIF2α (#9721L; at 1:500), anti-PERK (D11A8, #5683S; at 1:2000), anti-PKR (D7F7, #12297S; at 1:2000), anti-Ire1α (14C10, #3294S; at 1:1000), anti-HRI (MBS2538114, MyBioSource, San Diego, CA; at 1:500) and anti-GCN2 and anti-GCN2 pT899 antibody (ab-134053 and ab-75836, Abcam, Cambtidge, UK; at 1:2000). Anti-β-actin (ab-6276, Abcam, Cambtidge, UK; at 1:5000) was used as loading control. All primary antibodies were incubated overnight at 4°C. Anti-rabbit immunoglobulin G (IgG) and anti-Mouse immunoglobulin HRP-conjugated secondary antibodies (at 1:4000) were applied for 2 hr at room temperature prior to imaging. In all cases, proteins were visualized using a mix of ProSignal Pico and ProSignal Femto ECL Reagent at a 1:1 ratio (Prometheus Laboratories Inc, California) and images were taken using a Bio-Rad ChemiDoc XRS+ with Image Lab software. Data were analyzed using ImageJ software (National Institutes of Health, NIH).</p><p>To measure LC3BII accumulation and LC3BI to LC3BII conversion in the presence or absence of MAL3-101, cells were seeded as above in six-well plates, and after 24 hr, the cells were treated with 12 µM MAL3-101 or with DMSO for 6 hr. A total of 2 hr before the end of the 6 hr time point, 250 µM CQ was added for the remaining 2 hr. A corresponding volume of vehicle (i.e. water) was added for the CQ mock treated samples. Cells were processed and LC3B abundance was detected as described above. The CQ concentration was selected after conducting experiments with increasing doses (50, 100, 150, 200, 250, 300, and 350 µM) in which LC3BII accumulation was analyzed by immunoblot and apoptosis induction was monitored by cleaved caspase-3 and caspase-7 appearance (data not shown). The CQ concentration, which gave the highest LC3BII accumulation but no significant apoptosis induction after a 2 hr treatment, was selected.</p><p>To induce non-selective (macro) autophagy, cells were washed twice in sterile PBS to remove any remaining media and then starved for 6 hr in Earle's Balanced Salt Solution (EBSS, Thermo Fisher Scientific). A total of 2 hr before the end of the 6 hr time point, 250 µM CQ was added for 2 hr. A corresponding volume of vehicle (i.e. water) was added for the mock treated samples.</p><p>To inhibit PERK, cells were pre-treated with GSK-2606414 at a final concentration of 2 µM for 2 hr in complete media and then 12 µM MAL3-101 or a corresponding volume of vehicle (DMSO) was added for 6 hr. To inhibit the ISR pathway, resistant and sensitive cells were treated with 10 µM ISRIB for for 10 hr and 15 µM MAL3-101 or a corresponding volume of DMSO was added for 6 hr before the 10 hr endpoint. Cells were processed as described above.</p><p>To detect levels of total protein ubiquitination, cells were seeded at the density mentioned above in six-well plates and allowed to adhere overnight, before they were treating with 18 nM bortezomib for 4 hr. Samples were collected and processed as above and 10 μg of total protein was subject to SDS-PAGE and proteins were transferred to nitrocellulose. Prior to incubating the blots in a milk solution, the nitrocellulose membranes were incubated in a boiling water bath for 1 hr to expose antibody epitopes. An anti-ubiquitin antibody, P4D1 (Santa Cruz Biotechnology, Dallas, TX), was used at 1:1000, and anti-mouse immunoglobulin G (IgG) HRP-conjugated secondary antibodies (at 1:4000) were applied for 2 hr at room temperature prior to imaging.</p><p>To detect ATF6, cells were plated at a density of 220,000 cells/well for the MDA MB 361 cells and 150,000 cells/well for the other cell lines in six-well plates and allowed to adhere overnight. Next, the cells were treated as indicated and 2 mM DTT was applied for 1 hr as a positive control. All treatments were performed in the presence of 5 μM MG 132 to avoid ATF6 degradation (<xref ref-type="bibr" rid="bib64">Horimoto et al., 2013</xref>). The supernatant/medium was then collected, and after the cells were washed in PBS containing 5 μM MG 132, the cells were detached with trypsin, centrifuged in a clinical centrifuge, and the cell pellets were resuspended in 10 mM Tris-HCl, pH 7.5, 150 mM NaCl, 10 μM MG 132, and 1% SDS buffer, supplemented with protease inhibitors (cOmplete Mini EDTA free tablets; Roche, Indianapolis, IN), 10 mM NEM (Sigma-Aldrich), and 5 mM PMSF (Sigma-Aldrich). The lysate was then clarified by sonication and centrifugation at 13,000 g for 5 min at 4°C, and total protein was quantified with the BCA assay kit as described above. A total of 50 μg protein was incubated at 95°C for 5 min, subjected to SDS-PAGE using a 8% polyacrylamide gel (acrylamide:Bis-acrylamide, 29:1, 40% solution, OmniPur, Sigma-Millipore, Germany), and the resulting nitrocellulose filter was incubated in Tris-buffered saline with 0.1% Tween 20 (TBST) containing 10% non-fat dry milk for 1 hr at room temperature with gentle shaking. The nitrocellulose filter was then incubated with an aliquot of anti-ATF6 antibody (73–500, Bio Academia, Japan; at 1:1000) in the presence of 5% non-fat dried milk powder for 1 hr at room temperature. An anti-light chain-specific anti-mouse IgG monoclonal antibody (115-035-174, Jackson ImmunoResearch, West Grove, PA) was then used as the HRP-conjugated secondary antibody at 1:5000 in 1% non-fat milk TBST for 2 hr at room temperature. Decorated proteins were visualized using the ProSignal Femto ECL Reagent kit (Prometheus Laboratories Inc, California) and images were taken using a Bio-Rad ChemiDoc XRS+ with Image Lab software. Full-length ATF6 was quantified as an indicator of ATF6-mediated UPR induction using ImageJ software.</p></sec><sec id="s4-6"><title>Real-time quantitative PCR</title><p>Cells were seeded at 150,000 cells/well for MDA MB 231, MDA MB 453, and MCF7 cells and at 220,000 cells/well for the MDA MB 361 line in six-well plates, grown overnight, and then treated for the indicated times with the indicated compounds. RNA was extracted using the RNeasy kit (Qiagen, Hilden, Germany) according to the manufacturer’s instructions. cDNA was synthetized from 1 µg of the extracted RNA using qScript cDNA SuperMix reverse transcriptase kit (Quantabio, Beverly, MA), and 70 ng were used for Real Time qPCR using the QuantStudio 3 (Thermo Fisher Scientific). Each PCR was performed on three or more biological replicates and with three technical replicates for each reaction. Primer efficiency was determined by serial dilution of the template and the relative expression ratios were calculated (<xref ref-type="bibr" rid="bib129">Pfaffl, 2001</xref>). Primers amplifying β-actin were used as an internal control. All primer sequences were published in previous work (<xref ref-type="bibr" rid="bib144">Sabnis et al., 2016</xref>; <xref ref-type="bibr" rid="bib146">Sannino et al., 2018</xref>).</p></sec><sec id="s4-7"><title>Proteasome activity assays</title><p>Cell lysates from MDA MB 231, MDA MB 453, MDA MB 361, and MCF7 cells were collected as described (<xref ref-type="bibr" rid="bib105">Milan et al., 2015</xref>), and proteasome activity was assessed by monitoring the production of 7-amino-4-methylcoumarin (AMC) from the Suc-LLVY-AMC proteasome substrate (cat. no. I-1395; Bachem, Torrance, CA), which specifically detects the chymotrypsin-like activity of the proteasome (<xref ref-type="bibr" rid="bib161">Stein et al., 1996</xref>). To this end, 10 µL aliquots of each lysate were incubated with 1 µL of a 5 mM stock solution of Suc-LLVY-AMC in 20 mM Tris-HCl, pH 7.5, 2 mM ATP, 2 mM MgCl<sub>2</sub>, and 0.2% bovine serum albumin in the presence or absence of 10 µM MG 132 (<xref ref-type="bibr" rid="bib48">Gleixner et al., 2017</xref>; <xref ref-type="bibr" rid="bib146">Sannino et al., 2018</xref>). The fluorescence of released AMC was measured at time 0 and after 30 min in a Cytation5 plate reader at an excitation wavelength of 380 nm and an emission wavelength of 460 nm (BioTek, Winooski, Vermont). To calibrate the assay, a standard free fluorophore solution containing a range of AMC concentrations was used (VWR, Randor, PA). All measurements were performed in duplicate and values were normalized to protein content as determined by the BCA protein assay kit according to the manufacturer’s instructions (Thermo Fisher Scientific). Proteasome activity was calculated by: ((RFU2 – RFU1) / (T2-T1)) / [protein]. One unit of proteasome activity is defined as the amount of proteasome that generates 1.0 picomol of AMC per min at 37°C.</p></sec><sec id="s4-8"><title>RNA sequencing and sequence analysis</title><p>MDA MB 231 and MDA MB 453 cells were seeded at 150,000 cells/well in six-well plates, grown overnight, and then treated for 6 hr with a final concentration of 12 µM MAL3-101 or an equal volume of DMSO. RNA was extracted using the RNeasy kit (Qiagen, Hilden, Germany) according to the manufacturer’s instructions. Each total RNA extraction was performed on three biological replicates. RNA sequencing library construction, quality control, and PE150 sequencing were performed by Novogene Co., Ltd. according to their protocol. Transcript counts from all samples were quantified with Salmon v. 1.3.0 (<xref ref-type="bibr" rid="bib126">Patro et al., 2017</xref>), converted to gene-level counts with tximport (<xref ref-type="bibr" rid="bib160">Soneson et al., 2015</xref>), and were then used in the DESeq2 function: ‘DESeqDataSetFromTximport’ (<xref ref-type="bibr" rid="bib92">Love et al., 2014</xref>).</p><p>Differential gene expression analysis was performed using the DESeq2 package (<xref ref-type="bibr" rid="bib92">Love et al., 2014</xref>). Principal component analysis plots were generated from variance stabilizing transformed (VST) DESeq2 data-frames. For RNAseq datasets corresponding to MAL3-101 treated and untreated cells, the top 35 VST differentially expressing genes were displayed in <xref ref-type="fig" rid="fig13">Figure 13D</xref>. Differentially expressed genes with a p-value below 0.05 were used for Gene Ontology analysis applying the ‘clusterProfiler’ package (<xref ref-type="bibr" rid="bib191">Yu et al., 2012</xref>; <xref ref-type="fig" rid="fig13">Figure 13E</xref>). The RNAseq data is deposited onto the Gene Expression Omnibus database (GEO, GSE178352). All raw data are available upon request from the corresponding authors.</p></sec><sec id="s4-9"><title>Gene and protein expression cluster analysis</title><p>For publicly available RNAseq datasets, RNAseq fastq files from the 14 breast cancer cell lines tested for MAL3-101 sensitivity in <xref ref-type="fig" rid="fig1">Figure 1A</xref> were downloaded with GEO Accession Numbers GSE36133 (CCLE) or GSE73526 (<xref ref-type="bibr" rid="bib12">Barretina et al., 2012</xref>; <xref ref-type="bibr" rid="bib98">Marcotte et al., 2016</xref>). Transcript counts from all samples were quantified with Salmon v.0.12.0 (<xref ref-type="bibr" rid="bib126">Patro et al., 2017</xref>) and converted to gene-level counts with tximport (<xref ref-type="bibr" rid="bib160">Soneson et al., 2015</xref>). Differential gene expression analysis was performed using the DESeq2 package (<xref ref-type="bibr" rid="bib92">Love et al., 2014</xref>). Publicly available RPPA data was obtained from the Neel Lab (<ext-link ext-link-type="uri" xlink:href="http://neellab.github.io/simem/">http://neellab.github.io/simem/</ext-link>) (<xref ref-type="bibr" rid="bib98">Marcotte et al., 2016</xref>) and normalized Log<sub>2</sub> median centered reads were used for analysis. Data visualization was performed using ‘ggpubr’ and the CRAN ‘heatmap’ packages.</p></sec><sec id="s4-10"><title>Statistical analysis</title><p>IC<sub>50</sub> concentrations from CellTiter-Glo assays were calculated as described (<xref ref-type="bibr" rid="bib144">Sabnis et al., 2016</xref>) using SigmaPlot 11.0 (Systat Software, Inc). GraphPad Prism (GraphPad Software, Inc) was used to carry out a two-tailed Student’s t test between two samples and a non-parametric Kruskal-Wallis test analysis was performed to establish statistical significance between control and compound-treated samples in the same line for the RFP-GFP-LC3B autophagy reporter assay (<xref ref-type="fig" rid="fig5">Figure 5</xref>). In all experiments, p&lt;0.05 was considered significant with the exception of the data presented in <xref ref-type="fig" rid="fig13">Figure 13B</xref>, where protein expression levels between resistant and sensitive cell lines with a p-value below 0.1 were displayed.</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>We thank Dr. Tia-Lynn Ashman for reagents and instrumentation used in this study. We also thank Dr. Simon Watkins and the CBI imaging center for access to their workstation data analysis facility, Dr. Alexandra Manos-Turvey for the preparation of MAL3-101, Dr. Ronald C Wek for providing the plasmid for GCN2 overexpression, and Ms. Taber S Maskrey for LCMS QC of MAL3-101 batches. This work was supported by grants from the long-term European Molecular Biology Organization (EMBO) via a post-doctoral fellowship (ALTF 823–2016) to SS, from the National Institutes of Health (F30CA250167) to MEY, and from the National Institutes of Health (GM131732 and DK79307), the University of Pittsburgh/UPMC Institute for Precision Medicine, the UPMC Hillman Cancer Center supported by National Institutes of Health award number P30CA047904, Pilot Funding from the Translational and Precision Pharmacology programs, and by a Howard Hughes Medical Institute Collaborative Innovation award to JLB AVL and SO are Hillman Fellows. Screening was supported by Cancer Center Support Grant (CCSG), P30 CA047904. We also thank David Zaidins for technical assistance.</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Resources, Data curation, Formal analysis, Funding acquisition, Validation, Investigation, Visualization, Methodology, Writing - original draft</p></fn><fn fn-type="con" id="con2"><p>Data curation, Software, Formal analysis, Validation, Investigation, Methodology</p></fn><fn fn-type="con" id="con3"><p>Data curation, Formal analysis, Supervision, Validation, Investigation, Writing - review and editing</p></fn><fn fn-type="con" id="con4"><p>Resources, Supervision, Writing - review and editing</p></fn><fn fn-type="con" id="con5"><p>Resources, Supervision, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con6"><p>Formal analysis, Supervision, Validation, Project administration, Writing - review and editing</p></fn><fn fn-type="con" id="con7"><p>Conceptualization, Resources, Supervision, Funding acquisition, Validation, Methodology, Project administration, Writing - review and editing</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="pdf" mimetype="application" xlink:href="elife-64977-transrepform-v3.pdf"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>All data generated or analysed during this study are included in the manuscript and source files.</p></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Acevo-Rodríguez</surname> <given-names>PS</given-names></name><name><surname>Maldonado</surname> <given-names>G</given-names></name><name><surname>Castro-Obregón</surname> <given-names>S</given-names></name><name><surname>Hernández</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Autophagy regulation by the translation machinery and its implications in cancer</article-title><source>Frontiers in Oncology</source><volume>10</volume><elocation-id>322</elocation-id><pub-id pub-id-type="doi">10.3389/fonc.2020.00322</pub-id><pub-id pub-id-type="pmid">32232004</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adam</surname> <given-names>C</given-names></name><name><surname>Baeurle</surname> <given-names>A</given-names></name><name><surname>Brodsky</surname> <given-names>JL</given-names></name><name><surname>Wipf</surname> <given-names>P</given-names></name><name><surname>Schrama</surname> <given-names>D</given-names></name><name><surname>Becker</surname> <given-names>JC</given-names></name><name><surname>Houben</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>The HSP70 modulator MAL3-101 inhibits merkel cell carcinoma</article-title><source>PLOS ONE</source><volume>9</volume><elocation-id>e92041</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0092041</pub-id><pub-id pub-id-type="pmid">24694787</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahlberg</surname> <given-names>J</given-names></name><name><surname>Berkenstam</surname> <given-names>A</given-names></name><name><surname>Henell</surname> <given-names>F</given-names></name><name><surname>Glaumann</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="1985">1985</year><article-title>Degradation of short and long lived proteins in isolated rat liver lysosomes. effects of pH, temperature, and proteolytic inhibitors</article-title><source>Journal of Biological Chemistry</source><volume>260</volume><fpage>5847</fpage><lpage>5854</lpage><pub-id pub-id-type="doi">10.1016/S0021-9258(18)89099-8</pub-id><pub-id pub-id-type="pmid">3988775</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amaravadi</surname> <given-names>RK</given-names></name><name><surname>Lippincott-Schwartz</surname> <given-names>J</given-names></name><name><surname>Yin</surname> <given-names>XM</given-names></name><name><surname>Weiss</surname> <given-names>WA</given-names></name><name><surname>Takebe</surname> <given-names>N</given-names></name><name><surname>Timmer</surname> <given-names>W</given-names></name><name><surname>DiPaola</surname> <given-names>RS</given-names></name><name><surname>Lotze</surname> <given-names>MT</given-names></name><name><surname>White</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Principles and current strategies for targeting autophagy for cancer treatment</article-title><source>Clinical Cancer Research</source><volume>17</volume><fpage>654</fpage><lpage>666</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-10-2634</pub-id><pub-id pub-id-type="pmid">21325294</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amaravadi</surname> <given-names>R</given-names></name><name><surname>Kimmelman</surname> <given-names>AC</given-names></name><name><surname>White</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Recent insights into the function of autophagy in cancer</article-title><source>Genes &amp; Development</source><volume>30</volume><fpage>1913</fpage><lpage>1930</lpage><pub-id pub-id-type="doi">10.1101/gad.287524.116</pub-id><pub-id pub-id-type="pmid">27664235</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Axten</surname> <given-names>JM</given-names></name><name><surname>Medina</surname> <given-names>JR</given-names></name><name><surname>Feng</surname> <given-names>Y</given-names></name><name><surname>Shu</surname> <given-names>A</given-names></name><name><surname>Romeril</surname> <given-names>SP</given-names></name><name><surname>Grant</surname> <given-names>SW</given-names></name><name><surname>Li</surname> <given-names>WHH</given-names></name><name><surname>Heerding</surname> <given-names>DA</given-names></name><name><surname>Minthorn</surname> <given-names>E</given-names></name><name><surname>Mencken</surname> <given-names>T</given-names></name><name><surname>Atkins</surname> <given-names>C</given-names></name><name><surname>Liu</surname> <given-names>Q</given-names></name><name><surname>Rabindran</surname> <given-names>S</given-names></name><name><surname>Kumar</surname> <given-names>R</given-names></name><name><surname>Hong</surname> <given-names>X</given-names></name><name><surname>Goetz</surname> <given-names>A</given-names></name><name><surname>Stanley</surname> <given-names>T</given-names></name><name><surname>Taylor</surname> <given-names>JD</given-names></name><name><surname>Sigethy</surname> <given-names>SD</given-names></name><name><surname>Tomberlin</surname> <given-names>GH</given-names></name><name><surname>Hassell</surname> <given-names>AM</given-names></name><name><surname>Kahler</surname> <given-names>KM</given-names></name><name><surname>Shewchuk</surname> <given-names>LM</given-names></name><name><surname>Gampe</surname> <given-names>RT</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Discovery of 7-Methyl-5-(1-{[3-(trifluoromethyl)phenyl]acetyl}-2,3-dihydro-1 <italic>H</italic> -indol-5-yl)-7 <italic>H</italic> -pyrrolo[2,3- <italic>d</italic> ]pyrimidin-4-amine (GSK2606414), a Potent an<italic>d</italic> Selective First-in-Class Inhibitor of Protein Kinase R (PKR)-like Endoplasmic Reticulum Kinase (PERK)</article-title><source>Journal of Medicinal Chemistry</source><volume>55</volume><fpage>7193</fpage><lpage>7207</lpage><pub-id pub-id-type="doi">10.1021/jm300713s</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>B'chir</surname> <given-names>W</given-names></name><name><surname>Maurin</surname> <given-names>AC</given-names></name><name><surname>Carraro</surname> <given-names>V</given-names></name><name><surname>Averous</surname> <given-names>J</given-names></name><name><surname>Jousse</surname> <given-names>C</given-names></name><name><surname>Muranishi</surname> <given-names>Y</given-names></name><name><surname>Parry</surname> <given-names>L</given-names></name><name><surname>Stepien</surname> <given-names>G</given-names></name><name><surname>Fafournoux</surname> <given-names>P</given-names></name><name><surname>Bruhat</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>The eIF2α/ATF4 pathway is essential for stress-induced autophagy gene expression</article-title><source>Nucleic Acids Research</source><volume>41</volume><fpage>7683</fpage><lpage>7699</lpage><pub-id pub-id-type="doi">10.1093/nar/gkt563</pub-id><pub-id pub-id-type="pmid">23804767</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bagola</surname> <given-names>K</given-names></name><name><surname>Mehnert</surname> <given-names>M</given-names></name><name><surname>Jarosch</surname> <given-names>E</given-names></name><name><surname>Sommer</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Protein dislocation from the ER</article-title><source>Biochimica Et Biophysica Acta (BBA) - Biomembranes</source><volume>1808</volume><fpage>925</fpage><lpage>936</lpage><pub-id pub-id-type="doi">10.1016/j.bbamem.2010.06.025</pub-id><pub-id pub-id-type="pmid">20599420</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Balch</surname> <given-names>WE</given-names></name><name><surname>Morimoto</surname> <given-names>RI</given-names></name><name><surname>Dillin</surname> <given-names>A</given-names></name><name><surname>Kelly</surname> <given-names>JW</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Adapting proteostasis for disease intervention</article-title><source>Science</source><volume>319</volume><fpage>916</fpage><lpage>919</lpage><pub-id pub-id-type="doi">10.1126/science.1141448</pub-id><pub-id pub-id-type="pmid">18276881</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Balchin</surname> <given-names>D</given-names></name><name><surname>Hayer-Hartl</surname> <given-names>M</given-names></name><name><surname>Hartl</surname> <given-names>FU</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>In vivo aspects of protein folding and quality control</article-title><source>Science</source><volume>353</volume><elocation-id>aac4354</elocation-id><pub-id pub-id-type="doi">10.1126/science.aac4354</pub-id><pub-id pub-id-type="pmid">27365453</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bareche</surname> <given-names>Y</given-names></name><name><surname>Venet</surname> <given-names>D</given-names></name><name><surname>Ignatiadis</surname> <given-names>M</given-names></name><name><surname>Aftimos</surname> <given-names>P</given-names></name><name><surname>Piccart</surname> <given-names>M</given-names></name><name><surname>Rothe</surname> <given-names>F</given-names></name><name><surname>Sotiriou</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis</article-title><source>Annals of Oncology</source><volume>29</volume><fpage>895</fpage><lpage>902</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdy024</pub-id><pub-id pub-id-type="pmid">29365031</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barretina</surname> <given-names>J</given-names></name><name><surname>Caponigro</surname> <given-names>G</given-names></name><name><surname>Stransky</surname> <given-names>N</given-names></name><name><surname>Venkatesan</surname> <given-names>K</given-names></name><name><surname>Margolin</surname> <given-names>AA</given-names></name><name><surname>Kim</surname> <given-names>S</given-names></name><name><surname>Wilson</surname> <given-names>CJ</given-names></name><name><surname>Lehár</surname> <given-names>J</given-names></name><name><surname>Kryukov</surname> <given-names>GV</given-names></name><name><surname>Sonkin</surname> <given-names>D</given-names></name><name><surname>Reddy</surname> <given-names>A</given-names></name><name><surname>Liu</surname> <given-names>M</given-names></name><name><surname>Murray</surname> <given-names>L</given-names></name><name><surname>Berger</surname> <given-names>MF</given-names></name><name><surname>Monahan</surname> <given-names>JE</given-names></name><name><surname>Morais</surname> <given-names>P</given-names></name><name><surname>Meltzer</surname> <given-names>J</given-names></name><name><surname>Korejwa</surname> <given-names>A</given-names></name><name><surname>Jané-Valbuena</surname> <given-names>J</given-names></name><name><surname>Mapa</surname> <given-names>FA</given-names></name><name><surname>Thibault</surname> <given-names>J</given-names></name><name><surname>Bric-Furlong</surname> <given-names>E</given-names></name><name><surname>Raman</surname> <given-names>P</given-names></name><name><surname>Shipway</surname> <given-names>A</given-names></name><name><surname>Engels</surname> <given-names>IH</given-names></name><name><surname>Cheng</surname> <given-names>J</given-names></name><name><surname>Yu</surname> <given-names>GK</given-names></name><name><surname>Yu</surname> <given-names>J</given-names></name><name><surname>Aspesi</surname> <given-names>P</given-names></name><name><surname>de Silva</surname> <given-names>M</given-names></name><name><surname>Jagtap</surname> <given-names>K</given-names></name><name><surname>Jones</surname> <given-names>MD</given-names></name><name><surname>Wang</surname> <given-names>L</given-names></name><name><surname>Hatton</surname> <given-names>C</given-names></name><name><surname>Palescandolo</surname> <given-names>E</given-names></name><name><surname>Gupta</surname> <given-names>S</given-names></name><name><surname>Mahan</surname> <given-names>S</given-names></name><name><surname>Sougnez</surname> <given-names>C</given-names></name><name><surname>Onofrio</surname> <given-names>RC</given-names></name><name><surname>Liefeld</surname> <given-names>T</given-names></name><name><surname>MacConaill</surname> <given-names>L</given-names></name><name><surname>Winckler</surname> <given-names>W</given-names></name><name><surname>Reich</surname> <given-names>M</given-names></name><name><surname>Li</surname> <given-names>N</given-names></name><name><surname>Mesirov</surname> <given-names>JP</given-names></name><name><surname>Gabriel</surname> <given-names>SB</given-names></name><name><surname>Getz</surname> <given-names>G</given-names></name><name><surname>Ardlie</surname> <given-names>K</given-names></name><name><surname>Chan</surname> <given-names>V</given-names></name><name><surname>Myer</surname> <given-names>VE</given-names></name><name><surname>Weber</surname> <given-names>BL</given-names></name><name><surname>Porter</surname> <given-names>J</given-names></name><name><surname>Warmuth</surname> <given-names>M</given-names></name><name><surname>Finan</surname> <given-names>P</given-names></name><name><surname>Harris</surname> <given-names>JL</given-names></name><name><surname>Meyerson</surname> <given-names>M</given-names></name><name><surname>Golub</surname> <given-names>TR</given-names></name><name><surname>Morrissey</surname> <given-names>MP</given-names></name><name><surname>Sellers</surname> <given-names>WR</given-names></name><name><surname>Schlegel</surname> <given-names>R</given-names></name><name><surname>Garraway</surname> <given-names>LA</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity</article-title><source>Nature</source><volume>483</volume><fpage>603</fpage><lpage>607</lpage><pub-id pub-id-type="doi">10.1038/nature11003</pub-id><pub-id pub-id-type="pmid">22460905</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barth</surname> <given-names>S</given-names></name><name><surname>Glick</surname> <given-names>D</given-names></name><name><surname>Macleod</surname> <given-names>KF</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Autophagy: assays and artifacts</article-title><source>The Journal of Pathology</source><volume>221</volume><fpage>117</fpage><lpage>124</lpage><pub-id pub-id-type="doi">10.1002/path.2694</pub-id><pub-id pub-id-type="pmid">20225337</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Basso</surname> <given-names>AD</given-names></name><name><surname>Solit</surname> <given-names>DB</given-names></name><name><surname>Chiosis</surname> <given-names>G</given-names></name><name><surname>Giri</surname> <given-names>B</given-names></name><name><surname>Tsichlis</surname> <given-names>P</given-names></name><name><surname>Rosen</surname> <given-names>N</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function</article-title><source>Journal of Biological Chemistry</source><volume>277</volume><fpage>39858</fpage><lpage>39866</lpage><pub-id pub-id-type="doi">10.1074/jbc.M206322200</pub-id><pub-id pub-id-type="pmid">12176997</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benbrook</surname> <given-names>DM</given-names></name><name><surname>Long</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Integration of autophagy, proteasomal degradation, unfolded protein response and apoptosis</article-title><source>Experimental Oncology</source><volume>34</volume><fpage>286</fpage><lpage>297</lpage><pub-id pub-id-type="pmid">23070014</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bertolotti</surname> <given-names>A</given-names></name><name><surname>Zhang</surname> <given-names>Y</given-names></name><name><surname>Hendershot</surname> <given-names>LM</given-names></name><name><surname>Harding</surname> <given-names>HP</given-names></name><name><surname>Ron</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Dynamic interaction of BiP and ER stress transducers in the unfolded-protein response</article-title><source>Nature Cell Biology</source><volume>2</volume><fpage>326</fpage><lpage>332</lpage><pub-id pub-id-type="doi">10.1038/35014014</pub-id><pub-id pub-id-type="pmid">10854322</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bi</surname> <given-names>M</given-names></name><name><surname>Naczki</surname> <given-names>C</given-names></name><name><surname>Koritzinsky</surname> <given-names>M</given-names></name><name><surname>Fels</surname> <given-names>D</given-names></name><name><surname>Blais</surname> <given-names>J</given-names></name><name><surname>Hu</surname> <given-names>N</given-names></name><name><surname>Harding</surname> <given-names>H</given-names></name><name><surname>Novoa</surname> <given-names>I</given-names></name><name><surname>Varia</surname> <given-names>M</given-names></name><name><surname>Raleigh</surname> <given-names>J</given-names></name><name><surname>Scheuner</surname> <given-names>D</given-names></name><name><surname>Kaufman</surname> <given-names>RJ</given-names></name><name><surname>Bell</surname> <given-names>J</given-names></name><name><surname>Ron</surname> <given-names>D</given-names></name><name><surname>Wouters</surname> <given-names>BG</given-names></name><name><surname>Koumenis</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>ER stress-regulated translation increases tolerance to extreme hypoxia and promotes tumor growth</article-title><source>The EMBO Journal</source><volume>24</volume><fpage>3470</fpage><lpage>3481</lpage><pub-id pub-id-type="doi">10.1038/sj.emboj.7600777</pub-id><pub-id pub-id-type="pmid">16148948</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blagden</surname> <given-names>SP</given-names></name><name><surname>Willis</surname> <given-names>AE</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>The biological and therapeutic relevance of mRNA translation in cancer</article-title><source>Nature Reviews Clinical Oncology</source><volume>8</volume><fpage>280</fpage><lpage>291</lpage><pub-id pub-id-type="doi">10.1038/nrclinonc.2011.16</pub-id><pub-id pub-id-type="pmid">21364523</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braunstein</surname> <given-names>MJ</given-names></name><name><surname>Scott</surname> <given-names>SS</given-names></name><name><surname>Scott</surname> <given-names>CM</given-names></name><name><surname>Behrman</surname> <given-names>S</given-names></name><name><surname>Walter</surname> <given-names>P</given-names></name><name><surname>Wipf</surname> <given-names>P</given-names></name><name><surname>Coplan</surname> <given-names>JD</given-names></name><name><surname>Chrico</surname> <given-names>W</given-names></name><name><surname>Joseph</surname> <given-names>D</given-names></name><name><surname>Brodsky</surname> <given-names>JL</given-names></name><name><surname>Batuman</surname> <given-names>O</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Antimyeloma effects of the heat shock protein 70 molecular chaperone inhibitor MAL3-101</article-title><source>Journal of Oncology</source><volume>2011</volume><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1155/2011/232037</pub-id><pub-id pub-id-type="pmid">21977030</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bray</surname> <given-names>F</given-names></name><name><surname>Ferlay</surname> <given-names>J</given-names></name><name><surname>Soerjomataram</surname> <given-names>I</given-names></name><name><surname>Siegel</surname> <given-names>RL</given-names></name><name><surname>Torre</surname> <given-names>LA</given-names></name><name><surname>Jemal</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Global Cancer statistics 2018: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries</article-title><source>CA: A Cancer Journal for Clinicians</source><volume>68</volume><fpage>394</fpage><lpage>424</lpage><pub-id pub-id-type="doi">10.3322/caac.21492</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brondani Da Rocha</surname> <given-names>A</given-names></name><name><surname>Regner</surname> <given-names>A</given-names></name><name><surname>Grivicich</surname> <given-names>I</given-names></name><name><surname>Pretto Schunemann</surname> <given-names>D</given-names></name><name><surname>Diel</surname> <given-names>C</given-names></name><name><surname>Kovaleski</surname> <given-names>G</given-names></name><name><surname>Brunetto De Farias</surname> <given-names>C</given-names></name><name><surname>Mondadori</surname> <given-names>E</given-names></name><name><surname>Almeida</surname> <given-names>L</given-names></name><name><surname>Braga Filho</surname> <given-names>A</given-names></name><name><surname>Schwartsmann</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Radioresistance is associated to increased Hsp70 content in human glioblastoma cell lines</article-title><source>International Journal of Oncology</source><volume>25</volume><fpage>777</fpage><lpage>785</lpage><pub-id pub-id-type="doi">10.3892/ijo.25.3.777</pub-id><pub-id pub-id-type="pmid">15289883</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calderwood</surname> <given-names>SK</given-names></name><name><surname>Gong</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Heat shock proteins promote cancer: it's a protection racket</article-title><source>Trends in Biochemical Sciences</source><volume>41</volume><fpage>311</fpage><lpage>323</lpage><pub-id pub-id-type="doi">10.1016/j.tibs.2016.01.003</pub-id><pub-id pub-id-type="pmid">26874923</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Cancer Genome Atlas Network</collab></person-group><year iso-8601-date="2012">2012</year><article-title>Comprehensive molecular portraits of human breast tumours</article-title><source>Nature</source><volume>490</volume><fpage>61</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1038/nature11412</pub-id><pub-id pub-id-type="pmid">23000897</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cavalli</surname> <given-names>G</given-names></name><name><surname>Cenci</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Autophagy and protein secretion</article-title><source>Journal of Molecular Biology</source><volume>432</volume><fpage>2525</fpage><lpage>2545</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2020.01.015</pub-id><pub-id pub-id-type="pmid">31972172</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cerezo</surname> <given-names>M</given-names></name><name><surname>Lehraiki</surname> <given-names>A</given-names></name><name><surname>Millet</surname> <given-names>A</given-names></name><name><surname>Rouaud</surname> <given-names>F</given-names></name><name><surname>Plaisant</surname> <given-names>M</given-names></name><name><surname>Jaune</surname> <given-names>E</given-names></name><name><surname>Botton</surname> <given-names>T</given-names></name><name><surname>Ronco</surname> <given-names>C</given-names></name><name><surname>Abbe</surname> <given-names>P</given-names></name><name><surname>Amdouni</surname> <given-names>H</given-names></name><name><surname>Passeron</surname> <given-names>T</given-names></name><name><surname>Hofman</surname> <given-names>V</given-names></name><name><surname>Mograbi</surname> <given-names>B</given-names></name><name><surname>Dabert-Gay</surname> <given-names>AS</given-names></name><name><surname>Debayle</surname> <given-names>D</given-names></name><name><surname>Alcor</surname> <given-names>D</given-names></name><name><surname>Rabhi</surname> <given-names>N</given-names></name><name><surname>Annicotte</surname> <given-names>JS</given-names></name><name><surname>Héliot</surname> <given-names>L</given-names></name><name><surname>Gonzalez-Pisfil</surname> <given-names>M</given-names></name><name><surname>Robert</surname> <given-names>C</given-names></name><name><surname>Moréra</surname> <given-names>S</given-names></name><name><surname>Vigouroux</surname> <given-names>A</given-names></name><name><surname>Gual</surname> <given-names>P</given-names></name><name><surname>Ali</surname> <given-names>MMU</given-names></name><name><surname>Bertolotto</surname> <given-names>C</given-names></name><name><surname>Hofman</surname> <given-names>P</given-names></name><name><surname>Ballotti</surname> <given-names>R</given-names></name><name><surname>Benhida</surname> <given-names>R</given-names></name><name><surname>Rocchi</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Compounds triggering ER stress exert Anti-Melanoma effects and overcome BRAF inhibitor resistance</article-title><source>Cancer Cell</source><volume>30</volume><elocation-id>183</elocation-id><pub-id pub-id-type="doi">10.1016/j.ccell.2016.06.007</pub-id><pub-id pub-id-type="pmid">27479035</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>D</given-names></name><name><surname>Frezza</surname> <given-names>M</given-names></name><name><surname>Schmitt</surname> <given-names>S</given-names></name><name><surname>Kanwar</surname> <given-names>J</given-names></name><name><surname>Dou</surname> <given-names>QP</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives</article-title><source>Current Cancer Drug Targets</source><volume>11</volume><fpage>239</fpage><lpage>253</lpage><pub-id pub-id-type="doi">10.2174/156800911794519752</pub-id><pub-id pub-id-type="pmid">21247388</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>L</given-names></name><name><surname>He</surname> <given-names>J</given-names></name><name><surname>Zhou</surname> <given-names>J</given-names></name><name><surname>Xiao</surname> <given-names>Z</given-names></name><name><surname>Ding</surname> <given-names>N</given-names></name><name><surname>Duan</surname> <given-names>Y</given-names></name><name><surname>Li</surname> <given-names>W</given-names></name><name><surname>Sun</surname> <given-names>LQ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>EIF2A promotes cell survival during paclitaxel treatment in vitro and in vivo</article-title><source>Journal of Cellular and Molecular Medicine</source><volume>23</volume><fpage>6060</fpage><lpage>6071</lpage><pub-id pub-id-type="doi">10.1111/jcmm.14469</pub-id><pub-id pub-id-type="pmid">31211507</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>JJ</given-names></name><name><surname>London</surname> <given-names>IM</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Regulation of protein synthesis by heme-regulated eIF-2 alpha kinase</article-title><source>Trends in Biochemical Sciences</source><volume>20</volume><fpage>105</fpage><lpage>108</lpage><pub-id pub-id-type="doi">10.1016/S0968-0004(00)88975-6</pub-id><pub-id pub-id-type="pmid">7709427</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>Y</given-names></name><name><surname>Zhou</surname> <given-names>X</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Research progress of mTOR inhibitors</article-title><source>European Journal of Medicinal Chemistry</source><volume>208</volume><elocation-id>112820</elocation-id><pub-id pub-id-type="doi">10.1016/j.ejmech.2020.112820</pub-id><pub-id pub-id-type="pmid">32966896</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiang</surname> <given-names>GG</given-names></name><name><surname>Abraham</surname> <given-names>RT</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Targeting the mTOR signaling network in cancer</article-title><source>Trends in Molecular Medicine</source><volume>13</volume><fpage>433</fpage><lpage>442</lpage><pub-id pub-id-type="doi">10.1016/j.molmed.2007.08.001</pub-id><pub-id pub-id-type="pmid">17905659</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiti</surname> <given-names>F</given-names></name><name><surname>Dobson</surname> <given-names>CM</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Protein misfolding, functional amyloid, and human disease</article-title><source>Annual Review of Biochemistry</source><volume>75</volume><fpage>333</fpage><lpage>366</lpage><pub-id pub-id-type="doi">10.1146/annurev.biochem.75.101304.123901</pub-id><pub-id pub-id-type="pmid">16756495</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chude</surname> <given-names>CI</given-names></name><name><surname>Amaravadi</surname> <given-names>RK</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Targeting autophagy in cancer: update on clinical trials and novel inhibitors</article-title><source>International Journal of Molecular Sciences</source><volume>18</volume><elocation-id>1279</elocation-id><pub-id pub-id-type="doi">10.3390/ijms18061279</pub-id><pub-id pub-id-type="pmid">28621712</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Citri</surname> <given-names>A</given-names></name><name><surname>Kochupurakkal</surname> <given-names>BS</given-names></name><name><surname>Yarden</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>The achilles heel of ErbB-2/HER2: regulation by the Hsp90 chaperone machine and potential for pharmacological intervention</article-title><source>Cell Cycle</source><volume>3</volume><fpage>50</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.4161/cc.3.1.607</pub-id><pub-id pub-id-type="pmid">14657666</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clarke</surname> <given-names>R</given-names></name><name><surname>Shajahan</surname> <given-names>AN</given-names></name><name><surname>Wang</surname> <given-names>Y</given-names></name><name><surname>Tyson</surname> <given-names>JJ</given-names></name><name><surname>Riggins</surname> <given-names>RB</given-names></name><name><surname>Weiner</surname> <given-names>LM</given-names></name><name><surname>Bauman</surname> <given-names>WT</given-names></name><name><surname>Xuan</surname> <given-names>J</given-names></name><name><surname>Zhang</surname> <given-names>B</given-names></name><name><surname>Facey</surname> <given-names>C</given-names></name><name><surname>Aiyer</surname> <given-names>H</given-names></name><name><surname>Cook</surname> <given-names>K</given-names></name><name><surname>Hickman</surname> <given-names>FE</given-names></name><name><surname>Tavassoly</surname> <given-names>I</given-names></name><name><surname>Verdugo</surname> <given-names>A</given-names></name><name><surname>Chen</surname> <given-names>C</given-names></name><name><surname>Zwart</surname> <given-names>A</given-names></name><name><surname>Wärri</surname> <given-names>A</given-names></name><name><surname>Hilakivi-Clarke</surname> <given-names>LA</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Endoplasmic reticulum stress, the unfolded protein response, and gene network modeling in antiestrogen resistant breast Cancer</article-title><source>Hormone Molecular Biology and Clinical Investigation</source><volume>5</volume><fpage>35</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1515/HMBCI.2010.073</pub-id><pub-id pub-id-type="pmid">23930139</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cubillos-Ruiz</surname> <given-names>JR</given-names></name><name><surname>Bettigole</surname> <given-names>SE</given-names></name><name><surname>Glimcher</surname> <given-names>LH</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Tumorigenic and immunosuppressive effects of endoplasmic reticulum stress in cancer</article-title><source>Cell</source><volume>168</volume><fpage>692</fpage><lpage>706</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2016.12.004</pub-id><pub-id pub-id-type="pmid">28187289</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cuervo</surname> <given-names>AM</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Autophagy: many paths to the same end</article-title><source>Molecular and Cellular Biochemistry</source><volume>263</volume><fpage>55</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1023/B:MCBI.0000041848.57020.57</pub-id><pub-id pub-id-type="pmid">27520665</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Darini</surname> <given-names>C</given-names></name><name><surname>Ghaddar</surname> <given-names>N</given-names></name><name><surname>Chabot</surname> <given-names>C</given-names></name><name><surname>Assaker</surname> <given-names>G</given-names></name><name><surname>Sabri</surname> <given-names>S</given-names></name><name><surname>Wang</surname> <given-names>S</given-names></name><name><surname>Krishnamoorthy</surname> <given-names>J</given-names></name><name><surname>Buchanan</surname> <given-names>M</given-names></name><name><surname>Aguilar-Mahecha</surname> <given-names>A</given-names></name><name><surname>Abdulkarim</surname> <given-names>B</given-names></name><name><surname>Deschenes</surname> <given-names>J</given-names></name><name><surname>Torres</surname> <given-names>J</given-names></name><name><surname>Ursini-Siegel</surname> <given-names>J</given-names></name><name><surname>Basik</surname> <given-names>M</given-names></name><name><surname>Koromilas</surname> <given-names>AE</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>An integrated stress response via PKR suppresses HER2+ cancers and improves trastuzumab therapy</article-title><source>Nature Communications</source><volume>10</volume><elocation-id>2139</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-019-10138-8</pub-id><pub-id pub-id-type="pmid">31086176</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deshaies</surname> <given-names>RJ</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Proteotoxic crisis, the ubiquitin-proteasome system, and cancer therapy</article-title><source>BMC Biology</source><volume>12</volume><elocation-id>94</elocation-id><pub-id pub-id-type="doi">10.1186/s12915-014-0094-0</pub-id><pub-id pub-id-type="pmid">25385277</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doddareddy</surname> <given-names>MR</given-names></name><name><surname>Thorat</surname> <given-names>DA</given-names></name><name><surname>Seo</surname> <given-names>SH</given-names></name><name><surname>Hong</surname> <given-names>TJ</given-names></name><name><surname>Cho</surname> <given-names>YS</given-names></name><name><surname>Hahn</surname> <given-names>JS</given-names></name><name><surname>Pae</surname> <given-names>AN</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Structure based design of heat shock protein 90 inhibitors acting as anticancer agents</article-title><source>Bioorganic &amp; Medicinal Chemistry</source><volume>19</volume><fpage>1714</fpage><lpage>1720</lpage><pub-id pub-id-type="doi">10.1016/j.bmc.2011.01.023</pub-id><pub-id pub-id-type="pmid">21306907</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Evans</surname> <given-names>CG</given-names></name><name><surname>Chang</surname> <given-names>L</given-names></name><name><surname>Gestwicki</surname> <given-names>JE</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Heat shock protein 70 (hsp70) as an emerging drug target</article-title><source>Journal of Medicinal Chemistry</source><volume>53</volume><fpage>4585</fpage><lpage>4602</lpage><pub-id pub-id-type="doi">10.1021/jm100054f</pub-id><pub-id pub-id-type="pmid">20334364</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fan</surname> <given-names>T</given-names></name><name><surname>Huang</surname> <given-names>Z</given-names></name><name><surname>Wang</surname> <given-names>W</given-names></name><name><surname>Zhang</surname> <given-names>B</given-names></name><name><surname>Xu</surname> <given-names>Y</given-names></name><name><surname>Mao</surname> <given-names>Z</given-names></name><name><surname>Chen</surname> <given-names>L</given-names></name><name><surname>Hu</surname> <given-names>H</given-names></name><name><surname>Geng</surname> <given-names>Q</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Proteasome inhibition promotes autophagy and protects from endoplasmic reticulum stress in rat alveolar macrophages exposed to hypoxia-reoxygenation injury</article-title><source>Journal of Cellular Physiology</source><volume>233</volume><fpage>6748</fpage><lpage>6758</lpage><pub-id pub-id-type="doi">10.1002/jcp.26516</pub-id><pub-id pub-id-type="pmid">29741768</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fewell</surname> <given-names>SW</given-names></name><name><surname>Smith</surname> <given-names>CM</given-names></name><name><surname>Lyon</surname> <given-names>MA</given-names></name><name><surname>Dumitrescu</surname> <given-names>TP</given-names></name><name><surname>Wipf</surname> <given-names>P</given-names></name><name><surname>Day</surname> <given-names>BW</given-names></name><name><surname>Brodsky</surname> <given-names>JL</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Small molecule modulators of endogenous and co-chaperone-stimulated Hsp70 ATPase activity</article-title><source>Journal of Biological Chemistry</source><volume>279</volume><fpage>51131</fpage><lpage>51140</lpage><pub-id pub-id-type="doi">10.1074/jbc.M404857200</pub-id><pub-id pub-id-type="pmid">15448148</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Füllgrabe</surname> <given-names>J</given-names></name><name><surname>Ghislat</surname> <given-names>G</given-names></name><name><surname>Cho</surname> <given-names>DH</given-names></name><name><surname>Rubinsztein</surname> <given-names>DC</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Transcriptional regulation of mammalian autophagy at a glance</article-title><source>Journal of Cell Science</source><volume>129</volume><fpage>3059</fpage><lpage>3066</lpage><pub-id pub-id-type="doi">10.1242/jcs.188920</pub-id><pub-id pub-id-type="pmid">27528206</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galehdar</surname> <given-names>Z</given-names></name><name><surname>Swan</surname> <given-names>P</given-names></name><name><surname>Fuerth</surname> <given-names>B</given-names></name><name><surname>Callaghan</surname> <given-names>SM</given-names></name><name><surname>Park</surname> <given-names>DS</given-names></name><name><surname>Cregan</surname> <given-names>SP</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Neuronal apoptosis induced by endoplasmic reticulum stress is regulated by ATF4-CHOP-mediated induction of the Bcl-2 homology 3-only member PUMA</article-title><source>Journal of Neuroscience</source><volume>30</volume><fpage>16938</fpage><lpage>16948</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.1598-10.2010</pub-id><pub-id pub-id-type="pmid">21159964</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia</surname> <given-names>D</given-names></name><name><surname>Shaw</surname> <given-names>RJ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>AMPK: mechanisms of cellular energy sensing and restoration of metabolic balance</article-title><source>Molecular Cell</source><volume>66</volume><fpage>789</fpage><lpage>800</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2017.05.032</pub-id><pub-id pub-id-type="pmid">28622524</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garrido</surname> <given-names>C</given-names></name><name><surname>Brunet</surname> <given-names>M</given-names></name><name><surname>Didelot</surname> <given-names>C</given-names></name><name><surname>Zermati</surname> <given-names>Y</given-names></name><name><surname>Schmitt</surname> <given-names>E</given-names></name><name><surname>Kroemer</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Heat shock proteins 27 and 70: anti-apoptotic proteins with tumorigenic properties</article-title><source>Cell Cycle</source><volume>5</volume><fpage>2592</fpage><lpage>2601</lpage><pub-id pub-id-type="doi">10.4161/cc.5.22.3448</pub-id><pub-id pub-id-type="pmid">17106261</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gestwicki</surname> <given-names>JE</given-names></name><name><surname>Shao</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Inhibitors and chemical probes for molecular chaperone networks</article-title><source>Journal of Biological Chemistry</source><volume>294</volume><fpage>2151</fpage><lpage>2161</lpage><pub-id pub-id-type="doi">10.1074/jbc.TM118.002813</pub-id><pub-id pub-id-type="pmid">30213856</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gleixner</surname> <given-names>AM</given-names></name><name><surname>Hutchison</surname> <given-names>DF</given-names></name><name><surname>Sannino</surname> <given-names>S</given-names></name><name><surname>Bhatia</surname> <given-names>TN</given-names></name><name><surname>Leak</surname> <given-names>LC</given-names></name><name><surname>Flaherty</surname> <given-names>PT</given-names></name><name><surname>Wipf</surname> <given-names>P</given-names></name><name><surname>Brodsky</surname> <given-names>JL</given-names></name><name><surname>Leak</surname> <given-names>RK</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title><italic>N</italic>-Acetyl-l-cysteine protects astrocytes against proteotoxicity without recourse to glutathione</article-title><source>Molecular Pharmacology</source><volume>92</volume><fpage>564</fpage><lpage>575</lpage><pub-id pub-id-type="doi">10.1124/mol.117.109926</pub-id><pub-id pub-id-type="pmid">28830914</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goloudina</surname> <given-names>AR</given-names></name><name><surname>Demidov</surname> <given-names>ON</given-names></name><name><surname>Garrido</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Inhibition of HSP70: a challenging anti-cancer strategy</article-title><source>Cancer Letters</source><volume>325</volume><fpage>117</fpage><lpage>124</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2012.06.003</pub-id><pub-id pub-id-type="pmid">22750096</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grandjean</surname> <given-names>JMD</given-names></name><name><surname>Wiseman</surname> <given-names>RL</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Small molecule strategies to harness the unfolded protein response: where do we go from here?</article-title><source>Journal of Biological Chemistry</source><volume>295</volume><fpage>15692</fpage><lpage>15711</lpage><pub-id pub-id-type="doi">10.1074/jbc.REV120.010218</pub-id><pub-id pub-id-type="pmid">32887796</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grzmil</surname> <given-names>M</given-names></name><name><surname>Hemmings</surname> <given-names>BA</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Translation regulation as a therapeutic target in cancer</article-title><source>Cancer Research</source><volume>72</volume><fpage>3891</fpage><lpage>3900</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-12-0026</pub-id><pub-id pub-id-type="pmid">22850420</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname> <given-names>F</given-names></name><name><surname>Rocha</surname> <given-names>K</given-names></name><name><surname>Bali</surname> <given-names>P</given-names></name><name><surname>Pranpat</surname> <given-names>M</given-names></name><name><surname>Fiskus</surname> <given-names>W</given-names></name><name><surname>Boyapalle</surname> <given-names>S</given-names></name><name><surname>Kumaraswamy</surname> <given-names>S</given-names></name><name><surname>Balasis</surname> <given-names>M</given-names></name><name><surname>Greedy</surname> <given-names>B</given-names></name><name><surname>Armitage</surname> <given-names>ES</given-names></name><name><surname>Lawrence</surname> <given-names>N</given-names></name><name><surname>Bhalla</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Abrogation of heat shock protein 70 induction as a strategy to increase antileukemia activity of heat shock protein 90 inhibitor 17-allylamino-demethoxy geldanamycin</article-title><source>Cancer Research</source><volume>65</volume><fpage>10536</fpage><lpage>10544</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-05-1799</pub-id><pub-id pub-id-type="pmid">16288046</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname> <given-names>L</given-names></name><name><surname>Chi</surname> <given-names>Y</given-names></name><name><surname>Xue</surname> <given-names>J</given-names></name><name><surname>Ma</surname> <given-names>L</given-names></name><name><surname>Shao</surname> <given-names>Z</given-names></name><name><surname>Wu</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Phosphorylated eIF2α predicts disease-free survival in triple-negative breast cancer patients</article-title><source>Scientific Reports</source><volume>7</volume><elocation-id>44674</elocation-id><pub-id pub-id-type="doi">10.1038/srep44674</pub-id><pub-id pub-id-type="pmid">28294178</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname> <given-names>X</given-names></name><name><surname>Aviles</surname> <given-names>G</given-names></name><name><surname>Liu</surname> <given-names>Y</given-names></name><name><surname>Tian</surname> <given-names>R</given-names></name><name><surname>Unger</surname> <given-names>BA</given-names></name><name><surname>Lin</surname> <given-names>YT</given-names></name><name><surname>Wiita</surname> <given-names>AP</given-names></name><name><surname>Xu</surname> <given-names>K</given-names></name><name><surname>Correia</surname> <given-names>MA</given-names></name><name><surname>Kampmann</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Mitochondrial stress is relayed to the cytosol by an OMA1-DELE1-HRI pathway</article-title><source>Nature</source><volume>579</volume><fpage>427</fpage><lpage>432</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2078-2</pub-id><pub-id pub-id-type="pmid">32132707</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Halliday</surname> <given-names>M</given-names></name><name><surname>Radford</surname> <given-names>H</given-names></name><name><surname>Sekine</surname> <given-names>Y</given-names></name><name><surname>Moreno</surname> <given-names>J</given-names></name><name><surname>Verity</surname> <given-names>N</given-names></name><name><surname>le Quesne</surname> <given-names>J</given-names></name><name><surname>Ortori</surname> <given-names>CA</given-names></name><name><surname>Barrett</surname> <given-names>DA</given-names></name><name><surname>Fromont</surname> <given-names>C</given-names></name><name><surname>Fischer</surname> <given-names>PM</given-names></name><name><surname>Harding</surname> <given-names>HP</given-names></name><name><surname>Ron</surname> <given-names>D</given-names></name><name><surname>Mallucci</surname> <given-names>GR</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Partial restoration of protein synthesis rates by the small molecule ISRIB prevents neurodegeneration without pancreatic toxicity</article-title><source>Cell Death &amp; Disease</source><volume>6</volume><elocation-id>e1672</elocation-id><pub-id pub-id-type="doi">10.1038/cddis.2015.49</pub-id><pub-id pub-id-type="pmid">25741597</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harding</surname> <given-names>HP</given-names></name><name><surname>Zhang</surname> <given-names>Y</given-names></name><name><surname>Bertolotti</surname> <given-names>A</given-names></name><name><surname>Zeng</surname> <given-names>H</given-names></name><name><surname>Ron</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Perk is essential for translational regulation and cell survival during the unfolded protein response</article-title><source>Molecular Cell</source><volume>5</volume><fpage>897</fpage><lpage>904</lpage><pub-id pub-id-type="doi">10.1016/S1097-2765(00)80330-5</pub-id><pub-id pub-id-type="pmid">10882126</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harding</surname> <given-names>HP</given-names></name><name><surname>Zhang</surname> <given-names>Y</given-names></name><name><surname>Zeng</surname> <given-names>H</given-names></name><name><surname>Novoa</surname> <given-names>I</given-names></name><name><surname>Lu</surname> <given-names>PD</given-names></name><name><surname>Calfon</surname> <given-names>M</given-names></name><name><surname>Sadri</surname> <given-names>N</given-names></name><name><surname>Yun</surname> <given-names>C</given-names></name><name><surname>Popko</surname> <given-names>B</given-names></name><name><surname>Paules</surname> <given-names>R</given-names></name><name><surname>Stojdl</surname> <given-names>DF</given-names></name><name><surname>Bell</surname> <given-names>JC</given-names></name><name><surname>Hettmann</surname> <given-names>T</given-names></name><name><surname>Leiden</surname> <given-names>JM</given-names></name><name><surname>Ron</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>An integrated stress response regulates amino acid metabolism and resistance to oxidative stress</article-title><source>Molecular Cell</source><volume>11</volume><fpage>619</fpage><lpage>633</lpage><pub-id pub-id-type="doi">10.1016/S1097-2765(03)00105-9</pub-id><pub-id pub-id-type="pmid">12667446</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harding</surname> <given-names>HP</given-names></name><name><surname>Ordonez</surname> <given-names>A</given-names></name><name><surname>Allen</surname> <given-names>F</given-names></name><name><surname>Parts</surname> <given-names>L</given-names></name><name><surname>Inglis</surname> <given-names>AJ</given-names></name><name><surname>Williams</surname> <given-names>RL</given-names></name><name><surname>Ron</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The ribosomal P-stalk couples amino acid starvation to GCN2 activation in mammalian cells</article-title><source>eLife</source><volume>8</volume><elocation-id>e50149</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.50149</pub-id><pub-id pub-id-type="pmid">31749445</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hazari</surname> <given-names>YM</given-names></name><name><surname>Bashir</surname> <given-names>A</given-names></name><name><surname>Haq</surname> <given-names>EU</given-names></name><name><surname>Fazili</surname> <given-names>KM</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Emerging tale of UPR and cancer: an essentiality for malignancy</article-title><source>Tumor Biology</source><volume>37</volume><fpage>14381</fpage><lpage>14390</lpage><pub-id pub-id-type="doi">10.1007/s13277-016-5343-0</pub-id><pub-id pub-id-type="pmid">27629140</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haze</surname> <given-names>K</given-names></name><name><surname>Yoshida</surname> <given-names>H</given-names></name><name><surname>Yanagi</surname> <given-names>H</given-names></name><name><surname>Yura</surname> <given-names>T</given-names></name><name><surname>Mori</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Mammalian transcription factor ATF6 is synthesized as a transmembrane protein and activated by proteolysis in response to endoplasmic reticulum stress</article-title><source>Molecular Biology of the Cell</source><volume>10</volume><fpage>3787</fpage><lpage>3799</lpage><pub-id pub-id-type="doi">10.1091/mbc.10.11.3787</pub-id><pub-id pub-id-type="pmid">10564271</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname> <given-names>C</given-names></name><name><surname>Klionsky</surname> <given-names>DJ</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Regulation mechanisms and signaling pathways of autophagy</article-title><source>Annual Review of Genetics</source><volume>43</volume><fpage>67</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1146/annurev-genet-102808-114910</pub-id><pub-id pub-id-type="pmid">19653858</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hetz</surname> <given-names>C</given-names></name><name><surname>Zhang</surname> <given-names>K</given-names></name><name><surname>Kaufman</surname> <given-names>RJ</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Mechanisms, regulation and functions of the unfolded protein response</article-title><source>Nature Reviews Molecular Cell Biology</source><volume>21</volume><fpage>421</fpage><lpage>438</lpage><pub-id pub-id-type="doi">10.1038/s41580-020-0250-z</pub-id><pub-id pub-id-type="pmid">32457508</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hindupur</surname> <given-names>SK</given-names></name><name><surname>González</surname> <given-names>A</given-names></name><name><surname>Hall</surname> <given-names>MN</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The opposing actions of target of rapamycin and AMP-activated protein kinase in cell growth control</article-title><source>Cold Spring Harbor Perspectives in Biology</source><volume>7</volume><elocation-id>a019141</elocation-id><pub-id pub-id-type="doi">10.1101/cshperspect.a019141</pub-id><pub-id pub-id-type="pmid">26238356</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horimoto</surname> <given-names>S</given-names></name><name><surname>Ninagawa</surname> <given-names>S</given-names></name><name><surname>Okada</surname> <given-names>T</given-names></name><name><surname>Koba</surname> <given-names>H</given-names></name><name><surname>Sugimoto</surname> <given-names>T</given-names></name><name><surname>Kamiya</surname> <given-names>Y</given-names></name><name><surname>Kato</surname> <given-names>K</given-names></name><name><surname>Takeda</surname> <given-names>S</given-names></name><name><surname>Mori</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>The unfolded protein response transducer ATF6 represents a novel transmembrane-type endoplasmic reticulum-associated degradation substrate requiring both mannose trimming and SEL1L protein</article-title><source>Journal of Biological Chemistry</source><volume>288</volume><fpage>31517</fpage><lpage>31527</lpage><pub-id pub-id-type="doi">10.1074/jbc.M113.476010</pub-id><pub-id pub-id-type="pmid">24043630</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huryn</surname> <given-names>DM</given-names></name><name><surname>Brodsky</surname> <given-names>JL</given-names></name><name><surname>Brummond</surname> <given-names>KM</given-names></name><name><surname>Chambers</surname> <given-names>PG</given-names></name><name><surname>Eyer</surname> <given-names>B</given-names></name><name><surname>Ireland</surname> <given-names>AW</given-names></name><name><surname>Kawasumi</surname> <given-names>M</given-names></name><name><surname>Laporte</surname> <given-names>MG</given-names></name><name><surname>Lloyd</surname> <given-names>K</given-names></name><name><surname>Manteau</surname> <given-names>B</given-names></name><name><surname>Nghiem</surname> <given-names>P</given-names></name><name><surname>Quade</surname> <given-names>B</given-names></name><name><surname>Seguin</surname> <given-names>SP</given-names></name><name><surname>Wipf</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Chemical methodology as a source of small-molecule checkpoint inhibitors and heat shock protein 70 (Hsp70) modulators</article-title><source>PNAS</source><volume>108</volume><fpage>6757</fpage><lpage>6762</lpage><pub-id pub-id-type="doi">10.1073/pnas.1015251108</pub-id><pub-id pub-id-type="pmid">21502524</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inglis</surname> <given-names>AJ</given-names></name><name><surname>Masson</surname> <given-names>GR</given-names></name><name><surname>Shao</surname> <given-names>S</given-names></name><name><surname>Perisic</surname> <given-names>O</given-names></name><name><surname>McLaughlin</surname> <given-names>SH</given-names></name><name><surname>Hegde</surname> <given-names>RS</given-names></name><name><surname>Williams</surname> <given-names>RL</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Activation of GCN2 by the ribosomal P-stalk</article-title><source>PNAS</source><volume>116</volume><fpage>4946</fpage><lpage>4954</lpage><pub-id pub-id-type="doi">10.1073/pnas.1813352116</pub-id><pub-id pub-id-type="pmid">30804176</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ishida</surname> <given-names>Y</given-names></name><name><surname>Yamamoto</surname> <given-names>A</given-names></name><name><surname>Kitamura</surname> <given-names>A</given-names></name><name><surname>Lamandé</surname> <given-names>SR</given-names></name><name><surname>Yoshimori</surname> <given-names>T</given-names></name><name><surname>Bateman</surname> <given-names>JF</given-names></name><name><surname>Kubota</surname> <given-names>H</given-names></name><name><surname>Nagata</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Autophagic elimination of misfolded procollagen aggregates in the endoplasmic reticulum as a means of cell protection</article-title><source>Molecular Biology of the Cell</source><volume>20</volume><fpage>2744</fpage><lpage>2754</lpage><pub-id pub-id-type="doi">10.1091/mbc.e08-11-1092</pub-id><pub-id pub-id-type="pmid">19357194</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jayaraj</surname> <given-names>GG</given-names></name><name><surname>Hipp</surname> <given-names>MS</given-names></name><name><surname>Hartl</surname> <given-names>FU</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Functional modules of the proteostasis network</article-title><source>Cold Spring Harbor Perspectives in Biology</source><volume>12</volume><elocation-id>a033951</elocation-id><pub-id pub-id-type="doi">10.1101/cshperspect.a033951</pub-id><pub-id pub-id-type="pmid">30833457</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joshi</surname> <given-names>S</given-names></name><name><surname>Wang</surname> <given-names>T</given-names></name><name><surname>Araujo</surname> <given-names>TLS</given-names></name><name><surname>Sharma</surname> <given-names>S</given-names></name><name><surname>Brodsky</surname> <given-names>JL</given-names></name><name><surname>Chiosis</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Adapting to stress - chaperome networks in cancer</article-title><source>Nature Reviews Cancer</source><volume>18</volume><fpage>562</fpage><lpage>575</lpage><pub-id pub-id-type="doi">10.1038/s41568-018-0020-9</pub-id><pub-id pub-id-type="pmid">29795326</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kabeya</surname> <given-names>Y</given-names></name><name><surname>Mizushima</surname> <given-names>N</given-names></name><name><surname>Ueno</surname> <given-names>T</given-names></name><name><surname>Yamamoto</surname> <given-names>A</given-names></name><name><surname>Kirisako</surname> <given-names>T</given-names></name><name><surname>Noda</surname> <given-names>T</given-names></name><name><surname>Kominami</surname> <given-names>E</given-names></name><name><surname>Ohsumi</surname> <given-names>Y</given-names></name><name><surname>Yoshimori</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing</article-title><source>The EMBO Journal</source><volume>19</volume><fpage>5720</fpage><lpage>5728</lpage><pub-id pub-id-type="doi">10.1093/emboj/19.21.5720</pub-id><pub-id pub-id-type="pmid">11060023</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kagawa</surname> <given-names>S</given-names></name><name><surname>Gu</surname> <given-names>J</given-names></name><name><surname>Honda</surname> <given-names>T</given-names></name><name><surname>McDonnell</surname> <given-names>TJ</given-names></name><name><surname>Swisher</surname> <given-names>SG</given-names></name><name><surname>Roth</surname> <given-names>JA</given-names></name><name><surname>Fang</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Deficiency of caspase-3 in MCF7 cells blocks Bax-mediated nuclear fragmentation but not cell death</article-title><source>Clinical Cancer Research</source><volume>7</volume><fpage>1474</fpage><lpage>1480</lpage><pub-id pub-id-type="pmid">11350920</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kardos</surname> <given-names>GR</given-names></name><name><surname>Gowda</surname> <given-names>R</given-names></name><name><surname>Dinavahi</surname> <given-names>SS</given-names></name><name><surname>Kimball</surname> <given-names>S</given-names></name><name><surname>Robertson</surname> <given-names>GP</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Salubrinal in combination with 4E1RCat synergistically impairs melanoma development by disrupting the protein synthetic machinery</article-title><source>Frontiers in Oncology</source><volume>10</volume><elocation-id>834</elocation-id><pub-id pub-id-type="doi">10.3389/fonc.2020.00834</pub-id><pub-id pub-id-type="pmid">32637352</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname> <given-names>J</given-names></name><name><surname>Kundu</surname> <given-names>M</given-names></name><name><surname>Viollet</surname> <given-names>B</given-names></name><name><surname>Guan</surname> <given-names>KL</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1</article-title><source>Nature Cell Biology</source><volume>13</volume><fpage>132</fpage><lpage>141</lpage><pub-id pub-id-type="doi">10.1038/ncb2152</pub-id><pub-id pub-id-type="pmid">21258367</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname> <given-names>H</given-names></name><name><surname>Bhattacharya</surname> <given-names>A</given-names></name><name><surname>Qi</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Endoplasmic reticulum quality control in cancer: friend or foe</article-title><source>Seminars in Cancer Biology</source><volume>33</volume><fpage>25</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1016/j.semcancer.2015.02.003</pub-id><pub-id pub-id-type="pmid">25794824</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kimura</surname> <given-names>S</given-names></name><name><surname>Noda</surname> <given-names>T</given-names></name><name><surname>Yoshimori</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Dissection of the autophagosome maturation process by a novel reporter protein, tandem fluorescent-tagged LC3</article-title><source>Autophagy</source><volume>3</volume><fpage>452</fpage><lpage>460</lpage><pub-id pub-id-type="doi">10.4161/auto.4451</pub-id><pub-id pub-id-type="pmid">17534139</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klionsky</surname> <given-names>DJ</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Autophagy</article-title><source>Current Biology</source><volume>15</volume><fpage>R282</fpage><lpage>R283</lpage><pub-id pub-id-type="doi">10.1016/j.cub.2005.04.013</pub-id><pub-id pub-id-type="pmid">15854889</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klionsky</surname> <given-names>DJ</given-names></name><name><surname>Abdelmohsen</surname> <given-names>K</given-names></name><name><surname>Abe</surname> <given-names>A</given-names></name><name><surname>Abedin</surname> <given-names>MJ</given-names></name><name><surname>Abeliovich</surname> <given-names>H</given-names></name><name><surname>Acevedo Arozena</surname> <given-names>A</given-names></name><name><surname>Adachi</surname> <given-names>H</given-names></name><name><surname>Adams</surname> <given-names>CM</given-names></name><name><surname>Adams</surname> <given-names>PD</given-names></name><name><surname>Adeli</surname> <given-names>K</given-names></name><name><surname>Adhihetty</surname> <given-names>PJ</given-names></name><name><surname>Adler</surname> <given-names>SG</given-names></name><name><surname>Agam</surname> <given-names>G</given-names></name><name><surname>Agarwal</surname> <given-names>R</given-names></name><name><surname>Aghi</surname> <given-names>MK</given-names></name><name><surname>Agnello</surname> <given-names>M</given-names></name><name><surname>Agostinis</surname> <given-names>P</given-names></name><name><surname>Aguilar</surname> <given-names>PV</given-names></name><name><surname>Aguirre-Ghiso</surname> <given-names>J</given-names></name><name><surname>Airoldi</surname> <given-names>EM</given-names></name><name><surname>Ait-Si-Ali</surname> <given-names>S</given-names></name><name><surname>Akematsu</surname> <given-names>T</given-names></name><name><surname>Akporiaye</surname> <given-names>ET</given-names></name><name><surname>Al-Rubeai</surname> <given-names>M</given-names></name><name><surname>Albaiceta</surname> <given-names>GM</given-names></name><name><surname>Albanese</surname> <given-names>C</given-names></name><name><surname>Albani</surname> <given-names>D</given-names></name><name><surname>Albert</surname> <given-names>ML</given-names></name><name><surname>Aldudo</surname> <given-names>J</given-names></name><name><surname>Algül</surname> <given-names>H</given-names></name><name><surname>Alirezaei</surname> <given-names>M</given-names></name><name><surname>Alloza</surname> <given-names>I</given-names></name><name><surname>Almasan</surname> <given-names>A</given-names></name><name><surname>Almonte-Beceril</surname> <given-names>M</given-names></name><name><surname>Alnemri</surname> <given-names>ES</given-names></name><name><surname>Alonso</surname> <given-names>C</given-names></name><name><surname>Altan-Bonnet</surname> <given-names>N</given-names></name><name><surname>Altieri</surname> <given-names>DC</given-names></name><name><surname>Alvarez</surname> <given-names>S</given-names></name><name><surname>Alvarez-Erviti</surname> <given-names>L</given-names></name><name><surname>Alves</surname> <given-names>S</given-names></name><name><surname>Amadoro</surname> <given-names>G</given-names></name><name><surname>Amano</surname> <given-names>A</given-names></name><name><surname>Amantini</surname> <given-names>C</given-names></name><name><surname>Ambrosio</surname> <given-names>S</given-names></name><name><surname>Amelio</surname> <given-names>I</given-names></name><name><surname>Amer</surname> <given-names>AO</given-names></name><name><surname>Amessou</surname> <given-names>M</given-names></name><name><surname>Amon</surname> <given-names>A</given-names></name><name><surname>An</surname> <given-names>Z</given-names></name><name><surname>Anania</surname> <given-names>FA</given-names></name><name><surname>Andersen</surname> <given-names>SU</given-names></name><name><surname>Andley</surname> <given-names>UP</given-names></name><name><surname>Andreadi</surname> <given-names>CK</given-names></name><name><surname>Andrieu-Abadie</surname> <given-names>N</given-names></name><name><surname>Anel</surname> <given-names>A</given-names></name><name><surname>Ann</surname> <given-names>DK</given-names></name><name><surname>Anoopkumar-Dukie</surname> <given-names>S</given-names></name><name><surname>Antonioli</surname> <given-names>M</given-names></name><name><surname>Aoki</surname> <given-names>H</given-names></name><name><surname>Apostolova</surname> <given-names>N</given-names></name><name><surname>Aquila</surname> <given-names>S</given-names></name><name><surname>Aquilano</surname> <given-names>K</given-names></name><name><surname>Araki</surname> <given-names>K</given-names></name><name><surname>Arama</surname> <given-names>E</given-names></name><name><surname>Aranda</surname> <given-names>A</given-names></name><name><surname>Araya</surname> <given-names>J</given-names></name><name><surname>Arcaro</surname> <given-names>A</given-names></name><name><surname>Arias</surname> <given-names>E</given-names></name><name><surname>Arimoto</surname> <given-names>H</given-names></name><name><surname>Ariosa</surname> <given-names>AR</given-names></name><name><surname>Armstrong</surname> <given-names>JL</given-names></name><name><surname>Arnould</surname> <given-names>T</given-names></name><name><surname>Arsov</surname> <given-names>I</given-names></name><name><surname>Asanuma</surname> <given-names>K</given-names></name><name><surname>Askanas</surname> <given-names>V</given-names></name><name><surname>Asselin</surname> <given-names>E</given-names></name><name><surname>Atarashi</surname> <given-names>R</given-names></name><name><surname>Atherton</surname> <given-names>SS</given-names></name><name><surname>Atkin</surname> <given-names>JD</given-names></name><name><surname>Attardi</surname> <given-names>LD</given-names></name><name><surname>Auberger</surname> <given-names>P</given-names></name><name><surname>Auburger</surname> <given-names>G</given-names></name><name><surname>Aurelian</surname> <given-names>L</given-names></name><name><surname>Autelli</surname> <given-names>R</given-names></name><name><surname>Avagliano</surname> <given-names>L</given-names></name><name><surname>Avantaggiati</surname> <given-names>ML</given-names></name><name><surname>Avrahami</surname> <given-names>L</given-names></name><name><surname>Awale</surname> <given-names>S</given-names></name><name><surname>Azad</surname> <given-names>N</given-names></name><name><surname>Bachetti</surname> <given-names>T</given-names></name><name><surname>Backer</surname> <given-names>JM</given-names></name><name><surname>Bae</surname> <given-names>DH</given-names></name><name><surname>Bae</surname> <given-names>JS</given-names></name><name><surname>Bae</surname> <given-names>ON</given-names></name><name><surname>Bae</surname> <given-names>SH</given-names></name><name><surname>Baehrecke</surname> <given-names>EH</given-names></name><name><surname>Baek</surname> <given-names>SH</given-names></name><name><surname>Baghdiguian</surname> <given-names>S</given-names></name><name><surname>Bagniewska-Zadworna</surname> <given-names>A</given-names></name><name><surname>Bai</surname> <given-names>H</given-names></name><name><surname>Bai</surname> <given-names>J</given-names></name><name><surname>Bai</surname> <given-names>XY</given-names></name><name><surname>Bailly</surname> <given-names>Y</given-names></name><name><surname>Balaji</surname> <given-names>KN</given-names></name><name><surname>Balduini</surname> <given-names>W</given-names></name><name><surname>Ballabio</surname> <given-names>A</given-names></name><name><surname>Balzan</surname> <given-names>R</given-names></name><name><surname>Banerjee</surname> <given-names>R</given-names></name><name><surname>Bánhegyi</surname> <given-names>G</given-names></name><name><surname>Bao</surname> <given-names>H</given-names></name><name><surname>Barbeau</surname> <given-names>B</given-names></name><name><surname>Barrachina</surname> <given-names>MD</given-names></name><name><surname>Barreiro</surname> <given-names>E</given-names></name><name><surname>Bartel</surname> <given-names>B</given-names></name><name><surname>Bartolomé</surname> <given-names>A</given-names></name><name><surname>Bassham</surname> <given-names>DC</given-names></name><name><surname>Bassi</surname> <given-names>MT</given-names></name><name><surname>Bast</surname> <given-names>RC</given-names></name><name><surname>Basu</surname> <given-names>A</given-names></name><name><surname>Batista</surname> <given-names>MT</given-names></name><name><surname>Batoko</surname> <given-names>H</given-names></name><name><surname>Battino</surname> <given-names>M</given-names></name><name><surname>Bauckman</surname> <given-names>K</given-names></name><name><surname>Baumgarner</surname> <given-names>BL</given-names></name><name><surname>Bayer</surname> <given-names>KU</given-names></name><name><surname>Beale</surname> <given-names>R</given-names></name><name><surname>Beaulieu</surname> <given-names>JF</given-names></name><name><surname>Beck</surname> <given-names>GR</given-names></name><name><surname>Becker</surname> <given-names>C</given-names></name><name><surname>Beckham</surname> <given-names>JD</given-names></name><name><surname>Bédard</surname> <given-names>PA</given-names></name><name><surname>Bednarski</surname> <given-names>PJ</given-names></name><name><surname>Begley</surname> <given-names>TJ</given-names></name><name><surname>Behl</surname> <given-names>C</given-names></name><name><surname>Behrends</surname> <given-names>C</given-names></name><name><surname>Behrens</surname> <given-names>GM</given-names></name><name><surname>Behrns</surname> <given-names>KE</given-names></name><name><surname>Bejarano</surname> <given-names>E</given-names></name><name><surname>Belaid</surname> <given-names>A</given-names></name><name><surname>Belleudi</surname> <given-names>F</given-names></name><name><surname>Bénard</surname> <given-names>G</given-names></name><name><surname>Berchem</surname> <given-names>G</given-names></name><name><surname>Bergamaschi</surname> <given-names>D</given-names></name><name><surname>Bergami</surname> <given-names>M</given-names></name><name><surname>Berkhout</surname> <given-names>B</given-names></name><name><surname>Berliocchi</surname> <given-names>L</given-names></name><name><surname>Bernard</surname> <given-names>A</given-names></name><name><surname>Bernard</surname> <given-names>M</given-names></name><name><surname>Bernassola</surname> <given-names>F</given-names></name><name><surname>Bertolotti</surname> <given-names>A</given-names></name><name><surname>Bess</surname> <given-names>AS</given-names></name><name><surname>Besteiro</surname> <given-names>S</given-names></name><name><surname>Bettuzzi</surname> <given-names>S</given-names></name><name><surname>Bhalla</surname> <given-names>S</given-names></name><name><surname>Bhattacharyya</surname> <given-names>S</given-names></name><name><surname>Bhutia</surname> <given-names>SK</given-names></name><name><surname>Biagosch</surname> <given-names>C</given-names></name><name><surname>Bianchi</surname> <given-names>MW</given-names></name><name><surname>Biard-Piechaczyk</surname> <given-names>M</given-names></name><name><surname>Billes</surname> <given-names>V</given-names></name><name><surname>Bincoletto</surname> <given-names>C</given-names></name><name><surname>Bingol</surname> <given-names>B</given-names></name><name><surname>Bird</surname> <given-names>SW</given-names></name><name><surname>Bitoun</surname> <given-names>M</given-names></name><name><surname>Bjedov</surname> <given-names>I</given-names></name><name><surname>Blackstone</surname> <given-names>C</given-names></name><name><surname>Blanc</surname> <given-names>L</given-names></name><name><surname>Blanco</surname> <given-names>GA</given-names></name><name><surname>Blomhoff</surname> <given-names>HK</given-names></name><name><surname>Boada-Romero</surname> <given-names>E</given-names></name><name><surname>Böckler</surname> <given-names>S</given-names></name><name><surname>Boes</surname> <given-names>M</given-names></name><name><surname>Boesze-Battaglia</surname> <given-names>K</given-names></name><name><surname>Boise</surname> <given-names>LH</given-names></name><name><surname>Bolino</surname> <given-names>A</given-names></name><name><surname>Boman</surname> <given-names>A</given-names></name><name><surname>Bonaldo</surname> <given-names>P</given-names></name><name><surname>Bordi</surname> <given-names>M</given-names></name><name><surname>Bosch</surname> <given-names>J</given-names></name><name><surname>Botana</surname> <given-names>LM</given-names></name><name><surname>Botti</surname> <given-names>J</given-names></name><name><surname>Bou</surname> <given-names>G</given-names></name><name><surname>Bouché</surname> <given-names>M</given-names></name><name><surname>Bouchecareilh</surname> <given-names>M</given-names></name><name><surname>Boucher</surname> <given-names>MJ</given-names></name><name><surname>Boulton</surname> <given-names>ME</given-names></name><name><surname>Bouret</surname> <given-names>SG</given-names></name><name><surname>Boya</surname> <given-names>P</given-names></name><name><surname>Boyer-Guittaut</surname> <given-names>M</given-names></name><name><surname>Bozhkov</surname> <given-names>PV</given-names></name><name><surname>Brady</surname> <given-names>N</given-names></name><name><surname>Braga</surname> <given-names>VM</given-names></name><name><surname>Brancolini</surname> <given-names>C</given-names></name><name><surname>Braus</surname> <given-names>GH</given-names></name><name><surname>Bravo-San Pedro</surname> <given-names>JM</given-names></name><name><surname>Brennan</surname> <given-names>LA</given-names></name><name><surname>Bresnick</surname> <given-names>EH</given-names></name><name><surname>Brest</surname> <given-names>P</given-names></name><name><surname>Bridges</surname> <given-names>D</given-names></name><name><surname>Bringer</surname> <given-names>MA</given-names></name><name><surname>Brini</surname> <given-names>M</given-names></name><name><surname>Brito</surname> <given-names>GC</given-names></name><name><surname>Brodin</surname> <given-names>B</given-names></name><name><surname>Brookes</surname> <given-names>PS</given-names></name><name><surname>Brown</surname> <given-names>EJ</given-names></name><name><surname>Brown</surname> <given-names>K</given-names></name><name><surname>Broxmeyer</surname> <given-names>HE</given-names></name><name><surname>Bruhat</surname> <given-names>A</given-names></name><name><surname>Brum</surname> <given-names>PC</given-names></name><name><surname>Brumell</surname> <given-names>JH</given-names></name><name><surname>Brunetti-Pierri</surname> <given-names>N</given-names></name><name><surname>Bryson-Richardson</surname> <given-names>RJ</given-names></name><name><surname>Buch</surname> <given-names>S</given-names></name><name><surname>Buchan</surname> <given-names>AM</given-names></name><name><surname>Budak</surname> <given-names>H</given-names></name><name><surname>Bulavin</surname> <given-names>DV</given-names></name><name><surname>Bultman</surname> <given-names>SJ</given-names></name><name><surname>Bultynck</surname> <given-names>G</given-names></name><name><surname>Bumbasirevic</surname> <given-names>V</given-names></name><name><surname>Burelle</surname> <given-names>Y</given-names></name><name><surname>Burke</surname> <given-names>RE</given-names></name><name><surname>Burmeister</surname> <given-names>M</given-names></name><name><surname>Bütikofer</surname> <given-names>P</given-names></name><name><surname>Caberlotto</surname> <given-names>L</given-names></name><name><surname>Cadwell</surname> <given-names>K</given-names></name><name><surname>Cahova</surname> <given-names>M</given-names></name><name><surname>Cai</surname> <given-names>D</given-names></name><name><surname>Cai</surname> <given-names>J</given-names></name><name><surname>Cai</surname> <given-names>Q</given-names></name><name><surname>Calatayud</surname> <given-names>S</given-names></name><name><surname>Camougrand</surname> <given-names>N</given-names></name><name><surname>Campanella</surname> <given-names>M</given-names></name><name><surname>Campbell</surname> <given-names>GR</given-names></name><name><surname>Campbell</surname> <given-names>M</given-names></name><name><surname>Campello</surname> <given-names>S</given-names></name><name><surname>Candau</surname> <given-names>R</given-names></name><name><surname>Caniggia</surname> <given-names>I</given-names></name><name><surname>Cantoni</surname> <given-names>L</given-names></name><name><surname>Cao</surname> <given-names>L</given-names></name><name><surname>Caplan</surname> <given-names>AB</given-names></name><name><surname>Caraglia</surname> <given-names>M</given-names></name><name><surname>Cardinali</surname> <given-names>C</given-names></name><name><surname>Cardoso</surname> <given-names>SM</given-names></name><name><surname>Carew</surname> <given-names>JS</given-names></name><name><surname>Carleton</surname> <given-names>LA</given-names></name><name><surname>Carlin</surname> <given-names>CR</given-names></name><name><surname>Carloni</surname> <given-names>S</given-names></name><name><surname>Carlsson</surname> <given-names>SR</given-names></name><name><surname>Carmona-Gutierrez</surname> <given-names>D</given-names></name><name><surname>Carneiro</surname> <given-names>LA</given-names></name><name><surname>Carnevali</surname> <given-names>O</given-names></name><name><surname>Carra</surname> <given-names>S</given-names></name><name><surname>Carrier</surname> <given-names>A</given-names></name><name><surname>Carroll</surname> <given-names>B</given-names></name><name><surname>Casas</surname> <given-names>C</given-names></name><name><surname>Casas</surname> <given-names>J</given-names></name><name><surname>Cassinelli</surname> <given-names>G</given-names></name><name><surname>Castets</surname> <given-names>P</given-names></name><name><surname>Castro-Obregon</surname> <given-names>S</given-names></name><name><surname>Cavallini</surname> <given-names>G</given-names></name><name><surname>Ceccherini</surname> <given-names>I</given-names></name><name><surname>Cecconi</surname> <given-names>F</given-names></name><name><surname>Cederbaum</surname> <given-names>AI</given-names></name><name><surname>Ceña</surname> <given-names>V</given-names></name><name><surname>Cenci</surname> <given-names>S</given-names></name><name><surname>Cerella</surname> <given-names>C</given-names></name><name><surname>Cervia</surname> <given-names>D</given-names></name><name><surname>Cetrullo</surname> <given-names>S</given-names></name><name><surname>Chaachouay</surname> <given-names>H</given-names></name><name><surname>Chae</surname> <given-names>HJ</given-names></name><name><surname>Chagin</surname> <given-names>AS</given-names></name><name><surname>Chai</surname> <given-names>CY</given-names></name><name><surname>Chakrabarti</surname> <given-names>G</given-names></name><name><surname>Chamilos</surname> <given-names>G</given-names></name><name><surname>Chan</surname> <given-names>EY</given-names></name><name><surname>Chan</surname> <given-names>MT</given-names></name><name><surname>Chandra</surname> <given-names>D</given-names></name><name><surname>Chandra</surname> <given-names>P</given-names></name><name><surname>Chang</surname> <given-names>CP</given-names></name><name><surname>Chang</surname> <given-names>RC</given-names></name><name><surname>Chang</surname> <given-names>TY</given-names></name><name><surname>Chatham</surname> <given-names>JC</given-names></name><name><surname>Chatterjee</surname> <given-names>S</given-names></name><name><surname>Chauhan</surname> <given-names>S</given-names></name><name><surname>Che</surname> <given-names>Y</given-names></name><name><surname>Cheetham</surname> <given-names>ME</given-names></name><name><surname>Cheluvappa</surname> <given-names>R</given-names></name><name><surname>Chen</surname> <given-names>CJ</given-names></name><name><surname>Chen</surname> <given-names>G</given-names></name><name><surname>Chen</surname> <given-names>GC</given-names></name><name><surname>Chen</surname> <given-names>G</given-names></name><name><surname>Chen</surname> <given-names>H</given-names></name><name><surname>Chen</surname> <given-names>JW</given-names></name><name><surname>Chen</surname> <given-names>JK</given-names></name><name><surname>Chen</surname> <given-names>M</given-names></name><name><surname>Chen</surname> <given-names>M</given-names></name><name><surname>Chen</surname> <given-names>P</given-names></name><name><surname>Chen</surname> <given-names>Q</given-names></name><name><surname>Chen</surname> <given-names>Q</given-names></name><name><surname>Chen</surname> <given-names>SD</given-names></name><name><surname>Chen</surname> <given-names>S</given-names></name><name><surname>Chen</surname> <given-names>SS</given-names></name><name><surname>Chen</surname> <given-names>W</given-names></name><name><surname>Chen</surname> <given-names>WJ</given-names></name><name><surname>Chen</surname> <given-names>WQ</given-names></name><name><surname>Chen</surname> <given-names>W</given-names></name><name><surname>Chen</surname> <given-names>X</given-names></name><name><surname>Chen</surname> <given-names>YH</given-names></name><name><surname>Chen</surname> <given-names>YG</given-names></name><name><surname>Chen</surname> <given-names>Y</given-names></name><name><surname>Chen</surname> <given-names>Y</given-names></name><name><surname>Chen</surname> <given-names>Y</given-names></name><name><surname>Chen</surname> <given-names>YJ</given-names></name><name><surname>Chen</surname> <given-names>YQ</given-names></name><name><surname>Chen</surname> <given-names>Y</given-names></name><name><surname>Chen</surname> <given-names>Z</given-names></name><name><surname>Chen</surname> <given-names>Z</given-names></name><name><surname>Cheng</surname> <given-names>A</given-names></name><name><surname>Cheng</surname> <given-names>CH</given-names></name><name><surname>Cheng</surname> <given-names>H</given-names></name><name><surname>Cheong</surname> <given-names>H</given-names></name><name><surname>Cherry</surname> <given-names>S</given-names></name><name><surname>Chesney</surname> <given-names>J</given-names></name><name><surname>Cheung</surname> <given-names>CH</given-names></name><name><surname>Chevet</surname> <given-names>E</given-names></name><name><surname>Chi</surname> <given-names>HC</given-names></name><name><surname>Chi</surname> <given-names>SG</given-names></name><name><surname>Chiacchiera</surname> <given-names>F</given-names></name><name><surname>Chiang</surname> <given-names>HL</given-names></name><name><surname>Chiarelli</surname> <given-names>R</given-names></name><name><surname>Chiariello</surname> <given-names>M</given-names></name><name><surname>Chieppa</surname> <given-names>M</given-names></name><name><surname>Chin</surname> <given-names>LS</given-names></name><name><surname>Chiong</surname> <given-names>M</given-names></name><name><surname>Chiu</surname> <given-names>GN</given-names></name><name><surname>Cho</surname> <given-names>DH</given-names></name><name><surname>Cho</surname> <given-names>SG</given-names></name><name><surname>Cho</surname> <given-names>WC</given-names></name><name><surname>Cho</surname> <given-names>YY</given-names></name><name><surname>Cho</surname> <given-names>YS</given-names></name><name><surname>Choi</surname> <given-names>AM</given-names></name><name><surname>Choi</surname> <given-names>EJ</given-names></name><name><surname>Choi</surname> <given-names>EK</given-names></name><name><surname>Choi</surname> <given-names>J</given-names></name><name><surname>Choi</surname> <given-names>ME</given-names></name><name><surname>Choi</surname> <given-names>SI</given-names></name><name><surname>Chou</surname> <given-names>TF</given-names></name><name><surname>Chouaib</surname> <given-names>S</given-names></name><name><surname>Choubey</surname> <given-names>D</given-names></name><name><surname>Choubey</surname> <given-names>V</given-names></name><name><surname>Chow</surname> <given-names>KC</given-names></name><name><surname>Chowdhury</surname> <given-names>K</given-names></name><name><surname>Chu</surname> <given-names>CT</given-names></name><name><surname>Chuang</surname> <given-names>TH</given-names></name><name><surname>Chun</surname> <given-names>T</given-names></name><name><surname>Chung</surname> <given-names>H</given-names></name><name><surname>Chung</surname> <given-names>T</given-names></name><name><surname>Chung</surname> <given-names>YL</given-names></name><name><surname>Chwae</surname> <given-names>YJ</given-names></name><name><surname>Cianfanelli</surname> <given-names>V</given-names></name><name><surname>Ciarcia</surname> <given-names>R</given-names></name><name><surname>Ciechomska</surname> <given-names>IA</given-names></name><name><surname>Ciriolo</surname> <given-names>MR</given-names></name><name><surname>Cirone</surname> <given-names>M</given-names></name><name><surname>Claerhout</surname> <given-names>S</given-names></name><name><surname>Clague</surname> <given-names>MJ</given-names></name><name><surname>Clària</surname> <given-names>J</given-names></name><name><surname>Clarke</surname> <given-names>PG</given-names></name><name><surname>Clarke</surname> <given-names>R</given-names></name><name><surname>Clementi</surname> <given-names>E</given-names></name><name><surname>Cleyrat</surname> <given-names>C</given-names></name><name><surname>Cnop</surname> <given-names>M</given-names></name><name><surname>Coccia</surname> <given-names>EM</given-names></name><name><surname>Cocco</surname> <given-names>T</given-names></name><name><surname>Codogno</surname> <given-names>P</given-names></name><name><surname>Coers</surname> <given-names>J</given-names></name><name><surname>Cohen</surname> <given-names>EE</given-names></name><name><surname>Colecchia</surname> <given-names>D</given-names></name><name><surname>Coletto</surname> <given-names>L</given-names></name><name><surname>Coll</surname> <given-names>NS</given-names></name><name><surname>Colucci-Guyon</surname> <given-names>E</given-names></name><name><surname>Comincini</surname> <given-names>S</given-names></name><name><surname>Condello</surname> <given-names>M</given-names></name><name><surname>Cook</surname> <given-names>KL</given-names></name><name><surname>Coombs</surname> <given-names>GH</given-names></name><name><surname>Cooper</surname> <given-names>CD</given-names></name><name><surname>Cooper</surname> <given-names>JM</given-names></name><name><surname>Coppens</surname> <given-names>I</given-names></name><name><surname>Corasaniti</surname> <given-names>MT</given-names></name><name><surname>Corazzari</surname> <given-names>M</given-names></name><name><surname>Corbalan</surname> <given-names>R</given-names></name><name><surname>Corcelle-Termeau</surname> <given-names>E</given-names></name><name><surname>Cordero</surname> <given-names>MD</given-names></name><name><surname>Corral-Ramos</surname> <given-names>C</given-names></name><name><surname>Corti</surname> <given-names>O</given-names></name><name><surname>Cossarizza</surname> <given-names>A</given-names></name><name><surname>Costelli</surname> <given-names>P</given-names></name><name><surname>Costes</surname> <given-names>S</given-names></name><name><surname>Cotman</surname> <given-names>SL</given-names></name><name><surname>Coto-Montes</surname> <given-names>A</given-names></name><name><surname>Cottet</surname> <given-names>S</given-names></name><name><surname>Couve</surname> <given-names>E</given-names></name><name><surname>Covey</surname> <given-names>LR</given-names></name><name><surname>Cowart</surname> <given-names>LA</given-names></name><name><surname>Cox</surname> <given-names>JS</given-names></name><name><surname>Coxon</surname> <given-names>FP</given-names></name><name><surname>Coyne</surname> <given-names>CB</given-names></name><name><surname>Cragg</surname> <given-names>MS</given-names></name><name><surname>Craven</surname> <given-names>RJ</given-names></name><name><surname>Crepaldi</surname> <given-names>T</given-names></name><name><surname>Crespo</surname> <given-names>JL</given-names></name><name><surname>Criollo</surname> <given-names>A</given-names></name><name><surname>Crippa</surname> <given-names>V</given-names></name><name><surname>Cruz</surname> <given-names>MT</given-names></name><name><surname>Cuervo</surname> <given-names>AM</given-names></name><name><surname>Cuezva</surname> <given-names>JM</given-names></name><name><surname>Cui</surname> <given-names>T</given-names></name><name><surname>Cutillas</surname> <given-names>PR</given-names></name><name><surname>Czaja</surname> <given-names>MJ</given-names></name><name><surname>Czyzyk-Krzeska</surname> <given-names>MF</given-names></name><name><surname>Dagda</surname> <given-names>RK</given-names></name><name><surname>Dahmen</surname> <given-names>U</given-names></name><name><surname>Dai</surname> <given-names>C</given-names></name><name><surname>Dai</surname> <given-names>W</given-names></name><name><surname>Dai</surname> <given-names>Y</given-names></name><name><surname>Dalby</surname> <given-names>KN</given-names></name><name><surname>Dalla Valle</surname> <given-names>L</given-names></name><name><surname>Dalmasso</surname> <given-names>G</given-names></name><name><surname>D'Amelio</surname> <given-names>M</given-names></name><name><surname>Damme</surname> <given-names>M</given-names></name><name><surname>Darfeuille-Michaud</surname> <given-names>A</given-names></name><name><surname>Dargemont</surname> <given-names>C</given-names></name><name><surname>Darley-Usmar</surname> <given-names>VM</given-names></name><name><surname>Dasarathy</surname> <given-names>S</given-names></name><name><surname>Dasgupta</surname> <given-names>B</given-names></name><name><surname>Dash</surname> <given-names>S</given-names></name><name><surname>Dass</surname> <given-names>CR</given-names></name><name><surname>Davey</surname> <given-names>HM</given-names></name><name><surname>Davids</surname> <given-names>LM</given-names></name><name><surname>Dávila</surname> <given-names>D</given-names></name><name><surname>Davis</surname> <given-names>RJ</given-names></name><name><surname>Dawson</surname> <given-names>TM</given-names></name><name><surname>Dawson</surname> <given-names>VL</given-names></name><name><surname>Daza</surname> <given-names>P</given-names></name><name><surname>de Belleroche</surname> <given-names>J</given-names></name><name><surname>de Figueiredo</surname> <given-names>P</given-names></name><name><surname>de Figueiredo</surname> <given-names>RC</given-names></name><name><surname>de la Fuente</surname> <given-names>J</given-names></name><name><surname>De Martino</surname> <given-names>L</given-names></name><name><surname>De Matteis</surname> <given-names>A</given-names></name><name><surname>De Meyer</surname> <given-names>GR</given-names></name><name><surname>De Milito</surname> <given-names>A</given-names></name><name><surname>De Santi</surname> <given-names>M</given-names></name><name><surname>de Souza</surname> <given-names>W</given-names></name><name><surname>De Tata</surname> <given-names>V</given-names></name><name><surname>De Zio</surname> <given-names>D</given-names></name><name><surname>Debnath</surname> <given-names>J</given-names></name><name><surname>Dechant</surname> <given-names>R</given-names></name><name><surname>Decuypere</surname> <given-names>JP</given-names></name><name><surname>Deegan</surname> <given-names>S</given-names></name><name><surname>Dehay</surname> <given-names>B</given-names></name><name><surname>Del Bello</surname> <given-names>B</given-names></name><name><surname>Del Re</surname> <given-names>DP</given-names></name><name><surname>Delage-Mourroux</surname> <given-names>R</given-names></name><name><surname>Delbridge</surname> <given-names>LM</given-names></name><name><surname>Deldicque</surname> <given-names>L</given-names></name><name><surname>Delorme-Axford</surname> <given-names>E</given-names></name><name><surname>Deng</surname> <given-names>Y</given-names></name><name><surname>Dengjel</surname> <given-names>J</given-names></name><name><surname>Denizot</surname> <given-names>M</given-names></name><name><surname>Dent</surname> <given-names>P</given-names></name><name><surname>Der</surname> <given-names>CJ</given-names></name><name><surname>Deretic</surname> <given-names>V</given-names></name><name><surname>Derrien</surname> <given-names>B</given-names></name><name><surname>Deutsch</surname> <given-names>E</given-names></name><name><surname>Devarenne</surname> <given-names>TP</given-names></name><name><surname>Devenish</surname> <given-names>RJ</given-names></name><name><surname>Di Bartolomeo</surname> <given-names>S</given-names></name><name><surname>Di Daniele</surname> <given-names>N</given-names></name><name><surname>Di Domenico</surname> <given-names>F</given-names></name><name><surname>Di Nardo</surname> <given-names>A</given-names></name><name><surname>Di Paola</surname> <given-names>S</given-names></name><name><surname>Di Pietro</surname> <given-names>A</given-names></name><name><surname>Di Renzo</surname> <given-names>L</given-names></name><name><surname>DiAntonio</surname> <given-names>A</given-names></name><name><surname>Díaz-Araya</surname> <given-names>G</given-names></name><name><surname>Díaz-Laviada</surname> <given-names>I</given-names></name><name><surname>Diaz-Meco</surname> <given-names>MT</given-names></name><name><surname>Diaz-Nido</surname> <given-names>J</given-names></name><name><surname>Dickey</surname> <given-names>CA</given-names></name><name><surname>Dickson</surname> <given-names>RC</given-names></name><name><surname>Diederich</surname> <given-names>M</given-names></name><name><surname>Digard</surname> <given-names>P</given-names></name><name><surname>Dikic</surname> <given-names>I</given-names></name><name><surname>Dinesh-Kumar</surname> <given-names>SP</given-names></name><name><surname>Ding</surname> <given-names>C</given-names></name><name><surname>Ding</surname> <given-names>WX</given-names></name><name><surname>Ding</surname> <given-names>Z</given-names></name><name><surname>Dini</surname> <given-names>L</given-names></name><name><surname>Distler</surname> <given-names>JH</given-names></name><name><surname>Diwan</surname> <given-names>A</given-names></name><name><surname>Djavaheri-Mergny</surname> <given-names>M</given-names></name><name><surname>Dmytruk</surname> <given-names>K</given-names></name><name><surname>Dobson</surname> <given-names>RC</given-names></name><name><surname>Doetsch</surname> <given-names>V</given-names></name><name><surname>Dokladny</surname> <given-names>K</given-names></name><name><surname>Dokudovskaya</surname> <given-names>S</given-names></name><name><surname>Donadelli</surname> <given-names>M</given-names></name><name><surname>Dong</surname> <given-names>XC</given-names></name><name><surname>Dong</surname> <given-names>X</given-names></name><name><surname>Dong</surname> <given-names>Z</given-names></name><name><surname>Donohue</surname> <given-names>TM</given-names></name><name><surname>Doran</surname> <given-names>KS</given-names></name><name><surname>D'Orazi</surname> <given-names>G</given-names></name><name><surname>Dorn</surname> <given-names>GW</given-names></name><name><surname>Dosenko</surname> <given-names>V</given-names></name><name><surname>Dridi</surname> <given-names>S</given-names></name><name><surname>Drucker</surname> <given-names>L</given-names></name><name><surname>Du</surname> <given-names>J</given-names></name><name><surname>Du</surname> <given-names>LL</given-names></name><name><surname>Du</surname> <given-names>L</given-names></name><name><surname>du Toit</surname> <given-names>A</given-names></name><name><surname>Dua</surname> <given-names>P</given-names></name><name><surname>Duan</surname> <given-names>L</given-names></name><name><surname>Duann</surname> <given-names>P</given-names></name><name><surname>Dubey</surname> <given-names>VK</given-names></name><name><surname>Duchen</surname> <given-names>MR</given-names></name><name><surname>Duchosal</surname> <given-names>MA</given-names></name><name><surname>Duez</surname> <given-names>H</given-names></name><name><surname>Dugail</surname> <given-names>I</given-names></name><name><surname>Dumit</surname> <given-names>VI</given-names></name><name><surname>Duncan</surname> <given-names>MC</given-names></name><name><surname>Dunlop</surname> <given-names>EA</given-names></name><name><surname>Dunn</surname> <given-names>WA</given-names></name><name><surname>Dupont</surname> <given-names>N</given-names></name><name><surname>Dupuis</surname> <given-names>L</given-names></name><name><surname>Durán</surname> <given-names>RV</given-names></name><name><surname>Durcan</surname> <given-names>TM</given-names></name><name><surname>Duvezin-Caubet</surname> <given-names>S</given-names></name><name><surname>Duvvuri</surname> <given-names>U</given-names></name><name><surname>Eapen</surname> <given-names>V</given-names></name><name><surname>Ebrahimi-Fakhari</surname> <given-names>D</given-names></name><name><surname>Echard</surname> <given-names>A</given-names></name><name><surname>Eckhart</surname> <given-names>L</given-names></name><name><surname>Edelstein</surname> <given-names>CL</given-names></name><name><surname>Edinger</surname> <given-names>AL</given-names></name><name><surname>Eichinger</surname> <given-names>L</given-names></name><name><surname>Eisenberg</surname> <given-names>T</given-names></name><name><surname>Eisenberg-Lerner</surname> <given-names>A</given-names></name><name><surname>Eissa</surname> <given-names>NT</given-names></name><name><surname>El-Deiry</surname> <given-names>WS</given-names></name><name><surname>El-Khoury</surname> <given-names>V</given-names></name><name><surname>Elazar</surname> <given-names>Z</given-names></name><name><surname>Eldar-Finkelman</surname> <given-names>H</given-names></name><name><surname>Elliott</surname> <given-names>CJ</given-names></name><name><surname>Emanuele</surname> <given-names>E</given-names></name><name><surname>Emmenegger</surname> <given-names>U</given-names></name><name><surname>Engedal</surname> <given-names>N</given-names></name><name><surname>Engelbrecht</surname> <given-names>AM</given-names></name><name><surname>Engelender</surname> <given-names>S</given-names></name><name><surname>Enserink</surname> <given-names>JM</given-names></name><name><surname>Erdmann</surname> <given-names>R</given-names></name><name><surname>Erenpreisa</surname> <given-names>J</given-names></name><name><surname>Eri</surname> <given-names>R</given-names></name><name><surname>Eriksen</surname> <given-names>JL</given-names></name><name><surname>Erman</surname> <given-names>A</given-names></name><name><surname>Escalante</surname> <given-names>R</given-names></name><name><surname>Eskelinen</surname> <given-names>EL</given-names></name><name><surname>Espert</surname> <given-names>L</given-names></name><name><surname>Esteban-Martínez</surname> <given-names>L</given-names></name><name><surname>Evans</surname> <given-names>TJ</given-names></name><name><surname>Fabri</surname> <given-names>M</given-names></name><name><surname>Fabrias</surname> <given-names>G</given-names></name><name><surname>Fabrizi</surname> <given-names>C</given-names></name><name><surname>Facchiano</surname> <given-names>A</given-names></name><name><surname>Færgeman</surname> <given-names>NJ</given-names></name><name><surname>Faggioni</surname> <given-names>A</given-names></name><name><surname>Fairlie</surname> <given-names>WD</given-names></name><name><surname>Fan</surname> <given-names>C</given-names></name><name><surname>Fan</surname> <given-names>D</given-names></name><name><surname>Fan</surname> <given-names>J</given-names></name><name><surname>Fang</surname> <given-names>S</given-names></name><name><surname>Fanto</surname> <given-names>M</given-names></name><name><surname>Fanzani</surname> <given-names>A</given-names></name><name><surname>Farkas</surname> <given-names>T</given-names></name><name><surname>Faure</surname> <given-names>M</given-names></name><name><surname>Favier</surname> <given-names>FB</given-names></name><name><surname>Fearnhead</surname> <given-names>H</given-names></name><name><surname>Federici</surname> <given-names>M</given-names></name><name><surname>Fei</surname> <given-names>E</given-names></name><name><surname>Felizardo</surname> <given-names>TC</given-names></name><name><surname>Feng</surname> <given-names>H</given-names></name><name><surname>Feng</surname> <given-names>Y</given-names></name><name><surname>Feng</surname> <given-names>Y</given-names></name><name><surname>Ferguson</surname> <given-names>TA</given-names></name><name><surname>Fernández</surname> <given-names>ÁF</given-names></name><name><surname>Fernandez-Barrena</surname> <given-names>MG</given-names></name><name><surname>Fernandez-Checa</surname> <given-names>JC</given-names></name><name><surname>Fernández-López</surname> <given-names>A</given-names></name><name><surname>Fernandez-Zapico</surname> <given-names>ME</given-names></name><name><surname>Feron</surname> <given-names>O</given-names></name><name><surname>Ferraro</surname> <given-names>E</given-names></name><name><surname>Ferreira-Halder</surname> <given-names>CV</given-names></name><name><surname>Fesus</surname> <given-names>L</given-names></name><name><surname>Feuer</surname> <given-names>R</given-names></name><name><surname>Fiesel</surname> <given-names>FC</given-names></name><name><surname>Filippi-Chiela</surname> <given-names>EC</given-names></name><name><surname>Filomeni</surname> <given-names>G</given-names></name><name><surname>Fimia</surname> <given-names>GM</given-names></name><name><surname>Fingert</surname> <given-names>JH</given-names></name><name><surname>Finkbeiner</surname> <given-names>S</given-names></name><name><surname>Finkel</surname> <given-names>T</given-names></name><name><surname>Fiorito</surname> <given-names>F</given-names></name><name><surname>Fisher</surname> <given-names>PB</given-names></name><name><surname>Flajolet</surname> <given-names>M</given-names></name><name><surname>Flamigni</surname> <given-names>F</given-names></name><name><surname>Florey</surname> <given-names>O</given-names></name><name><surname>Florio</surname> <given-names>S</given-names></name><name><surname>Floto</surname> <given-names>RA</given-names></name><name><surname>Folini</surname> <given-names>M</given-names></name><name><surname>Follo</surname> <given-names>C</given-names></name><name><surname>Fon</surname> <given-names>EA</given-names></name><name><surname>Fornai</surname> <given-names>F</given-names></name><name><surname>Fortunato</surname> <given-names>F</given-names></name><name><surname>Fraldi</surname> <given-names>A</given-names></name><name><surname>Franco</surname> <given-names>R</given-names></name><name><surname>Francois</surname> <given-names>A</given-names></name><name><surname>François</surname> <given-names>A</given-names></name><name><surname>Frankel</surname> <given-names>LB</given-names></name><name><surname>Fraser</surname> <given-names>ID</given-names></name><name><surname>Frey</surname> <given-names>N</given-names></name><name><surname>Freyssenet</surname> <given-names>DG</given-names></name><name><surname>Frezza</surname> <given-names>C</given-names></name><name><surname>Friedman</surname> <given-names>SL</given-names></name><name><surname>Frigo</surname> <given-names>DE</given-names></name><name><surname>Fu</surname> <given-names>D</given-names></name><name><surname>Fuentes</surname> <given-names>JM</given-names></name><name><surname>Fueyo</surname> <given-names>J</given-names></name><name><surname>Fujitani</surname> <given-names>Y</given-names></name><name><surname>Fujiwara</surname> <given-names>Y</given-names></name><name><surname>Fujiya</surname> <given-names>M</given-names></name><name><surname>Fukuda</surname> <given-names>M</given-names></name><name><surname>Fulda</surname> <given-names>S</given-names></name><name><surname>Fusco</surname> <given-names>C</given-names></name><name><surname>Gabryel</surname> <given-names>B</given-names></name><name><surname>Gaestel</surname> <given-names>M</given-names></name><name><surname>Gailly</surname> <given-names>P</given-names></name><name><surname>Gajewska</surname> <given-names>M</given-names></name><name><surname>Galadari</surname> <given-names>S</given-names></name><name><surname>Galili</surname> <given-names>G</given-names></name><name><surname>Galindo</surname> <given-names>I</given-names></name><name><surname>Galindo</surname> <given-names>MF</given-names></name><name><surname>Galliciotti</surname> <given-names>G</given-names></name><name><surname>Galluzzi</surname> <given-names>L</given-names></name><name><surname>Galluzzi</surname> <given-names>L</given-names></name><name><surname>Galy</surname> <given-names>V</given-names></name><name><surname>Gammoh</surname> <given-names>N</given-names></name><name><surname>Gandy</surname> <given-names>S</given-names></name><name><surname>Ganesan</surname> <given-names>AK</given-names></name><name><surname>Ganesan</surname> <given-names>S</given-names></name><name><surname>Ganley</surname> <given-names>IG</given-names></name><name><surname>Gannagé</surname> <given-names>M</given-names></name><name><surname>Gao</surname> <given-names>FB</given-names></name><name><surname>Gao</surname> <given-names>F</given-names></name><name><surname>Gao</surname> <given-names>JX</given-names></name><name><surname>García Nannig</surname> <given-names>L</given-names></name><name><surname>García Véscovi</surname> <given-names>E</given-names></name><name><surname>Garcia-Macía</surname> <given-names>M</given-names></name><name><surname>Garcia-Ruiz</surname> <given-names>C</given-names></name><name><surname>Garg</surname> <given-names>AD</given-names></name><name><surname>Garg</surname> <given-names>PK</given-names></name><name><surname>Gargini</surname> <given-names>R</given-names></name><name><surname>Gassen</surname> <given-names>NC</given-names></name><name><surname>Gatica</surname> <given-names>D</given-names></name><name><surname>Gatti</surname> <given-names>E</given-names></name><name><surname>Gavard</surname> <given-names>J</given-names></name><name><surname>Gavathiotis</surname> <given-names>E</given-names></name><name><surname>Ge</surname> <given-names>L</given-names></name><name><surname>Ge</surname> <given-names>P</given-names></name><name><surname>Ge</surname> <given-names>S</given-names></name><name><surname>Gean</surname> <given-names>PW</given-names></name><name><surname>Gelmetti</surname> <given-names>V</given-names></name><name><surname>Genazzani</surname> <given-names>AA</given-names></name><name><surname>Geng</surname> <given-names>J</given-names></name><name><surname>Genschik</surname> <given-names>P</given-names></name><name><surname>Gerner</surname> <given-names>L</given-names></name><name><surname>Gestwicki</surname> <given-names>JE</given-names></name><name><surname>Gewirtz</surname> <given-names>DA</given-names></name><name><surname>Ghavami</surname> <given-names>S</given-names></name><name><surname>Ghigo</surname> <given-names>E</given-names></name><name><surname>Ghosh</surname> <given-names>D</given-names></name><name><surname>Giammarioli</surname> <given-names>AM</given-names></name><name><surname>Giampieri</surname> <given-names>F</given-names></name><name><surname>Giampietri</surname> <given-names>C</given-names></name><name><surname>Giatromanolaki</surname> <given-names>A</given-names></name><name><surname>Gibbings</surname> <given-names>DJ</given-names></name><name><surname>Gibellini</surname> <given-names>L</given-names></name><name><surname>Gibson</surname> <given-names>SB</given-names></name><name><surname>Ginet</surname> <given-names>V</given-names></name><name><surname>Giordano</surname> <given-names>A</given-names></name><name><surname>Giorgini</surname> <given-names>F</given-names></name><name><surname>Giovannetti</surname> <given-names>E</given-names></name><name><surname>Girardin</surname> <given-names>SE</given-names></name><name><surname>Gispert</surname> <given-names>S</given-names></name><name><surname>Giuliano</surname> <given-names>S</given-names></name><name><surname>Gladson</surname> <given-names>CL</given-names></name><name><surname>Glavic</surname> <given-names>A</given-names></name><name><surname>Gleave</surname> <given-names>M</given-names></name><name><surname>Godefroy</surname> <given-names>N</given-names></name><name><surname>Gogal</surname> <given-names>RM</given-names></name><name><surname>Gokulan</surname> <given-names>K</given-names></name><name><surname>Goldman</surname> <given-names>GH</given-names></name><name><surname>Goletti</surname> <given-names>D</given-names></name><name><surname>Goligorsky</surname> <given-names>MS</given-names></name><name><surname>Gomes</surname> <given-names>AV</given-names></name><name><surname>Gomes</surname> <given-names>LC</given-names></name><name><surname>Gomez</surname> <given-names>H</given-names></name><name><surname>Gomez-Manzano</surname> <given-names>C</given-names></name><name><surname>Gómez-Sánchez</surname> <given-names>R</given-names></name><name><surname>Gonçalves</surname> <given-names>DA</given-names></name><name><surname>Goncu</surname> <given-names>E</given-names></name><name><surname>Gong</surname> <given-names>Q</given-names></name><name><surname>Gongora</surname> <given-names>C</given-names></name><name><surname>Gonzalez</surname> <given-names>CB</given-names></name><name><surname>Gonzalez-Alegre</surname> <given-names>P</given-names></name><name><surname>Gonzalez-Cabo</surname> <given-names>P</given-names></name><name><surname>González-Polo</surname> <given-names>RA</given-names></name><name><surname>Goping</surname> <given-names>IS</given-names></name><name><surname>Gorbea</surname> <given-names>C</given-names></name><name><surname>Gorbunov</surname> <given-names>NV</given-names></name><name><surname>Goring</surname> <given-names>DR</given-names></name><name><surname>Gorman</surname> <given-names>AM</given-names></name><name><surname>Gorski</surname> <given-names>SM</given-names></name><name><surname>Goruppi</surname> <given-names>S</given-names></name><name><surname>Goto-Yamada</surname> <given-names>S</given-names></name><name><surname>Gotor</surname> <given-names>C</given-names></name><name><surname>Gottlieb</surname> <given-names>RA</given-names></name><name><surname>Gozes</surname> <given-names>I</given-names></name><name><surname>Gozuacik</surname> <given-names>D</given-names></name><name><surname>Graba</surname> <given-names>Y</given-names></name><name><surname>Graef</surname> <given-names>M</given-names></name><name><surname>Granato</surname> <given-names>GE</given-names></name><name><surname>Grant</surname> <given-names>GD</given-names></name><name><surname>Grant</surname> <given-names>S</given-names></name><name><surname>Gravina</surname> <given-names>GL</given-names></name><name><surname>Green</surname> <given-names>DR</given-names></name><name><surname>Greenhough</surname> <given-names>A</given-names></name><name><surname>Greenwood</surname> <given-names>MT</given-names></name><name><surname>Grimaldi</surname> <given-names>B</given-names></name><name><surname>Gros</surname> <given-names>F</given-names></name><name><surname>Grose</surname> <given-names>C</given-names></name><name><surname>Groulx</surname> <given-names>JF</given-names></name><name><surname>Gruber</surname> <given-names>F</given-names></name><name><surname>Grumati</surname> <given-names>P</given-names></name><name><surname>Grune</surname> <given-names>T</given-names></name><name><surname>Guan</surname> <given-names>JL</given-names></name><name><surname>Guan</surname> <given-names>KL</given-names></name><name><surname>Guerra</surname> <given-names>B</given-names></name><name><surname>Guillen</surname> <given-names>C</given-names></name><name><surname>Gulshan</surname> <given-names>K</given-names></name><name><surname>Gunst</surname> <given-names>J</given-names></name><name><surname>Guo</surname> <given-names>C</given-names></name><name><surname>Guo</surname> <given-names>L</given-names></name><name><surname>Guo</surname> <given-names>M</given-names></name><name><surname>Guo</surname> <given-names>W</given-names></name><name><surname>Guo</surname> <given-names>XG</given-names></name><name><surname>Gust</surname> <given-names>AA</given-names></name><name><surname>Gustafsson</surname> <given-names>ÅB</given-names></name><name><surname>Gutierrez</surname> <given-names>E</given-names></name><name><surname>Gutierrez</surname> <given-names>MG</given-names></name><name><surname>Gwak</surname> <given-names>HS</given-names></name><name><surname>Haas</surname> <given-names>A</given-names></name><name><surname>Haber</surname> <given-names>JE</given-names></name><name><surname>Hadano</surname> <given-names>S</given-names></name><name><surname>Hagedorn</surname> <given-names>M</given-names></name><name><surname>Hahn</surname> <given-names>DR</given-names></name><name><surname>Halayko</surname> <given-names>AJ</given-names></name><name><surname>Hamacher-Brady</surname> <given-names>A</given-names></name><name><surname>Hamada</surname> <given-names>K</given-names></name><name><surname>Hamai</surname> <given-names>A</given-names></name><name><surname>Hamann</surname> <given-names>A</given-names></name><name><surname>Hamasaki</surname> <given-names>M</given-names></name><name><surname>Hamer</surname> <given-names>I</given-names></name><name><surname>Hamid</surname> <given-names>Q</given-names></name><name><surname>Hammond</surname> <given-names>EM</given-names></name><name><surname>Han</surname> <given-names>F</given-names></name><name><surname>Han</surname> <given-names>W</given-names></name><name><surname>Handa</surname> <given-names>JT</given-names></name><name><surname>Hanover</surname> <given-names>JA</given-names></name><name><surname>Hansen</surname> <given-names>M</given-names></name><name><surname>Harada</surname> <given-names>M</given-names></name><name><surname>Harhaji-Trajkovic</surname> <given-names>L</given-names></name><name><surname>Harper</surname> <given-names>JW</given-names></name><name><surname>Harrath</surname> <given-names>AH</given-names></name><name><surname>Harris</surname> <given-names>AL</given-names></name><name><surname>Harris</surname> <given-names>J</given-names></name><name><surname>Hasler</surname> <given-names>U</given-names></name><name><surname>Hasselblatt</surname> <given-names>P</given-names></name><name><surname>Hasui</surname> <given-names>K</given-names></name><name><surname>Hawley</surname> <given-names>RG</given-names></name><name><surname>Hawley</surname> <given-names>TS</given-names></name><name><surname>He</surname> <given-names>C</given-names></name><name><surname>He</surname> <given-names>CY</given-names></name><name><surname>He</surname> <given-names>F</given-names></name><name><surname>He</surname> <given-names>G</given-names></name><name><surname>He</surname> <given-names>RR</given-names></name><name><surname>He</surname> <given-names>XH</given-names></name><name><surname>He</surname> <given-names>YW</given-names></name><name><surname>He</surname> <given-names>YY</given-names></name><name><surname>Heath</surname> <given-names>JK</given-names></name><name><surname>Hébert</surname> <given-names>MJ</given-names></name><name><surname>Heinzen</surname> <given-names>RA</given-names></name><name><surname>Helgason</surname> <given-names>GV</given-names></name><name><surname>Hensel</surname> <given-names>M</given-names></name><name><surname>Henske</surname> <given-names>EP</given-names></name><name><surname>Her</surname> <given-names>C</given-names></name><name><surname>Herman</surname> <given-names>PK</given-names></name><name><surname>Hernández</surname> <given-names>A</given-names></name><name><surname>Hernandez</surname> <given-names>C</given-names></name><name><surname>Hernández-Tiedra</surname> <given-names>S</given-names></name><name><surname>Hetz</surname> <given-names>C</given-names></name><name><surname>Hiesinger</surname> <given-names>PR</given-names></name><name><surname>Higaki</surname> <given-names>K</given-names></name><name><surname>Hilfiker</surname> <given-names>S</given-names></name><name><surname>Hill</surname> <given-names>BG</given-names></name><name><surname>Hill</surname> <given-names>JA</given-names></name><name><surname>Hill</surname> <given-names>WD</given-names></name><name><surname>Hino</surname> <given-names>K</given-names></name><name><surname>Hofius</surname> <given-names>D</given-names></name><name><surname>Hofman</surname> <given-names>P</given-names></name><name><surname>Höglinger</surname> <given-names>GU</given-names></name><name><surname>Höhfeld</surname> <given-names>J</given-names></name><name><surname>Holz</surname> <given-names>MK</given-names></name><name><surname>Hong</surname> <given-names>Y</given-names></name><name><surname>Hood</surname> <given-names>DA</given-names></name><name><surname>Hoozemans</surname> <given-names>JJ</given-names></name><name><surname>Hoppe</surname> <given-names>T</given-names></name><name><surname>Hsu</surname> <given-names>C</given-names></name><name><surname>Hsu</surname> <given-names>CY</given-names></name><name><surname>Hsu</surname> <given-names>LC</given-names></name><name><surname>Hu</surname> <given-names>D</given-names></name><name><surname>Hu</surname> <given-names>G</given-names></name><name><surname>Hu</surname> <given-names>HM</given-names></name><name><surname>Hu</surname> <given-names>H</given-names></name><name><surname>Hu</surname> <given-names>MC</given-names></name><name><surname>Hu</surname> <given-names>YC</given-names></name><name><surname>Hu</surname> <given-names>ZW</given-names></name><name><surname>Hua</surname> <given-names>F</given-names></name><name><surname>Hua</surname> <given-names>Y</given-names></name><name><surname>Huang</surname> <given-names>C</given-names></name><name><surname>Huang</surname> <given-names>HL</given-names></name><name><surname>Huang</surname> <given-names>KH</given-names></name><name><surname>Huang</surname> <given-names>KY</given-names></name><name><surname>Huang</surname> <given-names>S</given-names></name><name><surname>Huang</surname> <given-names>S</given-names></name><name><surname>Huang</surname> <given-names>WP</given-names></name><name><surname>Huang</surname> <given-names>YR</given-names></name><name><surname>Huang</surname> <given-names>Y</given-names></name><name><surname>Huang</surname> <given-names>Y</given-names></name><name><surname>Huber</surname> <given-names>TB</given-names></name><name><surname>Huebbe</surname> <given-names>P</given-names></name><name><surname>Huh</surname> <given-names>WK</given-names></name><name><surname>Hulmi</surname> <given-names>JJ</given-names></name><name><surname>Hur</surname> <given-names>GM</given-names></name><name><surname>Hurley</surname> <given-names>JH</given-names></name><name><surname>Husak</surname> <given-names>Z</given-names></name><name><surname>Hussain</surname> <given-names>SN</given-names></name><name><surname>Hussain</surname> <given-names>S</given-names></name><name><surname>Hwang</surname> <given-names>JJ</given-names></name><name><surname>Hwang</surname> <given-names>S</given-names></name><name><surname>Hwang</surname> <given-names>TI</given-names></name><name><surname>Ichihara</surname> <given-names>A</given-names></name><name><surname>Imai</surname> <given-names>Y</given-names></name><name><surname>Imbriano</surname> <given-names>C</given-names></name><name><surname>Inomata</surname> <given-names>M</given-names></name><name><surname>Into</surname> <given-names>T</given-names></name><name><surname>Iovane</surname> <given-names>V</given-names></name><name><surname>Iovanna</surname> <given-names>JL</given-names></name><name><surname>Iozzo</surname> <given-names>RV</given-names></name><name><surname>Ip</surname> <given-names>NY</given-names></name><name><surname>Irazoqui</surname> <given-names>JE</given-names></name><name><surname>Iribarren</surname> <given-names>P</given-names></name><name><surname>Isaka</surname> <given-names>Y</given-names></name><name><surname>Isakovic</surname> <given-names>AJ</given-names></name><name><surname>Ischiropoulos</surname> <given-names>H</given-names></name><name><surname>Isenberg</surname> <given-names>JS</given-names></name><name><surname>Ishaq</surname> <given-names>M</given-names></name><name><surname>Ishida</surname> <given-names>H</given-names></name><name><surname>Ishii</surname> <given-names>I</given-names></name><name><surname>Ishmael</surname> <given-names>JE</given-names></name><name><surname>Isidoro</surname> <given-names>C</given-names></name><name><surname>Isobe</surname> <given-names>K</given-names></name><name><surname>Isono</surname> <given-names>E</given-names></name><name><surname>Issazadeh-Navikas</surname> <given-names>S</given-names></name><name><surname>Itahana</surname> <given-names>K</given-names></name><name><surname>Itakura</surname> <given-names>E</given-names></name><name><surname>Ivanov</surname> <given-names>AI</given-names></name><name><surname>Iyer</surname> <given-names>AK</given-names></name><name><surname>Izquierdo</surname> <given-names>JM</given-names></name><name><surname>Izumi</surname> <given-names>Y</given-names></name><name><surname>Izzo</surname> <given-names>V</given-names></name><name><surname>Jäättelä</surname> <given-names>M</given-names></name><name><surname>Jaber</surname> <given-names>N</given-names></name><name><surname>Jackson</surname> <given-names>DJ</given-names></name><name><surname>Jackson</surname> <given-names>WT</given-names></name><name><surname>Jacob</surname> <given-names>TG</given-names></name><name><surname>Jacques</surname> <given-names>TS</given-names></name><name><surname>Jagannath</surname> <given-names>C</given-names></name><name><surname>Jain</surname> <given-names>A</given-names></name><name><surname>Jana</surname> <given-names>NR</given-names></name><name><surname>Jang</surname> <given-names>BK</given-names></name><name><surname>Jani</surname> <given-names>A</given-names></name><name><surname>Janji</surname> <given-names>B</given-names></name><name><surname>Jannig</surname> <given-names>PR</given-names></name><name><surname>Jansson</surname> <given-names>PJ</given-names></name><name><surname>Jean</surname> <given-names>S</given-names></name><name><surname>Jendrach</surname> <given-names>M</given-names></name><name><surname>Jeon</surname> <given-names>JH</given-names></name><name><surname>Jessen</surname> <given-names>N</given-names></name><name><surname>Jeung</surname> <given-names>EB</given-names></name><name><surname>Jia</surname> <given-names>K</given-names></name><name><surname>Jia</surname> <given-names>L</given-names></name><name><surname>Jiang</surname> <given-names>H</given-names></name><name><surname>Jiang</surname> <given-names>H</given-names></name><name><surname>Jiang</surname> <given-names>L</given-names></name><name><surname>Jiang</surname> <given-names>T</given-names></name><name><surname>Jiang</surname> <given-names>X</given-names></name><name><surname>Jiang</surname> <given-names>X</given-names></name><name><surname>Jiang</surname> <given-names>X</given-names></name><name><surname>Jiang</surname> <given-names>Y</given-names></name><name><surname>Jiang</surname> <given-names>Y</given-names></name><name><surname>Jiménez</surname> <given-names>A</given-names></name><name><surname>Jin</surname> <given-names>C</given-names></name><name><surname>Jin</surname> <given-names>H</given-names></name><name><surname>Jin</surname> <given-names>L</given-names></name><name><surname>Jin</surname> <given-names>M</given-names></name><name><surname>Jin</surname> <given-names>S</given-names></name><name><surname>Jinwal</surname> <given-names>UK</given-names></name><name><surname>Jo</surname> <given-names>EK</given-names></name><name><surname>Johansen</surname> <given-names>T</given-names></name><name><surname>Johnson</surname> <given-names>DE</given-names></name><name><surname>Johnson</surname> <given-names>GV</given-names></name><name><surname>Johnson</surname> <given-names>JD</given-names></name><name><surname>Jonasch</surname> <given-names>E</given-names></name><name><surname>Jones</surname> <given-names>C</given-names></name><name><surname>Joosten</surname> <given-names>LA</given-names></name><name><surname>Jordan</surname> <given-names>J</given-names></name><name><surname>Joseph</surname> <given-names>AM</given-names></name><name><surname>Joseph</surname> <given-names>B</given-names></name><name><surname>Joubert</surname> <given-names>AM</given-names></name><name><surname>Ju</surname> <given-names>D</given-names></name><name><surname>Ju</surname> <given-names>J</given-names></name><name><surname>Juan</surname> <given-names>HF</given-names></name><name><surname>Juenemann</surname> <given-names>K</given-names></name><name><surname>Juhász</surname> <given-names>G</given-names></name><name><surname>Jung</surname> <given-names>HS</given-names></name><name><surname>Jung</surname> <given-names>JU</given-names></name><name><surname>Jung</surname> <given-names>YK</given-names></name><name><surname>Jungbluth</surname> <given-names>H</given-names></name><name><surname>Justice</surname> <given-names>MJ</given-names></name><name><surname>Jutten</surname> <given-names>B</given-names></name><name><surname>Kaakoush</surname> <given-names>NO</given-names></name><name><surname>Kaarniranta</surname> <given-names>K</given-names></name><name><surname>Kaasik</surname> <given-names>A</given-names></name><name><surname>Kabuta</surname> <given-names>T</given-names></name><name><surname>Kaeffer</surname> <given-names>B</given-names></name><name><surname>Kågedal</surname> <given-names>K</given-names></name><name><surname>Kahana</surname> <given-names>A</given-names></name><name><surname>Kajimura</surname> <given-names>S</given-names></name><name><surname>Kakhlon</surname> <given-names>O</given-names></name><name><surname>Kalia</surname> <given-names>M</given-names></name><name><surname>Kalvakolanu</surname> <given-names>DV</given-names></name><name><surname>Kamada</surname> <given-names>Y</given-names></name><name><surname>Kambas</surname> <given-names>K</given-names></name><name><surname>Kaminskyy</surname> <given-names>VO</given-names></name><name><surname>Kampinga</surname> <given-names>HH</given-names></name><name><surname>Kandouz</surname> <given-names>M</given-names></name><name><surname>Kang</surname> <given-names>C</given-names></name><name><surname>Kang</surname> <given-names>R</given-names></name><name><surname>Kang</surname> <given-names>TC</given-names></name><name><surname>Kanki</surname> <given-names>T</given-names></name><name><surname>Kanneganti</surname> <given-names>TD</given-names></name><name><surname>Kanno</surname> <given-names>H</given-names></name><name><surname>Kanthasamy</surname> <given-names>AG</given-names></name><name><surname>Kantorow</surname> <given-names>M</given-names></name><name><surname>Kaparakis-Liaskos</surname> <given-names>M</given-names></name><name><surname>Kapuy</surname> <given-names>O</given-names></name><name><surname>Karantza</surname> <given-names>V</given-names></name><name><surname>Karim</surname> <given-names>MR</given-names></name><name><surname>Karmakar</surname> <given-names>P</given-names></name><name><surname>Kaser</surname> <given-names>A</given-names></name><name><surname>Kaushik</surname> <given-names>S</given-names></name><name><surname>Kawula</surname> <given-names>T</given-names></name><name><surname>Kaynar</surname> <given-names>AM</given-names></name><name><surname>Ke</surname> <given-names>PY</given-names></name><name><surname>Ke</surname> <given-names>ZJ</given-names></name><name><surname>Kehrl</surname> <given-names>JH</given-names></name><name><surname>Keller</surname> <given-names>KE</given-names></name><name><surname>Kemper</surname> <given-names>JK</given-names></name><name><surname>Kenworthy</surname> <given-names>AK</given-names></name><name><surname>Kepp</surname> <given-names>O</given-names></name><name><surname>Kern</surname> <given-names>A</given-names></name><name><surname>Kesari</surname> <given-names>S</given-names></name><name><surname>Kessel</surname> <given-names>D</given-names></name><name><surname>Ketteler</surname> <given-names>R</given-names></name><name><surname>Kettelhut</surname> <given-names>IC</given-names></name><name><surname>Khambu</surname> <given-names>B</given-names></name><name><surname>Khan</surname> <given-names>MM</given-names></name><name><surname>Khandelwal</surname> <given-names>VK</given-names></name><name><surname>Khare</surname> <given-names>S</given-names></name><name><surname>Kiang</surname> <given-names>JG</given-names></name><name><surname>Kiger</surname> <given-names>AA</given-names></name><name><surname>Kihara</surname> <given-names>A</given-names></name><name><surname>Kim</surname> <given-names>AL</given-names></name><name><surname>Kim</surname> <given-names>CH</given-names></name><name><surname>Kim</surname> <given-names>DR</given-names></name><name><surname>Kim</surname> <given-names>DH</given-names></name><name><surname>Kim</surname> <given-names>EK</given-names></name><name><surname>Kim</surname> <given-names>HY</given-names></name><name><surname>Kim</surname> <given-names>HR</given-names></name><name><surname>Kim</surname> <given-names>JS</given-names></name><name><surname>Kim</surname> <given-names>JH</given-names></name><name><surname>Kim</surname> <given-names>JC</given-names></name><name><surname>Kim</surname> <given-names>JH</given-names></name><name><surname>Kim</surname> <given-names>KW</given-names></name><name><surname>Kim</surname> <given-names>MD</given-names></name><name><surname>Kim</surname> <given-names>MM</given-names></name><name><surname>Kim</surname> <given-names>PK</given-names></name><name><surname>Kim</surname> <given-names>SW</given-names></name><name><surname>Kim</surname> <given-names>SY</given-names></name><name><surname>Kim</surname> <given-names>YS</given-names></name><name><surname>Kim</surname> <given-names>Y</given-names></name><name><surname>Kimchi</surname> <given-names>A</given-names></name><name><surname>Kimmelman</surname> <given-names>AC</given-names></name><name><surname>Kimura</surname> <given-names>T</given-names></name><name><surname>King</surname> <given-names>JS</given-names></name><name><surname>Kirkegaard</surname> <given-names>K</given-names></name><name><surname>Kirkin</surname> <given-names>V</given-names></name><name><surname>Kirshenbaum</surname> <given-names>LA</given-names></name><name><surname>Kishi</surname> <given-names>S</given-names></name><name><surname>Kitajima</surname> <given-names>Y</given-names></name><name><surname>Kitamoto</surname> <given-names>K</given-names></name><name><surname>Kitaoka</surname> <given-names>Y</given-names></name><name><surname>Kitazato</surname> <given-names>K</given-names></name><name><surname>Kley</surname> <given-names>RA</given-names></name><name><surname>Klimecki</surname> <given-names>WT</given-names></name><name><surname>Klinkenberg</surname> <given-names>M</given-names></name><name><surname>Klucken</surname> <given-names>J</given-names></name><name><surname>Knævelsrud</surname> <given-names>H</given-names></name><name><surname>Knecht</surname> <given-names>E</given-names></name><name><surname>Knuppertz</surname> <given-names>L</given-names></name><name><surname>Ko</surname> <given-names>JL</given-names></name><name><surname>Kobayashi</surname> <given-names>S</given-names></name><name><surname>Koch</surname> <given-names>JC</given-names></name><name><surname>Koechlin-Ramonatxo</surname> <given-names>C</given-names></name><name><surname>Koenig</surname> <given-names>U</given-names></name><name><surname>Koh</surname> <given-names>YH</given-names></name><name><surname>Köhler</surname> <given-names>K</given-names></name><name><surname>Kohlwein</surname> <given-names>SD</given-names></name><name><surname>Koike</surname> <given-names>M</given-names></name><name><surname>Komatsu</surname> <given-names>M</given-names></name><name><surname>Kominami</surname> <given-names>E</given-names></name><name><surname>Kong</surname> <given-names>D</given-names></name><name><surname>Kong</surname> <given-names>HJ</given-names></name><name><surname>Konstantakou</surname> <given-names>EG</given-names></name><name><surname>Kopp</surname> <given-names>BT</given-names></name><name><surname>Korcsmaros</surname> <given-names>T</given-names></name><name><surname>Korhonen</surname> <given-names>L</given-names></name><name><surname>Korolchuk</surname> <given-names>VI</given-names></name><name><surname>Koshkina</surname> <given-names>NV</given-names></name><name><surname>Kou</surname> <given-names>Y</given-names></name><name><surname>Koukourakis</surname> <given-names>MI</given-names></name><name><surname>Koumenis</surname> <given-names>C</given-names></name><name><surname>Kovács</surname> <given-names>AL</given-names></name><name><surname>Kovács</surname> <given-names>T</given-names></name><name><surname>Kovacs</surname> <given-names>WJ</given-names></name><name><surname>Koya</surname> <given-names>D</given-names></name><name><surname>Kraft</surname> <given-names>C</given-names></name><name><surname>Krainc</surname> <given-names>D</given-names></name><name><surname>Kramer</surname> <given-names>H</given-names></name><name><surname>Kravic-Stevovic</surname> <given-names>T</given-names></name><name><surname>Krek</surname> <given-names>W</given-names></name><name><surname>Kretz-Remy</surname> <given-names>C</given-names></name><name><surname>Krick</surname> <given-names>R</given-names></name><name><surname>Krishnamurthy</surname> <given-names>M</given-names></name><name><surname>Kriston-Vizi</surname> <given-names>J</given-names></name><name><surname>Kroemer</surname> <given-names>G</given-names></name><name><surname>Kruer</surname> <given-names>MC</given-names></name><name><surname>Kruger</surname> <given-names>R</given-names></name><name><surname>Ktistakis</surname> <given-names>NT</given-names></name><name><surname>Kuchitsu</surname> <given-names>K</given-names></name><name><surname>Kuhn</surname> <given-names>C</given-names></name><name><surname>Kumar</surname> <given-names>AP</given-names></name><name><surname>Kumar</surname> <given-names>A</given-names></name><name><surname>Kumar</surname> <given-names>A</given-names></name><name><surname>Kumar</surname> <given-names>D</given-names></name><name><surname>Kumar</surname> <given-names>D</given-names></name><name><surname>Kumar</surname> <given-names>R</given-names></name><name><surname>Kumar</surname> <given-names>S</given-names></name><name><surname>Kundu</surname> <given-names>M</given-names></name><name><surname>Kung</surname> <given-names>HJ</given-names></name><name><surname>Kuno</surname> <given-names>A</given-names></name><name><surname>Kuo</surname> <given-names>SH</given-names></name><name><surname>Kuret</surname> <given-names>J</given-names></name><name><surname>Kurz</surname> <given-names>T</given-names></name><name><surname>Kwok</surname> <given-names>T</given-names></name><name><surname>Kwon</surname> <given-names>TK</given-names></name><name><surname>Kwon</surname> <given-names>YT</given-names></name><name><surname>Kyrmizi</surname> <given-names>I</given-names></name><name><surname>La Spada</surname> <given-names>AR</given-names></name><name><surname>Lafont</surname> <given-names>F</given-names></name><name><surname>Lahm</surname> <given-names>T</given-names></name><name><surname>Lakkaraju</surname> <given-names>A</given-names></name><name><surname>Lam</surname> <given-names>T</given-names></name><name><surname>Lamark</surname> <given-names>T</given-names></name><name><surname>Lancel</surname> <given-names>S</given-names></name><name><surname>Landowski</surname> <given-names>TH</given-names></name><name><surname>Lane</surname> <given-names>DJ</given-names></name><name><surname>Lane</surname> <given-names>JD</given-names></name><name><surname>Lanzi</surname> <given-names>C</given-names></name><name><surname>Lapaquette</surname> <given-names>P</given-names></name><name><surname>Lapierre</surname> <given-names>LR</given-names></name><name><surname>Laporte</surname> <given-names>J</given-names></name><name><surname>Laukkarinen</surname> <given-names>J</given-names></name><name><surname>Laurie</surname> <given-names>GW</given-names></name><name><surname>Lavandero</surname> <given-names>S</given-names></name><name><surname>Lavie</surname> <given-names>L</given-names></name><name><surname>LaVoie</surname> <given-names>MJ</given-names></name><name><surname>Law</surname> <given-names>BY</given-names></name><name><surname>Law</surname> <given-names>HK</given-names></name><name><surname>Law</surname> <given-names>KB</given-names></name><name><surname>Layfield</surname> <given-names>R</given-names></name><name><surname>Lazo</surname> <given-names>PA</given-names></name><name><surname>Le Cam</surname> <given-names>L</given-names></name><name><surname>Le Roch</surname> <given-names>KG</given-names></name><name><surname>Le Stunff</surname> <given-names>H</given-names></name><name><surname>Leardkamolkarn</surname> <given-names>V</given-names></name><name><surname>Lecuit</surname> <given-names>M</given-names></name><name><surname>Lee</surname> <given-names>BH</given-names></name><name><surname>Lee</surname> <given-names>CH</given-names></name><name><surname>Lee</surname> <given-names>EF</given-names></name><name><surname>Lee</surname> <given-names>GM</given-names></name><name><surname>Lee</surname> <given-names>HJ</given-names></name><name><surname>Lee</surname> <given-names>H</given-names></name><name><surname>Lee</surname> <given-names>JK</given-names></name><name><surname>Lee</surname> <given-names>J</given-names></name><name><surname>Lee</surname> <given-names>JH</given-names></name><name><surname>Lee</surname> <given-names>JH</given-names></name><name><surname>Lee</surname> <given-names>M</given-names></name><name><surname>Lee</surname> <given-names>MS</given-names></name><name><surname>Lee</surname> <given-names>PJ</given-names></name><name><surname>Lee</surname> <given-names>SW</given-names></name><name><surname>Lee</surname> <given-names>SJ</given-names></name><name><surname>Lee</surname> <given-names>SJ</given-names></name><name><surname>Lee</surname> <given-names>SY</given-names></name><name><surname>Lee</surname> <given-names>SH</given-names></name><name><surname>Lee</surname> <given-names>SS</given-names></name><name><surname>Lee</surname> <given-names>SJ</given-names></name><name><surname>Lee</surname> <given-names>S</given-names></name><name><surname>Lee</surname> <given-names>YR</given-names></name><name><surname>Lee</surname> <given-names>YJ</given-names></name><name><surname>Lee</surname> <given-names>YH</given-names></name><name><surname>Leeuwenburgh</surname> <given-names>C</given-names></name><name><surname>Lefort</surname> <given-names>S</given-names></name><name><surname>Legouis</surname> <given-names>R</given-names></name><name><surname>Lei</surname> <given-names>J</given-names></name><name><surname>Lei</surname> <given-names>QY</given-names></name><name><surname>Leib</surname> <given-names>DA</given-names></name><name><surname>Leibowitz</surname> <given-names>G</given-names></name><name><surname>Lekli</surname> <given-names>I</given-names></name><name><surname>Lemaire</surname> <given-names>SD</given-names></name><name><surname>Lemasters</surname> <given-names>JJ</given-names></name><name><surname>Lemberg</surname> <given-names>MK</given-names></name><name><surname>Lemoine</surname> <given-names>A</given-names></name><name><surname>Leng</surname> <given-names>S</given-names></name><name><surname>Lenz</surname> <given-names>G</given-names></name><name><surname>Lenzi</surname> <given-names>P</given-names></name><name><surname>Lerman</surname> <given-names>LO</given-names></name><name><surname>Lettieri Barbato</surname> <given-names>D</given-names></name><name><surname>Leu</surname> <given-names>JI</given-names></name><name><surname>Leung</surname> <given-names>HY</given-names></name><name><surname>Levine</surname> <given-names>B</given-names></name><name><surname>Lewis</surname> <given-names>PA</given-names></name><name><surname>Lezoualc'h</surname> <given-names>F</given-names></name><name><surname>Li</surname> <given-names>C</given-names></name><name><surname>Li</surname> <given-names>F</given-names></name><name><surname>Li</surname> <given-names>FJ</given-names></name><name><surname>Li</surname> <given-names>J</given-names></name><name><surname>Li</surname> <given-names>K</given-names></name><name><surname>Li</surname> <given-names>L</given-names></name><name><surname>Li</surname> <given-names>M</given-names></name><name><surname>Li</surname> <given-names>M</given-names></name><name><surname>Li</surname> <given-names>Q</given-names></name><name><surname>Li</surname> <given-names>R</given-names></name><name><surname>Li</surname> <given-names>S</given-names></name><name><surname>Li</surname> <given-names>W</given-names></name><name><surname>Li</surname> <given-names>W</given-names></name><name><surname>Li</surname> <given-names>X</given-names></name><name><surname>Li</surname> <given-names>Y</given-names></name><name><surname>Lian</surname> <given-names>J</given-names></name><name><surname>Liang</surname> <given-names>C</given-names></name><name><surname>Liang</surname> <given-names>Q</given-names></name><name><surname>Liao</surname> <given-names>Y</given-names></name><name><surname>Liberal</surname> <given-names>J</given-names></name><name><surname>Liberski</surname> <given-names>PP</given-names></name><name><surname>Lie</surname> <given-names>P</given-names></name><name><surname>Lieberman</surname> <given-names>AP</given-names></name><name><surname>Lim</surname> <given-names>HJ</given-names></name><name><surname>Lim</surname> <given-names>KL</given-names></name><name><surname>Lim</surname> <given-names>K</given-names></name><name><surname>Lima</surname> <given-names>RT</given-names></name><name><surname>Lin</surname> <given-names>CS</given-names></name><name><surname>Lin</surname> <given-names>CF</given-names></name><name><surname>Lin</surname> <given-names>F</given-names></name><name><surname>Lin</surname> <given-names>F</given-names></name><name><surname>Lin</surname> <given-names>FC</given-names></name><name><surname>Lin</surname> <given-names>K</given-names></name><name><surname>Lin</surname> <given-names>KH</given-names></name><name><surname>Lin</surname> <given-names>PH</given-names></name><name><surname>Lin</surname> <given-names>T</given-names></name><name><surname>Lin</surname> <given-names>WW</given-names></name><name><surname>Lin</surname> <given-names>YS</given-names></name><name><surname>Lin</surname> <given-names>Y</given-names></name><name><surname>Linden</surname> <given-names>R</given-names></name><name><surname>Lindholm</surname> <given-names>D</given-names></name><name><surname>Lindqvist</surname> <given-names>LM</given-names></name><name><surname>Lingor</surname> <given-names>P</given-names></name><name><surname>Linkermann</surname> <given-names>A</given-names></name><name><surname>Liotta</surname> <given-names>LA</given-names></name><name><surname>Lipinski</surname> <given-names>MM</given-names></name><name><surname>Lira</surname> <given-names>VA</given-names></name><name><surname>Lisanti</surname> <given-names>MP</given-names></name><name><surname>Liton</surname> <given-names>PB</given-names></name><name><surname>Liu</surname> <given-names>B</given-names></name><name><surname>Liu</surname> <given-names>C</given-names></name><name><surname>Liu</surname> <given-names>CF</given-names></name><name><surname>Liu</surname> <given-names>F</given-names></name><name><surname>Liu</surname> <given-names>HJ</given-names></name><name><surname>Liu</surname> <given-names>J</given-names></name><name><surname>Liu</surname> <given-names>JJ</given-names></name><name><surname>Liu</surname> <given-names>JL</given-names></name><name><surname>Liu</surname> <given-names>K</given-names></name><name><surname>Liu</surname> <given-names>L</given-names></name><name><surname>Liu</surname> <given-names>L</given-names></name><name><surname>Liu</surname> <given-names>Q</given-names></name><name><surname>Liu</surname> <given-names>RY</given-names></name><name><surname>Liu</surname> <given-names>S</given-names></name><name><surname>Liu</surname> <given-names>S</given-names></name><name><surname>Liu</surname> <given-names>W</given-names></name><name><surname>Liu</surname> <given-names>XD</given-names></name><name><surname>Liu</surname> <given-names>X</given-names></name><name><surname>Liu</surname> <given-names>XH</given-names></name><name><surname>Liu</surname> <given-names>X</given-names></name><name><surname>Liu</surname> <given-names>X</given-names></name><name><surname>Liu</surname> <given-names>X</given-names></name><name><surname>Liu</surname> <given-names>Y</given-names></name><name><surname>Liu</surname> <given-names>Y</given-names></name><name><surname>Liu</surname> <given-names>Z</given-names></name><name><surname>Liu</surname> <given-names>Z</given-names></name><name><surname>Liuzzi</surname> <given-names>JP</given-names></name><name><surname>Lizard</surname> <given-names>G</given-names></name><name><surname>Ljujic</surname> <given-names>M</given-names></name><name><surname>Lodhi</surname> <given-names>IJ</given-names></name><name><surname>Logue</surname> <given-names>SE</given-names></name><name><surname>Lokeshwar</surname> <given-names>BL</given-names></name><name><surname>Long</surname> <given-names>YC</given-names></name><name><surname>Lonial</surname> <given-names>S</given-names></name><name><surname>Loos</surname> <given-names>B</given-names></name><name><surname>López-Otín</surname> <given-names>C</given-names></name><name><surname>López-Vicario</surname> <given-names>C</given-names></name><name><surname>Lorente</surname> <given-names>M</given-names></name><name><surname>Lorenzi</surname> <given-names>PL</given-names></name><name><surname>Lõrincz</surname> <given-names>P</given-names></name><name><surname>Los</surname> <given-names>M</given-names></name><name><surname>Lotze</surname> <given-names>MT</given-names></name><name><surname>Lovat</surname> <given-names>PE</given-names></name><name><surname>Lu</surname> <given-names>B</given-names></name><name><surname>Lu</surname> <given-names>B</given-names></name><name><surname>Lu</surname> <given-names>J</given-names></name><name><surname>Lu</surname> <given-names>Q</given-names></name><name><surname>Lu</surname> <given-names>SM</given-names></name><name><surname>Lu</surname> <given-names>S</given-names></name><name><surname>Lu</surname> <given-names>Y</given-names></name><name><surname>Luciano</surname> <given-names>F</given-names></name><name><surname>Luckhart</surname> <given-names>S</given-names></name><name><surname>Lucocq</surname> <given-names>JM</given-names></name><name><surname>Ludovico</surname> <given-names>P</given-names></name><name><surname>Lugea</surname> <given-names>A</given-names></name><name><surname>Lukacs</surname> <given-names>NW</given-names></name><name><surname>Lum</surname> <given-names>JJ</given-names></name><name><surname>Lund</surname> <given-names>AH</given-names></name><name><surname>Luo</surname> <given-names>H</given-names></name><name><surname>Luo</surname> <given-names>J</given-names></name><name><surname>Luo</surname> <given-names>S</given-names></name><name><surname>Luparello</surname> <given-names>C</given-names></name><name><surname>Lyons</surname> <given-names>T</given-names></name><name><surname>Ma</surname> <given-names>J</given-names></name><name><surname>Ma</surname> <given-names>Y</given-names></name><name><surname>Ma</surname> <given-names>Y</given-names></name><name><surname>Ma</surname> <given-names>Z</given-names></name><name><surname>Machado</surname> <given-names>J</given-names></name><name><surname>Machado-Santelli</surname> <given-names>GM</given-names></name><name><surname>Macian</surname> <given-names>F</given-names></name><name><surname>MacIntosh</surname> <given-names>GC</given-names></name><name><surname>MacKeigan</surname> <given-names>JP</given-names></name><name><surname>Macleod</surname> <given-names>KF</given-names></name><name><surname>MacMicking</surname> <given-names>JD</given-names></name><name><surname>MacMillan-Crow</surname> <given-names>LA</given-names></name><name><surname>Madeo</surname> <given-names>F</given-names></name><name><surname>Madesh</surname> <given-names>M</given-names></name><name><surname>Madrigal-Matute</surname> <given-names>J</given-names></name><name><surname>Maeda</surname> <given-names>A</given-names></name><name><surname>Maeda</surname> <given-names>T</given-names></name><name><surname>Maegawa</surname> <given-names>G</given-names></name><name><surname>Maellaro</surname> <given-names>E</given-names></name><name><surname>Maes</surname> <given-names>H</given-names></name><name><surname>Magariños</surname> <given-names>M</given-names></name><name><surname>Maiese</surname> <given-names>K</given-names></name><name><surname>Maiti</surname> <given-names>TK</given-names></name><name><surname>Maiuri</surname> <given-names>L</given-names></name><name><surname>Maiuri</surname> <given-names>MC</given-names></name><name><surname>Maki</surname> <given-names>CG</given-names></name><name><surname>Malli</surname> <given-names>R</given-names></name><name><surname>Malorni</surname> <given-names>W</given-names></name><name><surname>Maloyan</surname> <given-names>A</given-names></name><name><surname>Mami-Chouaib</surname> <given-names>F</given-names></name><name><surname>Man</surname> <given-names>N</given-names></name><name><surname>Mancias</surname> <given-names>JD</given-names></name><name><surname>Mandelkow</surname> <given-names>EM</given-names></name><name><surname>Mandell</surname> <given-names>MA</given-names></name><name><surname>Manfredi</surname> <given-names>AA</given-names></name><name><surname>Manié</surname> <given-names>SN</given-names></name><name><surname>Manzoni</surname> <given-names>C</given-names></name><name><surname>Mao</surname> <given-names>K</given-names></name><name><surname>Mao</surname> <given-names>Z</given-names></name><name><surname>Mao</surname> <given-names>ZW</given-names></name><name><surname>Marambaud</surname> <given-names>P</given-names></name><name><surname>Marconi</surname> <given-names>AM</given-names></name><name><surname>Marelja</surname> <given-names>Z</given-names></name><name><surname>Marfe</surname> <given-names>G</given-names></name><name><surname>Margeta</surname> <given-names>M</given-names></name><name><surname>Margittai</surname> <given-names>E</given-names></name><name><surname>Mari</surname> <given-names>M</given-names></name><name><surname>Mariani</surname> <given-names>FV</given-names></name><name><surname>Marin</surname> <given-names>C</given-names></name><name><surname>Marinelli</surname> <given-names>S</given-names></name><name><surname>Mariño</surname> <given-names>G</given-names></name><name><surname>Markovic</surname> <given-names>I</given-names></name><name><surname>Marquez</surname> <given-names>R</given-names></name><name><surname>Martelli</surname> <given-names>AM</given-names></name><name><surname>Martens</surname> <given-names>S</given-names></name><name><surname>Martin</surname> <given-names>KR</given-names></name><name><surname>Martin</surname> <given-names>SJ</given-names></name><name><surname>Martin</surname> <given-names>S</given-names></name><name><surname>Martin-Acebes</surname> <given-names>MA</given-names></name><name><surname>Martín-Sanz</surname> <given-names>P</given-names></name><name><surname>Martinand-Mari</surname> <given-names>C</given-names></name><name><surname>Martinet</surname> <given-names>W</given-names></name><name><surname>Martinez</surname> <given-names>J</given-names></name><name><surname>Martinez-Lopez</surname> <given-names>N</given-names></name><name><surname>Martinez-Outschoorn</surname> <given-names>U</given-names></name><name><surname>Martínez-Velázquez</surname> <given-names>M</given-names></name><name><surname>Martinez-Vicente</surname> <given-names>M</given-names></name><name><surname>Martins</surname> <given-names>WK</given-names></name><name><surname>Mashima</surname> <given-names>H</given-names></name><name><surname>Mastrianni</surname> <given-names>JA</given-names></name><name><surname>Matarese</surname> <given-names>G</given-names></name><name><surname>Matarrese</surname> <given-names>P</given-names></name><name><surname>Mateo</surname> <given-names>R</given-names></name><name><surname>Matoba</surname> <given-names>S</given-names></name><name><surname>Matsumoto</surname> <given-names>N</given-names></name><name><surname>Matsushita</surname> <given-names>T</given-names></name><name><surname>Matsuura</surname> <given-names>A</given-names></name><name><surname>Matsuzawa</surname> <given-names>T</given-names></name><name><surname>Mattson</surname> <given-names>MP</given-names></name><name><surname>Matus</surname> <given-names>S</given-names></name><name><surname>Maugeri</surname> <given-names>N</given-names></name><name><surname>Mauvezin</surname> <given-names>C</given-names></name><name><surname>Mayer</surname> <given-names>A</given-names></name><name><surname>Maysinger</surname> <given-names>D</given-names></name><name><surname>Mazzolini</surname> <given-names>GD</given-names></name><name><surname>McBrayer</surname> <given-names>MK</given-names></name><name><surname>McCall</surname> <given-names>K</given-names></name><name><surname>McCormick</surname> <given-names>C</given-names></name><name><surname>McInerney</surname> <given-names>GM</given-names></name><name><surname>McIver</surname> <given-names>SC</given-names></name><name><surname>McKenna</surname> <given-names>S</given-names></name><name><surname>McMahon</surname> <given-names>JJ</given-names></name><name><surname>McNeish</surname> <given-names>IA</given-names></name><name><surname>Mechta-Grigoriou</surname> <given-names>F</given-names></name><name><surname>Medema</surname> <given-names>JP</given-names></name><name><surname>Medina</surname> <given-names>DL</given-names></name><name><surname>Megyeri</surname> <given-names>K</given-names></name><name><surname>Mehrpour</surname> <given-names>M</given-names></name><name><surname>Mehta</surname> <given-names>JL</given-names></name><name><surname>Mei</surname> <given-names>Y</given-names></name><name><surname>Meier</surname> <given-names>UC</given-names></name><name><surname>Meijer</surname> <given-names>AJ</given-names></name><name><surname>Meléndez</surname> <given-names>A</given-names></name><name><surname>Melino</surname> <given-names>G</given-names></name><name><surname>Melino</surname> <given-names>S</given-names></name><name><surname>de Melo</surname> <given-names>EJ</given-names></name><name><surname>Mena</surname> <given-names>MA</given-names></name><name><surname>Meneghini</surname> <given-names>MD</given-names></name><name><surname>Menendez</surname> <given-names>JA</given-names></name><name><surname>Menezes</surname> <given-names>R</given-names></name><name><surname>Meng</surname> <given-names>L</given-names></name><name><surname>Meng</surname> <given-names>LH</given-names></name><name><surname>Meng</surname> <given-names>S</given-names></name><name><surname>Menghini</surname> <given-names>R</given-names></name><name><surname>Menko</surname> <given-names>AS</given-names></name><name><surname>Menna-Barreto</surname> <given-names>RF</given-names></name><name><surname>Menon</surname> <given-names>MB</given-names></name><name><surname>Meraz-Ríos</surname> <given-names>MA</given-names></name><name><surname>Merla</surname> <given-names>G</given-names></name><name><surname>Merlini</surname> <given-names>L</given-names></name><name><surname>Merlot</surname> <given-names>AM</given-names></name><name><surname>Meryk</surname> <given-names>A</given-names></name><name><surname>Meschini</surname> <given-names>S</given-names></name><name><surname>Meyer</surname> <given-names>JN</given-names></name><name><surname>Mi</surname> <given-names>MT</given-names></name><name><surname>Miao</surname> <given-names>CY</given-names></name><name><surname>Micale</surname> <given-names>L</given-names></name><name><surname>Michaeli</surname> <given-names>S</given-names></name><name><surname>Michiels</surname> <given-names>C</given-names></name><name><surname>Migliaccio</surname> <given-names>AR</given-names></name><name><surname>Mihailidou</surname> <given-names>AS</given-names></name><name><surname>Mijaljica</surname> <given-names>D</given-names></name><name><surname>Mikoshiba</surname> <given-names>K</given-names></name><name><surname>Milan</surname> <given-names>E</given-names></name><name><surname>Miller-Fleming</surname> <given-names>L</given-names></name><name><surname>Mills</surname> <given-names>GB</given-names></name><name><surname>Mills</surname> <given-names>IG</given-names></name><name><surname>Minakaki</surname> <given-names>G</given-names></name><name><surname>Minassian</surname> <given-names>BA</given-names></name><name><surname>Ming</surname> <given-names>XF</given-names></name><name><surname>Minibayeva</surname> <given-names>F</given-names></name><name><surname>Minina</surname> <given-names>EA</given-names></name><name><surname>Mintern</surname> <given-names>JD</given-names></name><name><surname>Minucci</surname> <given-names>S</given-names></name><name><surname>Miranda-Vizuete</surname> <given-names>A</given-names></name><name><surname>Mitchell</surname> <given-names>CH</given-names></name><name><surname>Miyamoto</surname> <given-names>S</given-names></name><name><surname>Miyazawa</surname> <given-names>K</given-names></name><name><surname>Mizushima</surname> <given-names>N</given-names></name><name><surname>Mnich</surname> <given-names>K</given-names></name><name><surname>Mograbi</surname> <given-names>B</given-names></name><name><surname>Mohseni</surname> <given-names>S</given-names></name><name><surname>Moita</surname> <given-names>LF</given-names></name><name><surname>Molinari</surname> <given-names>M</given-names></name><name><surname>Molinari</surname> <given-names>M</given-names></name><name><surname>Møller</surname> <given-names>AB</given-names></name><name><surname>Mollereau</surname> <given-names>B</given-names></name><name><surname>Mollinedo</surname> <given-names>F</given-names></name><name><surname>Mongillo</surname> <given-names>M</given-names></name><name><surname>Monick</surname> <given-names>MM</given-names></name><name><surname>Montagnaro</surname> <given-names>S</given-names></name><name><surname>Montell</surname> <given-names>C</given-names></name><name><surname>Moore</surname> <given-names>DJ</given-names></name><name><surname>Moore</surname> <given-names>MN</given-names></name><name><surname>Mora-Rodriguez</surname> <given-names>R</given-names></name><name><surname>Moreira</surname> <given-names>PI</given-names></name><name><surname>Morel</surname> <given-names>E</given-names></name><name><surname>Morelli</surname> <given-names>MB</given-names></name><name><surname>Moreno</surname> <given-names>S</given-names></name><name><surname>Morgan</surname> <given-names>MJ</given-names></name><name><surname>Moris</surname> <given-names>A</given-names></name><name><surname>Moriyasu</surname> <given-names>Y</given-names></name><name><surname>Morrison</surname> <given-names>JL</given-names></name><name><surname>Morrison</surname> <given-names>LA</given-names></name><name><surname>Morselli</surname> <given-names>E</given-names></name><name><surname>Moscat</surname> <given-names>J</given-names></name><name><surname>Moseley</surname> <given-names>PL</given-names></name><name><surname>Mostowy</surname> <given-names>S</given-names></name><name><surname>Motori</surname> <given-names>E</given-names></name><name><surname>Mottet</surname> <given-names>D</given-names></name><name><surname>Mottram</surname> <given-names>JC</given-names></name><name><surname>Moussa</surname> <given-names>CE</given-names></name><name><surname>Mpakou</surname> <given-names>VE</given-names></name><name><surname>Mukhtar</surname> <given-names>H</given-names></name><name><surname>Mulcahy Levy</surname> <given-names>JM</given-names></name><name><surname>Muller</surname> <given-names>S</given-names></name><name><surname>Muñoz-Moreno</surname> <given-names>R</given-names></name><name><surname>Muñoz-Pinedo</surname> <given-names>C</given-names></name><name><surname>Münz</surname> <given-names>C</given-names></name><name><surname>Murphy</surname> <given-names>ME</given-names></name><name><surname>Murray</surname> <given-names>JT</given-names></name><name><surname>Murthy</surname> <given-names>A</given-names></name><name><surname>Mysorekar</surname> <given-names>IU</given-names></name><name><surname>Nabi</surname> <given-names>IR</given-names></name><name><surname>Nabissi</surname> <given-names>M</given-names></name><name><surname>Nader</surname> <given-names>GA</given-names></name><name><surname>Nagahara</surname> <given-names>Y</given-names></name><name><surname>Nagai</surname> <given-names>Y</given-names></name><name><surname>Nagata</surname> <given-names>K</given-names></name><name><surname>Nagelkerke</surname> <given-names>A</given-names></name><name><surname>Nagy</surname> <given-names>P</given-names></name><name><surname>Naidu</surname> <given-names>SR</given-names></name><name><surname>Nair</surname> <given-names>S</given-names></name><name><surname>Nakano</surname> <given-names>H</given-names></name><name><surname>Nakatogawa</surname> <given-names>H</given-names></name><name><surname>Nanjundan</surname> <given-names>M</given-names></name><name><surname>Napolitano</surname> <given-names>G</given-names></name><name><surname>Naqvi</surname> <given-names>NI</given-names></name><name><surname>Nardacci</surname> <given-names>R</given-names></name><name><surname>Narendra</surname> <given-names>DP</given-names></name><name><surname>Narita</surname> <given-names>M</given-names></name><name><surname>Nascimbeni</surname> <given-names>AC</given-names></name><name><surname>Natarajan</surname> <given-names>R</given-names></name><name><surname>Navegantes</surname> <given-names>LC</given-names></name><name><surname>Nawrocki</surname> <given-names>ST</given-names></name><name><surname>Nazarko</surname> <given-names>TY</given-names></name><name><surname>Nazarko</surname> <given-names>VY</given-names></name><name><surname>Neill</surname> <given-names>T</given-names></name><name><surname>Neri</surname> <given-names>LM</given-names></name><name><surname>Netea</surname> <given-names>MG</given-names></name><name><surname>Netea-Maier</surname> <given-names>RT</given-names></name><name><surname>Neves</surname> <given-names>BM</given-names></name><name><surname>Ney</surname> <given-names>PA</given-names></name><name><surname>Nezis</surname> <given-names>IP</given-names></name><name><surname>Nguyen</surname> <given-names>HT</given-names></name><name><surname>Nguyen</surname> <given-names>HP</given-names></name><name><surname>Nicot</surname> <given-names>AS</given-names></name><name><surname>Nilsen</surname> <given-names>H</given-names></name><name><surname>Nilsson</surname> <given-names>P</given-names></name><name><surname>Nishimura</surname> <given-names>M</given-names></name><name><surname>Nishino</surname> <given-names>I</given-names></name><name><surname>Niso-Santano</surname> <given-names>M</given-names></name><name><surname>Niu</surname> <given-names>H</given-names></name><name><surname>Nixon</surname> <given-names>RA</given-names></name><name><surname>Njar</surname> <given-names>VC</given-names></name><name><surname>Noda</surname> <given-names>T</given-names></name><name><surname>Noegel</surname> <given-names>AA</given-names></name><name><surname>Nolte</surname> <given-names>EM</given-names></name><name><surname>Norberg</surname> <given-names>E</given-names></name><name><surname>Norga</surname> <given-names>KK</given-names></name><name><surname>Noureini</surname> <given-names>SK</given-names></name><name><surname>Notomi</surname> <given-names>S</given-names></name><name><surname>Notterpek</surname> <given-names>L</given-names></name><name><surname>Nowikovsky</surname> <given-names>K</given-names></name><name><surname>Nukina</surname> <given-names>N</given-names></name><name><surname>Nürnberger</surname> <given-names>T</given-names></name><name><surname>O'Donnell</surname> <given-names>VB</given-names></name><name><surname>O'Donovan</surname> <given-names>T</given-names></name><name><surname>O'Dwyer</surname> <given-names>PJ</given-names></name><name><surname>Oehme</surname> <given-names>I</given-names></name><name><surname>Oeste</surname> <given-names>CL</given-names></name><name><surname>Ogawa</surname> <given-names>M</given-names></name><name><surname>Ogretmen</surname> <given-names>B</given-names></name><name><surname>Ogura</surname> <given-names>Y</given-names></name><name><surname>Oh</surname> <given-names>YJ</given-names></name><name><surname>Ohmuraya</surname> <given-names>M</given-names></name><name><surname>Ohshima</surname> <given-names>T</given-names></name><name><surname>Ojha</surname> <given-names>R</given-names></name><name><surname>Okamoto</surname> <given-names>K</given-names></name><name><surname>Okazaki</surname> <given-names>T</given-names></name><name><surname>Oliver</surname> <given-names>FJ</given-names></name><name><surname>Ollinger</surname> <given-names>K</given-names></name><name><surname>Olsson</surname> <given-names>S</given-names></name><name><surname>Orban</surname> <given-names>DP</given-names></name><name><surname>Ordonez</surname> <given-names>P</given-names></name><name><surname>Orhon</surname> <given-names>I</given-names></name><name><surname>Orosz</surname> <given-names>L</given-names></name><name><surname>O'Rourke</surname> <given-names>EJ</given-names></name><name><surname>Orozco</surname> <given-names>H</given-names></name><name><surname>Ortega</surname> <given-names>AL</given-names></name><name><surname>Ortona</surname> <given-names>E</given-names></name><name><surname>Osellame</surname> <given-names>LD</given-names></name><name><surname>Oshima</surname> <given-names>J</given-names></name><name><surname>Oshima</surname> <given-names>S</given-names></name><name><surname>Osiewacz</surname> <given-names>HD</given-names></name><name><surname>Otomo</surname> <given-names>T</given-names></name><name><surname>Otsu</surname> <given-names>K</given-names></name><name><surname>Ou</surname> <given-names>JH</given-names></name><name><surname>Outeiro</surname> <given-names>TF</given-names></name><name><surname>Ouyang</surname> <given-names>DY</given-names></name><name><surname>Ouyang</surname> <given-names>H</given-names></name><name><surname>Overholtzer</surname> <given-names>M</given-names></name><name><surname>Ozbun</surname> <given-names>MA</given-names></name><name><surname>Ozdinler</surname> <given-names>PH</given-names></name><name><surname>Ozpolat</surname> <given-names>B</given-names></name><name><surname>Pacelli</surname> <given-names>C</given-names></name><name><surname>Paganetti</surname> <given-names>P</given-names></name><name><surname>Page</surname> <given-names>G</given-names></name><name><surname>Pages</surname> <given-names>G</given-names></name><name><surname>Pagnini</surname> <given-names>U</given-names></name><name><surname>Pajak</surname> <given-names>B</given-names></name><name><surname>Pak</surname> <given-names>SC</given-names></name><name><surname>Pakos-Zebrucka</surname> <given-names>K</given-names></name><name><surname>Pakpour</surname> <given-names>N</given-names></name><name><surname>Palková</surname> <given-names>Z</given-names></name><name><surname>Palladino</surname> <given-names>F</given-names></name><name><surname>Pallauf</surname> <given-names>K</given-names></name><name><surname>Pallet</surname> <given-names>N</given-names></name><name><surname>Palmieri</surname> <given-names>M</given-names></name><name><surname>Paludan</surname> <given-names>SR</given-names></name><name><surname>Palumbo</surname> <given-names>C</given-names></name><name><surname>Palumbo</surname> <given-names>S</given-names></name><name><surname>Pampliega</surname> <given-names>O</given-names></name><name><surname>Pan</surname> <given-names>H</given-names></name><name><surname>Pan</surname> <given-names>W</given-names></name><name><surname>Panaretakis</surname> <given-names>T</given-names></name><name><surname>Pandey</surname> <given-names>A</given-names></name><name><surname>Pantazopoulou</surname> <given-names>A</given-names></name><name><surname>Papackova</surname> <given-names>Z</given-names></name><name><surname>Papademetrio</surname> <given-names>DL</given-names></name><name><surname>Papassideri</surname> <given-names>I</given-names></name><name><surname>Papini</surname> <given-names>A</given-names></name><name><surname>Parajuli</surname> <given-names>N</given-names></name><name><surname>Pardo</surname> <given-names>J</given-names></name><name><surname>Parekh</surname> <given-names>VV</given-names></name><name><surname>Parenti</surname> <given-names>G</given-names></name><name><surname>Park</surname> <given-names>JI</given-names></name><name><surname>Park</surname> <given-names>J</given-names></name><name><surname>Park</surname> <given-names>OK</given-names></name><name><surname>Parker</surname> <given-names>R</given-names></name><name><surname>Parlato</surname> <given-names>R</given-names></name><name><surname>Parys</surname> <given-names>JB</given-names></name><name><surname>Parzych</surname> <given-names>KR</given-names></name><name><surname>Pasquet</surname> <given-names>JM</given-names></name><name><surname>Pasquier</surname> <given-names>B</given-names></name><name><surname>Pasumarthi</surname> <given-names>KB</given-names></name><name><surname>Patschan</surname> <given-names>D</given-names></name><name><surname>Patterson</surname> <given-names>C</given-names></name><name><surname>Pattingre</surname> <given-names>S</given-names></name><name><surname>Pattison</surname> <given-names>S</given-names></name><name><surname>Pause</surname> <given-names>A</given-names></name><name><surname>Pavenstädt</surname> <given-names>H</given-names></name><name><surname>Pavone</surname> <given-names>F</given-names></name><name><surname>Pedrozo</surname> <given-names>Z</given-names></name><name><surname>Peña</surname> <given-names>FJ</given-names></name><name><surname>Peñalva</surname> <given-names>MA</given-names></name><name><surname>Pende</surname> <given-names>M</given-names></name><name><surname>Peng</surname> <given-names>J</given-names></name><name><surname>Penna</surname> <given-names>F</given-names></name><name><surname>Penninger</surname> <given-names>JM</given-names></name><name><surname>Pensalfini</surname> <given-names>A</given-names></name><name><surname>Pepe</surname> <given-names>S</given-names></name><name><surname>Pereira</surname> <given-names>GJ</given-names></name><name><surname>Pereira</surname> <given-names>PC</given-names></name><name><surname>Pérez-de la Cruz</surname> <given-names>V</given-names></name><name><surname>Pérez-Pérez</surname> <given-names>ME</given-names></name><name><surname>Pérez-Rodríguez</surname> <given-names>D</given-names></name><name><surname>Pérez-Sala</surname> <given-names>D</given-names></name><name><surname>Perier</surname> <given-names>C</given-names></name><name><surname>Perl</surname> <given-names>A</given-names></name><name><surname>Perlmutter</surname> <given-names>DH</given-names></name><name><surname>Perrotta</surname> <given-names>I</given-names></name><name><surname>Pervaiz</surname> <given-names>S</given-names></name><name><surname>Pesonen</surname> <given-names>M</given-names></name><name><surname>Pessin</surname> <given-names>JE</given-names></name><name><surname>Peters</surname> <given-names>GJ</given-names></name><name><surname>Petersen</surname> <given-names>M</given-names></name><name><surname>Petrache</surname> <given-names>I</given-names></name><name><surname>Petrof</surname> <given-names>BJ</given-names></name><name><surname>Petrovski</surname> <given-names>G</given-names></name><name><surname>Phang</surname> <given-names>JM</given-names></name><name><surname>Piacentini</surname> <given-names>M</given-names></name><name><surname>Pierdominici</surname> <given-names>M</given-names></name><name><surname>Pierre</surname> <given-names>P</given-names></name><name><surname>Pierrefite-Carle</surname> <given-names>V</given-names></name><name><surname>Pietrocola</surname> <given-names>F</given-names></name><name><surname>Pimentel-Muiños</surname> <given-names>FX</given-names></name><name><surname>Pinar</surname> <given-names>M</given-names></name><name><surname>Pineda</surname> <given-names>B</given-names></name><name><surname>Pinkas-Kramarski</surname> <given-names>R</given-names></name><name><surname>Pinti</surname> <given-names>M</given-names></name><name><surname>Pinton</surname> <given-names>P</given-names></name><name><surname>Piperdi</surname> <given-names>B</given-names></name><name><surname>Piret</surname> <given-names>JM</given-names></name><name><surname>Platanias</surname> <given-names>LC</given-names></name><name><surname>Platta</surname> <given-names>HW</given-names></name><name><surname>Plowey</surname> <given-names>ED</given-names></name><name><surname>Pöggeler</surname> <given-names>S</given-names></name><name><surname>Poirot</surname> <given-names>M</given-names></name><name><surname>Polčic</surname> <given-names>P</given-names></name><name><surname>Poletti</surname> <given-names>A</given-names></name><name><surname>Poon</surname> <given-names>AH</given-names></name><name><surname>Popelka</surname> <given-names>H</given-names></name><name><surname>Popova</surname> <given-names>B</given-names></name><name><surname>Poprawa</surname> <given-names>I</given-names></name><name><surname>Poulose</surname> <given-names>SM</given-names></name><name><surname>Poulton</surname> <given-names>J</given-names></name><name><surname>Powers</surname> <given-names>SK</given-names></name><name><surname>Powers</surname> <given-names>T</given-names></name><name><surname>Pozuelo-Rubio</surname> <given-names>M</given-names></name><name><surname>Prak</surname> <given-names>K</given-names></name><name><surname>Prange</surname> <given-names>R</given-names></name><name><surname>Prescott</surname> <given-names>M</given-names></name><name><surname>Priault</surname> <given-names>M</given-names></name><name><surname>Prince</surname> <given-names>S</given-names></name><name><surname>Proia</surname> <given-names>RL</given-names></name><name><surname>Proikas-Cezanne</surname> <given-names>T</given-names></name><name><surname>Prokisch</surname> <given-names>H</given-names></name><name><surname>Promponas</surname> <given-names>VJ</given-names></name><name><surname>Przyklenk</surname> <given-names>K</given-names></name><name><surname>Puertollano</surname> <given-names>R</given-names></name><name><surname>Pugazhenthi</surname> <given-names>S</given-names></name><name><surname>Puglielli</surname> <given-names>L</given-names></name><name><surname>Pujol</surname> <given-names>A</given-names></name><name><surname>Puyal</surname> <given-names>J</given-names></name><name><surname>Pyeon</surname> <given-names>D</given-names></name><name><surname>Qi</surname> <given-names>X</given-names></name><name><surname>Qian</surname> <given-names>WB</given-names></name><name><surname>Qin</surname> <given-names>ZH</given-names></name><name><surname>Qiu</surname> <given-names>Y</given-names></name><name><surname>Qu</surname> <given-names>Z</given-names></name><name><surname>Quadrilatero</surname> <given-names>J</given-names></name><name><surname>Quinn</surname> <given-names>F</given-names></name><name><surname>Raben</surname> <given-names>N</given-names></name><name><surname>Rabinowich</surname> <given-names>H</given-names></name><name><surname>Radogna</surname> <given-names>F</given-names></name><name><surname>Ragusa</surname> <given-names>MJ</given-names></name><name><surname>Rahmani</surname> <given-names>M</given-names></name><name><surname>Raina</surname> <given-names>K</given-names></name><name><surname>Ramanadham</surname> <given-names>S</given-names></name><name><surname>Ramesh</surname> <given-names>R</given-names></name><name><surname>Rami</surname> <given-names>A</given-names></name><name><surname>Randall-Demllo</surname> <given-names>S</given-names></name><name><surname>Randow</surname> <given-names>F</given-names></name><name><surname>Rao</surname> <given-names>H</given-names></name><name><surname>Rao</surname> <given-names>VA</given-names></name><name><surname>Rasmussen</surname> <given-names>BB</given-names></name><name><surname>Rasse</surname> <given-names>TM</given-names></name><name><surname>Ratovitski</surname> <given-names>EA</given-names></name><name><surname>Rautou</surname> <given-names>PE</given-names></name><name><surname>Ray</surname> <given-names>SK</given-names></name><name><surname>Razani</surname> <given-names>B</given-names></name><name><surname>Reed</surname> <given-names>BH</given-names></name><name><surname>Reggiori</surname> <given-names>F</given-names></name><name><surname>Rehm</surname> <given-names>M</given-names></name><name><surname>Reichert</surname> <given-names>AS</given-names></name><name><surname>Rein</surname> <given-names>T</given-names></name><name><surname>Reiner</surname> <given-names>DJ</given-names></name><name><surname>Reits</surname> <given-names>E</given-names></name><name><surname>Ren</surname> <given-names>J</given-names></name><name><surname>Ren</surname> <given-names>X</given-names></name><name><surname>Renna</surname> <given-names>M</given-names></name><name><surname>Reusch</surname> <given-names>JE</given-names></name><name><surname>Revuelta</surname> <given-names>JL</given-names></name><name><surname>Reyes</surname> <given-names>L</given-names></name><name><surname>Rezaie</surname> <given-names>AR</given-names></name><name><surname>Richards</surname> <given-names>RI</given-names></name><name><surname>Richardson</surname> <given-names>DR</given-names></name><name><surname>Richetta</surname> <given-names>C</given-names></name><name><surname>Riehle</surname> <given-names>MA</given-names></name><name><surname>Rihn</surname> <given-names>BH</given-names></name><name><surname>Rikihisa</surname> <given-names>Y</given-names></name><name><surname>Riley</surname> <given-names>BE</given-names></name><name><surname>Rimbach</surname> <given-names>G</given-names></name><name><surname>Rippo</surname> <given-names>MR</given-names></name><name><surname>Ritis</surname> <given-names>K</given-names></name><name><surname>Rizzi</surname> <given-names>F</given-names></name><name><surname>Rizzo</surname> <given-names>E</given-names></name><name><surname>Roach</surname> <given-names>PJ</given-names></name><name><surname>Robbins</surname> <given-names>J</given-names></name><name><surname>Roberge</surname> <given-names>M</given-names></name><name><surname>Roca</surname> <given-names>G</given-names></name><name><surname>Roccheri</surname> <given-names>MC</given-names></name><name><surname>Rocha</surname> <given-names>S</given-names></name><name><surname>Rodrigues</surname> <given-names>CM</given-names></name><name><surname>Rodríguez</surname> <given-names>CI</given-names></name><name><surname>de Cordoba</surname> <given-names>SR</given-names></name><name><surname>Rodriguez-Muela</surname> <given-names>N</given-names></name><name><surname>Roelofs</surname> <given-names>J</given-names></name><name><surname>Rogov</surname> <given-names>VV</given-names></name><name><surname>Rohn</surname> <given-names>TT</given-names></name><name><surname>Rohrer</surname> <given-names>B</given-names></name><name><surname>Romanelli</surname> <given-names>D</given-names></name><name><surname>Romani</surname> <given-names>L</given-names></name><name><surname>Romano</surname> <given-names>PS</given-names></name><name><surname>Roncero</surname> <given-names>MI</given-names></name><name><surname>Rosa</surname> <given-names>JL</given-names></name><name><surname>Rosello</surname> <given-names>A</given-names></name><name><surname>Rosen</surname> <given-names>KV</given-names></name><name><surname>Rosenstiel</surname> <given-names>P</given-names></name><name><surname>Rost-Roszkowska</surname> <given-names>M</given-names></name><name><surname>Roth</surname> <given-names>KA</given-names></name><name><surname>Roué</surname> <given-names>G</given-names></name><name><surname>Rouis</surname> <given-names>M</given-names></name><name><surname>Rouschop</surname> <given-names>KM</given-names></name><name><surname>Ruan</surname> <given-names>DT</given-names></name><name><surname>Ruano</surname> <given-names>D</given-names></name><name><surname>Rubinsztein</surname> <given-names>DC</given-names></name><name><surname>Rucker</surname> <given-names>EB</given-names></name><name><surname>Rudich</surname> <given-names>A</given-names></name><name><surname>Rudolf</surname> <given-names>E</given-names></name><name><surname>Rudolf</surname> <given-names>R</given-names></name><name><surname>Ruegg</surname> <given-names>MA</given-names></name><name><surname>Ruiz-Roldan</surname> <given-names>C</given-names></name><name><surname>Ruparelia</surname> <given-names>AA</given-names></name><name><surname>Rusmini</surname> <given-names>P</given-names></name><name><surname>Russ</surname> <given-names>DW</given-names></name><name><surname>Russo</surname> <given-names>GL</given-names></name><name><surname>Russo</surname> <given-names>G</given-names></name><name><surname>Russo</surname> <given-names>R</given-names></name><name><surname>Rusten</surname> <given-names>TE</given-names></name><name><surname>Ryabovol</surname> <given-names>V</given-names></name><name><surname>Ryan</surname> <given-names>KM</given-names></name><name><surname>Ryter</surname> <given-names>SW</given-names></name><name><surname>Sabatini</surname> <given-names>DM</given-names></name><name><surname>Sacher</surname> <given-names>M</given-names></name><name><surname>Sachse</surname> <given-names>C</given-names></name><name><surname>Sack</surname> <given-names>MN</given-names></name><name><surname>Sadoshima</surname> <given-names>J</given-names></name><name><surname>Saftig</surname> <given-names>P</given-names></name><name><surname>Sagi-Eisenberg</surname> <given-names>R</given-names></name><name><surname>Sahni</surname> <given-names>S</given-names></name><name><surname>Saikumar</surname> <given-names>P</given-names></name><name><surname>Saito</surname> <given-names>T</given-names></name><name><surname>Saitoh</surname> <given-names>T</given-names></name><name><surname>Sakakura</surname> <given-names>K</given-names></name><name><surname>Sakoh-Nakatogawa</surname> <given-names>M</given-names></name><name><surname>Sakuraba</surname> <given-names>Y</given-names></name><name><surname>Salazar-Roa</surname> <given-names>M</given-names></name><name><surname>Salomoni</surname> <given-names>P</given-names></name><name><surname>Saluja</surname> <given-names>AK</given-names></name><name><surname>Salvaterra</surname> <given-names>PM</given-names></name><name><surname>Salvioli</surname> <given-names>R</given-names></name><name><surname>Samali</surname> <given-names>A</given-names></name><name><surname>Sanchez</surname> <given-names>AM</given-names></name><name><surname>Sánchez-Alcázar</surname> <given-names>JA</given-names></name><name><surname>Sanchez-Prieto</surname> <given-names>R</given-names></name><name><surname>Sandri</surname> <given-names>M</given-names></name><name><surname>Sanjuan</surname> <given-names>MA</given-names></name><name><surname>Santaguida</surname> <given-names>S</given-names></name><name><surname>Santambrogio</surname> <given-names>L</given-names></name><name><surname>Santoni</surname> <given-names>G</given-names></name><name><surname>Dos Santos</surname> <given-names>CN</given-names></name><name><surname>Saran</surname> <given-names>S</given-names></name><name><surname>Sardiello</surname> <given-names>M</given-names></name><name><surname>Sargent</surname> <given-names>G</given-names></name><name><surname>Sarkar</surname> <given-names>P</given-names></name><name><surname>Sarkar</surname> <given-names>S</given-names></name><name><surname>Sarrias</surname> <given-names>MR</given-names></name><name><surname>Sarwal</surname> <given-names>MM</given-names></name><name><surname>Sasakawa</surname> <given-names>C</given-names></name><name><surname>Sasaki</surname> <given-names>M</given-names></name><name><surname>Sass</surname> <given-names>M</given-names></name><name><surname>Sato</surname> <given-names>K</given-names></name><name><surname>Sato</surname> <given-names>M</given-names></name><name><surname>Satriano</surname> <given-names>J</given-names></name><name><surname>Savaraj</surname> <given-names>N</given-names></name><name><surname>Saveljeva</surname> <given-names>S</given-names></name><name><surname>Schaefer</surname> <given-names>L</given-names></name><name><surname>Schaible</surname> <given-names>UE</given-names></name><name><surname>Scharl</surname> <given-names>M</given-names></name><name><surname>Schatzl</surname> <given-names>HM</given-names></name><name><surname>Schekman</surname> <given-names>R</given-names></name><name><surname>Scheper</surname> <given-names>W</given-names></name><name><surname>Schiavi</surname> <given-names>A</given-names></name><name><surname>Schipper</surname> <given-names>HM</given-names></name><name><surname>Schmeisser</surname> <given-names>H</given-names></name><name><surname>Schmidt</surname> <given-names>J</given-names></name><name><surname>Schmitz</surname> <given-names>I</given-names></name><name><surname>Schneider</surname> <given-names>BE</given-names></name><name><surname>Schneider</surname> <given-names>EM</given-names></name><name><surname>Schneider</surname> <given-names>JL</given-names></name><name><surname>Schon</surname> <given-names>EA</given-names></name><name><surname>Schönenberger</surname> <given-names>MJ</given-names></name><name><surname>Schönthal</surname> <given-names>AH</given-names></name><name><surname>Schorderet</surname> <given-names>DF</given-names></name><name><surname>Schröder</surname> <given-names>B</given-names></name><name><surname>Schuck</surname> <given-names>S</given-names></name><name><surname>Schulze</surname> <given-names>RJ</given-names></name><name><surname>Schwarten</surname> <given-names>M</given-names></name><name><surname>Schwarz</surname> <given-names>TL</given-names></name><name><surname>Sciarretta</surname> <given-names>S</given-names></name><name><surname>Scotto</surname> <given-names>K</given-names></name><name><surname>Scovassi</surname> <given-names>AI</given-names></name><name><surname>Screaton</surname> <given-names>RA</given-names></name><name><surname>Screen</surname> <given-names>M</given-names></name><name><surname>Seca</surname> <given-names>H</given-names></name><name><surname>Sedej</surname> <given-names>S</given-names></name><name><surname>Segatori</surname> <given-names>L</given-names></name><name><surname>Segev</surname> <given-names>N</given-names></name><name><surname>Seglen</surname> <given-names>PO</given-names></name><name><surname>Seguí-Simarro</surname> <given-names>JM</given-names></name><name><surname>Segura-Aguilar</surname> <given-names>J</given-names></name><name><surname>Seki</surname> <given-names>E</given-names></name><name><surname>Sell</surname> <given-names>C</given-names></name><name><surname>Seiliez</surname> <given-names>I</given-names></name><name><surname>Semenkovich</surname> <given-names>CF</given-names></name><name><surname>Semenza</surname> <given-names>GL</given-names></name><name><surname>Sen</surname> <given-names>U</given-names></name><name><surname>Serra</surname> <given-names>AL</given-names></name><name><surname>Serrano-Puebla</surname> <given-names>A</given-names></name><name><surname>Sesaki</surname> <given-names>H</given-names></name><name><surname>Setoguchi</surname> <given-names>T</given-names></name><name><surname>Settembre</surname> <given-names>C</given-names></name><name><surname>Shacka</surname> <given-names>JJ</given-names></name><name><surname>Shajahan-Haq</surname> <given-names>AN</given-names></name><name><surname>Shapiro</surname> <given-names>IM</given-names></name><name><surname>Sharma</surname> <given-names>S</given-names></name><name><surname>She</surname> <given-names>H</given-names></name><name><surname>Shen</surname> <given-names>CK</given-names></name><name><surname>Shen</surname> <given-names>CC</given-names></name><name><surname>Shen</surname> <given-names>HM</given-names></name><name><surname>Shen</surname> <given-names>S</given-names></name><name><surname>Shen</surname> <given-names>W</given-names></name><name><surname>Sheng</surname> <given-names>R</given-names></name><name><surname>Sheng</surname> <given-names>X</given-names></name><name><surname>Sheng</surname> <given-names>ZH</given-names></name><name><surname>Shepherd</surname> <given-names>TG</given-names></name><name><surname>Shi</surname> <given-names>J</given-names></name><name><surname>Shi</surname> <given-names>Q</given-names></name><name><surname>Shi</surname> <given-names>Q</given-names></name><name><surname>Shi</surname> <given-names>Y</given-names></name><name><surname>Shibutani</surname> <given-names>S</given-names></name><name><surname>Shibuya</surname> <given-names>K</given-names></name><name><surname>Shidoji</surname> <given-names>Y</given-names></name><name><surname>Shieh</surname> <given-names>JJ</given-names></name><name><surname>Shih</surname> <given-names>CM</given-names></name><name><surname>Shimada</surname> <given-names>Y</given-names></name><name><surname>Shimizu</surname> <given-names>S</given-names></name><name><surname>Shin</surname> <given-names>DW</given-names></name><name><surname>Shinohara</surname> <given-names>ML</given-names></name><name><surname>Shintani</surname> <given-names>M</given-names></name><name><surname>Shintani</surname> <given-names>T</given-names></name><name><surname>Shioi</surname> <given-names>T</given-names></name><name><surname>Shirabe</surname> <given-names>K</given-names></name><name><surname>Shiri-Sverdlov</surname> <given-names>R</given-names></name><name><surname>Shirihai</surname> <given-names>O</given-names></name><name><surname>Shore</surname> <given-names>GC</given-names></name><name><surname>Shu</surname> <given-names>CW</given-names></name><name><surname>Shukla</surname> <given-names>D</given-names></name><name><surname>Sibirny</surname> <given-names>AA</given-names></name><name><surname>Sica</surname> <given-names>V</given-names></name><name><surname>Sigurdson</surname> <given-names>CJ</given-names></name><name><surname>Sigurdsson</surname> <given-names>EM</given-names></name><name><surname>Sijwali</surname> <given-names>PS</given-names></name><name><surname>Sikorska</surname> <given-names>B</given-names></name><name><surname>Silveira</surname> <given-names>WA</given-names></name><name><surname>Silvente-Poirot</surname> <given-names>S</given-names></name><name><surname>Silverman</surname> <given-names>GA</given-names></name><name><surname>Simak</surname> <given-names>J</given-names></name><name><surname>Simmet</surname> <given-names>T</given-names></name><name><surname>Simon</surname> <given-names>AK</given-names></name><name><surname>Simon</surname> <given-names>HU</given-names></name><name><surname>Simone</surname> <given-names>C</given-names></name><name><surname>Simons</surname> <given-names>M</given-names></name><name><surname>Simonsen</surname> <given-names>A</given-names></name><name><surname>Singh</surname> <given-names>R</given-names></name><name><surname>Singh</surname> <given-names>SV</given-names></name><name><surname>Singh</surname> <given-names>SK</given-names></name><name><surname>Sinha</surname> <given-names>D</given-names></name><name><surname>Sinha</surname> <given-names>S</given-names></name><name><surname>Sinicrope</surname> <given-names>FA</given-names></name><name><surname>Sirko</surname> <given-names>A</given-names></name><name><surname>Sirohi</surname> <given-names>K</given-names></name><name><surname>Sishi</surname> <given-names>BJ</given-names></name><name><surname>Sittler</surname> <given-names>A</given-names></name><name><surname>Siu</surname> <given-names>PM</given-names></name><name><surname>Sivridis</surname> <given-names>E</given-names></name><name><surname>Skwarska</surname> <given-names>A</given-names></name><name><surname>Slack</surname> <given-names>R</given-names></name><name><surname>Slaninová</surname> <given-names>I</given-names></name><name><surname>Slavov</surname> <given-names>N</given-names></name><name><surname>Smaili</surname> <given-names>SS</given-names></name><name><surname>Smalley</surname> <given-names>KS</given-names></name><name><surname>Smith</surname> <given-names>DR</given-names></name><name><surname>Soenen</surname> <given-names>SJ</given-names></name><name><surname>Soleimanpour</surname> <given-names>SA</given-names></name><name><surname>Solhaug</surname> <given-names>A</given-names></name><name><surname>Somasundaram</surname> <given-names>K</given-names></name><name><surname>Son</surname> <given-names>JH</given-names></name><name><surname>Sonawane</surname> <given-names>A</given-names></name><name><surname>Song</surname> <given-names>C</given-names></name><name><surname>Song</surname> <given-names>F</given-names></name><name><surname>Song</surname> <given-names>HK</given-names></name><name><surname>Song</surname> <given-names>JX</given-names></name><name><surname>Song</surname> <given-names>W</given-names></name><name><surname>Soo</surname> <given-names>KY</given-names></name><name><surname>Sood</surname> <given-names>AK</given-names></name><name><surname>Soong</surname> <given-names>TW</given-names></name><name><surname>Soontornniyomkij</surname> <given-names>V</given-names></name><name><surname>Sorice</surname> <given-names>M</given-names></name><name><surname>Sotgia</surname> <given-names>F</given-names></name><name><surname>Soto-Pantoja</surname> <given-names>DR</given-names></name><name><surname>Sotthibundhu</surname> <given-names>A</given-names></name><name><surname>Sousa</surname> <given-names>MJ</given-names></name><name><surname>Spaink</surname> <given-names>HP</given-names></name><name><surname>Span</surname> <given-names>PN</given-names></name><name><surname>Spang</surname> <given-names>A</given-names></name><name><surname>Sparks</surname> <given-names>JD</given-names></name><name><surname>Speck</surname> <given-names>PG</given-names></name><name><surname>Spector</surname> <given-names>SA</given-names></name><name><surname>Spies</surname> <given-names>CD</given-names></name><name><surname>Springer</surname> <given-names>W</given-names></name><name><surname>Clair</surname> <given-names>DS</given-names></name><name><surname>Stacchiotti</surname> <given-names>A</given-names></name><name><surname>Staels</surname> <given-names>B</given-names></name><name><surname>Stang</surname> <given-names>MT</given-names></name><name><surname>Starczynowski</surname> <given-names>DT</given-names></name><name><surname>Starokadomskyy</surname> <given-names>P</given-names></name><name><surname>Steegborn</surname> <given-names>C</given-names></name><name><surname>Steele</surname> <given-names>JW</given-names></name><name><surname>Stefanis</surname> <given-names>L</given-names></name><name><surname>Steffan</surname> <given-names>J</given-names></name><name><surname>Stellrecht</surname> <given-names>CM</given-names></name><name><surname>Stenmark</surname> <given-names>H</given-names></name><name><surname>Stepkowski</surname> <given-names>TM</given-names></name><name><surname>Stern</surname> <given-names>ST</given-names></name><name><surname>Stevens</surname> <given-names>C</given-names></name><name><surname>Stockwell</surname> <given-names>BR</given-names></name><name><surname>Stoka</surname> <given-names>V</given-names></name><name><surname>Storchova</surname> <given-names>Z</given-names></name><name><surname>Stork</surname> <given-names>B</given-names></name><name><surname>Stratoulias</surname> <given-names>V</given-names></name><name><surname>Stravopodis</surname> <given-names>DJ</given-names></name><name><surname>Strnad</surname> <given-names>P</given-names></name><name><surname>Strohecker</surname> <given-names>AM</given-names></name><name><surname>Ström</surname> <given-names>AL</given-names></name><name><surname>Stromhaug</surname> <given-names>P</given-names></name><name><surname>Stulik</surname> <given-names>J</given-names></name><name><surname>Su</surname> <given-names>YX</given-names></name><name><surname>Su</surname> <given-names>Z</given-names></name><name><surname>Subauste</surname> <given-names>CS</given-names></name><name><surname>Subramaniam</surname> <given-names>S</given-names></name><name><surname>Sue</surname> <given-names>CM</given-names></name><name><surname>Suh</surname> <given-names>SW</given-names></name><name><surname>Sui</surname> <given-names>X</given-names></name><name><surname>Sukseree</surname> <given-names>S</given-names></name><name><surname>Sulzer</surname> <given-names>D</given-names></name><name><surname>Sun</surname> <given-names>FL</given-names></name><name><surname>Sun</surname> <given-names>J</given-names></name><name><surname>Sun</surname> <given-names>J</given-names></name><name><surname>Sun</surname> <given-names>SY</given-names></name><name><surname>Sun</surname> <given-names>Y</given-names></name><name><surname>Sun</surname> <given-names>Y</given-names></name><name><surname>Sun</surname> <given-names>Y</given-names></name><name><surname>Sundaramoorthy</surname> <given-names>V</given-names></name><name><surname>Sung</surname> <given-names>J</given-names></name><name><surname>Suzuki</surname> <given-names>H</given-names></name><name><surname>Suzuki</surname> <given-names>K</given-names></name><name><surname>Suzuki</surname> <given-names>N</given-names></name><name><surname>Suzuki</surname> <given-names>T</given-names></name><name><surname>Suzuki</surname> <given-names>YJ</given-names></name><name><surname>Swanson</surname> <given-names>MS</given-names></name><name><surname>Swanton</surname> <given-names>C</given-names></name><name><surname>Swärd</surname> <given-names>K</given-names></name><name><surname>Swarup</surname> <given-names>G</given-names></name><name><surname>Sweeney</surname> <given-names>ST</given-names></name><name><surname>Sylvester</surname> <given-names>PW</given-names></name><name><surname>Szatmari</surname> <given-names>Z</given-names></name><name><surname>Szegezdi</surname> <given-names>E</given-names></name><name><surname>Szlosarek</surname> <given-names>PW</given-names></name><name><surname>Taegtmeyer</surname> <given-names>H</given-names></name><name><surname>Tafani</surname> <given-names>M</given-names></name><name><surname>Taillebourg</surname> <given-names>E</given-names></name><name><surname>Tait</surname> <given-names>SW</given-names></name><name><surname>Takacs-Vellai</surname> <given-names>K</given-names></name><name><surname>Takahashi</surname> <given-names>Y</given-names></name><name><surname>Takáts</surname> <given-names>S</given-names></name><name><surname>Takemura</surname> <given-names>G</given-names></name><name><surname>Takigawa</surname> <given-names>N</given-names></name><name><surname>Talbot</surname> <given-names>NJ</given-names></name><name><surname>Tamagno</surname> <given-names>E</given-names></name><name><surname>Tamburini</surname> <given-names>J</given-names></name><name><surname>Tan</surname> <given-names>CP</given-names></name><name><surname>Tan</surname> <given-names>L</given-names></name><name><surname>Tan</surname> <given-names>ML</given-names></name><name><surname>Tan</surname> <given-names>M</given-names></name><name><surname>Tan</surname> <given-names>YJ</given-names></name><name><surname>Tanaka</surname> <given-names>K</given-names></name><name><surname>Tanaka</surname> <given-names>M</given-names></name><name><surname>Tang</surname> <given-names>D</given-names></name><name><surname>Tang</surname> <given-names>D</given-names></name><name><surname>Tang</surname> <given-names>G</given-names></name><name><surname>Tanida</surname> <given-names>I</given-names></name><name><surname>Tanji</surname> <given-names>K</given-names></name><name><surname>Tannous</surname> <given-names>BA</given-names></name><name><surname>Tapia</surname> <given-names>JA</given-names></name><name><surname>Tasset-Cuevas</surname> <given-names>I</given-names></name><name><surname>Tatar</surname> <given-names>M</given-names></name><name><surname>Tavassoly</surname> <given-names>I</given-names></name><name><surname>Tavernarakis</surname> <given-names>N</given-names></name><name><surname>Taylor</surname> <given-names>A</given-names></name><name><surname>Taylor</surname> <given-names>GS</given-names></name><name><surname>Taylor</surname> <given-names>GA</given-names></name><name><surname>Taylor</surname> <given-names>JP</given-names></name><name><surname>Taylor</surname> <given-names>MJ</given-names></name><name><surname>Tchetina</surname> <given-names>EV</given-names></name><name><surname>Tee</surname> <given-names>AR</given-names></name><name><surname>Teixeira-Clerc</surname> <given-names>F</given-names></name><name><surname>Telang</surname> <given-names>S</given-names></name><name><surname>Tencomnao</surname> <given-names>T</given-names></name><name><surname>Teng</surname> <given-names>BB</given-names></name><name><surname>Teng</surname> <given-names>RJ</given-names></name><name><surname>Terro</surname> <given-names>F</given-names></name><name><surname>Tettamanti</surname> <given-names>G</given-names></name><name><surname>Theiss</surname> <given-names>AL</given-names></name><name><surname>Theron</surname> <given-names>AE</given-names></name><name><surname>Thomas</surname> <given-names>KJ</given-names></name><name><surname>Thomé</surname> <given-names>MP</given-names></name><name><surname>Thomes</surname> <given-names>PG</given-names></name><name><surname>Thorburn</surname> <given-names>A</given-names></name><name><surname>Thorner</surname> <given-names>J</given-names></name><name><surname>Thum</surname> <given-names>T</given-names></name><name><surname>Thumm</surname> <given-names>M</given-names></name><name><surname>Thurston</surname> <given-names>TL</given-names></name><name><surname>Tian</surname> <given-names>L</given-names></name><name><surname>Till</surname> <given-names>A</given-names></name><name><surname>Ting</surname> <given-names>JP</given-names></name><name><surname>Titorenko</surname> <given-names>VI</given-names></name><name><surname>Toker</surname> <given-names>L</given-names></name><name><surname>Toldo</surname> <given-names>S</given-names></name><name><surname>Tooze</surname> <given-names>SA</given-names></name><name><surname>Topisirovic</surname> <given-names>I</given-names></name><name><surname>Torgersen</surname> <given-names>ML</given-names></name><name><surname>Torosantucci</surname> <given-names>L</given-names></name><name><surname>Torriglia</surname> <given-names>A</given-names></name><name><surname>Torrisi</surname> <given-names>MR</given-names></name><name><surname>Tournier</surname> <given-names>C</given-names></name><name><surname>Towns</surname> <given-names>R</given-names></name><name><surname>Trajkovic</surname> <given-names>V</given-names></name><name><surname>Travassos</surname> <given-names>LH</given-names></name><name><surname>Triola</surname> <given-names>G</given-names></name><name><surname>Tripathi</surname> <given-names>DN</given-names></name><name><surname>Trisciuoglio</surname> <given-names>D</given-names></name><name><surname>Troncoso</surname> <given-names>R</given-names></name><name><surname>Trougakos</surname> <given-names>IP</given-names></name><name><surname>Truttmann</surname> <given-names>AC</given-names></name><name><surname>Tsai</surname> <given-names>KJ</given-names></name><name><surname>Tschan</surname> <given-names>MP</given-names></name><name><surname>Tseng</surname> <given-names>YH</given-names></name><name><surname>Tsukuba</surname> <given-names>T</given-names></name><name><surname>Tsung</surname> <given-names>A</given-names></name><name><surname>Tsvetkov</surname> <given-names>AS</given-names></name><name><surname>Tu</surname> <given-names>S</given-names></name><name><surname>Tuan</surname> <given-names>HY</given-names></name><name><surname>Tucci</surname> <given-names>M</given-names></name><name><surname>Tumbarello</surname> <given-names>DA</given-names></name><name><surname>Turk</surname> <given-names>B</given-names></name><name><surname>Turk</surname> <given-names>V</given-names></name><name><surname>Turner</surname> <given-names>RF</given-names></name><name><surname>Tveita</surname> <given-names>AA</given-names></name><name><surname>Tyagi</surname> <given-names>SC</given-names></name><name><surname>Ubukata</surname> <given-names>M</given-names></name><name><surname>Uchiyama</surname> <given-names>Y</given-names></name><name><surname>Udelnow</surname> <given-names>A</given-names></name><name><surname>Ueno</surname> <given-names>T</given-names></name><name><surname>Umekawa</surname> <given-names>M</given-names></name><name><surname>Umemiya-Shirafuji</surname> <given-names>R</given-names></name><name><surname>Underwood</surname> <given-names>BR</given-names></name><name><surname>Ungermann</surname> <given-names>C</given-names></name><name><surname>Ureshino</surname> <given-names>RP</given-names></name><name><surname>Ushioda</surname> <given-names>R</given-names></name><name><surname>Uversky</surname> <given-names>VN</given-names></name><name><surname>Uzcátegui</surname> <given-names>NL</given-names></name><name><surname>Vaccari</surname> <given-names>T</given-names></name><name><surname>Vaccaro</surname> <given-names>MI</given-names></name><name><surname>Váchová</surname> <given-names>L</given-names></name><name><surname>Vakifahmetoglu-Norberg</surname> <given-names>H</given-names></name><name><surname>Valdor</surname> <given-names>R</given-names></name><name><surname>Valente</surname> <given-names>EM</given-names></name><name><surname>Vallette</surname> <given-names>F</given-names></name><name><surname>Valverde</surname> <given-names>AM</given-names></name><name><surname>Van den Berghe</surname> <given-names>G</given-names></name><name><surname>Van Den Bosch</surname> <given-names>L</given-names></name><name><surname>van den Brink</surname> <given-names>GR</given-names></name><name><surname>van der Goot</surname> <given-names>FG</given-names></name><name><surname>van der Klei</surname> <given-names>IJ</given-names></name><name><surname>van der Laan</surname> <given-names>LJ</given-names></name><name><surname>van Doorn</surname> <given-names>WG</given-names></name><name><surname>van Egmond</surname> <given-names>M</given-names></name><name><surname>van Golen</surname> <given-names>KL</given-names></name><name><surname>Van Kaer</surname> <given-names>L</given-names></name><name><surname>van Lookeren Campagne</surname> <given-names>M</given-names></name><name><surname>Vandenabeele</surname> <given-names>P</given-names></name><name><surname>Vandenberghe</surname> <given-names>W</given-names></name><name><surname>Vanhorebeek</surname> <given-names>I</given-names></name><name><surname>Varela-Nieto</surname> <given-names>I</given-names></name><name><surname>Vasconcelos</surname> <given-names>MH</given-names></name><name><surname>Vasko</surname> <given-names>R</given-names></name><name><surname>Vavvas</surname> <given-names>DG</given-names></name><name><surname>Vega-Naredo</surname> <given-names>I</given-names></name><name><surname>Velasco</surname> <given-names>G</given-names></name><name><surname>Velentzas</surname> <given-names>AD</given-names></name><name><surname>Velentzas</surname> <given-names>PD</given-names></name><name><surname>Vellai</surname> <given-names>T</given-names></name><name><surname>Vellenga</surname> <given-names>E</given-names></name><name><surname>Vendelbo</surname> <given-names>MH</given-names></name><name><surname>Venkatachalam</surname> <given-names>K</given-names></name><name><surname>Ventura</surname> <given-names>N</given-names></name><name><surname>Ventura</surname> <given-names>S</given-names></name><name><surname>Veras</surname> <given-names>PS</given-names></name><name><surname>Verdier</surname> <given-names>M</given-names></name><name><surname>Vertessy</surname> <given-names>BG</given-names></name><name><surname>Viale</surname> <given-names>A</given-names></name><name><surname>Vidal</surname> <given-names>M</given-names></name><name><surname>Vieira</surname> <given-names>HL</given-names></name><name><surname>Vierstra</surname> <given-names>RD</given-names></name><name><surname>Vigneswaran</surname> <given-names>N</given-names></name><name><surname>Vij</surname> <given-names>N</given-names></name><name><surname>Vila</surname> <given-names>M</given-names></name><name><surname>Villar</surname> <given-names>M</given-names></name><name><surname>Villar</surname> <given-names>VH</given-names></name><name><surname>Villarroya</surname> <given-names>J</given-names></name><name><surname>Vindis</surname> <given-names>C</given-names></name><name><surname>Viola</surname> <given-names>G</given-names></name><name><surname>Viscomi</surname> <given-names>MT</given-names></name><name><surname>Vitale</surname> <given-names>G</given-names></name><name><surname>Vogl</surname> <given-names>DT</given-names></name><name><surname>Voitsekhovskaja</surname> <given-names>OV</given-names></name><name><surname>von Haefen</surname> <given-names>C</given-names></name><name><surname>von Schwarzenberg</surname> <given-names>K</given-names></name><name><surname>Voth</surname> <given-names>DE</given-names></name><name><surname>Vouret-Craviari</surname> <given-names>V</given-names></name><name><surname>Vuori</surname> <given-names>K</given-names></name><name><surname>Vyas</surname> <given-names>JM</given-names></name><name><surname>Waeber</surname> <given-names>C</given-names></name><name><surname>Walker</surname> <given-names>CL</given-names></name><name><surname>Walker</surname> <given-names>MJ</given-names></name><name><surname>Walter</surname> <given-names>J</given-names></name><name><surname>Wan</surname> <given-names>L</given-names></name><name><surname>Wan</surname> <given-names>X</given-names></name><name><surname>Wang</surname> <given-names>B</given-names></name><name><surname>Wang</surname> <given-names>C</given-names></name><name><surname>Wang</surname> <given-names>CY</given-names></name><name><surname>Wang</surname> <given-names>C</given-names></name><name><surname>Wang</surname> <given-names>C</given-names></name><name><surname>Wang</surname> <given-names>C</given-names></name><name><surname>Wang</surname> <given-names>D</given-names></name><name><surname>Wang</surname> <given-names>F</given-names></name><name><surname>Wang</surname> <given-names>F</given-names></name><name><surname>Wang</surname> <given-names>G</given-names></name><name><surname>Wang</surname> <given-names>HJ</given-names></name><name><surname>Wang</surname> <given-names>H</given-names></name><name><surname>Wang</surname> <given-names>HG</given-names></name><name><surname>Wang</surname> <given-names>H</given-names></name><name><surname>Wang</surname> <given-names>HD</given-names></name><name><surname>Wang</surname> <given-names>J</given-names></name><name><surname>Wang</surname> <given-names>J</given-names></name><name><surname>Wang</surname> <given-names>M</given-names></name><name><surname>Wang</surname> <given-names>MQ</given-names></name><name><surname>Wang</surname> <given-names>PY</given-names></name><name><surname>Wang</surname> <given-names>P</given-names></name><name><surname>Wang</surname> <given-names>RC</given-names></name><name><surname>Wang</surname> <given-names>S</given-names></name><name><surname>Wang</surname> <given-names>TF</given-names></name><name><surname>Wang</surname> <given-names>X</given-names></name><name><surname>Wang</surname> <given-names>XJ</given-names></name><name><surname>Wang</surname> <given-names>XW</given-names></name><name><surname>Wang</surname> <given-names>X</given-names></name><name><surname>Wang</surname> <given-names>X</given-names></name><name><surname>Wang</surname> <given-names>Y</given-names></name><name><surname>Wang</surname> <given-names>Y</given-names></name><name><surname>Wang</surname> <given-names>Y</given-names></name><name><surname>Wang</surname> <given-names>YJ</given-names></name><name><surname>Wang</surname> <given-names>Y</given-names></name><name><surname>Wang</surname> <given-names>Y</given-names></name><name><surname>Wang</surname> <given-names>YT</given-names></name><name><surname>Wang</surname> <given-names>Y</given-names></name><name><surname>Wang</surname> <given-names>ZN</given-names></name><name><surname>Wappner</surname> <given-names>P</given-names></name><name><surname>Ward</surname> <given-names>C</given-names></name><name><surname>Ward</surname> <given-names>DM</given-names></name><name><surname>Warnes</surname> <given-names>G</given-names></name><name><surname>Watada</surname> <given-names>H</given-names></name><name><surname>Watanabe</surname> <given-names>Y</given-names></name><name><surname>Watase</surname> <given-names>K</given-names></name><name><surname>Weaver</surname> <given-names>TE</given-names></name><name><surname>Weekes</surname> <given-names>CD</given-names></name><name><surname>Wei</surname> <given-names>J</given-names></name><name><surname>Weide</surname> <given-names>T</given-names></name><name><surname>Weihl</surname> <given-names>CC</given-names></name><name><surname>Weindl</surname> <given-names>G</given-names></name><name><surname>Weis</surname> <given-names>SN</given-names></name><name><surname>Wen</surname> <given-names>L</given-names></name><name><surname>Wen</surname> <given-names>X</given-names></name><name><surname>Wen</surname> <given-names>Y</given-names></name><name><surname>Westermann</surname> <given-names>B</given-names></name><name><surname>Weyand</surname> <given-names>CM</given-names></name><name><surname>White</surname> <given-names>AR</given-names></name><name><surname>White</surname> <given-names>E</given-names></name><name><surname>Whitton</surname> <given-names>JL</given-names></name><name><surname>Whitworth</surname> <given-names>AJ</given-names></name><name><surname>Wiels</surname> <given-names>J</given-names></name><name><surname>Wild</surname> <given-names>F</given-names></name><name><surname>Wildenberg</surname> <given-names>ME</given-names></name><name><surname>Wileman</surname> <given-names>T</given-names></name><name><surname>Wilkinson</surname> <given-names>DS</given-names></name><name><surname>Wilkinson</surname> <given-names>S</given-names></name><name><surname>Willbold</surname> <given-names>D</given-names></name><name><surname>Williams</surname> <given-names>C</given-names></name><name><surname>Williams</surname> <given-names>K</given-names></name><name><surname>Williamson</surname> <given-names>PR</given-names></name><name><surname>Winklhofer</surname> <given-names>KF</given-names></name><name><surname>Witkin</surname> <given-names>SS</given-names></name><name><surname>Wohlgemuth</surname> <given-names>SE</given-names></name><name><surname>Wollert</surname> <given-names>T</given-names></name><name><surname>Wolvetang</surname> <given-names>EJ</given-names></name><name><surname>Wong</surname> <given-names>E</given-names></name><name><surname>Wong</surname> <given-names>GW</given-names></name><name><surname>Wong</surname> <given-names>RW</given-names></name><name><surname>Wong</surname> <given-names>VK</given-names></name><name><surname>Woodcock</surname> <given-names>EA</given-names></name><name><surname>Wright</surname> <given-names>KL</given-names></name><name><surname>Wu</surname> <given-names>C</given-names></name><name><surname>Wu</surname> <given-names>D</given-names></name><name><surname>Wu</surname> <given-names>GS</given-names></name><name><surname>Wu</surname> <given-names>J</given-names></name><name><surname>Wu</surname> <given-names>J</given-names></name><name><surname>Wu</surname> <given-names>M</given-names></name><name><surname>Wu</surname> <given-names>M</given-names></name><name><surname>Wu</surname> <given-names>S</given-names></name><name><surname>Wu</surname> <given-names>WK</given-names></name><name><surname>Wu</surname> <given-names>Y</given-names></name><name><surname>Wu</surname> <given-names>Z</given-names></name><name><surname>Xavier</surname> <given-names>CP</given-names></name><name><surname>Xavier</surname> <given-names>RJ</given-names></name><name><surname>Xia</surname> <given-names>GX</given-names></name><name><surname>Xia</surname> <given-names>T</given-names></name><name><surname>Xia</surname> <given-names>W</given-names></name><name><surname>Xia</surname> <given-names>Y</given-names></name><name><surname>Xiao</surname> <given-names>H</given-names></name><name><surname>Xiao</surname> <given-names>J</given-names></name><name><surname>Xiao</surname> <given-names>S</given-names></name><name><surname>Xiao</surname> <given-names>W</given-names></name><name><surname>Xie</surname> <given-names>CM</given-names></name><name><surname>Xie</surname> <given-names>Z</given-names></name><name><surname>Xie</surname> <given-names>Z</given-names></name><name><surname>Xilouri</surname> <given-names>M</given-names></name><name><surname>Xiong</surname> <given-names>Y</given-names></name><name><surname>Xu</surname> <given-names>C</given-names></name><name><surname>Xu</surname> <given-names>C</given-names></name><name><surname>Xu</surname> <given-names>F</given-names></name><name><surname>Xu</surname> <given-names>H</given-names></name><name><surname>Xu</surname> <given-names>H</given-names></name><name><surname>Xu</surname> <given-names>J</given-names></name><name><surname>Xu</surname> <given-names>J</given-names></name><name><surname>Xu</surname> <given-names>J</given-names></name><name><surname>Xu</surname> <given-names>L</given-names></name><name><surname>Xu</surname> <given-names>X</given-names></name><name><surname>Xu</surname> <given-names>Y</given-names></name><name><surname>Xu</surname> <given-names>Y</given-names></name><name><surname>Xu</surname> <given-names>ZX</given-names></name><name><surname>Xu</surname> <given-names>Z</given-names></name><name><surname>Xue</surname> <given-names>Y</given-names></name><name><surname>Yamada</surname> <given-names>T</given-names></name><name><surname>Yamamoto</surname> <given-names>A</given-names></name><name><surname>Yamanaka</surname> <given-names>K</given-names></name><name><surname>Yamashina</surname> <given-names>S</given-names></name><name><surname>Yamashiro</surname> <given-names>S</given-names></name><name><surname>Yan</surname> <given-names>B</given-names></name><name><surname>Yan</surname> <given-names>B</given-names></name><name><surname>Yan</surname> <given-names>X</given-names></name><name><surname>Yan</surname> <given-names>Z</given-names></name><name><surname>Yanagi</surname> <given-names>Y</given-names></name><name><surname>Yang</surname> <given-names>DS</given-names></name><name><surname>Yang</surname> <given-names>JM</given-names></name><name><surname>Yang</surname> <given-names>L</given-names></name><name><surname>Yang</surname> <given-names>M</given-names></name><name><surname>Yang</surname> <given-names>PM</given-names></name><name><surname>Yang</surname> <given-names>P</given-names></name><name><surname>Yang</surname> <given-names>Q</given-names></name><name><surname>Yang</surname> <given-names>W</given-names></name><name><surname>Yang</surname> <given-names>WY</given-names></name><name><surname>Yang</surname> <given-names>X</given-names></name><name><surname>Yang</surname> <given-names>Y</given-names></name><name><surname>Yang</surname> <given-names>Y</given-names></name><name><surname>Yang</surname> <given-names>Z</given-names></name><name><surname>Yang</surname> <given-names>Z</given-names></name><name><surname>Yao</surname> <given-names>MC</given-names></name><name><surname>Yao</surname> <given-names>PJ</given-names></name><name><surname>Yao</surname> <given-names>X</given-names></name><name><surname>Yao</surname> <given-names>Z</given-names></name><name><surname>Yao</surname> <given-names>Z</given-names></name><name><surname>Yasui</surname> <given-names>LS</given-names></name><name><surname>Ye</surname> <given-names>M</given-names></name><name><surname>Yedvobnick</surname> <given-names>B</given-names></name><name><surname>Yeganeh</surname> <given-names>B</given-names></name><name><surname>Yeh</surname> <given-names>ES</given-names></name><name><surname>Yeyati</surname> <given-names>PL</given-names></name><name><surname>Yi</surname> <given-names>F</given-names></name><name><surname>Yi</surname> <given-names>L</given-names></name><name><surname>Yin</surname> <given-names>XM</given-names></name><name><surname>Yip</surname> <given-names>CK</given-names></name><name><surname>Yoo</surname> <given-names>YM</given-names></name><name><surname>Yoo</surname> <given-names>YH</given-names></name><name><surname>Yoon</surname> <given-names>SY</given-names></name><name><surname>Yoshida</surname> <given-names>K</given-names></name><name><surname>Yoshimori</surname> <given-names>T</given-names></name><name><surname>Young</surname> <given-names>KH</given-names></name><name><surname>Yu</surname> <given-names>H</given-names></name><name><surname>Yu</surname> <given-names>JJ</given-names></name><name><surname>Yu</surname> <given-names>JT</given-names></name><name><surname>Yu</surname> <given-names>J</given-names></name><name><surname>Yu</surname> <given-names>L</given-names></name><name><surname>Yu</surname> <given-names>WH</given-names></name><name><surname>Yu</surname> <given-names>XF</given-names></name><name><surname>Yu</surname> <given-names>Z</given-names></name><name><surname>Yuan</surname> <given-names>J</given-names></name><name><surname>Yuan</surname> <given-names>ZM</given-names></name><name><surname>Yue</surname> <given-names>BY</given-names></name><name><surname>Yue</surname> <given-names>J</given-names></name><name><surname>Yue</surname> <given-names>Z</given-names></name><name><surname>Zacks</surname> <given-names>DN</given-names></name><name><surname>Zacksenhaus</surname> <given-names>E</given-names></name><name><surname>Zaffaroni</surname> <given-names>N</given-names></name><name><surname>Zaglia</surname> <given-names>T</given-names></name><name><surname>Zakeri</surname> <given-names>Z</given-names></name><name><surname>Zecchini</surname> <given-names>V</given-names></name><name><surname>Zeng</surname> <given-names>J</given-names></name><name><surname>Zeng</surname> <given-names>M</given-names></name><name><surname>Zeng</surname> <given-names>Q</given-names></name><name><surname>Zervos</surname> <given-names>AS</given-names></name><name><surname>Zhang</surname> <given-names>DD</given-names></name><name><surname>Zhang</surname> <given-names>F</given-names></name><name><surname>Zhang</surname> <given-names>G</given-names></name><name><surname>Zhang</surname> <given-names>GC</given-names></name><name><surname>Zhang</surname> <given-names>H</given-names></name><name><surname>Zhang</surname> <given-names>H</given-names></name><name><surname>Zhang</surname> <given-names>H</given-names></name><name><surname>Zhang</surname> <given-names>H</given-names></name><name><surname>Zhang</surname> <given-names>J</given-names></name><name><surname>Zhang</surname> <given-names>J</given-names></name><name><surname>Zhang</surname> <given-names>J</given-names></name><name><surname>Zhang</surname> <given-names>J</given-names></name><name><surname>Zhang</surname> <given-names>JP</given-names></name><name><surname>Zhang</surname> <given-names>L</given-names></name><name><surname>Zhang</surname> <given-names>L</given-names></name><name><surname>Zhang</surname> <given-names>L</given-names></name><name><surname>Zhang</surname> <given-names>L</given-names></name><name><surname>Zhang</surname> <given-names>MY</given-names></name><name><surname>Zhang</surname> <given-names>X</given-names></name><name><surname>Zhang</surname> <given-names>XD</given-names></name><name><surname>Zhang</surname> <given-names>Y</given-names></name><name><surname>Zhang</surname> <given-names>Y</given-names></name><name><surname>Zhang</surname> <given-names>Y</given-names></name><name><surname>Zhang</surname> <given-names>Y</given-names></name><name><surname>Zhang</surname> <given-names>Y</given-names></name><name><surname>Zhao</surname> <given-names>M</given-names></name><name><surname>Zhao</surname> <given-names>WL</given-names></name><name><surname>Zhao</surname> <given-names>X</given-names></name><name><surname>Zhao</surname> <given-names>YG</given-names></name><name><surname>Zhao</surname> <given-names>Y</given-names></name><name><surname>Zhao</surname> <given-names>Y</given-names></name><name><surname>Zhao</surname> <given-names>YX</given-names></name><name><surname>Zhao</surname> <given-names>Z</given-names></name><name><surname>Zhao</surname> <given-names>ZJ</given-names></name><name><surname>Zheng</surname> <given-names>D</given-names></name><name><surname>Zheng</surname> <given-names>XL</given-names></name><name><surname>Zheng</surname> <given-names>X</given-names></name><name><surname>Zhivotovsky</surname> <given-names>B</given-names></name><name><surname>Zhong</surname> <given-names>Q</given-names></name><name><surname>Zhou</surname> <given-names>GZ</given-names></name><name><surname>Zhou</surname> <given-names>G</given-names></name><name><surname>Zhou</surname> <given-names>H</given-names></name><name><surname>Zhou</surname> <given-names>SF</given-names></name><name><surname>Zhou</surname> <given-names>XJ</given-names></name><name><surname>Zhu</surname> <given-names>H</given-names></name><name><surname>Zhu</surname> <given-names>H</given-names></name><name><surname>Zhu</surname> <given-names>WG</given-names></name><name><surname>Zhu</surname> <given-names>W</given-names></name><name><surname>Zhu</surname> <given-names>XF</given-names></name><name><surname>Zhu</surname> <given-names>Y</given-names></name><name><surname>Zhuang</surname> <given-names>SM</given-names></name><name><surname>Zhuang</surname> <given-names>X</given-names></name><name><surname>Ziparo</surname> <given-names>E</given-names></name><name><surname>Zois</surname> <given-names>CE</given-names></name><name><surname>Zoladek</surname> <given-names>T</given-names></name><name><surname>Zong</surname> <given-names>WX</given-names></name><name><surname>Zorzano</surname> <given-names>A</given-names></name><name><surname>Zughaier</surname> <given-names>SM</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)</article-title><source>Autophagy</source><volume>12</volume><fpage>1</fpage><lpage>222</lpage><pub-id pub-id-type="doi">10.1080/15548627.2015.1100356</pub-id><pub-id pub-id-type="pmid">26799652</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kocaturk</surname> <given-names>NM</given-names></name><name><surname>Gozuacik</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Crosstalk between mammalian autophagy and the ubiquitin-proteasome system</article-title><source>Frontiers in Cell and Developmental Biology</source><volume>6</volume><elocation-id>128</elocation-id><pub-id pub-id-type="doi">10.3389/fcell.2018.00128</pub-id><pub-id pub-id-type="pmid">30333975</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kohler</surname> <given-names>BA</given-names></name><name><surname>Sherman</surname> <given-names>RL</given-names></name><name><surname>Howlader</surname> <given-names>N</given-names></name><name><surname>Jemal</surname> <given-names>A</given-names></name><name><surname>Ryerson</surname> <given-names>AB</given-names></name><name><surname>Henry</surname> <given-names>KA</given-names></name><name><surname>Boscoe</surname> <given-names>FP</given-names></name><name><surname>Cronin</surname> <given-names>KA</given-names></name><name><surname>Lake</surname> <given-names>A</given-names></name><name><surname>Noone</surname> <given-names>AM</given-names></name><name><surname>Henley</surname> <given-names>SJ</given-names></name><name><surname>Eheman</surname> <given-names>CR</given-names></name><name><surname>Anderson</surname> <given-names>RN</given-names></name><name><surname>Penberthy</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Annual report to the nation on the status of cancer, 1975-2011, featuring incidence of breast cancer subtypes by race/ethnicity, poverty, and state</article-title><source>JNCI: Journal of the National Cancer Institute</source><volume>107</volume><elocation-id>djv048</elocation-id><pub-id pub-id-type="doi">10.1093/jnci/djv048</pub-id><pub-id pub-id-type="pmid">25825511</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koopman</surname> <given-names>G</given-names></name><name><surname>Reutelingsperger</surname> <given-names>CP</given-names></name><name><surname>Kuijten</surname> <given-names>GA</given-names></name><name><surname>Keehnen</surname> <given-names>RM</given-names></name><name><surname>Pals</surname> <given-names>ST</given-names></name><name><surname>van Oers</surname> <given-names>MH</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis</article-title><source>Blood</source><volume>84</volume><fpage>1415</fpage><lpage>1420</lpage><pub-id pub-id-type="doi">10.1182/blood.V84.5.1415.bloodjournal8451415</pub-id><pub-id pub-id-type="pmid">8068938</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koromilas</surname> <given-names>AE</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Roles of the translation initiation factor eIF2α serine 51 phosphorylation in cancer formation and treatment</article-title><source>Biochimica Et Biophysica Acta (BBA) - Gene Regulatory Mechanisms</source><volume>1849</volume><fpage>871</fpage><lpage>880</lpage><pub-id pub-id-type="doi">10.1016/j.bbagrm.2014.12.007</pub-id><pub-id pub-id-type="pmid">25497381</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kouroku</surname> <given-names>Y</given-names></name><name><surname>Fujita</surname> <given-names>E</given-names></name><name><surname>Tanida</surname> <given-names>I</given-names></name><name><surname>Ueno</surname> <given-names>T</given-names></name><name><surname>Isoai</surname> <given-names>A</given-names></name><name><surname>Kumagai</surname> <given-names>H</given-names></name><name><surname>Ogawa</surname> <given-names>S</given-names></name><name><surname>Kaufman</surname> <given-names>RJ</given-names></name><name><surname>Kominami</surname> <given-names>E</given-names></name><name><surname>Momoi</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>ER stress (PERK/eIF2alpha phosphorylation) mediates the polyglutamine-induced LC3 conversion, an essential step for autophagy formation</article-title><source>Cell Death &amp; Differentiation</source><volume>14</volume><fpage>230</fpage><lpage>239</lpage><pub-id pub-id-type="doi">10.1038/sj.cdd.4401984</pub-id><pub-id pub-id-type="pmid">16794605</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kroemer</surname> <given-names>G</given-names></name><name><surname>Mariño</surname> <given-names>G</given-names></name><name><surname>Levine</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Autophagy and the integrated stress response</article-title><source>Molecular Cell</source><volume>40</volume><fpage>280</fpage><lpage>293</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2010.09.023</pub-id><pub-id pub-id-type="pmid">20965422</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kruse</surname> <given-names>KB</given-names></name><name><surname>Brodsky</surname> <given-names>JL</given-names></name><name><surname>McCracken</surname> <given-names>AA</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Characterization of an ERAD gene as VPS30/ATG6 reveals two alternative and functionally distinct protein quality control pathways: one for soluble Z variant of human alpha-1 proteinase inhibitor (A1PiZ) and another for aggregates of A1PiZ</article-title><source>Molecular Biology of the Cell</source><volume>17</volume><fpage>203</fpage><lpage>212</lpage><pub-id pub-id-type="doi">10.1091/mbc.e04-09-0779</pub-id><pub-id pub-id-type="pmid">16267277</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krzyzosiak</surname> <given-names>A</given-names></name><name><surname>Sigurdardottir</surname> <given-names>A</given-names></name><name><surname>Luh</surname> <given-names>L</given-names></name><name><surname>Carrara</surname> <given-names>M</given-names></name><name><surname>Das</surname> <given-names>I</given-names></name><name><surname>Schneider</surname> <given-names>K</given-names></name><name><surname>Bertolotti</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Target-based discovery of an inhibitor of the regulatory phosphatase PPP1R15B</article-title><source>Cell</source><volume>174</volume><fpage>1216</fpage><lpage>1228</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2018.06.030</pub-id><pub-id pub-id-type="pmid">30057111</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laplante</surname> <given-names>M</given-names></name><name><surname>Sabatini</surname> <given-names>DM</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>mTOR signaling</article-title><source>Cold Spring Harbor Perspectives in Biology</source><volume>4</volume><elocation-id>a011593</elocation-id><pub-id pub-id-type="doi">10.1101/cshperspect.a011593</pub-id><pub-id pub-id-type="pmid">22129599</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lazova</surname> <given-names>R</given-names></name><name><surname>Camp</surname> <given-names>RL</given-names></name><name><surname>Klump</surname> <given-names>V</given-names></name><name><surname>Siddiqui</surname> <given-names>SF</given-names></name><name><surname>Amaravadi</surname> <given-names>RK</given-names></name><name><surname>Pawelek</surname> <given-names>JM</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Punctate LC3B expression is a common feature of solid tumors and associated with proliferation, metastasis, and poor outcome</article-title><source>Clinical Cancer Research</source><volume>18</volume><fpage>370</fpage><lpage>379</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-11-1282</pub-id><pub-id pub-id-type="pmid">22080440</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levine</surname> <given-names>B</given-names></name><name><surname>Kroemer</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Autophagy in the pathogenesis of disease</article-title><source>Cell</source><volume>132</volume><fpage>27</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2007.12.018</pub-id><pub-id pub-id-type="pmid">18191218</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>XX</given-names></name><name><surname>Zhang</surname> <given-names>HS</given-names></name><name><surname>Xu</surname> <given-names>YM</given-names></name><name><surname>Zhang</surname> <given-names>RJ</given-names></name><name><surname>Chen</surname> <given-names>Y</given-names></name><name><surname>Fan</surname> <given-names>L</given-names></name><name><surname>Qin</surname> <given-names>YQ</given-names></name><name><surname>Liu</surname> <given-names>Y</given-names></name><name><surname>Li</surname> <given-names>M</given-names></name><name><surname>Fang</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Knockdown of IRE1alpha inhibits colonic tumorigenesis through decreasing beta-catenin and IRE1alpha targeting suppresses colon cancer cells</article-title><source>Oncogene</source><volume>36</volume><fpage>6738</fpage><lpage>6746</lpage><pub-id pub-id-type="doi">10.1038/onc.2017.284</pub-id><pub-id pub-id-type="pmid">28825721</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>L</given-names></name><name><surname>Liu</surname> <given-names>X</given-names></name><name><surname>Zhou</surname> <given-names>L</given-names></name><name><surname>Wang</surname> <given-names>W</given-names></name><name><surname>Liu</surname> <given-names>Z</given-names></name><name><surname>Cheng</surname> <given-names>Y</given-names></name><name><surname>Li</surname> <given-names>J</given-names></name><name><surname>Wei</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Autophagy plays a critical role in insulin resistance-mediated chemoresistance in hepatocellular carcinoma cells by regulating the ER stress</article-title><source>Journal of Cancer</source><volume>9</volume><fpage>4314</fpage><lpage>4324</lpage><pub-id pub-id-type="doi">10.7150/jca.27943</pub-id><pub-id pub-id-type="pmid">30519335</pub-id></element-citation></ref><ref id="bib91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname> <given-names>Y</given-names></name><name><surname>Jiang</surname> <given-names>M</given-names></name><name><surname>Chen</surname> <given-names>W</given-names></name><name><surname>Zhao</surname> <given-names>T</given-names></name><name><surname>Wei</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Cancer and ER stress: mutual crosstalk between autophagy, oxidative stress and inflammatory response</article-title><source>Biomedicine &amp; Pharmacotherapy</source><volume>118</volume><elocation-id>109249</elocation-id><pub-id pub-id-type="doi">10.1016/j.biopha.2019.109249</pub-id><pub-id pub-id-type="pmid">31351428</pub-id></element-citation></ref><ref id="bib92"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Love</surname> <given-names>MI</given-names></name><name><surname>Huber</surname> <given-names>W</given-names></name><name><surname>Anders</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2</article-title><source>Genome Biology</source><volume>15</volume><elocation-id>550</elocation-id><pub-id pub-id-type="doi">10.1186/s13059-014-0550-8</pub-id><pub-id pub-id-type="pmid">25516281</pub-id></element-citation></ref><ref id="bib93"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luh</surname> <given-names>LM</given-names></name><name><surname>Bertolotti</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Potential benefit of manipulating protein quality control systems in neurodegenerative diseases</article-title><source>Current Opinion in Neurobiology</source><volume>61</volume><fpage>125</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.1016/j.conb.2020.02.009</pub-id></element-citation></ref><ref id="bib94"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luhr</surname> <given-names>M</given-names></name><name><surname>Torgersen</surname> <given-names>ML</given-names></name><name><surname>Szalai</surname> <given-names>P</given-names></name><name><surname>Hashim</surname> <given-names>A</given-names></name><name><surname>Brech</surname> <given-names>A</given-names></name><name><surname>Staerk</surname> <given-names>J</given-names></name><name><surname>Engedal</surname> <given-names>N</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The kinase PERK and the transcription factor ATF4 play distinct and essential roles in autophagy resulting from tunicamycin-induced ER stress</article-title><source>Journal of Biological Chemistry</source><volume>294</volume><fpage>8197</fpage><lpage>8217</lpage><pub-id pub-id-type="doi">10.1074/jbc.RA118.002829</pub-id><pub-id pub-id-type="pmid">30926605</pub-id></element-citation></ref><ref id="bib95"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname> <given-names>XH</given-names></name><name><surname>Piao</surname> <given-names>SF</given-names></name><name><surname>Dey</surname> <given-names>S</given-names></name><name><surname>McAfee</surname> <given-names>Q</given-names></name><name><surname>Karakousis</surname> <given-names>G</given-names></name><name><surname>Villanueva</surname> <given-names>J</given-names></name><name><surname>Hart</surname> <given-names>LS</given-names></name><name><surname>Levi</surname> <given-names>S</given-names></name><name><surname>Hu</surname> <given-names>J</given-names></name><name><surname>Zhang</surname> <given-names>G</given-names></name><name><surname>Lazova</surname> <given-names>R</given-names></name><name><surname>Klump</surname> <given-names>V</given-names></name><name><surname>Pawelek</surname> <given-names>JM</given-names></name><name><surname>Xu</surname> <given-names>X</given-names></name><name><surname>Xu</surname> <given-names>W</given-names></name><name><surname>Schuchter</surname> <given-names>LM</given-names></name><name><surname>Davies</surname> <given-names>MA</given-names></name><name><surname>Herlyn</surname> <given-names>M</given-names></name><name><surname>Winkler</surname> <given-names>J</given-names></name><name><surname>Koumenis</surname> <given-names>C</given-names></name><name><surname>Amaravadi</surname> <given-names>RK</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Targeting ER stress-induced autophagy overcomes BRAF inhibitor resistance in melanoma</article-title><source>The Journal of Clinical Investigation</source><volume>124</volume><fpage>1406</fpage><lpage>1417</lpage><pub-id pub-id-type="doi">10.1172/JCI70454</pub-id><pub-id pub-id-type="pmid">24569374</pub-id></element-citation></ref><ref id="bib96"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manic</surname> <given-names>G</given-names></name><name><surname>Obrist</surname> <given-names>F</given-names></name><name><surname>Kroemer</surname> <given-names>G</given-names></name><name><surname>Vitale</surname> <given-names>I</given-names></name><name><surname>Galluzzi</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Chloroquine and hydroxychloroquine for cancer therapy</article-title><source>Molecular &amp; Cellular Oncology</source><volume>1</volume><elocation-id>e29911</elocation-id><pub-id pub-id-type="doi">10.4161/mco.29911</pub-id><pub-id pub-id-type="pmid">27308318</pub-id></element-citation></ref><ref id="bib97"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marciniak</surname> <given-names>SJ</given-names></name><name><surname>Yun</surname> <given-names>CY</given-names></name><name><surname>Oyadomari</surname> <given-names>S</given-names></name><name><surname>Novoa</surname> <given-names>I</given-names></name><name><surname>Zhang</surname> <given-names>Y</given-names></name><name><surname>Jungreis</surname> <given-names>R</given-names></name><name><surname>Nagata</surname> <given-names>K</given-names></name><name><surname>Harding</surname> <given-names>HP</given-names></name><name><surname>Ron</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>CHOP induces death by promoting protein synthesis and oxidation in the stressed endoplasmic reticulum</article-title><source>Genes &amp; Development</source><volume>18</volume><fpage>3066</fpage><lpage>3077</lpage><pub-id pub-id-type="doi">10.1101/gad.1250704</pub-id><pub-id pub-id-type="pmid">15601821</pub-id></element-citation></ref><ref id="bib98"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marcotte</surname> <given-names>R</given-names></name><name><surname>Sayad</surname> <given-names>A</given-names></name><name><surname>Brown</surname> <given-names>KR</given-names></name><name><surname>Sanchez-Garcia</surname> <given-names>F</given-names></name><name><surname>Reimand</surname> <given-names>J</given-names></name><name><surname>Haider</surname> <given-names>M</given-names></name><name><surname>Virtanen</surname> <given-names>C</given-names></name><name><surname>Bradner</surname> <given-names>JE</given-names></name><name><surname>Bader</surname> <given-names>GD</given-names></name><name><surname>Mills</surname> <given-names>GB</given-names></name><name><surname>Pe'er</surname> <given-names>D</given-names></name><name><surname>Moffat</surname> <given-names>J</given-names></name><name><surname>Neel</surname> <given-names>BG</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Functional genomic landscape of human breast cancer drivers, vulnerabilities, and resistance</article-title><source>Cell</source><volume>164</volume><fpage>293</fpage><lpage>309</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2015.11.062</pub-id><pub-id pub-id-type="pmid">26771497</pub-id></element-citation></ref><ref id="bib99"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname> <given-names>AP</given-names></name><name><surname>Mitchell</surname> <given-names>C</given-names></name><name><surname>Rahmani</surname> <given-names>M</given-names></name><name><surname>Nephew</surname> <given-names>KP</given-names></name><name><surname>Grant</surname> <given-names>S</given-names></name><name><surname>Dent</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Inhibition of MCL-1 enhances lapatinib toxicity and overcomes lapatinib resistance via BAK-dependent autophagy</article-title><source>Cancer Biology &amp; Therapy</source><volume>8</volume><fpage>2084</fpage><lpage>2096</lpage><pub-id pub-id-type="doi">10.4161/cbt.8.21.9895</pub-id><pub-id pub-id-type="pmid">19823038</pub-id></element-citation></ref><ref id="bib100"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matus</surname> <given-names>S</given-names></name><name><surname>Lopez</surname> <given-names>E</given-names></name><name><surname>Valenzuela</surname> <given-names>V</given-names></name><name><surname>Nassif</surname> <given-names>M</given-names></name><name><surname>Hetz</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Functional contribution of the transcription factor ATF4 to the pathogenesis of amyotrophic lateral sclerosis</article-title><source>PLOS ONE</source><volume>8</volume><elocation-id>e66672</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0066672</pub-id><pub-id pub-id-type="pmid">23874395</pub-id></element-citation></ref><ref id="bib101"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McConkey</surname> <given-names>DJ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>The integrated stress response and proteotoxicity in cancer therapy</article-title><source>Biochemical and Biophysical Research Communications</source><volume>482</volume><fpage>450</fpage><lpage>453</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2016.11.047</pub-id><pub-id pub-id-type="pmid">28212730</pub-id></element-citation></ref><ref id="bib102"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McLeland</surname> <given-names>CB</given-names></name><name><surname>Rodriguez</surname> <given-names>J</given-names></name><name><surname>Stern</surname> <given-names>ST</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Autophagy monitoring assay: qualitative analysis of MAP LC3-I to II conversion by immunoblot</article-title><source>Methods in Molecular Biology</source><volume>697</volume><fpage>199</fpage><lpage>206</lpage><pub-id pub-id-type="doi">10.1007/978-1-60327-198-1_21</pub-id><pub-id pub-id-type="pmid">21116969</pub-id></element-citation></ref><ref id="bib103"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mei</surname> <given-names>Y</given-names></name><name><surname>Thompson</surname> <given-names>MD</given-names></name><name><surname>Cohen</surname> <given-names>RA</given-names></name><name><surname>Tong</surname> <given-names>X</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Endoplasmic reticulum stress and related pathological processes</article-title><source>Journal of Pharmacological &amp; Biomedical Analysis</source><volume>1</volume><elocation-id>1000107</elocation-id><pub-id pub-id-type="pmid">24611136</pub-id></element-citation></ref><ref id="bib104"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meng</surname> <given-names>LH</given-names></name><name><surname>Zheng</surname> <given-names>XF</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Toward rapamycin analog (rapalog)-based precision cancer therapy</article-title><source>Acta Pharmacologica Sinica</source><volume>36</volume><fpage>1163</fpage><lpage>1169</lpage><pub-id pub-id-type="doi">10.1038/aps.2015.68</pub-id><pub-id pub-id-type="pmid">26299952</pub-id></element-citation></ref><ref id="bib105"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Milan</surname> <given-names>E</given-names></name><name><surname>Perini</surname> <given-names>T</given-names></name><name><surname>Resnati</surname> <given-names>M</given-names></name><name><surname>Orfanelli</surname> <given-names>U</given-names></name><name><surname>Oliva</surname> <given-names>L</given-names></name><name><surname>Raimondi</surname> <given-names>A</given-names></name><name><surname>Cascio</surname> <given-names>P</given-names></name><name><surname>Bachi</surname> <given-names>A</given-names></name><name><surname>Marcatti</surname> <given-names>M</given-names></name><name><surname>Ciceri</surname> <given-names>F</given-names></name><name><surname>Cenci</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>A plastic SQSTM1/p62-dependent autophagic reserve maintains proteostasis and determines proteasome inhibitor susceptibility in multiple myeloma cells</article-title><source>Autophagy</source><volume>11</volume><fpage>1161</fpage><lpage>1178</lpage><pub-id pub-id-type="doi">10.1080/15548627.2015.1052928</pub-id><pub-id pub-id-type="pmid">26043024</pub-id></element-citation></ref><ref id="bib106"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miracco</surname> <given-names>C</given-names></name><name><surname>Cevenini</surname> <given-names>G</given-names></name><name><surname>Franchi</surname> <given-names>A</given-names></name><name><surname>Luzi</surname> <given-names>P</given-names></name><name><surname>Cosci</surname> <given-names>E</given-names></name><name><surname>Mourmouras</surname> <given-names>V</given-names></name><name><surname>Monciatti</surname> <given-names>I</given-names></name><name><surname>Mannucci</surname> <given-names>S</given-names></name><name><surname>Biagioli</surname> <given-names>M</given-names></name><name><surname>Toscano</surname> <given-names>M</given-names></name><name><surname>Moretti</surname> <given-names>D</given-names></name><name><surname>Lio</surname> <given-names>R</given-names></name><name><surname>Massi</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Beclin 1 and LC3 autophagic gene expression in cutaneous melanocytic lesions</article-title><source>Human Pathology</source><volume>41</volume><fpage>503</fpage><lpage>512</lpage><pub-id pub-id-type="doi">10.1016/j.humpath.2009.09.004</pub-id><pub-id pub-id-type="pmid">20004946</pub-id></element-citation></ref><ref id="bib107"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mizushima</surname> <given-names>N</given-names></name><name><surname>Levine</surname> <given-names>B</given-names></name><name><surname>Cuervo</surname> <given-names>AM</given-names></name><name><surname>Klionsky</surname> <given-names>DJ</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Autophagy fights disease through cellular self-digestion</article-title><source>Nature</source><volume>451</volume><fpage>1069</fpage><lpage>1075</lpage><pub-id pub-id-type="doi">10.1038/nature06639</pub-id><pub-id pub-id-type="pmid">18305538</pub-id></element-citation></ref><ref id="bib108"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mizushima</surname> <given-names>N</given-names></name><name><surname>Yoshimori</surname> <given-names>T</given-names></name><name><surname>Ohsumi</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>The role of atg proteins in autophagosome formation</article-title><source>Annual Review of Cell and Developmental Biology</source><volume>27</volume><fpage>107</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.1146/annurev-cellbio-092910-154005</pub-id><pub-id pub-id-type="pmid">21801009</pub-id></element-citation></ref><ref id="bib109"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mizushima</surname> <given-names>N</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>The exponential growth of autophagy-related research: from the humble yeast to the nobel prize</article-title><source>FEBS Letters</source><volume>591</volume><fpage>681</fpage><lpage>689</lpage><pub-id pub-id-type="doi">10.1002/1873-3468.12594</pub-id><pub-id pub-id-type="pmid">28186333</pub-id></element-citation></ref><ref id="bib110"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mu</surname> <given-names>TW</given-names></name><name><surname>Ong</surname> <given-names>DS</given-names></name><name><surname>Wang</surname> <given-names>YJ</given-names></name><name><surname>Balch</surname> <given-names>WE</given-names></name><name><surname>Yates</surname> <given-names>JR</given-names></name><name><surname>Segatori</surname> <given-names>L</given-names></name><name><surname>Kelly</surname> <given-names>JW</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Chemical and biological approaches synergize to ameliorate protein-folding diseases</article-title><source>Cell</source><volume>134</volume><fpage>769</fpage><lpage>781</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2008.06.037</pub-id><pub-id pub-id-type="pmid">18775310</pub-id></element-citation></ref><ref id="bib111"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mukherjee</surname> <given-names>T</given-names></name><name><surname>Ramaglia</surname> <given-names>V</given-names></name><name><surname>Abdel-Nour</surname> <given-names>M</given-names></name><name><surname>Bianchi</surname> <given-names>AA</given-names></name><name><surname>Tsalikis</surname> <given-names>J</given-names></name><name><surname>Chau</surname> <given-names>HN</given-names></name><name><surname>Kalia</surname> <given-names>SK</given-names></name><name><surname>Kalia</surname> <given-names>LV</given-names></name><name><surname>Chen</surname> <given-names>J-J</given-names></name><name><surname>Arnoult</surname> <given-names>D</given-names></name><name><surname>Gommerman</surname> <given-names>JL</given-names></name><name><surname>Philpott</surname> <given-names>DJ</given-names></name><name><surname>Girardin</surname> <given-names>SE</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>The eIF2α kinase HRI triggers the autophagic clearance of cytosolic protein aggregates</article-title><source>Journal of Biological Chemistry</source><volume>296</volume><elocation-id>100050</elocation-id><pub-id pub-id-type="doi">10.1074/jbc.RA120.014415</pub-id></element-citation></ref><ref id="bib112"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naito</surname> <given-names>Y</given-names></name><name><surname>Urasaki</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Precision medicine in breast cancer</article-title><source>Chinese Clinical Oncology</source><volume>7</volume><elocation-id>29</elocation-id><pub-id pub-id-type="doi">10.21037/cco.2018.06.04</pub-id><pub-id pub-id-type="pmid">30056731</pub-id></element-citation></ref><ref id="bib113"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakamura</surname> <given-names>A</given-names></name><name><surname>Nambu</surname> <given-names>T</given-names></name><name><surname>Ebara</surname> <given-names>S</given-names></name><name><surname>Hasegawa</surname> <given-names>Y</given-names></name><name><surname>Toyoshima</surname> <given-names>K</given-names></name><name><surname>Tsuchiya</surname> <given-names>Y</given-names></name><name><surname>Tomita</surname> <given-names>D</given-names></name><name><surname>Fujimoto</surname> <given-names>J</given-names></name><name><surname>Kurasawa</surname> <given-names>O</given-names></name><name><surname>Takahara</surname> <given-names>C</given-names></name><name><surname>Ando</surname> <given-names>A</given-names></name><name><surname>Nishigaki</surname> <given-names>R</given-names></name><name><surname>Satomi</surname> <given-names>Y</given-names></name><name><surname>Hata</surname> <given-names>A</given-names></name><name><surname>Hara</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Inhibition of GCN2 sensitizes ASNS-low cancer cells to asparaginase by disrupting the amino acid response</article-title><source>PNAS</source><volume>115</volume><fpage>E7776</fpage><lpage>E7785</lpage><pub-id pub-id-type="doi">10.1073/pnas.1805523115</pub-id><pub-id pub-id-type="pmid">30061420</pub-id></element-citation></ref><ref id="bib114"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nam</surname> <given-names>SM</given-names></name><name><surname>Jeon</surname> <given-names>YJ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Proteostasis in the endoplasmic reticulum: road to cure</article-title><source>Cancers</source><volume>11</volume><elocation-id>1793</elocation-id><pub-id pub-id-type="doi">10.3390/cancers11111793</pub-id></element-citation></ref><ref id="bib115"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nanbu</surname> <given-names>K</given-names></name><name><surname>Konishi</surname> <given-names>I</given-names></name><name><surname>Mandai</surname> <given-names>M</given-names></name><name><surname>Kuroda</surname> <given-names>H</given-names></name><name><surname>Hamid</surname> <given-names>AA</given-names></name><name><surname>Komatsu</surname> <given-names>T</given-names></name><name><surname>Mori</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Prognostic significance of heat shock proteins HSP70 and HSP90 in endometrial carcinomas</article-title><source>Cancer Detection Prevention</source><volume>22</volume><fpage>549</fpage><lpage>555</lpage><pub-id pub-id-type="doi">10.1046/j.1525-1500.1998.00069.x</pub-id><pub-id pub-id-type="pmid">9824379</pub-id></element-citation></ref><ref id="bib116"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Needham</surname> <given-names>PG</given-names></name><name><surname>Brodsky</surname> <given-names>JL</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>How early studies on secreted and membrane protein quality control gave rise to the ER associated degradation (ERAD) pathway: the early history of ERAD</article-title><source>Biochimica Et Biophysica Acta (BBA) - Molecular Cell Research</source><volume>1833</volume><fpage>2447</fpage><lpage>2457</lpage><pub-id pub-id-type="doi">10.1016/j.bbamcr.2013.03.018</pub-id></element-citation></ref><ref id="bib117"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname> <given-names>HG</given-names></name><name><surname>Conn</surname> <given-names>CS</given-names></name><name><surname>Kye</surname> <given-names>Y</given-names></name><name><surname>Xue</surname> <given-names>L</given-names></name><name><surname>Forester</surname> <given-names>CM</given-names></name><name><surname>Cowan</surname> <given-names>JE</given-names></name><name><surname>Hsieh</surname> <given-names>AC</given-names></name><name><surname>Cunningham</surname> <given-names>JT</given-names></name><name><surname>Truillet</surname> <given-names>C</given-names></name><name><surname>Tameire</surname> <given-names>F</given-names></name><name><surname>Evans</surname> <given-names>MJ</given-names></name><name><surname>Evans</surname> <given-names>CP</given-names></name><name><surname>Yang</surname> <given-names>JC</given-names></name><name><surname>Hann</surname> <given-names>B</given-names></name><name><surname>Koumenis</surname> <given-names>C</given-names></name><name><surname>Walter</surname> <given-names>P</given-names></name><name><surname>Carroll</surname> <given-names>PR</given-names></name><name><surname>Ruggero</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Development of a stress response therapy targeting aggressive prostate cancer</article-title><source>Science Translational Medicine</source><volume>10</volume><elocation-id>eaar2036</elocation-id><pub-id pub-id-type="doi">10.1126/scitranslmed.aar2036</pub-id></element-citation></ref><ref id="bib118"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Notte</surname> <given-names>A</given-names></name><name><surname>Rebucci</surname> <given-names>M</given-names></name><name><surname>Fransolet</surname> <given-names>M</given-names></name><name><surname>Roegiers</surname> <given-names>E</given-names></name><name><surname>Genin</surname> <given-names>M</given-names></name><name><surname>Tellier</surname> <given-names>C</given-names></name><name><surname>Watillon</surname> <given-names>K</given-names></name><name><surname>Fattaccioli</surname> <given-names>A</given-names></name><name><surname>Arnould</surname> <given-names>T</given-names></name><name><surname>Michiels</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Taxol-induced unfolded protein response activation in breast cancer cells exposed to hypoxia: ATF4 activation regulates autophagy and inhibits apoptosis</article-title><source>The International Journal of Biochemistry &amp; Cell Biology</source><volume>62</volume><fpage>1</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1016/j.biocel.2015.02.010</pub-id><pub-id pub-id-type="pmid">25724736</pub-id></element-citation></ref><ref id="bib119"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ojha</surname> <given-names>R</given-names></name><name><surname>Amaravadi</surname> <given-names>RK</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Targeting the unfolded protein response in cancer</article-title><source>Pharmacological Research</source><volume>120</volume><fpage>258</fpage><lpage>266</lpage><pub-id pub-id-type="doi">10.1016/j.phrs.2017.04.003</pub-id><pub-id pub-id-type="pmid">28396092</pub-id></element-citation></ref><ref id="bib120"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oyadomari</surname> <given-names>S</given-names></name><name><surname>Mori</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Roles of CHOP/GADD153 in endoplasmic reticulum stress</article-title><source>Cell Death &amp; Differentiation</source><volume>11</volume><fpage>381</fpage><lpage>389</lpage><pub-id pub-id-type="doi">10.1038/sj.cdd.4401373</pub-id><pub-id pub-id-type="pmid">14685163</pub-id></element-citation></ref><ref id="bib121"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pakos-Zebrucka</surname> <given-names>K</given-names></name><name><surname>Koryga</surname> <given-names>I</given-names></name><name><surname>Mnich</surname> <given-names>K</given-names></name><name><surname>Ljujic</surname> <given-names>M</given-names></name><name><surname>Samali</surname> <given-names>A</given-names></name><name><surname>Gorman</surname> <given-names>AM</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The integrated stress response</article-title><source>EMBO Reports</source><volume>17</volume><fpage>1374</fpage><lpage>1395</lpage><pub-id pub-id-type="doi">10.15252/embr.201642195</pub-id><pub-id pub-id-type="pmid">27629041</pub-id></element-citation></ref><ref id="bib122"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palam</surname> <given-names>LR</given-names></name><name><surname>Baird</surname> <given-names>TD</given-names></name><name><surname>Wek</surname> <given-names>RC</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Phosphorylation of eIF2 facilitates ribosomal bypass of an inhibitory upstream ORF to enhance CHOP translation</article-title><source>Journal of Biological Chemistry</source><volume>286</volume><fpage>10939</fpage><lpage>10949</lpage><pub-id pub-id-type="doi">10.1074/jbc.M110.216093</pub-id><pub-id pub-id-type="pmid">21285359</pub-id></element-citation></ref><ref id="bib123"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pataer</surname> <given-names>A</given-names></name><name><surname>Ozpolat</surname> <given-names>B</given-names></name><name><surname>Shao</surname> <given-names>R</given-names></name><name><surname>Cashman</surname> <given-names>NR</given-names></name><name><surname>Plotkin</surname> <given-names>SS</given-names></name><name><surname>Samuel</surname> <given-names>CE</given-names></name><name><surname>Lin</surname> <given-names>SH</given-names></name><name><surname>Kabil</surname> <given-names>NN</given-names></name><name><surname>Wang</surname> <given-names>J</given-names></name><name><surname>Majidi</surname> <given-names>M</given-names></name><name><surname>Fang</surname> <given-names>B</given-names></name><name><surname>Roth</surname> <given-names>JA</given-names></name><name><surname>Vaporciyan</surname> <given-names>AA</given-names></name><name><surname>Wistuba</surname> <given-names>II</given-names></name><name><surname>Hung</surname> <given-names>MC</given-names></name><name><surname>Swisher</surname> <given-names>SG</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Therapeutic targeting of the PI4K2A/PKR lysosome network is critical for misfolded protein clearance and survival in cancer cells</article-title><source>Oncogene</source><volume>39</volume><fpage>801</fpage><lpage>813</lpage><pub-id pub-id-type="doi">10.1038/s41388-019-1010-4</pub-id><pub-id pub-id-type="pmid">31554935</pub-id></element-citation></ref><ref id="bib124"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname> <given-names>PD</given-names></name><name><surname>Yan</surname> <given-names>P</given-names></name><name><surname>Seidler</surname> <given-names>PM</given-names></name><name><surname>Patel</surname> <given-names>HJ</given-names></name><name><surname>Sun</surname> <given-names>W</given-names></name><name><surname>Yang</surname> <given-names>C</given-names></name><name><surname>Que</surname> <given-names>NS</given-names></name><name><surname>Taldone</surname> <given-names>T</given-names></name><name><surname>Finotti</surname> <given-names>P</given-names></name><name><surname>Stephani</surname> <given-names>RA</given-names></name><name><surname>Gewirth</surname> <given-names>DT</given-names></name><name><surname>Chiosis</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Paralog-selective Hsp90 inhibitors define tumor-specific regulation of HER2</article-title><source>Nature Chemical Biology</source><volume>9</volume><fpage>677</fpage><lpage>684</lpage><pub-id pub-id-type="doi">10.1038/nchembio.1335</pub-id><pub-id pub-id-type="pmid">23995768</pub-id></element-citation></ref><ref id="bib125"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patham</surname> <given-names>B</given-names></name><name><surname>Duffy</surname> <given-names>J</given-names></name><name><surname>Lane</surname> <given-names>A</given-names></name><name><surname>Davis</surname> <given-names>RC</given-names></name><name><surname>Wipf</surname> <given-names>P</given-names></name><name><surname>Fewell</surname> <given-names>SW</given-names></name><name><surname>Brodsky</surname> <given-names>JL</given-names></name><name><surname>Mensa-Wilmot</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Post-translational import of protein into the endoplasmic reticulum of a trypanosome: an in vitro system for discovery of anti-trypanosomal chemical entities</article-title><source>Biochemical Journal</source><volume>419</volume><fpage>507</fpage><lpage>517</lpage><pub-id pub-id-type="doi">10.1042/BJ20081787</pub-id><pub-id pub-id-type="pmid">19196237</pub-id></element-citation></ref><ref id="bib126"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patro</surname> <given-names>R</given-names></name><name><surname>Duggal</surname> <given-names>G</given-names></name><name><surname>Love</surname> <given-names>MI</given-names></name><name><surname>Irizarry</surname> <given-names>RA</given-names></name><name><surname>Kingsford</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Salmon provides fast and bias-aware quantification of transcript expression</article-title><source>Nature Methods</source><volume>14</volume><fpage>417</fpage><lpage>419</lpage><pub-id pub-id-type="doi">10.1038/nmeth.4197</pub-id><pub-id pub-id-type="pmid">28263959</pub-id></element-citation></ref><ref id="bib127"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perou</surname> <given-names>CM</given-names></name><name><surname>Sørlie</surname> <given-names>T</given-names></name><name><surname>Eisen</surname> <given-names>MB</given-names></name><name><surname>van de Rijn</surname> <given-names>M</given-names></name><name><surname>Jeffrey</surname> <given-names>SS</given-names></name><name><surname>Rees</surname> <given-names>CA</given-names></name><name><surname>Pollack</surname> <given-names>JR</given-names></name><name><surname>Ross</surname> <given-names>DT</given-names></name><name><surname>Johnsen</surname> <given-names>H</given-names></name><name><surname>Akslen</surname> <given-names>LA</given-names></name><name><surname>Fluge</surname> <given-names>O</given-names></name><name><surname>Pergamenschikov</surname> <given-names>A</given-names></name><name><surname>Williams</surname> <given-names>C</given-names></name><name><surname>Zhu</surname> <given-names>SX</given-names></name><name><surname>Lønning</surname> <given-names>PE</given-names></name><name><surname>Børresen-Dale</surname> <given-names>AL</given-names></name><name><surname>Brown</surname> <given-names>PO</given-names></name><name><surname>Botstein</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Molecular portraits of human breast tumours</article-title><source>Nature</source><volume>406</volume><fpage>747</fpage><lpage>752</lpage><pub-id pub-id-type="doi">10.1038/35021093</pub-id><pub-id pub-id-type="pmid">10963602</pub-id></element-citation></ref><ref id="bib128"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petersen</surname> <given-names>RB</given-names></name><name><surname>Lindquist</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="1989">1989</year><article-title>Regulation of HSP70 synthesis by messenger RNA degradation</article-title><source>Cell Regulation</source><volume>1</volume><fpage>135</fpage><lpage>149</lpage><pub-id pub-id-type="doi">10.1091/mbc.1.1.135</pub-id><pub-id pub-id-type="pmid">2519613</pub-id></element-citation></ref><ref id="bib129"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pfaffl</surname> <given-names>MW</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>A new mathematical model for relative quantification in real-time RT-PCR</article-title><source>Nucleic Acids Research</source><volume>29</volume><elocation-id>e45</elocation-id><pub-id pub-id-type="doi">10.1093/nar/29.9.e45</pub-id><pub-id pub-id-type="pmid">11328886</pub-id></element-citation></ref><ref id="bib130"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Piffoux</surname> <given-names>M</given-names></name><name><surname>Eriau</surname> <given-names>E</given-names></name><name><surname>Cassier</surname> <given-names>PA</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Autophagy as a therapeutic target in pancreatic cancer</article-title><source>British Journal of Cancer</source><volume>124</volume><fpage>333</fpage><lpage>344</lpage><pub-id pub-id-type="doi">10.1038/s41416-020-01039-5</pub-id><pub-id pub-id-type="pmid">32929194</pub-id></element-citation></ref><ref id="bib131"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Powers</surname> <given-names>MV</given-names></name><name><surname>Clarke</surname> <given-names>PA</given-names></name><name><surname>Workman</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Death by chaperone: HSP90, HSP70 or both?</article-title><source>Cell Cycle</source><volume>8</volume><fpage>518</fpage><lpage>526</lpage><pub-id pub-id-type="doi">10.4161/cc.8.4.7583</pub-id><pub-id pub-id-type="pmid">19197160</pub-id></element-citation></ref><ref id="bib132"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Powers</surname> <given-names>MV</given-names></name><name><surname>Jones</surname> <given-names>K</given-names></name><name><surname>Barillari</surname> <given-names>C</given-names></name><name><surname>Westwood</surname> <given-names>I</given-names></name><name><surname>van Montfort</surname> <given-names>RL</given-names></name><name><surname>Workman</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Targeting HSP70: the second potentially druggable heat shock protein and molecular chaperone?</article-title><source>Cell Cycle</source><volume>9</volume><fpage>1542</fpage><lpage>1550</lpage><pub-id pub-id-type="doi">10.4161/cc.9.8.11204</pub-id><pub-id pub-id-type="pmid">20372081</pub-id></element-citation></ref><ref id="bib133"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Powers</surname> <given-names>MV</given-names></name><name><surname>Valenti</surname> <given-names>M</given-names></name><name><surname>Miranda</surname> <given-names>S</given-names></name><name><surname>Maloney</surname> <given-names>A</given-names></name><name><surname>Eccles</surname> <given-names>SA</given-names></name><name><surname>Thomas</surname> <given-names>G</given-names></name><name><surname>Clarke</surname> <given-names>PA</given-names></name><name><surname>Workman</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Mode of cell death induced by the HSP90 inhibitor 17-AAG (tanespimycin) is dependent on the expression of pro-apoptotic BAX</article-title><source>Oncotarget</source><volume>4</volume><fpage>1963</fpage><lpage>1975</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.1419</pub-id><pub-id pub-id-type="pmid">24185264</pub-id></element-citation></ref><ref id="bib134"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pyo</surname> <given-names>JO</given-names></name><name><surname>Jang</surname> <given-names>MH</given-names></name><name><surname>Kwon</surname> <given-names>YK</given-names></name><name><surname>Lee</surname> <given-names>HJ</given-names></name><name><surname>Jun</surname> <given-names>JI</given-names></name><name><surname>Woo</surname> <given-names>HN</given-names></name><name><surname>Cho</surname> <given-names>DH</given-names></name><name><surname>Choi</surname> <given-names>B</given-names></name><name><surname>Lee</surname> <given-names>H</given-names></name><name><surname>Kim</surname> <given-names>JH</given-names></name><name><surname>Mizushima</surname> <given-names>N</given-names></name><name><surname>Oshumi</surname> <given-names>Y</given-names></name><name><surname>Jung</surname> <given-names>YK</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Essential roles of ATG5 and FADD in autophagic cell death: dissection of autophagic cell death into vacuole formation and cell death</article-title><source>The Journal of Biological Chemistry</source><volume>280</volume><fpage>20722</fpage><lpage>20729</lpage><pub-id pub-id-type="doi">10.1074/jbc.M413934200</pub-id><pub-id pub-id-type="pmid">15778222</pub-id></element-citation></ref><ref id="bib135"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rabouw</surname> <given-names>HH</given-names></name><name><surname>Langereis</surname> <given-names>MA</given-names></name><name><surname>Anand</surname> <given-names>AA</given-names></name><name><surname>Visser</surname> <given-names>LJ</given-names></name><name><surname>de Groot</surname> <given-names>RJ</given-names></name><name><surname>Walter</surname> <given-names>P</given-names></name><name><surname>van Kuppeveld</surname> <given-names>FJM</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Small molecule ISRIB suppresses the integrated stress response within a defined window of activation</article-title><source>PNAS</source><volume>116</volume><fpage>2097</fpage><lpage>2102</lpage><pub-id pub-id-type="doi">10.1073/pnas.1815767116</pub-id><pub-id pub-id-type="pmid">30674674</pub-id></element-citation></ref><ref id="bib136"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rajanala</surname> <given-names>SH</given-names></name><name><surname>Ringquist</surname> <given-names>R</given-names></name><name><surname>Cryns</surname> <given-names>VL</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Methionine restriction activates the integrated stress response in triple-negative breast cancer cells by a GCN2- and PERK-independent mechanism</article-title><source>American Journal of Cancer Research</source><volume>9</volume><fpage>1766</fpage><lpage>1775</lpage><pub-id pub-id-type="pmid">31497357</pub-id></element-citation></ref><ref id="bib137"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rebecca</surname> <given-names>VW</given-names></name><name><surname>Nicastri</surname> <given-names>MC</given-names></name><name><surname>Fennelly</surname> <given-names>C</given-names></name><name><surname>Chude</surname> <given-names>CI</given-names></name><name><surname>Barber-Rotenberg</surname> <given-names>JS</given-names></name><name><surname>Ronghe</surname> <given-names>A</given-names></name><name><surname>McAfee</surname> <given-names>Q</given-names></name><name><surname>McLaughlin</surname> <given-names>NP</given-names></name><name><surname>Zhang</surname> <given-names>G</given-names></name><name><surname>Goldman</surname> <given-names>AR</given-names></name><name><surname>Ojha</surname> <given-names>R</given-names></name><name><surname>Piao</surname> <given-names>S</given-names></name><name><surname>Noguera-Ortega</surname> <given-names>E</given-names></name><name><surname>Martorella</surname> <given-names>A</given-names></name><name><surname>Alicea</surname> <given-names>GM</given-names></name><name><surname>Lee</surname> <given-names>JJ</given-names></name><name><surname>Schuchter</surname> <given-names>LM</given-names></name><name><surname>Xu</surname> <given-names>X</given-names></name><name><surname>Herlyn</surname> <given-names>M</given-names></name><name><surname>Marmorstein</surname> <given-names>R</given-names></name><name><surname>Gimotty</surname> <given-names>PA</given-names></name><name><surname>Speicher</surname> <given-names>DW</given-names></name><name><surname>Winkler</surname> <given-names>JD</given-names></name><name><surname>Amaravadi</surname> <given-names>RK</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>PPT1 promotes tumor growth and is the molecular target of chloroquine derivatives in cancer</article-title><source>Cancer Discovery</source><volume>9</volume><fpage>220</fpage><lpage>229</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-18-0706</pub-id><pub-id pub-id-type="pmid">30442709</pub-id></element-citation></ref><ref id="bib138"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robainas</surname> <given-names>M</given-names></name><name><surname>Otano</surname> <given-names>R</given-names></name><name><surname>Bueno</surname> <given-names>S</given-names></name><name><surname>Ait-Oudhia</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Understanding the role of PD-L1/PD1 pathway blockade and autophagy in cancer therapy</article-title><source>OncoTargets and Therapy</source><volume>10</volume><fpage>1803</fpage><lpage>1807</lpage><pub-id pub-id-type="doi">10.2147/OTT.S132508</pub-id><pub-id pub-id-type="pmid">28367063</pub-id></element-citation></ref><ref id="bib139"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ron</surname> <given-names>D</given-names></name><name><surname>Walter</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Signal integration in the endoplasmic reticulum unfolded protein response</article-title><source>Nature Reviews Molecular Cell Biology</source><volume>8</volume><fpage>519</fpage><lpage>529</lpage><pub-id pub-id-type="doi">10.1038/nrm2199</pub-id><pub-id pub-id-type="pmid">17565364</pub-id></element-citation></ref><ref id="bib140"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenzweig</surname> <given-names>R</given-names></name><name><surname>Nillegoda</surname> <given-names>NB</given-names></name><name><surname>Mayer</surname> <given-names>MP</given-names></name><name><surname>Bukau</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The Hsp70 chaperone network</article-title><source>Nature Reviews Molecular Cell Biology</source><volume>20</volume><fpage>665</fpage><lpage>680</lpage><pub-id pub-id-type="doi">10.1038/s41580-019-0133-3</pub-id><pub-id pub-id-type="pmid">31253954</pub-id></element-citation></ref><ref id="bib141"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rouschop</surname> <given-names>KM</given-names></name><name><surname>van den Beucken</surname> <given-names>T</given-names></name><name><surname>Dubois</surname> <given-names>L</given-names></name><name><surname>Niessen</surname> <given-names>H</given-names></name><name><surname>Bussink</surname> <given-names>J</given-names></name><name><surname>Savelkouls</surname> <given-names>K</given-names></name><name><surname>Keulers</surname> <given-names>T</given-names></name><name><surname>Mujcic</surname> <given-names>H</given-names></name><name><surname>Landuyt</surname> <given-names>W</given-names></name><name><surname>Voncken</surname> <given-names>JW</given-names></name><name><surname>Lambin</surname> <given-names>P</given-names></name><name><surname>van der Kogel</surname> <given-names>AJ</given-names></name><name><surname>Koritzinsky</surname> <given-names>M</given-names></name><name><surname>Wouters</surname> <given-names>BG</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>The unfolded protein response protects human tumor cells during hypoxia through regulation of the autophagy genes MAP1LC3B and ATG5</article-title><source>Journal of Clinical Investigation</source><volume>120</volume><fpage>127</fpage><lpage>141</lpage><pub-id pub-id-type="doi">10.1172/JCI40027</pub-id><pub-id pub-id-type="pmid">20038797</pub-id></element-citation></ref><ref id="bib142"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rubinsztein</surname> <given-names>DC</given-names></name><name><surname>Gestwicki</surname> <given-names>JE</given-names></name><name><surname>Murphy</surname> <given-names>LO</given-names></name><name><surname>Klionsky</surname> <given-names>DJ</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Potential therapeutic applications of autophagy</article-title><source>Nature Reviews Drug Discovery</source><volume>6</volume><fpage>304</fpage><lpage>312</lpage><pub-id pub-id-type="doi">10.1038/nrd2272</pub-id><pub-id pub-id-type="pmid">17396135</pub-id></element-citation></ref><ref id="bib143"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ryoo</surname> <given-names>HD</given-names></name><name><surname>Vasudevan</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Two distinct nodes of translational inhibition in the integrated stress response</article-title><source>BMB Reports</source><volume>50</volume><fpage>539</fpage><lpage>545</lpage><pub-id pub-id-type="doi">10.5483/BMBRep.2017.50.11.157</pub-id><pub-id pub-id-type="pmid">28803610</pub-id></element-citation></ref><ref id="bib144"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sabnis</surname> <given-names>AJ</given-names></name><name><surname>Guerriero</surname> <given-names>CJ</given-names></name><name><surname>Olivas</surname> <given-names>V</given-names></name><name><surname>Sayana</surname> <given-names>A</given-names></name><name><surname>Shue</surname> <given-names>J</given-names></name><name><surname>Flanagan</surname> <given-names>J</given-names></name><name><surname>Asthana</surname> <given-names>S</given-names></name><name><surname>Paton</surname> <given-names>AW</given-names></name><name><surname>Paton</surname> <given-names>JC</given-names></name><name><surname>Gestwicki</surname> <given-names>JE</given-names></name><name><surname>Walter</surname> <given-names>P</given-names></name><name><surname>Weissman</surname> <given-names>JS</given-names></name><name><surname>Wipf</surname> <given-names>P</given-names></name><name><surname>Brodsky</surname> <given-names>JL</given-names></name><name><surname>Bivona</surname> <given-names>TG</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Combined chemical-genetic approach identifies cytosolic HSP70 dependence in Rhabdomyosarcoma</article-title><source>PNAS</source><volume>113</volume><fpage>9015</fpage><lpage>9020</lpage><pub-id pub-id-type="doi">10.1073/pnas.1603883113</pub-id><pub-id pub-id-type="pmid">27450084</pub-id></element-citation></ref><ref id="bib145"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Samaddar</surname> <given-names>JS</given-names></name><name><surname>Gaddy</surname> <given-names>VT</given-names></name><name><surname>Duplantier</surname> <given-names>J</given-names></name><name><surname>Thandavan</surname> <given-names>SP</given-names></name><name><surname>Shah</surname> <given-names>M</given-names></name><name><surname>Smith</surname> <given-names>MJ</given-names></name><name><surname>Browning</surname> <given-names>D</given-names></name><name><surname>Rawson</surname> <given-names>J</given-names></name><name><surname>Smith</surname> <given-names>SB</given-names></name><name><surname>Barrett</surname> <given-names>JT</given-names></name><name><surname>Schoenlein</surname> <given-names>PV</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>A role for macroautophagy in protection against 4-hydroxytamoxifen-induced cell death and the development of antiestrogen resistance</article-title><source>Molecular Cancer Therapeutics</source><volume>7</volume><fpage>2977</fpage><lpage>2987</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-08-0447</pub-id><pub-id pub-id-type="pmid">18790778</pub-id></element-citation></ref><ref id="bib146"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sannino</surname> <given-names>S</given-names></name><name><surname>Guerriero</surname> <given-names>CJ</given-names></name><name><surname>Sabnis</surname> <given-names>AJ</given-names></name><name><surname>Stolz</surname> <given-names>DB</given-names></name><name><surname>Wallace</surname> <given-names>CT</given-names></name><name><surname>Wipf</surname> <given-names>P</given-names></name><name><surname>Watkins</surname> <given-names>SC</given-names></name><name><surname>Bivona</surname> <given-names>TG</given-names></name><name><surname>Brodsky</surname> <given-names>JL</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Compensatory increases of select proteostasis networks after Hsp70 inhibition in Cancer cells</article-title><source>Journal of Cell Science</source><volume>131</volume><elocation-id>jcs217760</elocation-id><pub-id pub-id-type="doi">10.1242/jcs.217760</pub-id><pub-id pub-id-type="pmid">30131440</pub-id></element-citation></ref><ref id="bib147"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sannino</surname> <given-names>S</given-names></name><name><surname>Brodsky</surname> <given-names>JL</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Targeting protein quality control pathways in breast cancer</article-title><source>BMC Biology</source><volume>15</volume><elocation-id>109</elocation-id><pub-id pub-id-type="doi">10.1186/s12915-017-0449-4</pub-id><pub-id pub-id-type="pmid">29145850</pub-id></element-citation></ref><ref id="bib148"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schoenlein</surname> <given-names>PV</given-names></name><name><surname>Periyasamy-Thandavan</surname> <given-names>S</given-names></name><name><surname>Samaddar</surname> <given-names>JS</given-names></name><name><surname>Jackson</surname> <given-names>WH</given-names></name><name><surname>Barrett</surname> <given-names>JT</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Autophagy facilitates the progression of ERα-positive breast cancer cells to antiestrogen resistance</article-title><source>Autophagy</source><volume>5</volume><fpage>400</fpage><lpage>403</lpage><pub-id pub-id-type="doi">10.4161/auto.5.3.7784</pub-id></element-citation></ref><ref id="bib149"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schönthal</surname> <given-names>AH</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Endoplasmic reticulum stress: its role in disease and novel prospects for therapy</article-title><source>Scientifica</source><volume>2012</volume><elocation-id>857516</elocation-id><pub-id pub-id-type="doi">10.6064/2012/857516</pub-id><pub-id pub-id-type="pmid">24278747</pub-id></element-citation></ref><ref id="bib150"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schopf</surname> <given-names>FH</given-names></name><name><surname>Biebl</surname> <given-names>MM</given-names></name><name><surname>Buchner</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>The HSP90 chaperone machinery</article-title><source>Nature Reviews Molecular Cell Biology</source><volume>18</volume><fpage>345</fpage><lpage>360</lpage><pub-id pub-id-type="doi">10.1038/nrm.2017.20</pub-id><pub-id pub-id-type="pmid">28429788</pub-id></element-citation></ref><ref id="bib151"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schulte</surname> <given-names>TW</given-names></name><name><surname>Neckers</surname> <given-names>LM</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin</article-title><source>Cancer Chemotherapy and Pharmacology</source><volume>42</volume><fpage>273</fpage><lpage>279</lpage><pub-id pub-id-type="doi">10.1007/s002800050817</pub-id><pub-id pub-id-type="pmid">9744771</pub-id></element-citation></ref><ref id="bib152"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharifi</surname> <given-names>MN</given-names></name><name><surname>Mowers</surname> <given-names>EE</given-names></name><name><surname>Drake</surname> <given-names>LE</given-names></name><name><surname>Collier</surname> <given-names>C</given-names></name><name><surname>Chen</surname> <given-names>H</given-names></name><name><surname>Zamora</surname> <given-names>M</given-names></name><name><surname>Mui</surname> <given-names>S</given-names></name><name><surname>Macleod</surname> <given-names>KF</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Autophagy promotes focal adhesion disassembly and cell motility of metastatic tumor cells through the direct interaction of paxillin with LC3</article-title><source>Cell Reports</source><volume>15</volume><fpage>1660</fpage><lpage>1672</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2016.04.065</pub-id><pub-id pub-id-type="pmid">27184837</pub-id></element-citation></ref><ref id="bib153"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname> <given-names>J</given-names></name><name><surname>Chen</surname> <given-names>X</given-names></name><name><surname>Hendershot</surname> <given-names>L</given-names></name><name><surname>Prywes</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>ER stress regulation of ATF6 localization by dissociation of BiP/GRP78 binding and unmasking of golgi localization signals</article-title><source>Developmental Cell</source><volume>3</volume><fpage>99</fpage><lpage>111</lpage><pub-id pub-id-type="doi">10.1016/S1534-5807(02)00203-4</pub-id><pub-id pub-id-type="pmid">12110171</pub-id></element-citation></ref><ref id="bib154"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname> <given-names>TT</given-names></name><name><surname>Yu</surname> <given-names>XX</given-names></name><name><surname>Yan</surname> <given-names>LJ</given-names></name><name><surname>Xiao</surname> <given-names>HT</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Research progress of hydroxychloroquine and autophagy inhibitors on cancer</article-title><source>Cancer Chemotherapy and Pharmacology</source><volume>79</volume><fpage>287</fpage><lpage>294</lpage><pub-id pub-id-type="doi">10.1007/s00280-016-3197-1</pub-id><pub-id pub-id-type="pmid">27889812</pub-id></element-citation></ref><ref id="bib155"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname> <given-names>WZ</given-names></name><name><surname>Tian</surname> <given-names>Y</given-names></name><name><surname>Li</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>GCN2 suppression attenuates cerebral ischemia in mice by reducing apoptosis and endoplasmic reticulum (ER) stress through the blockage of FoxO3a-regulated ROS production</article-title><source>Biochemical and Biophysical Research Communications</source><volume>516</volume><fpage>285</fpage><lpage>292</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2019.05.181</pub-id><pub-id pub-id-type="pmid">31255283</pub-id></element-citation></ref><ref id="bib156"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sidrauski</surname> <given-names>C</given-names></name><name><surname>McGeachy</surname> <given-names>AM</given-names></name><name><surname>Ingolia</surname> <given-names>NT</given-names></name><name><surname>Walter</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The small molecule ISRIB reverses the effects of eIF2α phosphorylation on translation and stress granule assembly</article-title><source>eLife</source><volume>4</volume><elocation-id>e05033</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.05033</pub-id><pub-id pub-id-type="pmid">25719440</pub-id></element-citation></ref><ref id="bib157"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname> <given-names>N</given-names></name><name><surname>Joshi</surname> <given-names>R</given-names></name><name><surname>Komurov</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>HER2-mTOR signaling-driven breast cancer cells require ER-associated degradation to survive</article-title><source>Science Signaling</source><volume>8</volume><elocation-id>ra52</elocation-id><pub-id pub-id-type="doi">10.1126/scisignal.aaa6922</pub-id><pub-id pub-id-type="pmid">26012635</pub-id></element-citation></ref><ref id="bib158"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname> <given-names>A</given-names></name><name><surname>Vashistha</surname> <given-names>N</given-names></name><name><surname>Heck</surname> <given-names>J</given-names></name><name><surname>Tang</surname> <given-names>X</given-names></name><name><surname>Wipf</surname> <given-names>P</given-names></name><name><surname>Brodsky</surname> <given-names>JL</given-names></name><name><surname>Hampton</surname> <given-names>RY</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Direct involvement of Hsp70 ATP hydrolysis in Ubr1-dependent quality control</article-title><source>Molecular Biology of the Cell</source><volume>31</volume><fpage>2669</fpage><lpage>2686</lpage><pub-id pub-id-type="doi">10.1091/mbc.E20-08-0541</pub-id><pub-id pub-id-type="pmid">32966159</pub-id></element-citation></ref><ref id="bib159"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname> <given-names>MH</given-names></name><name><surname>Ploegh</surname> <given-names>HL</given-names></name><name><surname>Weissman</surname> <given-names>JS</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Road to ruin: targeting proteins for degradation in the endoplasmic reticulum</article-title><source>Science</source><volume>334</volume><fpage>1086</fpage><lpage>1090</lpage><pub-id pub-id-type="doi">10.1126/science.1209235</pub-id><pub-id pub-id-type="pmid">22116878</pub-id></element-citation></ref><ref id="bib160"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soneson</surname> <given-names>C</given-names></name><name><surname>Love</surname> <given-names>MI</given-names></name><name><surname>Robinson</surname> <given-names>MD</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Differential analyses for RNA-seq: transcript-level estimates improve gene-level inferences</article-title><source>F1000Research</source><volume>4</volume><elocation-id>1521</elocation-id><pub-id pub-id-type="doi">10.12688/f1000research.7563.1</pub-id><pub-id pub-id-type="pmid">26925227</pub-id></element-citation></ref><ref id="bib161"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stein</surname> <given-names>RL</given-names></name><name><surname>Melandri</surname> <given-names>F</given-names></name><name><surname>Dick</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Kinetic characterization of the chymotryptic activity of the 20S proteasome</article-title><source>Biochemistry</source><volume>35</volume><fpage>3899</fpage><lpage>3908</lpage><pub-id pub-id-type="doi">10.1021/bi952262x</pub-id><pub-id pub-id-type="pmid">8672420</pub-id></element-citation></ref><ref id="bib162"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strømhaug</surname> <given-names>PE</given-names></name><name><surname>Reggiori</surname> <given-names>F</given-names></name><name><surname>Guan</surname> <given-names>J</given-names></name><name><surname>Wang</surname> <given-names>CW</given-names></name><name><surname>Klionsky</surname> <given-names>DJ</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Atg21 is a phosphoinositide binding protein required for efficient lipidation and localization of Atg8 during uptake of aminopeptidase I by selective autophagy</article-title><source>Molecular Biology of the Cell</source><volume>15</volume><fpage>3553</fpage><lpage>3566</lpage><pub-id pub-id-type="doi">10.1091/mbc.e04-02-0147</pub-id><pub-id pub-id-type="pmid">15155809</pub-id></element-citation></ref><ref id="bib163"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sui</surname> <given-names>X</given-names></name><name><surname>Chen</surname> <given-names>R</given-names></name><name><surname>Wang</surname> <given-names>Z</given-names></name><name><surname>Huang</surname> <given-names>Z</given-names></name><name><surname>Kong</surname> <given-names>N</given-names></name><name><surname>Zhang</surname> <given-names>M</given-names></name><name><surname>Han</surname> <given-names>W</given-names></name><name><surname>Lou</surname> <given-names>F</given-names></name><name><surname>Yang</surname> <given-names>J</given-names></name><name><surname>Zhang</surname> <given-names>Q</given-names></name><name><surname>Wang</surname> <given-names>X</given-names></name><name><surname>He</surname> <given-names>C</given-names></name><name><surname>Pan</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment</article-title><source>Cell Death &amp; Disease</source><volume>4</volume><elocation-id>e838</elocation-id><pub-id pub-id-type="doi">10.1038/cddis.2013.350</pub-id><pub-id pub-id-type="pmid">24113172</pub-id></element-citation></ref><ref id="bib164"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname> <given-names>B</given-names></name><name><surname>Zhang</surname> <given-names>S</given-names></name><name><surname>Zhang</surname> <given-names>D</given-names></name><name><surname>Li</surname> <given-names>Y</given-names></name><name><surname>Zhao</surname> <given-names>X</given-names></name><name><surname>Luo</surname> <given-names>Y</given-names></name><name><surname>Guo</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Identification of metastasis-related proteins and their clinical relevance to triple-negative human breast cancer</article-title><source>Clinical Cancer Research</source><volume>14</volume><fpage>7050</fpage><lpage>7059</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-08-0520</pub-id><pub-id pub-id-type="pmid">18981002</pub-id></element-citation></ref><ref id="bib165"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taldone</surname> <given-names>T</given-names></name><name><surname>Sun</surname> <given-names>W</given-names></name><name><surname>Chiosis</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Discovery and development of heat shock protein 90 inhibitors</article-title><source>Bioorganic &amp; Medicinal Chemistry</source><volume>17</volume><fpage>2225</fpage><lpage>2235</lpage><pub-id pub-id-type="doi">10.1016/j.bmc.2008.10.087</pub-id><pub-id pub-id-type="pmid">19017562</pub-id></element-citation></ref><ref id="bib166"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname> <given-names>Y</given-names></name><name><surname>Shi</surname> <given-names>G</given-names></name><name><surname>Yang</surname> <given-names>J</given-names></name><name><surname>Zheng</surname> <given-names>W</given-names></name><name><surname>Tang</surname> <given-names>J</given-names></name><name><surname>Chen</surname> <given-names>XZ</given-names></name><name><surname>Yang</surname> <given-names>J</given-names></name><name><surname>Wang</surname> <given-names>Z</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Role of PKR in the inhibition of proliferation and translation by polycystin-1</article-title><source>BioMed Research International</source><volume>2019</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1155/2019/5320747</pub-id><pub-id pub-id-type="pmid">31341901</pub-id></element-citation></ref><ref id="bib167"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Theodorakis</surname> <given-names>NG</given-names></name><name><surname>Morimoto</surname> <given-names>RI</given-names></name></person-group><year iso-8601-date="1987">1987</year><article-title>Posttranscriptional regulation of hsp70 expression in human cells: effects of heat shock, inhibition of protein synthesis, and adenovirus infection on translation and mRNA stability</article-title><source>Molecular and Cellular Biology</source><volume>7</volume><fpage>4357</fpage><lpage>4368</lpage><pub-id pub-id-type="doi">10.1128/MCB.7.12.4357</pub-id><pub-id pub-id-type="pmid">3437893</pub-id></element-citation></ref><ref id="bib168"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Towers</surname> <given-names>CG</given-names></name><name><surname>Thorburn</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Therapeutic targeting of autophagy</article-title><source>EBioMedicine</source><volume>14</volume><fpage>15</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1016/j.ebiom.2016.10.034</pub-id><pub-id pub-id-type="pmid">28029600</pub-id></element-citation></ref><ref id="bib169"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tracey</surname> <given-names>N</given-names></name><name><surname>Creedon</surname> <given-names>H</given-names></name><name><surname>Kemp</surname> <given-names>AJ</given-names></name><name><surname>Culley</surname> <given-names>J</given-names></name><name><surname>Muir</surname> <given-names>M</given-names></name><name><surname>Klinowska</surname> <given-names>T</given-names></name><name><surname>Brunton</surname> <given-names>VG</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>HO-1 drives autophagy as a mechanism of resistance against HER2-targeted therapies</article-title><source>Breast Cancer Research and Treatment</source><volume>179</volume><fpage>543</fpage><lpage>555</lpage><pub-id pub-id-type="doi">10.1007/s10549-019-05489-1</pub-id><pub-id pub-id-type="pmid">31705351</pub-id></element-citation></ref><ref id="bib170"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Travers</surname> <given-names>KJ</given-names></name><name><surname>Patil</surname> <given-names>CK</given-names></name><name><surname>Wodicka</surname> <given-names>L</given-names></name><name><surname>Lockhart</surname> <given-names>DJ</given-names></name><name><surname>Weissman</surname> <given-names>JS</given-names></name><name><surname>Walter</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Functional and genomic analyses reveal an essential coordination between the unfolded protein response and ER-associated degradation</article-title><source>Cell</source><volume>101</volume><fpage>249</fpage><lpage>258</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(00)80835-1</pub-id><pub-id pub-id-type="pmid">10847680</pub-id></element-citation></ref><ref id="bib171"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsai</surname> <given-names>YC</given-names></name><name><surname>Weissman</surname> <given-names>AM</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Ubiquitylation in ERAD: reversing to go forward?</article-title><source>PLOS Biology</source><volume>9</volume><elocation-id>e1001038</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pbio.1001038</pub-id><pub-id pub-id-type="pmid">21468305</pub-id></element-citation></ref><ref id="bib172"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turner</surname> <given-names>C</given-names></name><name><surname>Devitt</surname> <given-names>A</given-names></name><name><surname>Parker</surname> <given-names>K</given-names></name><name><surname>MacFarlane</surname> <given-names>M</given-names></name><name><surname>Giuliano</surname> <given-names>M</given-names></name><name><surname>Cohen</surname> <given-names>GM</given-names></name><name><surname>Gregory</surname> <given-names>CD</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Macrophage-mediated clearance of cells undergoing caspase-3-independent death</article-title><source>Cell Death &amp; Differentiation</source><volume>10</volume><fpage>302</fpage><lpage>312</lpage><pub-id pub-id-type="doi">10.1038/sj.cdd.4401170</pub-id><pub-id pub-id-type="pmid">12700630</pub-id></element-citation></ref><ref id="bib173"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vargas-Roig</surname> <given-names>LM</given-names></name><name><surname>Gago</surname> <given-names>FE</given-names></name><name><surname>Tello</surname> <given-names>O</given-names></name><name><surname>Aznar</surname> <given-names>JC</given-names></name><name><surname>Ciocca</surname> <given-names>DR</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Heat shock protein expression and drug resistance in breast cancer patients treated with induction chemotherapy</article-title><source>International Journal of Cancer</source><volume>79</volume><fpage>468</fpage><lpage>475</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1097-0215(19981023)79:5&lt;468::AID-IJC4&gt;3.0.CO;2-Z</pub-id><pub-id pub-id-type="pmid">9761114</pub-id></element-citation></ref><ref id="bib174"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vazquez-Martin</surname> <given-names>A</given-names></name><name><surname>Oliveras-Ferraros</surname> <given-names>C</given-names></name><name><surname>Menendez</surname> <given-names>JA</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Autophagy facilitates the development of breast cancer resistance to the anti-HER2 monoclonal antibody trastuzumab</article-title><source>PLOS ONE</source><volume>4</volume><elocation-id>e6251</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0006251</pub-id><pub-id pub-id-type="pmid">19606230</pub-id></element-citation></ref><ref id="bib175"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vermes</surname> <given-names>I</given-names></name><name><surname>Haanen</surname> <given-names>C</given-names></name><name><surname>Steffens-Nakken</surname> <given-names>H</given-names></name><name><surname>Reutelingsperger</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>A novel assay for apoptosis. flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled annexin V</article-title><source>Journal of Immunological Methods</source><volume>184</volume><fpage>39</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1016/0022-1759(95)00072-I</pub-id><pub-id pub-id-type="pmid">7622868</pub-id></element-citation></ref><ref id="bib176"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walter</surname> <given-names>P</given-names></name><name><surname>Ron</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>The unfolded protein response: from stress pathway to homeostatic regulation</article-title><source>Science</source><volume>334</volume><fpage>1081</fpage><lpage>1086</lpage><pub-id pub-id-type="doi">10.1126/science.1209038</pub-id><pub-id pub-id-type="pmid">22116877</pub-id></element-citation></ref><ref id="bib177"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>M</given-names></name><name><surname>Kaufman</surname> <given-names>RJ</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>The impact of the endoplasmic reticulum protein-folding environment on cancer development</article-title><source>Nature Reviews Cancer</source><volume>14</volume><fpage>581</fpage><lpage>597</lpage><pub-id pub-id-type="doi">10.1038/nrc3800</pub-id><pub-id pub-id-type="pmid">25145482</pub-id></element-citation></ref><ref id="bib178"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wek</surname> <given-names>RC</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Role of eIF2α kinases in translational control and adaptation to cellular stress</article-title><source>Cold Spring Harbor Perspectives in Biology</source><volume>10</volume><elocation-id>a032870</elocation-id><pub-id pub-id-type="doi">10.1101/cshperspect.a032870</pub-id><pub-id pub-id-type="pmid">29440070</pub-id></element-citation></ref><ref id="bib179"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wek</surname> <given-names>RC</given-names></name><name><surname>Cavener</surname> <given-names>DR</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Translational control and the unfolded protein response</article-title><source>Antioxidants &amp; Redox Signaling</source><volume>9</volume><fpage>2357</fpage><lpage>2372</lpage><pub-id pub-id-type="doi">10.1089/ars.2007.1764</pub-id><pub-id pub-id-type="pmid">17760508</pub-id></element-citation></ref><ref id="bib180"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>White</surname> <given-names>MC</given-names></name><name><surname>Schroeder</surname> <given-names>RD</given-names></name><name><surname>Zhu</surname> <given-names>K</given-names></name><name><surname>Xiong</surname> <given-names>K</given-names></name><name><surname>McConkey</surname> <given-names>DJ</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>HRI-mediated translational repression reduces proteotoxicity and sensitivity to bortezomib in human pancreatic cancer cells</article-title><source>Oncogene</source><volume>37</volume><fpage>4413</fpage><lpage>4427</lpage><pub-id pub-id-type="doi">10.1038/s41388-018-0227-y</pub-id><pub-id pub-id-type="pmid">29720726</pub-id></element-citation></ref><ref id="bib181"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whitesell</surname> <given-names>L</given-names></name><name><surname>Lindquist</surname> <given-names>SL</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>HSP90 and the chaperoning of cancer</article-title><source>Nature Reviews Cancer</source><volume>5</volume><fpage>761</fpage><lpage>772</lpage><pub-id pub-id-type="doi">10.1038/nrc1716</pub-id><pub-id pub-id-type="pmid">16175177</pub-id></element-citation></ref><ref id="bib182"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname> <given-names>BR</given-names></name><name><surname>Amon</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Aneuploidy: cancer's fatal flaw?</article-title><source>Cancer Research</source><volume>69</volume><fpage>5289</fpage><lpage>5291</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-09-0944</pub-id><pub-id pub-id-type="pmid">19549887</pub-id></element-citation></ref><ref id="bib183"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wisén</surname> <given-names>S</given-names></name><name><surname>Bertelsen</surname> <given-names>EB</given-names></name><name><surname>Thompson</surname> <given-names>AD</given-names></name><name><surname>Patury</surname> <given-names>S</given-names></name><name><surname>Ung</surname> <given-names>P</given-names></name><name><surname>Chang</surname> <given-names>L</given-names></name><name><surname>Evans</surname> <given-names>CG</given-names></name><name><surname>Walter</surname> <given-names>GM</given-names></name><name><surname>Wipf</surname> <given-names>P</given-names></name><name><surname>Carlson</surname> <given-names>HA</given-names></name><name><surname>Brodsky</surname> <given-names>JL</given-names></name><name><surname>Zuiderweg</surname> <given-names>ER</given-names></name><name><surname>Gestwicki</surname> <given-names>JE</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Binding of a small molecule at a protein-protein interface regulates the chaperone activity of hsp70-hsp40</article-title><source>ACS Chemical Biology</source><volume>5</volume><fpage>611</fpage><lpage>622</lpage><pub-id pub-id-type="doi">10.1021/cb1000422</pub-id><pub-id pub-id-type="pmid">20481474</pub-id></element-citation></ref><ref id="bib184"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wojcik</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Crosstalk between autophagy and proteasome protein degradation systems: possible implications for cancer therapy</article-title><source>Folia Histochemica Et Cytobiologica</source><volume>51</volume><fpage>249</fpage><lpage>264</lpage><pub-id pub-id-type="doi">10.5603/FHC.2013.0036</pub-id><pub-id pub-id-type="pmid">24497130</pub-id></element-citation></ref><ref id="bib185"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname> <given-names>W</given-names></name><name><surname>Yuan</surname> <given-names>X</given-names></name><name><surname>Xiang</surname> <given-names>Z</given-names></name><name><surname>Mimnaugh</surname> <given-names>E</given-names></name><name><surname>Marcu</surname> <given-names>M</given-names></name><name><surname>Neckers</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Surface charge and hydrophobicity determine ErbB2 binding to the Hsp90 chaperone complex</article-title><source>Nature Structural &amp; Molecular Biology</source><volume>12</volume><fpage>120</fpage><lpage>126</lpage><pub-id pub-id-type="doi">10.1038/nsmb885</pub-id><pub-id pub-id-type="pmid">15643424</pub-id></element-citation></ref><ref id="bib186"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname> <given-names>MM</given-names></name><name><surname>Ni</surname> <given-names>JD</given-names></name><name><surname>Song</surname> <given-names>D</given-names></name><name><surname>Ding</surname> <given-names>M</given-names></name><name><surname>Huang</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Interplay between unfolded protein response and autophagy promotes tumor drug resistance</article-title><source>Oncology Letters</source><volume>10</volume><fpage>1959</fpage><lpage>1969</lpage><pub-id pub-id-type="doi">10.3892/ol.2015.3508</pub-id><pub-id pub-id-type="pmid">26622781</pub-id></element-citation></ref><ref id="bib187"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname> <given-names>J</given-names></name><name><surname>Kumanova</surname> <given-names>M</given-names></name><name><surname>Hart</surname> <given-names>LS</given-names></name><name><surname>Sloane</surname> <given-names>K</given-names></name><name><surname>Zhang</surname> <given-names>H</given-names></name><name><surname>De Panis</surname> <given-names>DN</given-names></name><name><surname>Bobrovnikova-Marjon</surname> <given-names>E</given-names></name><name><surname>Diehl</surname> <given-names>JA</given-names></name><name><surname>Ron</surname> <given-names>D</given-names></name><name><surname>Koumenis</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>The GCN2-ATF4 pathway is critical for tumour cell survival and proliferation in response to nutrient deprivation</article-title><source>The EMBO Journal</source><volume>29</volume><fpage>2082</fpage><lpage>2096</lpage><pub-id pub-id-type="doi">10.1038/emboj.2010.81</pub-id><pub-id pub-id-type="pmid">20473272</pub-id></element-citation></ref><ref id="bib188"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname> <given-names>J</given-names></name><name><surname>Palm</surname> <given-names>W</given-names></name><name><surname>Peng</surname> <given-names>M</given-names></name><name><surname>King</surname> <given-names>B</given-names></name><name><surname>Lindsten</surname> <given-names>T</given-names></name><name><surname>Li</surname> <given-names>MO</given-names></name><name><surname>Koumenis</surname> <given-names>C</given-names></name><name><surname>Thompson</surname> <given-names>CB</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>GCN2 sustains mTORC1 suppression upon amino acid deprivation by inducing Sestrin2</article-title><source>Genes &amp; Development</source><volume>29</volume><fpage>2331</fpage><lpage>2336</lpage><pub-id pub-id-type="doi">10.1101/gad.269324.115</pub-id><pub-id pub-id-type="pmid">26543160</pub-id></element-citation></ref><ref id="bib189"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshida</surname> <given-names>H</given-names></name><name><surname>Matsui</surname> <given-names>T</given-names></name><name><surname>Yamamoto</surname> <given-names>A</given-names></name><name><surname>Okada</surname> <given-names>T</given-names></name><name><surname>Mori</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2001">2001a</year><article-title>XBP1 mRNA is induced by ATF6 and spliced by IRE1 in response to ER stress to produce a highly active transcription factor</article-title><source>Cell</source><volume>107</volume><fpage>881</fpage><lpage>891</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(01)00611-0</pub-id><pub-id pub-id-type="pmid">11779464</pub-id></element-citation></ref><ref id="bib190"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshida</surname> <given-names>H</given-names></name><name><surname>Okada</surname> <given-names>T</given-names></name><name><surname>Haze</surname> <given-names>K</given-names></name><name><surname>Yanagi</surname> <given-names>H</given-names></name><name><surname>Yura</surname> <given-names>T</given-names></name><name><surname>Negishi</surname> <given-names>M</given-names></name><name><surname>Mori</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2001">2001b</year><article-title>Endoplasmic reticulum stress-induced formation of transcription factor complex ERSF including NF-Y (CBF) and activating transcription factors 6alpha and 6beta that activates the mammalian unfolded protein response</article-title><source>Molecular and Cellular Biology</source><volume>21</volume><fpage>1239</fpage><lpage>1248</lpage><pub-id pub-id-type="doi">10.1128/MCB.21.4.1239-1248.2001</pub-id><pub-id pub-id-type="pmid">11158310</pub-id></element-citation></ref><ref id="bib191"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname> <given-names>G</given-names></name><name><surname>Wang</surname> <given-names>LG</given-names></name><name><surname>Han</surname> <given-names>Y</given-names></name><name><surname>He</surname> <given-names>QY</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>clusterProfiler: an R package for comparing biological themes among gene clusters</article-title><source>OMICS: A Journal of Integrative Biology</source><volume>16</volume><fpage>284</fpage><lpage>287</lpage><pub-id pub-id-type="doi">10.1089/omi.2011.0118</pub-id><pub-id pub-id-type="pmid">22455463</pub-id></element-citation></ref><ref id="bib192"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zambrano</surname> <given-names>J</given-names></name><name><surname>Yeh</surname> <given-names>ES</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Autophagy and apoptotic crosstalk: mechanism of therapeutic resistance in HER2-Positive breast cancer</article-title><source>Breast Cancer : Basic and Clinical Research</source><volume>10</volume><fpage>13</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.4137/BCBCR.S32791</pub-id><pub-id pub-id-type="pmid">26997868</pub-id></element-citation></ref><ref id="bib193"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>Z</given-names></name><name><surname>Singh</surname> <given-names>R</given-names></name><name><surname>Aschner</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Methods for the detection of autophagy in mammalian cells</article-title><source>Current Protocols in Toxicology</source><volume>69</volume><fpage>20.12.1</fpage><lpage>20.1220</lpage><pub-id pub-id-type="doi">10.1002/cptx.11</pub-id><pub-id pub-id-type="pmid">27479363</pub-id></element-citation></ref><ref id="bib194"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>S</given-names></name><name><surname>Macias-Garcia</surname> <given-names>A</given-names></name><name><surname>Ulirsch</surname> <given-names>JC</given-names></name><name><surname>Velazquez</surname> <given-names>J</given-names></name><name><surname>Butty</surname> <given-names>VL</given-names></name><name><surname>Levine</surname> <given-names>SS</given-names></name><name><surname>Sankaran</surname> <given-names>VG</given-names></name><name><surname>Chen</surname> <given-names>JJ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>HRI coordinates translation necessary for protein homeostasis and mitochondrial function in erythropoiesis</article-title><source>eLife</source><volume>8</volume><elocation-id>e46976</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.46976</pub-id><pub-id pub-id-type="pmid">31033440</pub-id></element-citation></ref><ref id="bib195"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname> <given-names>HJ</given-names></name><name><surname>Wang</surname> <given-names>J</given-names></name><name><surname>Yao</surname> <given-names>B</given-names></name><name><surname>Wong</surname> <given-names>S</given-names></name><name><surname>Djakovic</surname> <given-names>S</given-names></name><name><surname>Kumar</surname> <given-names>B</given-names></name><name><surname>Rice</surname> <given-names>J</given-names></name><name><surname>Valle</surname> <given-names>E</given-names></name><name><surname>Soriano</surname> <given-names>F</given-names></name><name><surname>Menon</surname> <given-names>MK</given-names></name><name><surname>Madriaga</surname> <given-names>A</given-names></name><name><surname>Kiss von Soly</surname> <given-names>S</given-names></name><name><surname>Kumar</surname> <given-names>A</given-names></name><name><surname>Parlati</surname> <given-names>F</given-names></name><name><surname>Yakes</surname> <given-names>FM</given-names></name><name><surname>Shawver</surname> <given-names>L</given-names></name><name><surname>Le Moigne</surname> <given-names>R</given-names></name><name><surname>Anderson</surname> <given-names>DJ</given-names></name><name><surname>Rolfe</surname> <given-names>M</given-names></name><name><surname>Wustrow</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Discovery of a First-in-Class, potent, selective, and orally bioavailable inhibitor of the p97 AAA ATPase (CB-5083)</article-title><source>Journal of Medicinal Chemistry</source><volume>58</volume><fpage>9480</fpage><lpage>9497</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.5b01346</pub-id><pub-id pub-id-type="pmid">26565666</pub-id></element-citation></ref><ref id="bib196"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname> <given-names>PJ</given-names></name><name><surname>Khatiwada</surname> <given-names>S</given-names></name><name><surname>Cui</surname> <given-names>Y</given-names></name><name><surname>Reineke</surname> <given-names>LC</given-names></name><name><surname>Dooling</surname> <given-names>SW</given-names></name><name><surname>Kim</surname> <given-names>JJ</given-names></name><name><surname>Li</surname> <given-names>W</given-names></name><name><surname>Walter</surname> <given-names>P</given-names></name><name><surname>Costa-Mattioli</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Activation of the ISR mediates the behavioral and neurophysiological abnormalities in down syndrome</article-title><source>Science</source><volume>366</volume><fpage>843</fpage><lpage>849</lpage><pub-id pub-id-type="doi">10.1126/science.aaw5185</pub-id><pub-id pub-id-type="pmid">31727829</pub-id></element-citation></ref><ref id="bib197"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zyryanova</surname> <given-names>AF</given-names></name><name><surname>Weis</surname> <given-names>F</given-names></name><name><surname>Faille</surname> <given-names>A</given-names></name><name><surname>Alard</surname> <given-names>AA</given-names></name><name><surname>Crespillo-Casado</surname> <given-names>A</given-names></name><name><surname>Sekine</surname> <given-names>Y</given-names></name><name><surname>Harding</surname> <given-names>HP</given-names></name><name><surname>Allen</surname> <given-names>F</given-names></name><name><surname>Parts</surname> <given-names>L</given-names></name><name><surname>Fromont</surname> <given-names>C</given-names></name><name><surname>Fischer</surname> <given-names>PM</given-names></name><name><surname>Warren</surname> <given-names>AJ</given-names></name><name><surname>Ron</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Binding of ISRIB reveals a regulatory site in the nucleotide exchange factor eIF2B</article-title><source>Science</source><volume>359</volume><fpage>1533</fpage><lpage>1536</lpage><pub-id pub-id-type="doi">10.1126/science.aar5129</pub-id><pub-id pub-id-type="pmid">29599245</pub-id></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.64977.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Hartl</surname><given-names>Franz-Ulrich</given-names></name><role>Reviewing Editor</role><aff><institution>Max Planck Institute for Biochemistry</institution><country>Germany</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.</p></boxed-text><p><bold>Acceptance summary:</bold></p><p>This study systematically explored the response of breast cancer cells to proteotoxic challenges induced by inhibition of the chaperone Hsp70. Interestingly, resistance to Hsp70 inhibition correlated with high levels of autophagy and required the integrated stress response transducer GCN2 that is typically associated with amino acid starvation. In contrast, sensitivity to Hsp70 inhibition was mediated by activation of stress signaling via PERK. Based on these results, future studies can be designed to provide further insight into how cancer cells achieve resistance to proteotoxic stress.</p><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Unique integrated stress response sensors regulate cancer cell susceptibility when Hsp70 activity is compromised&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 3 peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Maureen Murphy as the Senior Editor. The reviewers have opted to remain anonymous.</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>The referees find your work interesting and recommend publication after appropriate revisions. All three reviewers agreed that additional mechanistic studies would significantly improve the manuscript (and make it acceptable for publication).</p><p>While the authors have performed numerous experiments to define the protein homeostasis remodeling associated with MAL3-101 sensitivity in breast cancer cell lines, further experiments are necessary regarding the conclusion that sensitive and resistant cells are differentially dependent on GCN2 and PERK for dictating survival or apoptosis. Although the idea that GCN2 and PERK (or other ISR kinases) can initiate distinct signaling in response to different types of insults is not new, this work does organize this idea in a defined way and adds new results that can continue to inform that area of study. The key question is how does ISR signaling through PERK and GCN2 integrate with other functional inputs to dictate distinct cellular responses. This is likely achieved through mechanisms including the posttranslational modification of different downstream transcriptional regulators, integration of ISR signaling with other stress-responsive signaling pathways, or through heterooligomerization of ISR transcription factors with other inputs (e.g., heterooligomerization of ATF4 with other b-ZIP transcription factors). The authors are in a unique position to address these questions, but ultimately, they are not pursued in this manuscript.</p><p>Essential revisions:</p><p>1. One interesting question emerging from this study is: What are the other inputs for resistant and sensitive cells that differentially alter ISR signaling outputs in these two models? This could be addressed by performing RNAseq of resistant or sensitive cells treated with Mal3-101 with or without depletion of Gcn2 or Perk. This would provide a better framework to interpret the differential ISR signaling between these two types of cell lines and likely reveal other signaling mechanism that serve as modulators of ISR signaling.</p><p>2. There are publicly available transcriptional profiles of many of these breast cancer cell lines, so a clustering analysis might reveal the patterns of transcription that define the sensitivity groups, shedding light on potential mechanisms in an unbiased way. Does sensitivity correlate to known driver oncogenes? Drug efflux protein expression? Amino acid transporters? Metabolism? Translation control machinery? More colloquially – the classical breast cancer categorization subtype (e.g. TNBC, luminal, HER2) do not correlate with Hsp70 inhibitor sensitivity, so what does at a molecular level? Similarly, the authors also systematically examined resistance to the Hsp90 inhibitor, 17-AAG, so a parallel analysis of transcriptional profiles could provide further insight into the similarities and differences.</p><p>3. Is GCN2 activation necessary/sufficient for Hsp70 inhibitor resistance. Does over-expression of GCN2 drive resistance in an otherwise sensitive cell type? How about amino acid starvation? mTor inhibitor? It seems likely that the story could be more complex, but a specific test would be informative either way.</p><p>Other comments:</p><p>1. The MAL3-101 compound has been reported previously, but considering the way it is used, it would be good to have a statement up front in the text about its selectivity and known engagement of different HSP70s. Which ones it hits, EC50, etc. For example, the potential for this compound to target BiP?. What about mitochondrial HSP70? This is addressed in the results and discussion, but it would be good to include this more clearly in the intro.</p><p>2. The differential activation of PERK and GCN2 in sensitive and resistant cells should be demonstrated more directly. For example, a phosphor-PERK and phosphor-GCN2 assay to show increased activity of these two eIF2a kinases should be done.</p><p>3) Overall, the paper appears too long and results seem a bit scattered across the many chapters/figures. Combining some data to focus on key messages would be very helpful.</p><p>4) Line 349: Please correct HSPSA5 to HSPA5.</p><p>5) Please correct protein/gene nomenclature for clarity (capitalized for human, e.g. lines 352-361).</p><p>6) The increase in ubiquitinated proteins upon proteasome inhibition may still be proteasome dependent. The capacity of the proteasome is sufficient for the higher loads and differences could be explained by e.g. increased E3-Ligase activity. Particularly in the light of the finding that bortezomib sensitized some of the resistant cell lines to MAL3-101 treatment as well (although to a lesser extent than CQ), it would be helpful to further discuss possible explanations.</p><p><italic>Reviewer #1:</italic></p><p>Here, the authors use a combined chemical and genetic approach to probe protein homeostasis remodeling in breast cancer cell lines treated with the HSP70 inhibitor Mal3-101. They identify select breast cancer cell lines of diverse types (e.g. luminal, TNBC) that are differentially sensitive to treatment with MAL3-101. Using RT-qPCR and immunoblotting, the authors show that this differential sensitivity does not appear to be associated with remodeling of HSP70 chaperoning activity. So the authors used pharmacologic and genetic strategies to define the underlying basis for the differential sensitivities to this HSP70 inhibitor. Initially, the authors used inhibitors of proteasome- and autophagy-associated degradation to demonstrate that breast cancer cell lines resistant to Mal3-101 have increased dependence on protein degradation. However, only pharmacologic inhibition of autophagy restored resistance of these lines to Mal3-101. These results and others probing autophagic flux in resistant cell lines treated with Mal3-101 indicate these cells increase autophagy to improve survival in response to pharmacologic HSP70 inhibition. The authors then probe the dependence on this increased autophagic flux on UPR and ISR signaling using both sensitive and resistant breast cancer cell lines. Through these efforts, the authors show that genetic depletion of the UPR/ISR kinase PERK selectively blocks MAL3-101-induced apoptosis in sensitive cells, while having no significant effect on resistant cells. Alternatively, genetic depletion of the ISR kinase GCN2 blocked increased autophagic flux and increased apoptosis in resistant cells, while minimally impacting sensitive cell lines. These results indicate that sensitive and resistant cell lines differentially rely on the PERK and GCN2 to dictating apoptosis or survival.</p><p>Overall, the authors have clearly performed numerous experiments to define the protein homeostasis remodeling associated with Mal3-101 sensitivity in breast cancer cell lines. Further, their concluding results that sensitive and resistant cells are differentially dependent on GCN2 and PERK for dictating survival or apoptosis, respectively are interesting. However, the idea that GCN2 and PERK (or other ISR kinases) can initiate distinct signaling in response to different types of insults is not exactly a new idea in the field, although admittedly, this work does organize this idea in a defined way and adds new results that can continue to inform that area of study. The key question is how does ISR signaling through PERK and GCN2 integrate with other functional inputs to dictate distinct cellular responses. This is likely achieved through mechanism including the posttranslational modification of different downstream transcriptional regulators, integration of ISR signaling with other stress-responsive signaling pathways, or through heterooligomerization of ISR transcription factors with other inputs (e.g., heterooligomerization of ATF4 with other b-ZIP transcription factors). The authors work uniquely positions them to address these types of questions, but ultimately, they are not pursued in this manuscript. In the current form, the manuscript sets up the next series of very interesting studies to get the bottom of this type of differential regulation. To be fair, it is not reasonable to expect the entire underlying mechanism highlighted by this work to be defined in a single paper, but I do think it is important to address some aspects of the differential sensitivity from either a biological or therapeutic perspective.</p><p>Below I include a few suggested experiments to bring some more closure to the manuscript. All are not necessary, especially considering the amount of work already included, but one of these types of experiments would significantly improve the impact of the work. There are, of course, other potential experiments too that would be suitable to bring closure to this story, but I think something similar to the below is required.</p><p>1. One interesting question emerging from this study is: 'what are the other inputs for resistant and sensitive cells that differentially alter ISR signaling outputs in these two models?'. This could potentially be addressed by performing RNAseq of resistant or sensitive cells treated with MAL3-101 and depleted of either GCN2 or PERK. This would provide a better framework to interpret the differential ISR signaling between these two types of cell lines and likely reveal other signaling mechanism that serve as modulators of ISR signaling.</p><p>2. Similar to #1, another interesting question is what are the functional differences that differentially activate GCN2 and PERK. The authors show that ER stress is similar between these two types of cell lines, but is this differential response dictated in part through altered metabolic signaling through reduced amino acids and/or mitochondrial imbalances, both of which can activate GCN2. Taking a step backward by showing that Mal3-101 differentially targets some aspect of metabolism to increase dependence on GCN2 in resistant cells would be quite interesting and significantly boost the impact of this work.</p><p>3. Alternatively, the authors could take a more therapeutic approach by incorporating the use of selective GCN2 or PERK inhibitors in this work, showing that combinations of GCN2 inhibitors and Mal3-101 increase apoptosis of resistant cells while more selective PERK inhibitors block apoptosis in the sensitive cells.</p><p>Other Comments.</p><p>1. I realize that the Mal3-101 compound has been reported previously, but considering the way it is used, it would be good to have a statement up front in the text about its selectivity and known engagement of different HSP70s. Which ones it hits, EC50, etc. For example, the potential for this compound to target BiP?. What about mitochondrial HSP70? It would be good to have a better description of the compound up front in this manuscript to help better understand its effects on different cancer cell lines. This is addressed in the results and discussion, but it would be good to include this more clearly in the intro.</p><p>2. It would be good to directly confirm the differential activation of PERK in GCN2 in sensitive and resistant cells more directly. For example, a phosphor-PERK and phosphor-GCN2 assay to show increased activity of these two eIF2a kinases.</p><p>I strongly encourage the authors to continue pursuing the interesting questions related to differential signaling through ISR kinases using the system they have established. Above, I provide some suggestions as to how to bring a bit of closure to this initial manuscript, which I imagine will represent the first of many pursuing this question.</p><p><italic>Reviewer #2:</italic></p><p>This article explores the response of cultured breast cancer cell lines to an inhibitor of heat shock protein 70 (Hsp70). The idea is to understand how different cells might be more/less sensitive to the same proteostatic stress. The concept of drug resistance in proteostasis is interesting and has only been studied extensively for inhibitors of Hsp90 and the 26S proteasome, so a significant amount is still unclear.</p><p>Here, the authors use the Hsp70 inhibitor, MAL3-101, and some observations from a recent study in rhabdomyosarcoma, to treat a panel of 14 breast cancer cells, ultimately placing them into categories based on their relative sensitivity (see table 1). To understand the origins of the sensitivity, they then use a hypothesis-driven approach to explore possible correlations with relative Hsp70 expression levels, ubiquitinated protein accumulation, autophagic flux and UPR activation. From this analysis, the only major correlation seemed to be with compensatory activation of autophagy through GCN2, which gave relative resistance to the inhibitor. While the mechanism of this difference remains unclear, this finding is potentially interesting for translation of the compounds (e.g. for patient stratification). More broadly, the results suggest that different cell types have inherently individualized tendencies to activate components of the proteostasis network (i.e. different arms of the UPR, autophagy vs. UPS). While perhaps not a surprising result when considered abstractly, the approach taken here, use of a chemical inhibitor to probe relative sensitivity, is powerful because it can be rapidly applied across many cell lines.</p><p>While the work is interesting, there does seem to be a missed opportunity because, in the end, one still wonders about the mechanism of the differential resistance. One idea to consider: there are publicly available transcriptional profiles of many of these breast cancer cell lines, so a clustering analysis might reveal the patterns of transcription that define the sensitivity groups, shedding light on potential mechanisms in an unbiased way. Does sensitivity correlate to known driver oncogenes? Drug efflux protein expression? Amino acid transporters? Metabolism? Translation control machinery? More colloquially – the classical breast cancer categorization subtype (e.g. TNBC, luminal, HER2) do not correlate with Hsp70 inhibitor sensitivity, so what does at a molecular level? Similarly, the authors also systematically examined resistance to the Hsp90 inhibitor, 17-AAG, so a parallel analysis of transcriptional profiles could provide further insight into the similarities and differences.</p><p>A second question is about whether GCN2 activation is necessary/sufficient for Hsp70 inhibitor resistance. Does over-expression of GCN2 drive resistance in an otherwise sensitive cell type? How about amino acid starvation? mTor inhibitor? It seems likely that the story could be more complex, but a specific test would be informative either way.</p><p><italic>Reviewer #3:</italic></p><p>The manuscript &quot;Unique integrated stress response sensors regulate cancer cell susceptibility when Hsp70 activity is compromised&quot; by Sannino and colleagues describes that autophagy confers resistance against HSP70 inhibition in cancer treatment. They grouped breast cancer cell lines according to their resistance to the HSP70 inhibitor MAL3-101 and showed that resistant cell lines exhibited higher levels of autophagy induction after MAL3-101 treatment when compared to the sensitive cells. Autophagy inhibition resensitized the resistant cells to MAL3-101 treatment, indicating autophagy as the underlying resistance mechanism. In the second part of the paper, the authors show that the unfolded protein response and the integrated stress response (ISR) were activated upon HSP70 inhibition and examined the role of the different eIF2a kinases activating the ISR.</p><p>Overall, the paper is well written and addresses an important topic. Chaperone inhibition has long been a target in cancer therapy and the connections to autophagy and cellular stress responses remain unclear. The study adds interesting new insight that will be of interest across the proteostasis, autophagy and cancer fields. The authors convincingly show different behaviour of tumor subgroups when treated with an HSP70 inhibitor and offer options to overcome resistance formation. However, some mechanistic details on the links with the ISR and autophagy flux reporters would need to be characterised better to make this paper stronger.</p><p>1) The mechanisms leading to eIF2a phosphorylation and whether the resulting phenotypes are indeed driven by the ISR remain unclear. A) The arguments towards omitting HRI from the analyses are not convincing. A large number of studies have shown that HRI activation is not exclusive to mitochondrial dysfunction (see e.g. PMID: 10454533). HRI also needs to be evaluated along with the other eIF2a kinases. B) Why is the ISR activated both in sensitive and resistant cells while the cell fate is different? This raises the possibility that the observed effects are driven by another pathway (several pathways have been shown to induce CHOP, ATF4, autophagy). Further tests using ISRIB or phosphorylation incompetent versions of eIF2a will be required to clarify the requirement of ISR activation. C) The 3 eIF2a kinases assessed show varying results across the different cell groups, treatments and outcomes. Additional clarification and interpretation of these seemingly contradictory results would be helpful. D) Considering the above points, there is a chance that the eIF2a knockdowns were not sufficient to prevent eIF2a phosphorylation. eIF2a phosphorylation Western blots after knockdown of the different kinases and treatment with positive controls (tunicamycin for PERK…) would clarify this issue.</p><p>2) Autophagy flux reporters, such as RFP-GFP-LC3 used by the authors, have become standard in the field. These are much more reliable than assessment of LC3 lipidation that can be hard to interpret or autophagy protein levels. It is a pity the authors did not assess flux more consistently. It would be crucial using the flux reporter to assess A) at least one more additional sensitive and resistant cell line for the effects of MAL3-101 (as in Figure S5), B) the proposed autophagy induction via the ISR. These experiments will much strengthen the proposed role of autophagy.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.64977.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Reviewer #1:</p><p>[…] Overall, the authors have clearly performed numerous experiments to define the protein homeostasis remodeling associated with Mal3-101 sensitivity in breast cancer cell lines. Further, their concluding results that sensitive and resistant cells are differentially dependent on GCN2 and PERK for dictating survival or apoptosis, respectively are interesting. However, the idea that GCN2 and PERK (or other ISR kinases) can initiate distinct signaling in response to different types of insults is not exactly a new idea in the field, although admittedly, this work does organize this idea in a defined way and adds new results that can continue to inform that area of study. The key question is how does ISR signaling through PERK and GCN2 integrate with other functional inputs to dictate distinct cellular responses. This is likely achieved through mechanism including the posttranslational modification of different downstream transcriptional regulators, integration of ISR signaling with other stress-responsive signaling pathways, or through heterooligomerization of ISR transcription factors with other inputs (e.g., heterooligomerization of ATF4 with other b-ZIP transcription factors). The authors work uniquely positions them to address these types of questions, but ultimately, they are not pursued in this manuscript. In the current form, the manuscript sets up the next series of very interesting studies to get the bottom of this type of differential regulation. To be fair, it is not reasonable to expect the entire underlying mechanism highlighted by this work to be defined in a single paper, but I do think it is important to address some aspects of the differential sensitivity from either a biological or therapeutic perspective.</p><p>Below I include a few suggested experiments to bring some more closure to the manuscript. All are not necessary, especially considering the amount of work already included, but one of these types of experiments would significantly improve the impact of the work. There are, of course, other potential experiments too that would be suitable to bring closure to this story, but I think something similar to the below is required.</p><p>1. One interesting question emerging from this study is: 'what are the other inputs for resistant and sensitive cells that differentially alter ISR signaling outputs in these two models?'. This could potentially be addressed by performing RNAseq of resistant or sensitive cells treated with Mal3-101 and depleted of either Gcn2 or Perk. This would provide a better framework to interpret the differential ISR signaling between these two types of cell lines and likely reveal other signaling mechanism that serve as modulators of ISR signaling.</p></disp-quote><p>The reviewer makes an excellent suggestion, and to address this point as well as the question raised in point 2, below, we analyzed the transcriptional profiles of a MAL3-101 sensitive and resistant cell line (MDA MB 231 and MDA MB 453) in the presence of 12 µM MAL3-101 for 6 hr (when robust transcriptional responses for the autophagy pathway were noted by qPCR) or in an equal volume of DMSO. Each experiment was performed in triplicate. We next performed total RNA extraction and performed a quality control analysis. RNA sequencing was performed by Novogene and analyzed by three new co-authors on the manuscript (Drs. Megan Yates, Steffi Oesterreich, and Adrian Lee). These colleagues are experts in the analysis of cancer cell genomics and transcriptomics. As shown in a new figure (Figure 13), we discovered that protein folding and ER stress response pathways are upregulated in sensitive cells (MDA MB 231), while select metabolic pathway components are upregulated in resistant cells (MDA MD 453) after MAL3-101 treatment. The RNAseq analysis shown in Figure 13 also confirm that Hsp70 inhibition causes unfolded proteins to accumulate and the consequent activation of the unfolded protein response (UPR). These results confirm other data in the manuscript that UPR induction, and in particular activation of the PERK branch of this pathway, induces MAL3-101-dependent cell death in sensitive cells (MDA MB 231). We also wish to note that we refrained from performing these experiments under specific knock-down conditions since secondary effects are likely, particularly in the sensitive cells, which initiate a global apoptotic program in the presence of MAL3-101 in the same time frame.</p><disp-quote content-type="editor-comment"><p>2. Similar to #1, another interesting question is what are the functional differences that differentially activate GCN2 and PERK. The authors show that ER stress is similar between these two types of cell lines, but is this differential response dictated in part through altered metabolic signaling through reduced amino acids and/or mitochondrial imbalances, both of which can activate GCN2. Taking a step backward by showing that Mal3-101 differentially targets some aspect of metabolism to increase dependence on GCN2 in resistant cells would be quite interesting and significantly boost the impact of this work.</p></disp-quote><p>Please see the comments to point 1, above. Please also note that hierarchical clustering the samples based upon the top 35 differential expressed genes in these cells reveals that MAL3-101 treated sensitive (MDA MB 231) cells cluster with untreated resistant MDA MB 453 cells, while no major variations were detected in the transcriptional profile of MAL3-101 resistant cells (MDA MB 453) in presence or absence of the drug (Figure 13C and13D). These findings suggest that Hsp70 inhibition perturbs translational and/or metabolic pathways rather than transcription in MAL3-101 resistant cells. This hypothesis will be pursued in full in future studies. In addition, we note that an autophagy related gene, MAP1LC3B, was highly induced upon MAL3-101 treatment in MDA MB 453 resistant cells. These data further support our conclusions that autophagy is induced in resistant cells upon Hsp70 inhibition.</p><disp-quote content-type="editor-comment"><p>3. Alternatively, the authors could take a more therapeutic approach by incorporating the use of selective GCN2 or PERK inhibitors in this work, showing that combinations of GCN2 inhibitors and Mal3-101 increase apoptosis of resistant cells while more selective PERK inhibitors block apoptosis in the sensitive cells.</p></disp-quote><p>This is an excellent point, one that we had considered as well. Therefore, to address this comment, we treated sensitive and resistance cells with MAL3-101 in the presence or absence of the PERK inhibitor, GSK-2606414 (“GSK”). Cells were pre-treated for 2 hours with this PERK inhibitor (or a vehicle control) to specifically block this ISR sensor, and then MAL3-101 or DMSO was added for an additional 6 hours. The magnitude of apoptotic induction under each of these conditions is reported in a revised figure, Figure 10D, and quantified in Figure 10—figure supplement 1D. As predicted by our PERK silencing experiments and consistent with one of our major conclusions, there was reduced accumulation of cleaved caspase-3, cleaved caspase-8, and CHOP in sensitive cells when PERK was inhibited upon MAL3-101 addition. Also as anticipated, there was apoptotic induction with MAL3-101 resistant cells when GSK was added in conjunction with the Hsp70 inhibitor. Therefore, while an ISR-based response is induced in both sensitive and resistant cells, PERK contributes to MAL3-101-mediated apoptosis in only the MAL3-101 sensitive cells.</p><disp-quote content-type="editor-comment"><p>Other Comments.</p><p>1. I realize that the Mal3-101 compound has been reported previously, but considering the way it is used, it would be good to have a statement up front in the text about its selectivity and known engagement of different HSP70s. Which ones it hits, EC50, etc. For example, the potential for this compound to target BiP?. What about mitochondrial HSP70? It would be good to have a better description of the compound up front in this manuscript to help better understand its effects on different cancer cell lines. This is addressed in the results and discussion, but it would be good to include this more clearly in the intro.</p></disp-quote><p>We have included more information on the isolation, characterization, and uses of the MAL3-101 compound in the Introduction section, as suggested (see page 7, lines 123-127).</p><disp-quote content-type="editor-comment"><p>2. It would be good to directly confirm the differential activation of PERK in GCN2 in sensitive and resistant cells more directly. For example, a phosphor-PERK and phosphor-GCN2 assay to show increased activity of these two eIF2a kinases.</p></disp-quote><p>To detect PERK activation (p-PERK), we monitored the shift in PERK migration by immunoblot after SDS-PAGE after sensitive and resistant cells were treated with a known UPR inducer, tunicamycin, MAL3-101, or the vehicle control. As shown in a new figure (Figure 10C), PERK mobility was reduced to a similar extent in MAL3-101 sensitive and resistant cells when Hsp70 was inhibited or when the cells were treated with tunicamycin. These data confirm that PERK is activated in both MAL3-101 sensitive and resistant cells upon Hsp70 inhibition.</p><p>To monitor GCN2 activation, the level of phosphorylated GCN2 at Thr-899 was investigated by using a pT899 specific antibody (anti-GCN2 pT899 antibody ab-75836, Abcam; see Figure 11—figure supplement 7A) (Romano et al., 1998). Interestingly, pT899 was apparent even before MAL3-101 was added in both sensitive and resistant cells, suggesting a requirement for activated GCN2 in the survival and perhaps immortalization of these breast cancer cells. This was therefore independent of whether Hsp70 was inhibited or not. Consistent with this hypothesis, no further change in pT899 GCN2 was detected when MAL3101 was added to either cell line (Figure 11—figure supplement 1A). Nevertheless, it is possible that other sites are being phosphorylated when Hsp70 is inhibited. In fact, there was a hint of this occurring in a previous study (Harding et al., 2019) in which the role of the ribosomal Pstalk on GCN2 activation was investigated. A discussion of these points and the relevant additional reference have been added to both the Results section of the manuscript (see page 25 in the Results section).</p><disp-quote content-type="editor-comment"><p>I strongly encourage the authors to continue pursuing the interesting questions related to differential signaling through ISR kinases using the system they have established. Above, I provide some suggestions as to how to bring a bit of closure to this initial manuscript, which I imagine will represent the first of many pursuing this question.</p><p>Reviewer #2:</p><p>This article explores the response of cultured breast cancer cell lines to an inhibitor of heat shock protein 70 (Hsp70). The idea is to understand how different cells might be more/less sensitive to the same proteostatic stress. The concept of drug resistance in proteostasis is interesting and has only been studied extensively for inhibitors of Hsp90 and the 26S proteasome, so a significant amount is still unclear.</p><p>Here, the authors use the Hsp70 inhibitor, MAL3-101, and some observations from a recent study in rhabdomyosarcoma, to treat a panel of 14 breast cancer cells, ultimately placing them into categories based on their relative sensitivity (see table 1). To understand the origins of the sensitivity, they then use a hypothesis-driven approach to explore possible correlations with relative Hsp70 expression levels, ubiquitinated protein accumulation, autophagic flux and UPR activation. From this analysis, the only major correlation seemed to be with compensatory activation of autophagy through GCN2, which gave relative resistance to the inhibitor. While the mechanism of this difference remains unclear, this finding is potentially interesting for translation of the compounds (e.g. for patient stratification). More broadly, the results suggest that different cell types have inherently individualized tendencies to activate components of the proteostasis network (i.e. different arms of the UPR, autophagy vs. UPS). While perhaps not a surprising result when considered abstractly, the approach taken here, use of a chemical inhibitor to probe relative sensitivity, is powerful because it can be rapidly applied across many cell lines.</p><p>While the work is interesting, there does seem to be a missed opportunity because, in the end, one still wonders about the mechanism of the differential resistance. One idea to consider: there are publicly available transcriptional profiles of many of these breast cancer cell lines, so a clustering analysis might reveal the patterns of transcription that define the sensitivity groups, shedding light on potential mechanisms in an unbiased way. Does sensitivity correlate to known driver oncogenes? Drug efflux protein expression? Amino acid transporters? Metabolism? Translation control machinery? More colloquially – the classical breast cancer categorization subtype (e.g. TNBC, luminal, HER2) do not correlate with Hsp70 inhibitor sensitivity, so what does at a molecular level? Similarly, the authors also systematically examined resistance to the Hsp90 inhibitor, 17-AAG, so a parallel analysis of transcriptional profiles could provide further insight into the similarities and differences.</p></disp-quote><p>As suggested by the reviewer, we analyzed available databases containing transcriptional profiles and proteomic data for the 14 breast cancer lines used in this study in order to identify pathways that might differentiate MAL3-101 sensitive and resistant breast cancer cells. As displayed in a new figure (Figure 13A and 13B), MAL3-101 sensitivity did not correlate with changes in breast cancer cell transcriptional profiles, suggesting that MAL3-101 sensitivity is related to translational variations rather than changes in gene expression. In line with this hypothesis, the analysis of publicly available RPPA datasets revealed that pT172 AMPK and p70-S6K-pT389 were present to a higher extent in MAL3-101 resistant cells (MDA MB 453, MDA MB 361 and HCC38) compared to the sensitive cell lines (Figure 13B). pT172 AMPK and p70-S6K-pT389 orchestrate the modulation of cellular metabolism and protein translation when cellular energy varies, suggesting that MAL3-101 resistant cells are more likely to modulate their metabolic state upon proteostasis stress. This hypothesis will be investigated in full in future studies. Interestingly, a previous study indicated that pT172 AMPK and p70-S6K-pT389 upregulation was also detected together with autophagy induction in HEK293 cells deprived of glucose (Kim et al., 2011). These findings provide further support for our conclusion that autophagy is a key compensatory pathway in resistant cells treated with MAL3-101. A discussion of these points – as well as the possibility that MAL3-101 alters AMPK activity and thus cellular metabolism – and the relevant references have been added to the “Induction of the ER stress response and protein folding pathway genes correlate with Hsp70 inhibition in sensitive cells” paragraph.</p><disp-quote content-type="editor-comment"><p>A second question is about whether GCN2 activation is necessary/sufficient for Hsp70 inhibitor resistance. Does over-expression of GCN2 drive resistance in an otherwise sensitive cell type? How about amino acid starvation? mTor inhibitor? It seems likely that the story could be more complex, but a specific test would be informative either way.</p></disp-quote><p>The reviewer raises two excellent points.</p><p>First, to investigate whether GCN2 was necessary and sufficient to confer MAL3-101 sensitivity, we overexpressed Flag-tagged GCN2 in sensitive and resistant cells, as suggested. Unfortunately, the overexpression of GCN2 alone caused the accumulation cleaved caspase-8 compared to vector-control transfected cells (<xref ref-type="fig" rid="sa2fig1">Author response image 1</xref>).</p><p>This result suggests that GCN2 overexpression per se is sufficient to trigger an apoptotic response. In theory, this problem might be rectified by creating stable, tunable GCN2 over-expression lines, a feat that will require a significant amount of work and might still indicate that overexpression of GCN2 – to any level – is toxic. Indeed, we were surprised that we were unable to find any papers in the literature in which GCN2 overexpression studies were performed, potentially supporting the phenomenon we observed.</p><fig id="sa2fig1"><label>Author response image 1.</label><caption><title>GCN2 overexpression induces apoptosis.</title><p>Accumulation of cleaved caspase -8, which is an indicator of apoptosis induction, was monitored in empty vector (CTRL) and Flag -GCN2 transfected MAL3-101 sensitive and resistant cells.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64977-resp-fig1-v3.tif"/></fig><p>Second, to investigate the role of mTOR in MAL3-101 sensitivity, we first tested MAL3-101 sensitive and resistant cell viability in presence or absence of the mTOR inhibitor, everolimus. As shown in a new figure (Figure 6C), only subtle differences were detected in the sensitivity to this inhibitor in the two representative cell lines (IC<sub>50</sub> 23.0 µM for MDA MB 231 cells and 18.7 µM for MDA MB 453 cells). However, when the sensitive line (MDA MB 231) was treated with increasing doses of MAL3-101 in the presence of a submaximal concentration of everolimus (2 µM), we discovered that autophagy induction via this mTOR inhibitor modestly decreased the sensitivity of MDA MB 231 cells to MAL3-101 (Figure 6D and Table 2, IC<sub>50s</sub> MAL3-101 alone 3.3 µM, MAL3-10 + everolimus 5.1 µM). In contrast addition of sub-critical doses of everolimus in the presence of MAL3-101 had no effect on cell viability in the resistant (MDA MB 453) cell line. These data confirm another one of our conclusions: Autophagy provides a compensatory pro-survival mechanism when Hsp70 activity is inhibited. These data also highlight the importance of monitoring protein degradation efficiency when analyzing chaperone-based inhibitors.</p><disp-quote content-type="editor-comment"><p>Reviewer #3:</p><p>The manuscript &quot;Unique integrated stress response sensors regulate cancer cell susceptibility when Hsp70 activity is compromised&quot; by Sannino and colleagues describes that autophagy confers resistance against HSP70 inhibition in cancer treatment. They grouped breast cancer cell lines according to their resistance to the HSP70 inhibitor MAL3-101 and showed that resistant cell lines exhibited higher levels of autophagy induction after MAL3-101 treatment when compared to the sensitive cells. Autophagy inhibition resensitized the resistant cells to MAL3-101 treatment, indicating autophagy as the underlying resistance mechanism. In the second part of the paper, the authors show that the unfolded protein response and the integrated stress response (ISR) were activated upon HSP70 inhibition and examined the role of the different eIF2a kinases activating the ISR.</p><p>Overall, the paper is well written and addresses an important topic. Chaperone inhibition has long been a target in cancer therapy and the connections to autophagy and cellular stress responses remain unclear. The study adds interesting new insight that will be of interest across the proteostasis, autophagy and cancer fields. The authors convincingly show different behaviour of tumor subgroups when treated with an HSP70 inhibitor and offer options to overcome resistance formation. However, some mechanistic details on the links with the ISR and autophagy flux reporters would need to be characterised better to make this paper stronger.</p><p>1) The mechanisms leading to eIF2a phosphorylation and whether the resulting phenotypes are indeed driven by the ISR remain unclear.</p><p>A) The arguments towards omitting HRI from the analyses are not convincing. A large number of studies have shown that HRI activation is not exclusive to mitochondrial dysfunction (see e.g. PMID: 10454533). HRI also needs to be evaluated along with the other eIF2a kinases.</p></disp-quote><p>The reviewer makes an excellent suggestion, and we apologize for not appreciating the potential role of HRI in this and other functions. Thus, in the revised manuscript, we present new data ont the role of HRI in the MAL3-101-dependent induction of apoptosis (Figure 9). Specifically, we found that HRI knockdown had no effect on the viability of the resistant (MDA MB 453) cells. On the contrary, accumulation of cleaved caspase-8 and CHOP, but not cleaved caspase-3, was detected in MDA MB 231 sensitive cells when MAL3101 was added to HRI-silenced cells. While the data did not reach statistical significance, these results suggest that HRI plays a minor role in the MAL3-101-initiated cellular response in drug-sensitive cells (Figure 9A and 9C). A discussion of this model has been added to the revised manuscript.</p><disp-quote content-type="editor-comment"><p>B) Why is the ISR activated both in sensitive and resistant cells while the cell fate is different? This raises the possibility that the observed effects are driven by another pathway (several pathways have been shown to induce CHOP, ATF4, autophagy). Further tests using ISRIB or phosphorylation incompetent versions of eIF2a will be required to clarify the requirement of ISR activation.</p></disp-quote><p>We thank the reviewer for this comment, and to address their excellent suggestion a new figure has been included the revised manuscript. Specifically, we measured the MAL3101-dependent apoptotic response in presence or absence of the ISR pathway inhibitor, ISRIB, as suggested (Figure 11—figure supplement 1). In line with our data on the effects of PERK silencing and chemical inhibition of this ISR transducer (Figure 10 and Figure 10—figure supplement 1), ISRIB treatment decreased the accumulation of cleaved caspase-3, cleaved caspase-8, and CHOP in MDA MB 231 sensitive cells when MAL3-101 was added. These data confirm that the ISR response does indeed initiate the apoptotic pathway in MAL3-101 sensitive cells when Hsp70 is inhibited.</p><p>In contrast to the measurable protective effect of ISRIB in the sensitive cells, only a minor change in one of the examined apoptotic markers, cleaved caspase-8, was apparent when Hsp70 was inhibited in the resistant (MDA MB 453) cell line upon ISRIB addition. These data suggest that inhibition of the ISR-eIF2α signaling pathway is insufficient to induce resistant cell apoptosis. Because this effect was subtle compared to the apoptotic effect when GCN2 expression was silenced and MAL3-101 was added, we hypothesize that another ISR sensor helps dictate MAL3-101-dependent apoptotic cell death in resistant cells in the presence of the drug. This hypothesis is outlined in the revised manuscript in conjunction with these newly acquired data (see Figure 11—figure supplement 1).</p><disp-quote content-type="editor-comment"><p>C) The 3 eIF2a kinases assessed show varying results across the different cell groups, treatments and outcomes. Additional clarification and interpretation of these seemingly contradictory results would be helpful. D) Considering the above points, there is a chance that the eIF2a knockdowns were not sufficient to prevent eIF2a phosphorylation. eIF2a phosphorylation Western blots after knockdown of the different kinases and treatment with positive controls (tunicamycin for PERK…) would clarify this issue.</p></disp-quote><p>As suggested by the reviewer, we addressed the effect of PERK silencing when a known UPR stressor (in this case, tunicamycin) was added to MAL3-101 sensitive and resistant cells. As quantified in a new figure, Figure 10—figure supplement 1B, PERK knockdown decreased the amount of p-eIF2α and CHOP in both sensitive and resistant cells treated with 10 µg/mL tunicamycin for 3 hours. Thus, the level of PERK knockdown achieved in our experiments is also sufficient to reduce PERK-p-eIF2α induction in sensitive and resistant cells treated with MAL3-101, which similarly initiates the ISR.</p><disp-quote content-type="editor-comment"><p>2) Autophagy flux reporters, such as RFP-GFP-LC3 used by the authors, have become standard in the field. These are much more reliable than assessment of LC3 lipidation that can be hard to interpret or autophagy protein levels. It is a pity the authors did not assess flux more consistently. It would be crucial using the flux reporter to assess A) at least one more additional sensitive and resistant cell line for the effects of MAL3-101 (as in Figure S5), B) the proposed autophagy induction via the ISR. These experiments will much strengthen the proposed role of autophagy.</p></disp-quote><p>We thank the reviewer for appreciating our development of the stable cell line in which autophagy is best measured. In fact, the construction, isolation, and verification of this line required ~ 6 months. Nevertheless, we note that a less-than-perfect alternate method to analyze autophagy induction, i.e., LC3 immunoblots, do show a marked difference in autophagy between two sensitive and two resistant lines, including the lines in which RFPGFP-LC3 was also used (Figure 2D, 4C and 4D). When taken together, these data indicate that the outcome of measuring LC3 by immunoblot mirrors the effects in the resistant and sensitive lines containing the stably integrated version of RFP-GFP-LC3.</p></body></sub-article></article>